
<html lang="en"     class="pb-page"  data-request-id="b61fdc6f-ec12-484d-8717-e2b21ffaa8ca"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;issue:issue:10.1021/jmcmar.2021.64.issue-6;article:article:10.1021/acs.jmedchem.0c02191;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Discovery of a First-In-Class Small Molecule Antagonist against the Adrenomedullin-2 Receptor: Structure–Activity Relationships and Optimization" /></meta><meta name="dc.Creator" content="Jean-Olivier  Zirimwabagabo" /></meta><meta name="dc.Creator" content="Ameera B. A.  Jailani" /></meta><meta name="dc.Creator" content="Paris  Avgoustou" /></meta><meta name="dc.Creator" content="Matthew J.  Tozer" /></meta><meta name="dc.Creator" content="Karl R.  Gibson" /></meta><meta name="dc.Creator" content="Paul A.  Glossop" /></meta><meta name="dc.Creator" content="James E. J.  Mills" /></meta><meta name="dc.Creator" content="Roderick A.  Porter" /></meta><meta name="dc.Creator" content="Paul  Blaney" /></meta><meta name="dc.Creator" content="Ning  Wang" /></meta><meta name="dc.Creator" content="Timothy M.  Skerry" /></meta><meta name="dc.Creator" content="Gareth O.  Richards" /></meta><meta name="dc.Creator" content="Joseph P. A.  Harrity" /></meta><meta name="dc.Description" content="Class B G-protein-coupled receptors (GPCRs) remain an underexploited target for drug development. The calcitonin receptor (CTR) family is particularly challenging, as its receptors are heteromers c..." /></meta><meta name="Description" content="Class B G-protein-coupled receptors (GPCRs) remain an underexploited target for drug development. The calcitonin receptor (CTR) family is particularly challenging, as its receptors are heteromers c..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="March 5, 2021" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c02191" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2021 The Authors. Published by American Chemical Society" /></meta><meta name="citation_fulltext_world_readable" content=""/></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c02191" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c02191" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c02191" /></link>
        
    
    

<title>Discovery of a First-In-Class Small Molecule Antagonist against the Adrenomedullin-2 Receptor: Structure–Activity Relationships and Optimization | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c02191" /></meta><meta property="og:title" content="Discovery of a First-In-Class Small Molecule Antagonist against the Adrenomedullin-2 Receptor: Structure–Activity Relationships and Optimization" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02191/20210408/images/large/jm0c02191_0017.jpeg" /></meta><meta property="og:description" content="Class B G-protein-coupled receptors (GPCRs) remain an underexploited target for drug development. The calcitonin receptor (CTR) family is particularly challenging, as its receptors are heteromers comprising two distinct components: the calcitonin receptor-like receptor (CLR) or calcitonin receptor (CTR) together with one of three accessory proteins known as receptor activity-modifying proteins (RAMPs). CLR/RAMP1 forms a CGRP receptor, CLR/RAMP2 forms an adrenomedullin-1 (AM1) receptor, and CLR/RAMP3 forms an adrenomedullin-2 (AM2) receptor. The CTR/RAMP complexes form three distinct amylin receptors. While the selective blockade of AM2 receptors would be therapeutically valuable, inhibition of AM1 receptors would cause clinically unacceptable increased blood pressure. We report here a systematic study of structure–activity relationships that has led to the development of first-in-class AM2 receptor antagonists. These compounds exhibit therapeutically valuable properties with 1000-fold selectivity over the AM1 receptor. These results highlight the therapeutic potential of AM2 antagonists." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c02191"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c02191">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c02191&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c02191&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c02191&amp;href=/doi/10.1021/acs.jmedchem.0c02191" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2021</span><span class="cit-fg-volume">, 64</span><span class="cit-fg-issue">, 6</span><span class="cit-fg-pageRange">, 3299-3319</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/64/6" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.0c02159" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.0c02195" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of a First-In-Class Small Molecule Antagonist against the Adrenomedullin-2 Receptor: Structure–Activity Relationships and Optimization</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Jean-Olivier Zirimwabagabo</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jean-Olivier Zirimwabagabo</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Chemistry, University of Sheffield, Sheffield S10 2TN, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jean-Olivier++Zirimwabagabo">Jean-Olivier Zirimwabagabo</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-4303-2139" title="Orcid link">http://orcid.org/0000-0002-4303-2139</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ameera B. A. Jailani</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ameera B. A. Jailani</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Oncology and Metabolism, University of Sheffield, Sheffield S10 2TN, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ameera+B.+A.++Jailani">Ameera B. A. Jailani</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-9837-6062" title="Orcid link">http://orcid.org/0000-0001-9837-6062</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Paris Avgoustou</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Paris Avgoustou</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Oncology and Metabolism, University of Sheffield, Sheffield S10 2TN, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Paris++Avgoustou">Paris Avgoustou</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-1642-1083" title="Orcid link">http://orcid.org/0000-0002-1642-1083</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Matthew J. Tozer</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Matthew J. Tozer</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Matt Tozer Consultancy, Bognor Regis PO21 1DY, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Matthew+J.++Tozer">Matthew J. Tozer</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-9046-4065" title="Orcid link">http://orcid.org/0000-0002-9046-4065</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Karl R. Gibson</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Karl R. Gibson</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Sandexis Medicinal Chemistry Ltd., Sandwich, Kent CT13 9ND, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Karl+R.++Gibson">Karl R. Gibson</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-7967-8476" title="Orcid link">http://orcid.org/0000-0002-7967-8476</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Paul A. Glossop</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Paul A. Glossop</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Sandexis Medicinal Chemistry Ltd., Sandwich, Kent CT13 9ND, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Paul+A.++Glossop">Paul A. Glossop</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-6567-5648" title="Orcid link">http://orcid.org/0000-0001-6567-5648</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">James E. J. Mills</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">James E. J. Mills</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Sandexis Medicinal Chemistry Ltd., Sandwich, Kent CT13 9ND, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=James+E.+J.++Mills">James E. J. Mills</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-2567-3872" title="Orcid link">http://orcid.org/0000-0002-2567-3872</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Roderick A. Porter</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Roderick A. Porter</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Rod Porter Consultancy, Ashwell, Hertfordshire SG7 5PG, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Roderick+A.++Porter">Roderick A. Porter</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-8252-0429" title="Orcid link">http://orcid.org/0000-0001-8252-0429</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Paul Blaney</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Paul Blaney</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Concept Life Sciences, High Peak SK23 0PG, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Paul++Blaney">Paul Blaney</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-8121-8594" title="Orcid link">http://orcid.org/0000-0001-8121-8594</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ning Wang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ning Wang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Oncology and Metabolism, University of Sheffield, Sheffield S10 2TN, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ning++Wang">Ning Wang</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-2663-7515" title="Orcid link">http://orcid.org/0000-0002-2663-7515</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Timothy M. Skerry</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Timothy M. Skerry</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Oncology and Metabolism, University of Sheffield, Sheffield S10 2TN, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Timothy+M.++Skerry">Timothy M. Skerry</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-1319-5575" title="Orcid link">http://orcid.org/0000-0003-1319-5575</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Gareth O. Richards</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Gareth O. Richards</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Oncology and Metabolism, University of Sheffield, Sheffield S10 2TN, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Gareth+O.++Richards">Gareth O. Richards</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-7984-6882" title="Orcid link">http://orcid.org/0000-0001-7984-6882</a></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Joseph P. A. Harrity</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Joseph P. A. Harrity</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Chemistry, University of Sheffield, Sheffield S10 2TN, U.K.</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#33591d5b5241415a474a73405b5655555a565f571d52501d4658"><span class="__cf_email__" data-cfemail="ed87c3858c9f9f849994ad9e85888b8b84888189c38c8ec39886">[email protected]</span></a></span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Joseph+P.+A.++Harrity">Joseph P. A. Harrity</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-5038-5699" title="Orcid link">http://orcid.org/0000-0001-5038-5699</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c02191&amp;href=/doi/10.1021%2Facs.jmedchem.0c02191" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2021</span></span><span class="cit-volume">, 64</span><span class="cit-issue">, 6</span><span class="cit-pageRange">, 3299–3319</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">March 5, 2021</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>18 December 2020</li><li><span class="item_label"><b>Published</b> online</span>5 March 2021</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 25 March 2021</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c02191" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c02191</a></div><div class="article_header-article-copyright"><strong>Copyright © 2021 The Authors. Published by American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/page/rightslinkno.jsp">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"><a href="https://acsopenscience.org/open-access/licensing-options/"><img src="/pb-assets/images/programsLogos/OA_Icons_Ac-1612971054130.svg" alt="ACS AuthorChoice" /></img><span>ACS AuthorChoice</span></a><span class="article_header-cc-by"><a href="https://creativecommons.org/licenses/by/4.0/"><img src="/pb-assets/images/licensesLogos/OA_Icons_cc-1612971093887.svg" alt="CC: Creative Commons" /></img><span><strong>CC: </strong>Creative Commons</span></a><a href="https://creativecommons.org/licenses/by/4.0/"><img src="/pb-assets/images/licensesLogos/OA_Icons_by-1612971093257.svg" alt="BY: Credit must be given to the creator" /></img><span><strong>BY: </strong>Credit must be given to the creator</span></a></span></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c02191"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2310</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">1</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c02191" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of a First-In-Class Small Molecule Antagonist against the Adrenomedullin-2 Receptor: Structure–Activity Relationships and Optimization&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Jean-Olivier&quot;,&quot;last_name&quot;:&quot;Zirimwabagabo&quot;},{&quot;first_name&quot;:&quot;Ameera&quot;,&quot;last_name&quot;:&quot;B. A. Jailani&quot;},{&quot;first_name&quot;:&quot;Paris&quot;,&quot;last_name&quot;:&quot;Avgoustou&quot;},{&quot;first_name&quot;:&quot;Matthew&quot;,&quot;last_name&quot;:&quot;J. Tozer&quot;},{&quot;first_name&quot;:&quot;Karl&quot;,&quot;last_name&quot;:&quot;R. Gibson&quot;},{&quot;first_name&quot;:&quot;Paul&quot;,&quot;last_name&quot;:&quot;A. Glossop&quot;},{&quot;first_name&quot;:&quot;James&quot;,&quot;last_name&quot;:&quot;E. J. Mills&quot;},{&quot;first_name&quot;:&quot;Roderick&quot;,&quot;last_name&quot;:&quot;A. Porter&quot;},{&quot;first_name&quot;:&quot;Paul&quot;,&quot;last_name&quot;:&quot;Blaney&quot;},{&quot;first_name&quot;:&quot;Ning&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Timothy&quot;,&quot;last_name&quot;:&quot;M. Skerry&quot;},{&quot;first_name&quot;:&quot;Gareth&quot;,&quot;last_name&quot;:&quot;O. Richards&quot;},{&quot;first_name&quot;:&quot;Joseph&quot;,&quot;last_name&quot;:&quot;P. A. Harrity&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2021&quot;,&quot;month&quot;:&quot;03&quot;,&quot;day&quot;:&quot;05&quot;,&quot;issue&quot;:&quot;6&quot;,&quot;volume&quot;:&quot;64&quot;,&quot;pages&quot;:&quot;3299-3319&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c02191&quot;},&quot;abstract&quot;:&quot;Class B G-protein-coupled receptors (GPCRs) remain an underexploited target for drug development. The calcitonin receptor (CTR) family is particularly challenging, as its receptors are heteromers comprising two distinct components: the calcitonin receptor-like receptor (CLR) or calcitonin receptor (CTR) together with one of three accessory proteins known as receptor activity-modifying proteins (RAMPs). CLR/RAMP1 forms a CGRP receptor, CLR/RAMP2 forms an adrenomedullin-1 (AM1) receptor, and CLR/RAMP3 forms an adrenomedullin-2 (AM2) receptor. The CTR/RAMP complexes form three distinct amylin receptors. While the selective blockade of AM2 receptors would be therapeutically valuable, inhibition of AM1 receptors would cause clinically unacceptable increased blood pressure. We report here a systematic study of structure–activity relationships that has led to the development of first-in-class AM2 receptor antagonists. These compounds exhibit therapeutically valuable properties with 1000-fold selectivity over the AM1&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c02191&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c02191" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c02191&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c02191" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c02191&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c02191" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c02191&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c02191&amp;href=/doi/10.1021/acs.jmedchem.0c02191" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c02191" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c02191" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (4 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c02191&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c02191%26sid%3Dliteratum%253Aachs%26pmid%3D33666424%26genre%3Darticle%26aulast%3DZirimwabagabo%26date%3D2021%26atitle%3DDiscovery%2Bof%2Ba%2BFirst-In-Class%2BSmall%2BMolecule%2BAntagonist%2Bagainst%2Bthe%2BAdrenomedullin-2%2BReceptor%253A%2BStructure%25E2%2580%2593Activity%2BRelationships%2Band%2BOptimization%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D64%26issue%3D6%26spage%3D3299%26epage%3D3319%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (7)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291316" title="Mixtures">Mixtures</a>,</li><li><a href="/action/doSearch?ConceptID=291651" title="Anions">Anions</a>,</li><li><a href="/action/doSearch?ConceptID=292317" title="Ethyl groups">Ethyl groups</a>,</li><li><a href="/action/doSearch?ConceptID=291768" title="Cations">Cations</a>,</li><li><a href="/action/doSearch?ConceptID=292186" title="Receptors">Receptors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/64/6" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/jmcmar.2021.64.issue-6/20210325/jmcmar.2021.64.issue-6.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02191/20210408/images/medium/jm0c02191_0017.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02191/20210408/images/large/jm0c02191_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02191&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Class B G-protein-coupled receptors (GPCRs) remain an underexploited target for drug development. The calcitonin receptor (CTR) family is particularly challenging, as its receptors are heteromers comprising two distinct components: the calcitonin receptor-like receptor (CLR) or calcitonin receptor (CTR) together with one of three accessory proteins known as receptor activity-modifying proteins (RAMPs). CLR/RAMP1 forms a CGRP receptor, CLR/RAMP2 forms an adrenomedullin-1 (AM<sub>1</sub>) receptor, and CLR/RAMP3 forms an adrenomedullin-2 (AM<sub>2</sub>) receptor. The CTR/RAMP complexes form three distinct amylin receptors. While the selective blockade of AM<sub>2</sub> receptors would be therapeutically valuable, inhibition of AM<sub>1</sub> receptors would cause clinically unacceptable increased blood pressure. We report here a systematic study of structure–activity relationships that has led to the development of first-in-class AM<sub>2</sub> receptor antagonists. These compounds exhibit therapeutically valuable properties with 1000-fold selectivity over the AM<sub>1</sub> receptor. These results highlight the therapeutic potential of AM<sub>2</sub> antagonists.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_50815" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_50815" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">G-protein-coupled receptors (GPCRs) are the largest family of cell surface receptors, with a broad range of physiological and pathophysiological roles.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> GPCRs have been promising and successful targets for many therapeutic interventions.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> Functional complexity and pharmacological diversity of GPCRs can be further influenced by interactions with receptor activity-modifying proteins (RAMPs). RAMPs are a family of single transmembrane domain proteins that complex with GPCRs to facilitate cell surface trafficking, receptor pharmacology as well as recycling and degradation.<a onclick="showRef(event, 'ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref3 ref4">(3,4)</a> Of the six classes of GPCRs, members of class B (secretin receptor family) have been most studied for their interactions with RAMPs and include calcitonin (CTR) and calcitonin receptor-like (CLR) receptors.<a onclick="showRef(event, 'ref4 ref5'); return false;" href="javascript:void(0);" class="ref ref4 ref5">(4,5)</a> Despite their physiological importance and promising therapeutic potential, the small number of full-length ligand-bound structures of class B GPCRs and the limited structural information on druggable binding sites have made the development of compounds that target this GPCR family challenging.<a onclick="showRef(event, 'ref6 ref7'); return false;" href="javascript:void(0);" class="ref ref6 ref7">(6,7)</a> However, a number of structures have been solved recently<a onclick="showRef(event, 'ref8 ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref8 ref9 ref10">(8−10)</a> due to advances in cryo-EM technology and resolution, so that further developments are now more feasible. Regardless, a number of compounds have been reported in the past decade, including synthetic modulators of glucagon, glucagon-like peptide-1, corticotropin-releasing factor 1, and calcitonin receptor-like receptors.<a onclick="showRef(event, 'ref11 ref12 ref13'); return false;" href="javascript:void(0);" class="ref ref11 ref12 ref13">(11−13)</a> The most successful target of class B GPCRs for small molecule modulators has been the CGRP receptor (comprising CLR and RAMP1) for which several antagonists and antibodies have been developed in recent years for the treatment of migraine.<a onclick="showRef(event, 'ref14 ref15 ref16 ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref14 ref15 ref16 ref17 ref18">(14−18)</a> Some of these have reached the market including the two oral small molecule antagonists, rimegepant<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> (Nurtec ODT) and ubrogepant<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> (Ubrelvy), as well as the three injectable signal blocking monoclonal antibodies, erenumab<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> (Aimovig), eptinezumab<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> (Vyepti), and galcanezumab<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> (Emgality). For small molecule antagonists, the binding site has been shown by X-ray crystallography studies to be at the interface between RAMP1 and the CLR.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a></div><div class="NLM_p">The selectivity of CGRP receptor antagonists indicates the potential of exploiting differences between CLR/RAMP receptor complexes to develop antagonists for other members of the CLR family, such as receptors of the hormone adrenomedullin (AM). While the CGRP receptor comprises CLR and RAMP1, adrenomedullin-1 (AM<sub>1</sub>) and adrenomedullin-2 (AM<sub>2</sub>) receptors form by the interaction of CLR with RAMP2 and RAMP3, respectively.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> AM is a potent vasodilator that regulates blood pressure.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> While AM signaling through the AM<sub>1</sub> receptor is required for cardiovascular homeostasis,<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> aberrant AM signaling is implicated in cancer development and progression.<a onclick="showRef(event, 'ref27 ref28'); return false;" href="javascript:void(0);" class="ref ref27 ref28">(27,28)</a> Both AM and the AM<sub>2</sub> receptors have been shown to be upregulated and mediate protumoral processes in many cancers,<a onclick="showRef(event, 'ref29 ref30 ref31'); return false;" href="javascript:void(0);" class="ref ref29 ref30 ref31">(29−31)</a> including breast and pancreatic cancers.<a onclick="showRef(event, 'ref32 ref33'); return false;" href="javascript:void(0);" class="ref ref32 ref33">(32,33)</a></div><div class="NLM_p">We have recently reported the discovery of the first-in-class small molecule antagonists against the AM<sub>2</sub> receptor.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> These molecules are important new tools that will provide significant insight into the pharmacology of the CLR/RAMP receptor family. Additionally, they show promising antitumoral effects in both <i>in vitro</i> and <i>in vivo</i> models of pancreatic cancer. With a view to therapeutic potential, the new AM<sub>2</sub> receptor antagonists show 1000-fold selectivity against the AM<sub>1</sub> receptor, enabling physiological signaling of AM to continue through AM<sub>1</sub> receptors, lowering the risk of off-target side effects mediated by the AM<sub>1</sub> receptor.</div><div class="NLM_p last">Here, we describe the development and structure–activity relationships (SARs) of this family of small molecule antagonists. The chemistry strategy is underpinned by simple and convergent synthesis routes, and the efficacy of these compounds was evaluated in <i>in vitro</i> and <i>in vivo</i> models of breast cancer. The exploration of full drug-like characteristics (ADME, PK, and <i>in vitro</i> safety markers) of lead compounds is described by Avgoustou et al.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a></div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_05214" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_05214" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Design and SAR</h3><div class="NLM_p">There are four significant differences between RAMP1 and RAMP3 in the vicinity of the small molecule ligand-binding pocket, namely, R67E, A70T, D71N, and W74E.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> Of these, we chose W74E as a residue difference to exploit because of its interaction with ligands that have been crystallized in the CGRP receptor. The incorporation of a basic center to interact with the glutamate carboxylate provided a compelling strategy for designing AM<sub>2</sub> receptor-selective ligands. The W74E change is also seen when comparing RAMP1 with RAMP2; therefore, the simplest approach to building a pseudo (hybrid)-model of the AM<sub>2</sub> receptor-binding pocket was to transpose the side-chain conformation of Glu105 from the RAMP2 crystal structure (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3AQF">3AQF</a><a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a>) into the Trp74 position of the CGRP receptor crystal structure (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3N7R">3N7R</a><a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a>). Alternative conformations of the glutamate side chain were examined but the results were not significantly affected. As all our compounds were active, at least to some extent at both CGRP and AM<sub>2</sub> receptors, it was decided to use this slightly modified structure of the CGRP receptor as a basis for docking, making the assumption that the binding modes in both CGRP and AM<sub>2</sub> receptors would be the same.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a></div><div class="NLM_p">The crystal structure of MK-3207 has been solved,<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> but the only information published is a figure that shows a stick representation of the ligand and a surface representation of the protein. The ligand was docked such that it replicated as much of the information presented in this image as possible. Conformations of ligands were initially built using Open Babel (version 2.3.1). The starting conformation of the CLR-binding spiro ring system was fixed to replicate the configuration observed in the image, and the resultant conformer was refined by density functional theory (DFT) minimization in ORCA.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> Docking was carried out using GOLD,<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> tethering the lactam or equivalent portion of the headgroup onto that observed in the PDB structure of telcagepant bound to the ectodomain of the CGRP receptor (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3N7R">3N7R</a><a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a>) and generating 30 docks per compound using default options. Results were processed using an in-house script to cluster the docks and assess the quality of hydrogen bonds, identifying docks with high GOLD scores, no antihydrogen bonds, and, where relevant, a high-quality interaction with the glutamate (distance between heavy atoms of 2.7–3.5 Å and the angle subtended at donor H of close to 180°).</div><div class="NLM_p">The dock of the published structure of compound <b>1</b>, a CGRP receptor antagonist with an encouraging activity against the AM<sub>2</sub> receptor,<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> overlaid well with telcagepant, preserving the interactions of the tethered headgroup (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). In addition, the carbonyl oxygen atom of the pivalamide substituent formed a hydrogen bond with the indole NH of CLR Trp72. The residue implicated in selectivity, W74E, appeared to be accessible from the ortho position of the phenyl ring, suggesting a position to introduce basic substituents (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>).</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02191/20210408/images/medium/jm0c02191_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02191/20210408/images/large/jm0c02191_0002.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Docking of telcagepant (magenta) and compound <b>1</b> (purple) in our pseudo (hybrid)-model of the AM<sub>2</sub> receptor-binding pocket. The Glu74 residue from RAMP3 is indicated in green. CLR is shown in yellow and RAMP3 in cyan. Hydrogen bonds are shown as dotted lines. Compound <b>1</b> has similar spatial occupancy and interactions to telcagepant (magenta) as observed in the CGRP receptor crystal structure (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3N7R">3N7R</a><a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02191/20210408/images/large/jm0c02191_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02191&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">From starting point compound <b>1</b>, the aim was to design and synthesize compounds that would bind strongly to the AM<sub>2</sub> receptor. Our strategy assumed that modulating the RAMP structural binding fragment, while conserving the CLR-binding fragment, would lead to the successful identification of RAMP3-binding groups (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>).</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02191/20210408/images/medium/jm0c02191_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02191/20210408/images/large/jm0c02191_0003.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Compound <b>1</b> structure analysis for SAR.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02191/20210408/images/large/jm0c02191_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02191&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">We first set out to investigate the antagonist behavior of several known CLR-binding fragments attached to the RAMP-binding motif present in <b>1</b>. As shown in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>, combining a set of known CLR fragments from CGRP inhibitors (specifically, telcagepant/rimegepant, MK-3207, and olcegepant) with the RAMP-binding portion of <b>1</b> led to analogues <b>2</b>–<b>4</b>, of which indene <b>3</b> showed moderately improved inhibition at the AM<sub>2</sub> receptor (pIC<sub>50</sub> = 6.7) relative to the initial indene lead <b>1</b>, with non-indenes losing measurable activity.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Investigating the Effect of Different CLR-Binding Fragments on the Antagonism against the AM<sub>2</sub> Receptor</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02191/20210408/images/medium/jm0c02191_0012.gif" alt="" id="fx1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02191/20210408/images/medium/jm0c02191_0013.gif" alt="" id="fx2" /></img><div></div></div><div class="NLM_p">Working on the basis that the CLR fragment in <b>3</b> was optimal for our purposes, we implemented the strategy of incorporating a basic moiety into the benzyl side chain of the RAMP fragment. The pIC<sub>50</sub> data of our compounds against AM<sub>2</sub>, together with data for selected compounds against AM<sub>1</sub> and CGRP, are summarized in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>. Compounds bearing a heterocyclic or heteroaromatic ring showed reduced potency (compounds <b>5</b>–<b>8</b>), while the activity was broadly maintained when a pyrrolidine-substituted benzyl group or an indazole was incorporated (compounds <b>9</b>, <b>10</b>). Pleasingly, aniline <b>11</b> provided our first significant increase in receptor affinity, with a pIC<sub>50</sub> of 8.2. Activity was maintained when the aniline was changed to a benzylic amine (compound <b>12</b>) but changing to the corresponding benzylic alcohol or moving the aminomethyl group to the meta-position led to a marked decrease in activity (compounds <b>13</b>, <b>14</b>). Returning to the positional scanning at the <i>ortho</i>-benzyl position, we were interested in finding that a primary amide, homologated primary amine, and tethered secondary amine produced pIC<sub>50</sub> values of around 7 (compounds <b>15</b>–<b>17</b>). In contrast, benzylic morpholine, imidazole, pyridine, and nitrile groups performed poorly (compounds <b>18</b>–<b>21</b>), as did the aminomethyl analogue attached to a pyridine ring (compound <b>22</b>). The incorporation of further basic residues via an imidazole (compound <b>23</b>) or by changing to a guanidine moiety (compound <b>24</b>) failed to improve potency. However, simply homologating the aminomethyl group to secondary amine <b>23</b> gave a dramatic increase in affinity, providing our first inhibitor in the subnanomolar range (compound <b>25</b>). Further efforts to increase activity by increasing alkylation at various points around the benzylic aminomethyl fragment did not result in a significant enhancement of activity (compounds <b>25</b>–<b>29</b>). Overall, this study highlighted the importance of the spatial orientation of the basic group (e.g., compound <b>12</b> versus compound <b>14</b>) and the sensitivity of the receptor to steric bulk in the RAMP3-binding region (cf. compounds <b>25</b>, <b>27</b>, <b>18</b>). Finally, in all cases where compounds were cross-screened against AM<sub>1</sub> receptor, very weak potency was observed. Although RAMP2 contains Asp and Glu at the equivalent positions, it is believed that other significant differences in the pocket are responsible for the lack of activity at the AM<sub>1</sub> receptor. For example, (i) residue 70 (Ala in RAMP1 and Thr in RAMP3) is the much larger Arg in RAMP2, which, in crystal structures (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4RWF">4RWF</a><a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a>), sits in space that would clash with these ligands, and (ii) Trp84 in RAMP3, which makes significant interactions with the core of these ligands, is a Trp in RAMP3 but the smaller Phe in RAMP2, which is unable to contact the ligands and therefore leaving an energetically unfavorable void.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. pIC<sub>50</sub> Values of RAMP with <i>N</i>-Alkyl-Substituent SAR Library against the AM<sub>2</sub> Receptor Compared to Those of AM<sub>1</sub> and CGRP Receptors<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02191/20210408/images/medium/jm0c02191_0014.gif" alt="" id="fx3" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02191/20210408/images/medium/jm0c02191_0015.gif" alt="" id="fx4" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02191/20210408/images/medium/jm0c02191_0016.gif" alt="" id="fx5" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">nd: not determined.</p></div></div><div></div></div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i7">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_81001" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_81001" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The modular nature of our inhibitors offered simple and efficient synthetic routes from commercially available and inexpensive starting materials, allowing us rapidly to identify analogues with increased potency against the AM<sub>2</sub> receptor. The general synthetic route is shown in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. The reductive amination of the appropriate aldehyde with Ala-OMe or simple alkylation of amines with ethyl bromoacetate provided intermediates that were subjected to acylation with pivaloyl chloride and saponification to produce the desired RAMP-binding acids. Amide bond formation promoted by EDCI or HATU generated the final RAMP–CLR inhibitor constructs that could be further manipulated using standard functional group transformations (detailed synthetic procedures are described in the <a href="/doi/suppl/10.1021/acs.jmedchem.0c02191/suppl_file/jm0c02191_si_006.pdf" class="ext-link">Supporting Information</a>).</div><figure id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02191/20210408/images/medium/jm0c02191_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02191/20210408/images/large/jm0c02191_0006.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Reagents and General Conditions<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02191/20210408/images/large/jm0c02191_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02191&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>(a) Ethyl bromoacetate, <i>N</i>,<i>N</i>-diisopropylethylamine (DIPEA), dimethylformamide (DMF) or benzylbromoacetate, Et<sub>3</sub>N, tetrahydrofuran (THF; when amine was used) and glycine ethyl ester hydrochloride, NaBH<sub>3</sub>CN, MeOH (when aldehyde or ketone was used); (b) (i) PivCl, DIPEA, dichloromethane (DCM); (ii) 2.5 N NaOH, MeOH or LiOH·H<sub>2</sub>O, MeOH/THF/H<sub>2</sub>O; (c) HATU, NMM, DM or EDCI, HOAt, DIPEA, DMF.</p></p></figure><div class="NLM_p">With a robust method in hand, we next wanted to assess the impact of the stereochemistry of the CLR-binding unit on activity as it is known to have an impact on the CGRP potency.<a onclick="showRef(event, 'ref43 ref44'); return false;" href="javascript:void(0);" class="ref ref43 ref44">(43,44)</a> For example, in the case of MK-3207, the analogue with a CLR-binding group in the (<i>S</i>) rather than (<i>R</i>) configuration reduces potency by 100-fold, from 0.12 to 10 nM. Indeed, as discussed in our preliminary report on this work,<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> the (<i>R</i>)-enantiomer of <b>25</b> (isolated by the preparative chiral high-performance liquid chromatography (HPLC) of the racemate) was found to have improved potency over the corresponding (<i>S</i>)-enantiomer (pIC<sub>50</sub> = 9.2 versus 7.2), so we set about devising an efficient synthesis of (<i>R</i>)-<b>25</b>.</div><div class="NLM_p">The synthesis of the (<i>R</i>)-CLR-binding motif amine <b>30</b> was accomplished by a modification of the method reported by Bulger and Yasuda.<a onclick="showRef(event, 'ref45 ref46'); return false;" href="javascript:void(0);" class="ref ref45 ref46">(45,46)</a> An enantioselective phase transfer-catalyzed alkylation of <b>31</b> with <b>32</b> was found to give a higher degree of selectivity when excess sodium hydroxide was employed in toluene/H<sub>2</sub>O. This method allowed us to generate intermediate <b>33</b> in an ∼90% yield with 83% <i>ee</i> although this sample could be delivered in >99% <i>ee</i> after a single recrystallization (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>). Finally, the removal of the Bn- and <sup><i>t</i></sup>Bu- groups gave the (<i>R</i>)-enantiomer of the desired amine <b>30</b> with >99% <i>ee</i>. Slow crystallization of <b>30</b> in methanol allowed us to confirm the product stereochemistry using single-crystal X-ray diffraction.</div><figure id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02191/20210408/images/medium/jm0c02191_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02191/20210408/images/large/jm0c02191_0007.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Reagents and Conditions<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02191/20210408/images/large/jm0c02191_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02191&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>(a) (i) NaOH, PTC*, toluene/H<sub>2</sub>O; (ii) recrystallized from toluene/MeOH; (b) (i) MsOH, toluene, 90 °C; (ii) ∼10% Pd/C, H<sub>2</sub>, HCl/MeOH, rt, o/n. PTC*: Chiral phase transfer catalyst. Please see <a class="ref internalNav" href="#sec5" aria-label="Experimental Section">Experimental Section</a> for details.</p></p></figure><div class="NLM_p">The docked pose of (<i>R</i>)-<b>25</b> was consistent with that of <b>1</b> in the placement of their common substructures. As predicted, the protonated amine formed salt bridges with the carboxylate of Glu74 and the carboxylate of Asp71 (an asparagine carboxamide in RAMP3), possibly explaining why it is tolerated in both CGRP and AM<sub>2</sub>. The apparent preference for RAMP3 over RAMP1 could be explained by the interactions with the acid of Glu74 and the carbonyl of Asn71 being more favorable than the indole of Trp74 and the acid of Asp71, either because of differences in the salt bridge geometry or because the carboxamide is a preferred partner when compared with the indole (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>).</div><figure id="fig3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02191/20210408/images/medium/jm0c02191_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02191/20210408/images/large/jm0c02191_0004.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Docking of compound (<i>R</i>)-25 in our pseudo (hybrid)-model of the AM<sub>2</sub> receptor-binding pocket. Glu74 residues from RAMP3 are indicated in green. CLR is shown in yellow and RAMP3 in cyan. Hydrogen bonds are shown as dotted lines. The protonated amine of compound (<i>R</i>)-25 forms salt bridges with the carboxylate of Glu74 and the carboxylate of Asp71 (an asparagine carboxamide in RAMP3).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02191/20210408/images/large/jm0c02191_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02191&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> Antitumor Effect of (±)-<b>25</b></h3><div class="NLM_p"><i>In vitro</i> viability and <i>in vivo</i> subcutaneous xenograft models were used to determine antitumor effects of the AM<sub>2</sub> receptor antagonist (±)-<b>25</b>, using the highly aggressive triple-negative breast cancer cell line MDA-MB-231. (±)-<b>25</b> decreased the MDA-MB-231 viability by 55% after 3 days of daily treatment at 10 μM concentration (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>a; <i>p</i> < 0.01). For the <i>in vivo</i> xenograft study, MDA-MB-231 cells were subcutaneously inoculated under the skin of the flank of female BALB/c nude mice. Once the tumors were palpable (5 days after inoculation), (±)-<b>25</b> (20 mg/kg) or vehicle control was administered ip once daily. Tumors were measured twice weekly, and the well-being of mice was assessed by measuring the body weight and monitoring behavior. (±)-<b>25</b> was well tolerated, and the body weight of (±)-<b>25</b>-treated mice did not differ significantly when compared with that of vehicle-treated mice. No adverse effects were observed, and all mice exhibited apparently normal activity, feeding, and inquisitiveness. Daily administration of (±)-<b>25</b> (20 mg/kg) significantly decreased breast cancer xenograft tumor growth by 47% (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>b; <i>p</i> < 0.001), 4 weeks after treatment.</div><figure id="fig4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02191/20210408/images/medium/jm0c02191_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02191/20210408/images/large/jm0c02191_0005.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. AM<sub>2</sub> receptor antagonist inhibits <i>in vitro</i> viability of human breast cancer cell line MDA-MB-231 as well as subcutaneous MDA-MB-231 tumor growth in BALB/c nude mice. (a) Daily treatment with small molecule AM<sub>2</sub> receptor antagonists significantly decreased the viability of MDA-MB-231 cells <i>in vitro</i> by 55% after 3 days when treated with 10 μM (±)-<b>25</b>, compared to that of vehicle-treated controls (<i>p</i> < 0.01, unpaired <i>t</i>-test). Data are from three independent experiments and presented as mean ± SD. (b) Mice (<i>n</i> = 10 per group) were inoculated subcutaneously with MDA-MB-231 cells to generate tumors, and first treatment was given on the day of the first tumor volume measurement (arrow). Tumor growth rates were significantly reduced in mice treated daily with 20 mg/kg ip (±)-<b>25</b> (<i>p</i> < 0.001, simple linear regression comparing the line of best fit). Data are presented as mean ± SD.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02191/20210408/images/large/jm0c02191_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02191&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i11">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_68876" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_68876" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">Here, we report a systematic and extensive structure–activity relationship study of our first-in-class AM<sub>2</sub> receptor small molecule antagonists.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> Through the careful optimization of CLR and RAMP domain-binding fragments, we have been able to develop a family of antagonists that show high selectivity for AM<sub>2</sub> over the closely related AM<sub>1</sub> heteromer, by exploiting differences in the RAMP structures, focusing on residues 70 and 84. A robust chemistry strategy allowed us to prepare a large library of analogues and led to numerous derivatives with nanomolar potencies. In addition, the products are readily generated as single enantiomers through the employment of an efficient asymmetric synthesis of the (<i>R</i>)-CLR-binding unit. While our original goal was to identify compounds with selectivity for AM<sub>2</sub> receptors over all of the CLR and CTR family receptors, we found it hard to separate AM<sub>2</sub> and CGRP receptors in this respect. However, since CGRP receptors mediate pain, particularly bone pain in metastatic cancers, this may be an additional benefit for therapy in oncology. Finally, although we have previously shown the full drug-like properties (ADME, hERG, and PK) and selectivity profile of compound <b>25</b> and the effects of this compound class in pancreatic cancer cell viability and apoptosis in both <i>in vitro</i> and <i>in vivo</i> tumor growth models,<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> we demonstrate here that similar potent antitumor effects are also observed in breast cancer models using the highly aggressive triple-negative breast cancer cell line MDA-MB-231.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i12">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_88232" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_88232" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">All reagents, unless otherwise stated, were obtained from commercial sources and used without further purification. Small molecule antagonists were prepared as 2 mM dimethyl sulfoxide (DMSO) stocks for cell culture experiments and stored at −20 °C. Based on each cell line’s ligand–receptor combination, the appropriate unlabeled peptide was used. Human CGRP was obtained from Sigma-Aldrich (SCP0060), and human AM was purchased from Anaspec (AS-60447).</div><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> Chemical Methods</h3><div class="NLM_p"><sup>1</sup>H NMR spectra were recorded on a Bruker AVIII HD 400 (400 MHz), Bruker AVI 400 (400 MHz), Bruker AMX-400 (400 MHz), or DPX-400 (400 MHz) supported by an Aspect 3000 data system and referenced to the residual solvent peak (CDCl<sub>3</sub>: δ 7.26 ppm). Signal positions were recorded in δ ppm with the abbreviations s, d, t, q, br, and m denoting singlet, doublet, triplet, quartet, broad, and multiplet, respectively. <sup>19</sup>F NMR spectra were recorded on a Bruker AVIII HD 400 (377 MHz) and are uncorrected. Flash chromatography was performed on silica gel (BDH Silica Gel 60 43-60 or Fluorochem Davisil silica gel 43-60) using head pressure by means of a compressed air line. Thin-layer chromatography (TLC) was performed on commercially available precoated aluminum-backed plates (Merck silica Kieselgel 60 F254). Spots were made visible either by the quenching of UV fluorescence or by staining with a potassium permanganate solution. All reactions were conducted in an oven or flame-dried glassware under an inert atmosphere of dry nitrogen or argon. Low-resolution mass spectra were (LC-MS) recorded on Micromass Autospec, operating in E.I., C.I., or FAB mode, or a PerkinElmer Turbomass Bench top GCMS operating in either E.I. or C.I. mode. All ultraperformance liquid chromatography-mass spectroscopy (UPLC-MS) analyses were carried out using Waters Acquity UPLC-MS (quaternary pump flow 0.8 mL/min, Acquity autosampler, PDA and QDA). All solvents, substrates, and reagents that were commercially available were used without further purification. Enantioselectivities were determined by high-performance liquid chromatography (HPLC) analysis employing a Gilson HPLC chain with an ABI Analytical Spectroflow 783 UV or an SPD-10 Shimadzu UV–vis detector. Purities of all final reported compounds were greater than 95% based on analytical HPLC chromatograms. Purification of the final compounds by preparative HPLC was accomplished on a C18 250 mm × 21 mm column in water/acetonitrile or with Biotage Isolera using a C18 Ultra cartridge in water/acetonitrile with pH = 10 buffer followed by freeze-drying of the pooled fractions containing pure products (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>).</div><figure id="sch3" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02191/20210408/images/medium/jm0c02191_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02191/20210408/images/large/jm0c02191_0008.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of <b>2</b> and <b>4</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02191/20210408/images/large/jm0c02191_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02191&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div id="sec5_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i15" class="anchor-spacer"></div><h4 class="article-section__title" id="_i15"> <i>N</i>-Benzyl-<i>N</i>-(2-oxo-2-(4-(2-oxo-2,3-dihydro-1<i>H</i>-imidazo[4,5-<i>b</i>]pyridin-1-yl)piperidin-1-yl)ethyl)pivalamide (<b>2</b>)</h4><div class="NLM_p last"><b>2A</b> (12 mg, 0.047 mmol), <b>2B</b> (13 mg, 0.052 mmol), and HATU (20 mg, 0.053 mmol) were dissolved in dry DMF (2 mL). <i>N</i>-Methylmorpholine (0.1 mL, 1.75 mmol) was added, and the mixture was stirred at rt for 5 min. The mixture was diluted with ethyl acetate and then washed with brine, dried over magnesium sulfate, filtered, and the filtrate was evaporated. The crude was purified using a Biotage Isolera (12 g, C18 Ultra cartridge, 60–80% acetonitrile/water with pH 10 buffer) and freeze-dried to provide <b>2</b> as a white solid (14.3 mg, 68%). <sup>1</sup>H NMR (CD<sub>3</sub>OD, 300 MHz) δ 1.38 (s, 9H), 2.12 (br, 4H), 3.10–3.22 (m, 1H), 3.48–3.59 (m, 1H), 3.85 (br, 2H), 4.25–4.39 (m, 1H), 4.48–4.58 (m, 1H), 4.72–4.83 (m, 1H), 5.06 (br, 2H), 6.90 (d, <i>J</i> = 7.5 Hz, 1H), 7.10 (t, <i>J</i> = 7.7 Hz, 1H), 7.25–7.34 (m, 4H), 7.35–7.43 (m, 2H); LC-MS [M + H]<sup>+</sup> 450.</div></div><div id="sec5_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i16" class="anchor-spacer"></div><h4 class="article-section__title" id="_i16"> <i>N</i>-Benzyl-<i>N</i>-(2-oxo-2-(4-(2-oxo-1,2-dihydroquinazolin-3(4<i>H</i>)-yl)piperidin-1-yl)ethyl)pivalamide (<b>4</b>)</h4><div class="NLM_p"><b>2A</b> (12.5 mg, 0.05 mmol), <b>2B</b> (15 mg, 0.06 mmol), and HATU (23 mg, 0.06 mmol) were dissolved in dry DMF (2 mL). <i>N</i>-Methylmorpholine (0.1 mL, 1.75 mmol) was added, and the mixture was stirred at rt for 5 min. The mixture was diluted with ethyl acetate, washed with brine, dried over magnesium sulfate, filtered, and the filtrate was evaporated. The crude was purified using a Biotage Isolera (12 g, C18 Ultra cartridge, 60–80% acetonitrile/water with pH 10 buffer) and freeze-dried to provide <b>2</b> as a white solid (18.3 mg, 79%). <sup>1</sup>H NMR (CD<sub>3</sub>OD, 300 MHz) δ 1.38 (s, 9H), 1.66–1.76 (m, 2H), 1.77–1.89 (m, 1H), 3.06–3.17 (m, 1H), 3.86–3.98 (m, 1H), 4.22 (br, 2H), 4.38 (s, 2H), 4.43–4.53 (m, 1H), 4.59–4.72 (m, 1H), 5.06 (br, 2H), 6.79 (d, <i>J</i> = 7.9 Hz, 1H), 6.94 (t, <i>J</i> = 7.5 Hz, 1H), 7.11–7.17 (m, 1H), 7.26–7.34 (m, 4H), 7.36–7.43 (m, 2H); LC-MS [M + H]<sup>+</sup> 463. (<a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>)</div><figure id="sch4" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02191/20210408/images/medium/jm0c02191_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02191/20210408/images/large/jm0c02191_0009.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of <b>5</b>, <b>6</b>, <b>9</b>–<b>14</b>, <b>16</b>–<b>21</b>, <b>24</b>, <b>25</b>, and <b>29</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02191/20210408/images/large/jm0c02191_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02191&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>(a) Ethyl bromoacetate, SIPEA, DMF, rt or benzyl bromoacetate, Et<sub>3</sub>N, THF, rt (from amine) or glycine ethyl ester hydrochloride, NaBH<sub>3</sub>CN, MeOH, rt (fromaldehyde or ketone); (b) (i) PivCl, DIPEA, DCM, rt; (ii) 2.5 N NaOH, MeOH, rt; (c) <b>D</b>, HATU, NMM, DMF, rt or <b>D</b>, EDCl, HOAt, DIPEA, DMF, rt; (d) H<sub>2</sub>, Pd/C, NH<sub>4</sub>COOH, MeOH, reflux; (e) TFA, DCM, rt or TsOH, MeOH, rt; (f) (i) <i>p</i>TsOH, acetone, rt; (ii) MeNH<sub>2</sub>, HCl, DIPEA, Na<sub>2</sub>SO<sub>4</sub>, DCM, rt then NaBH(OAc)<sub>3</sub>, rt; (g) 20% Pd(PPh<sub>3</sub>)<sub>4</sub>, 1,3-dimethylbarbituric acid, DCM, 35 °C; (h) Zn(CN)<sub>2</sub>, Pd(PPh<sub>3</sub>)<sub>4</sub>, DMF, 130 °C, MW; (j) H<sub>2</sub>, Raney-Ni, 2M NH<sub>3</sub> in MeOH, 55 °C; (k) 4-benzyl-3,5-dimethyl-1<i>H</i>-pyrazole-1-carboximidamide hydrochloride, 5 equiv, Et<sub>3</sub>N, MeCN/THF, MW, 90 °C; (m) (i) <i>p</i>TsOH, acetone, rt; (ii) NH<sub>4</sub>OAc, MeOH, reflux; then NaBH<sub>3</sub>CN, rt; (n) H<sub>2</sub>O<sub>2</sub>, H<sub>2</sub>O, NaOH, DMSO, rt.</p></p></figure></div><div id="sec5_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i18" class="anchor-spacer"></div><h4 class="article-section__title" id="_i18"> Ethyl 2-((Pyridin-2-ylmethyl)amino)acetate (<b>5B</b>)</h4><div class="NLM_p last">(2-Methylamino)pyridine <b>5A</b> (6 g, 55.4 mmol) was dissolved in dry THF (45 mL), and ethyl bromoacetate (4.63 g, 27.7 mmol) was added dropwise at 0 °C. The mixture was stirred at rt for 2 h. The reaction mixture was poured into water and extracted three times with ethyl acetate. The organic layer was washed twice with ammonium chloride, dried over sodium sulfate, filtered, and evaporated. The residue was purified by flash chromatography (1:1 ethyl acetate/heptane to 1:10 methanol/ethyl acetate) to provide <b>5B</b> (1.43 g, quantitative yield). (2.55 g, 47%) as an orange oil. UPLC-MS (short basic) <sup><i>t</i></sup>R 1.30 (195 [M + H]<sup>+</sup>).</div></div><div id="sec5_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i19" class="anchor-spacer"></div><h4 class="article-section__title" id="_i19"> Ethyl 2-(<i>N</i>-(Pyridin-2-ylmethyl)pivalamido)acetate</h4><div class="NLM_p last"><b>5B</b> (1 g, 5.14 mmol) was dissolved in dichloromethane (30 mL) under an argon atmosphere before trimethylamine (1.55 g, 15.42 mmol) was added. Trimethylacetyl chloride (743 mg, 6.17 mmol) was added dropwise at 0 °C. The mixture was stirred at rt for 2 h after which the reaction was shown to be complete by TLC. The mixture was poured into water, and the aqueous layer was extracted three times with dichloromethane. The combined organic extracts were washed with brine, dried over magnesium sulfate, filtered, and the filtrate was evaporated to provide the crude product. The residue was purified by flash chromatography (1:1–1:0 ethyl acetate/heptane) to provide ethyl 2-(<i>N</i>-(pyridin-2-ylmethyl)pivalamido)acetate (1.45 g, quantitative yield). UPLC-MS (short basic) <sup><i>t</i></sup>R 0.69 (279 [M + H]<sup>+</sup>).</div></div><div id="sec5_1_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20"> 2-(<i>N</i>-(Pyridin-2-ylmethyl)pivalamido)acetic Acid (<b>5C</b>)</h4><div class="NLM_p last">Ethyl 2-(<i>N</i>-(pyridin-2-ylmethyl)pivalamido)acetate (1.45 g, 5.21 mmol) was dissolved in THF (7 mL) and water (7 mL) and then lithium hydroxide monohydrate (655 mg, 15.62 mmol) was added, and the mixture was stirred at rt for 16 h. The aqueous pH was again adjusted to 6 and extracted with ethyl acetate (repeated 3 × 30 mL). The organics were washed with brine, dried over magnesium sulfate, filtered, and the filtrate was evaporated to provide <b>5C</b> as a yellow oil (871 mg, 67%). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz) δ 1.15 (s, 9H), 3.32 (s, 2H), 4.75 (s, 2H), 7.49–7.61 (m, 1H), 7.81–7.92 (m, 1H), 8.51–8.60 (m, 2H). UPLC-MS (short basic) <sup><i>t</i></sup>R 0.42 (251 [M + H]<sup>+</sup>).</div></div><div id="sec5_1_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21"> <i>N</i>-(2-Oxo-2-((2′-oxo-1,1′,2′,3-tetrahydrospiro[indene-2,3′-pyrrolo[2,3-<i>b</i>]pyridin]-5-yl)amino)ethyl)-<i>N</i>-(pyridin-2-ylmethyl)pivalamide (<b>5</b>)</h4><div class="NLM_p last"><b>5C</b> (50 mg, 0.20 mmol), <b>5D</b> (50 mg, 0.20 mmol), and HATU (75 mg, 0.20 mmol) were dissolved in dry DMF (2 mL). <i>N</i>,<i>N</i>-Diisopropylethylamine (76 mg, 0.59 mmol) was added, and the mixture was stirred at rt for 2 h. The mixture was diluted with ethyl acetate (50 mL) and washed with brine (3 × 30 mL), dried over magnesium sulfate, filtered, and the filtrate was evaporated. The crude was purified on reverse phase chromatography to provide <b>5</b> as a white solid (10.7 mg, 11%). <sup>1</sup>H NMR (CD<sub>3</sub>OD, 300 MHz) δ 1.30 (s, 9H), 3.06 (dd, <i>J</i> = 15.8, 5.0 Hz, 2H), 3.50 (dd, <i>J</i> = 15.9, 7.9 Hz, 2H), 4.01 (s, 2H), 4.87 (s, 2H), 6.84–6.90 (m, 1H), 7.12 (d, <i>J</i> = 7.3 Hz, 1H), 7.23 (d, <i>J</i> = 8.0 Hz, 1H), 7.33–7.38 (m, 3H), 7.57 (s, 1H), 7.75–7.83 (m, 1H), 8.03 (dd, <i>J</i> = 5.3, 1.5 Hz, 1H), 8.44–8.49 (m, 1H). UPLC-MS (short basic) <sup><i>t</i></sup>R 1.82 (484 [M + H]<sup>+</sup>).</div></div><div id="sec5_1_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> Benzyl 2-(((1-Methylpiperidin-3-yl)methyl)amino)acetate (<b>6B</b>)</h4><div class="NLM_p last"><b>6A</b> (0.5 g, 3.90 mmol) was dissolved in THF (10 mL), and triethylamine (1.1 mL, 7.80 mmol) and benzylbromoacetate (0.61 mL, 3.90 mmol) were added. The mixture was stirred at rt for 60 h. The mixture was poured into saturated sodium bicarbonate, and the aqueous layer was extracted three times with dichloromethane. The combined organic layers were dried over magnesium sulfate, filtered, and evaporated. The residue was purified via flash silica chromatography (19:1 dichloromethane/methanol) to provide <b>6B</b> (318 mg, 30%). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz) δ 0.80–0.97 (m, 1H), 1.40–1.91 (m, 6H), 2.24 (s, 3H), 2.40–2.55 (m, 2H), 2.75 (d, <i>J</i> = 11.1 Hz, 1H), 2.87 (d, <i>J</i> = 10.7 Hz, 2H), 3.43 (s, 2H), 5.16 (s, 2H), 7.29–7.40 (m, 5H). UPLC-MS (short basic) <sup><i>t</i></sup>R 1.81 (277 [M + H]<sup>+</sup>), 79% pure.</div></div><div id="sec5_1_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> Benzyl 2-(<i>N</i>-((1-Methylpiperidin-3-yl)methyl)pivalamido)acetate</h4><div class="NLM_p last"><b>6B</b> (318 mg, 1.152 mmol) was dissolved in dichloromethane (8 mL) under an argon atmosphere and triethylamine (0.19 mL, 1.382 mmol) was added, and the mixture was stirred at 5 °C (ice/water). Trimethylacetyl chloride (0.14 mL, 1.152 mmol) was added dropwise, and the mixture was stirred at rt for overnight. The reaction mixture was diluted in dichloromethane, washed with brine, saturated sodium bicarbonate, dried over magnesium sulfate, filtered, and the filtrate was evaporated to provide the intermediate of <b>6C</b> (344 mg, 83%). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz) δ 0.91 (d, <i>J</i> = 8.0 Hz, 1H), 1.13 (s, 9H), 1.32–1.70 (m, 4H), 2.07 (s, 3H), 2.78–2.90 (m, 2H), 3.05–3.15 (m, 2H), 3.15–3.32 (m, 2H), 4.12 (s, 2H), 5.10 (s, 2H), 7.25–7.37 (m, 5H). UPLC-MS (short basic) <sup><i>t</i></sup>R 2.06 (361 [M + H]<sup>+</sup>), 88% pure.</div></div><div id="sec5_1_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> 2-(<i>N</i>-((1-Methylpiperidin-3-yl)methyl)pivalamido)acetic Acid (<b>6C</b>)</h4><div class="NLM_p last">An intermediate of <b>6C</b> (344 mg, 0.955 mmol) was dissolved in ethanol (10 mL), and palladium-on-carbon (10% wet, 34 mg) was added, the vessel was sealed, and an atmosphere of hydrogen was introduced at a 400 psi pressure. The mixture was stirred at rt overnight. The reaction was filtered through celite, washed with methanol, and the filtrate was evaporated to provide <b>6C</b> as a clear glass (240 mg, 93%). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz) δ 0.88–1.02 (m,1H), 1.17 (s, 9H), 1.35–1.65 (m, 3H), 1.79–2.10 (m, 3H), 2.18 (s, 3H), 2.60 (d, <i>J</i> = 9.0 Hz, 2H), 3.22 (d, <i>J</i> = 7.0 Hz, 2H), 3.99 (s, 2H). UPLC-MS (short basic) <sup><i>t</i></sup>R 0.42 (271 [M + H]<sup>+</sup>).</div></div><div id="sec5_1_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> <i>N</i>-((1-Methylpiperidin-3-yl)methyl)-<i>N</i>-(2-oxo-2-((2′-oxo-1,1′,2′,3-tetrahydrospiro[indene-2,3′-pyrrolo[2,3-<i>b</i>]pyridin]-5-yl)amino)ethyl)pivalamide (<b>6</b>)</h4><div class="NLM_p last"><b>6C</b> (53 mg, 0.119 mmol), EDCI·HCl (46 mg, 0.239 mmol), and HOAt (33 mg, 0.239 mmol) were dissolved in dry DMF (1 mL). <i>N</i>,<i>N</i>-Diisopropylethylamine (110 μL, 0.597 mmol) and <b>6D</b> (50 mg, 0.119 mmol) were added, and the mixture was stirred at rt overnight. The reaction mixture was poured into saturated sodium bicarbonate and extracted three times with ethyl acetate and brine, dried over magnesium sulfate, filtered, and the filtrate was evaporated. The crude was directly purified using a Biotage Isolera (18 g, C18 Ultra cartridge, 10–70% acetonitrile/water with pH 10 buffer) to provide a crude compound. This was further purified via SP4 (12 g, C18 cartridge, 5–75% acetonitrile in water with 0.1% ammonium hydroxide) to provide <b>6</b> (3.1 mg, 5%). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz) δ 0.77–0.96 (m, 1H), 1.16 (s, 9H), 1.48–1.62 (m, 4H), 1.75–1.92 (m, 2H), 2.08 (s, 3H), 2.47–2.59 (m, 2H), 2.97–3.00 (m, 2H), 3.23–3.31 (m, 2H), 4.19 (s, 2H), 6.84 (dd, <i>J</i> = 7.3, 5.3 Hz, 1H), 7.12–7.21 (m, 2H), 7.33 (d, <i>J</i> = 7.9 Hz, 1H), 7.54 (s, 1H), 8.03 (dd, <i>J</i> = 5.3, 1.6 Hz, 1H), 9.97 (s, 1H), 11.08 (s, br, 1H). UPLC-MS (short basic) <sup><i>t</i></sup>R 1.78 (504 [M + H]<sup>+</sup>).</div></div><div id="sec5_1_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> <i>tert</i>-Butyl-2-((2-((1<i>H</i>-imidazol-1-yl)methyl)benzyl)amino)acetate (<b>19B</b>)</h4><div class="NLM_p last">(2-((1<i>H</i>-Imidazol-1-yl)methyl)phenyl)methanamine dihydrochloride <b>19A</b> (200 mg, 0.76 mmol) and <i>N</i>,<i>N</i>-diisopropylethylamine (596 mg, 4.61 mmol) were dissolved in dry DMF (5 mL). A solution of <i>tert</i>-butyl bromoacetate (135 mg, 0.69 mmol) in DMF (1 mL) was added slowly. The mixture was stirred at rt for 18 h. The reaction mixture was combined with another batch of material (0.192 mmol), quenched with saturated aqueous ammonium chloride solution, and extracted three times with ethyl acetate. The organic extracts were dried over sodium sulfate, filtered, and evaporated to provide <b>19B</b> (100 mg, 22%) as a pale yellow solid that was used directly in the next step. UPLC-MS (short basic) rt 0.58 (302 [M + H]<sup>+</sup>).</div></div><div id="sec5_1_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> <i>tert</i>-Butyl-2-(<i>N</i>-(2-((1<i>H</i>-imidazol-1-yl)methyl)benzyl)pivalamido)acetate</h4><div class="NLM_p last"><b>19B</b> (50 mg, 0.166 mmol) was dissolved in dichloromethane (3 mL) under an argon atmosphere, and <i>N</i>,<i>N</i>-diisopropylethylamine (43 mg, 0.332 mmol) was added. Trimethylacetyl chloride (30 mg, 0.249 mmol) was added, and the mixture was stirred at rt overnight. Further trimethylacetyl chloride (20 mg, 0.166 mmol) was added. UPLC indicated that the reaction was incomplete. The mixture was quenched with saturated aqueous ammonium chloride solution and extracted three times with dichloromethane. The organic extracts were dried over sodium sulfate, filtered, and the filtrate was evaporated. The residue was dissolved in pyridine (1 mL), and trimethylacetyl chloride (96 mg, 0.797 mmol) was added. The mixture was stirred at rt for 2 h and evaporated. The residue was dissolved in water and extracted three times with ethyl acetate. The organic extracts were dried over sodium sulfate, filtered, and the filtrate was evaporated. The crude residue was purified via reverse phase chromatography (30 g, C18 cartridge acetonitrile/pH 10 buffer with ammonium bicarbonate) to provide the intermediate of <b>19C</b> (80 mg, 83%) as a white solid that was used directly in the next step. UPLC-MS (long basic) rt 2.02 (386 [M + H]<sup>+</sup>).</div></div><div id="sec5_1_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> 2-(<i>N</i>-(2-((1<i>H</i>-Imidazol-1-yl)methyl)benzyl)pivalamido)acetic Acid (<b>19C</b>)</h4><div class="NLM_p last">An intermediate of <b>19C</b> (80 mg, 0.207 mmol) was dissolved in methanol (3 mL) and 2 M sodium hydroxide (0.311 mL, 0.622 mmol) was added, and the mixture was stirred at rt for 2 days. The mixture was acidified to pH 5 with 2 M aqueous HCl solution and extracted twice with ethyl acetate. The organic extracts were dried over sodium sulfate, evaporated, filtered, and the filtrate was evaporated to provide <b>19C</b> (40 mg, 59%) as a white solid. <sup>1</sup>H NMR (CD<sub>3</sub>OD, 300 MHz) δ 1.29 (s, 9H), 3.98 (s, 2H), 4.72 (s, 2H), 5.25 (s, 2H), 6.92–7.03 (m, 2H), 7.17–7.27 (m, 2H), 7.22–7.43 (m, 3H), 7.75 (s, br, 1H). UPLC-MS (short basic) <sup><i>t</i></sup>R 0.46 (330 [M + H]<sup>+</sup>), 100% pure.</div></div><div id="sec5_1_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> <i>N</i>-(2-((1<i>H</i>-Imidazol-1-yl)methyl)benzyl)-<i>N</i>-(2-oxo-2-((2′-oxo-1,1′,2′,3-tetrahydrospiro[indene-2,3′-pyrrolo[2,3-<i>b</i>]pyridin]-5-yl)amino)ethyl)pivalamide (<b>19</b>)</h4><div class="NLM_p last"><b>19C</b> (40 mg, 0.121 mmol), EDCI·HCl (25 mg, 0.182 mmol), and HOAt (35 mg, 0.182 mmol) were dissolved in dry DMF (2 mL). <i>N</i>,<i>N</i>-Diisopropylethylamine (83 mg, 0.73 mmol) and <b>19D</b> (37 mg, 0.147 mmol) were added, and the mixture was stirred at rt for 18 h. The mixture was poured into saturated ammonium chloride, and the aqueous layer was extracted three times with ethyl acetate. The organic extract was washed three times with sodium bicarbonate, dried over sodium sulfate, filtered, and the filtrate was evaporated. The residue was purified via reverse phase chromatography (SP4 30 g, C18 cartridge acetonitrile/pH 10 buffer with ammonium bicarbonate) to provide <b>19</b> (16 mg, 24%) as a colorless glass. <sup>1</sup>H NMR (CD<sub>3</sub>OD, 300 MHz) δ 1.20 (s, br, 9H), 3.03 (d, <i>J</i> = 15.7 Hz, 2H), 3.48 (d, <i>J</i> = 15.9 Hz, 2H), 4.01 (s, br, 2H), 4.76 (s, 2H), 5.29 (s, 2H), 6.81–7.46 (m, 10H), 7.52 (s, 1H), 7.68 (s, 1H), 8.02 (d, <i>J</i> = 5.5 Hz, 1H). UPLC-MS (long basic) <sup><i>t</i></sup>R 1.87 (563 [M + H]<sup>+</sup>), 100% pure.</div></div><div id="sec5_1_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> Ethyl 2-((2-(Hydroxymethyl)benzyl)amino)acetate (<b>13B</b>)</h4><div class="NLM_p last"><b>13A</b> (200 mg, 1.15 mmol) was dissolved in THF (2 mL) and dry DMF (4 mL), and triethylamine (744 mg, 5.76 mmol) and ethyl bromoacetate (173 mg, 1.04 mmol) were added. The mixture was stirred at rt for 3 h. The mixture was poured into saturated sodium bicarbonate, and the aqueous layer was extracted three times with ethyl acetate. The combined organic layers were dried over magnesium sulfate, filtered, and evaporated. The residue was purified via reverse phase chromatography (SP4 30 g, C18 cartridge acetonitrile/pH 10 buffer with ammonium bicarbonate) to provide <b>13B</b> (200 mg, 52%). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz) δ 1.27 (t, <i>J</i> = 7.1 Hz, 3H), 3.40 (s, 2H), 3.80 (s, 2H), 4.19 (q, <i>J</i> = 7.2 Hz, 2H), 4.69 (s, 2H), 7.22–7.37 (m, 4H). UPLC-MS (short basic) <sup><i>t</i></sup>R 0.62 (224 [M + H]<sup>+</sup>).</div></div><div id="sec5_1_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> Ethyl 2-(<i>N</i>-(2-(Hydroxymethyl)benzyl)pivalamido)acetate</h4><div class="NLM_p last"><b>13B</b> (210 mg, 0.94 mmol) was dissolved in dichloromethane (10 mL) and dry DMF (2 mL) under an argon atmosphere, <i>N</i>,<i>N</i>-diisopropylethylamine (364 mg, 2.82 mmol) was added, and the mixture was stirred at 5 °C (ice/water). Trimethylacetyl chloride (113 mg, 0.94 mmol) was added dropwise, and the mixture was stirred at rt overnight. The reaction mixture was diluted in dichloromethane, washed with brine and saturated ammonium chloride, dried over magnesium sulfate, filtered, and the filtrate was evaporated. The residue was purified via reverse phase chromatography (SP4 30 g, C18 cartridge acetonitrile/pH 10 buffer with ammonium bicarbonate) to provide intermediate <b>13C</b> (110 mg, 38%). UPLC-MS (short basic) <sup><i>t</i></sup>R 0.71 (308 [M + H]<sup>+</sup>).</div></div><div id="sec5_1_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> 2-(<i>N</i>-(2-(Hydroxymethyl)benzyl)pivalamido)acetic Acid (<b>13C</b>)</h4><div class="NLM_p last">Intermediate <b>13C</b> (110 mg, 0.36 mmol) was dissolved in THF (3 mL). Methanol (3 mL) and lithium hydroxide monohydrate (45 mg, 1.07 mmol) were added, and the mixture was stirred at rt for 3 h. The pH was adjusted carefully to 4 by the addition of 2 M HCl and extracted with ethyl acetate. The volatiles were removed, and the residue was purified via reverse phase chromatography (SP4 30 g, C18 cartridge acetonitrile/pH 10 buffer with ammonium bicarbonate) to provide <b>13C</b> (60 mg, 60%). <sup>1</sup>H NMR (CD<sub>3</sub>OD, 300 MHz) δ 1.24 (s, 9H), 3.86 (s, br, 2H), 4.61 (s, 2H), 4.90 (s, 2H), 7.00–7.30 (m, 4H). UPLC-MS (short basic) <sup><i>t</i></sup>R 0.44 (280 [M + H]<sup>+</sup>).</div></div><div id="sec5_1_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> <i>N-</i>(2-(Hydroxymethyl)benzyl)-<i>N</i>-(2-oxo-2-((2′-oxo-1,1′,2′,3-tetrahydrospiro[indene-2,3′-pyrrolo[2,3-<i>b</i>]pyridin]-5-yl)amino)ethyl)pivalamide (<b>13</b>)</h4><div class="NLM_p last"><b>13C</b> (60 mg, 0.21 mmol), EDCI·HCl (62 mg, 0.32 mmol), and HOAt (44 mg, 0.32 mmol) were dissolved in dry DMF (4 mL). <i>N</i>,<i>N</i>-Diisopropylethylamine (83 mg, 0.64 mmol) and <b>13D</b> (54 mg, 0.21 mmol) were added, and the mixture was stirred at rt overnight. The mixture was poured into saturated ammonium chloride, and the aqueous layer was extracted twice with ethyl acetate. The organic extract was dried over sodium sulfate, filtered, and the filtrate was evaporated. The residue was purified via reverse phase chromatography (SP4 30 g, C18 cartridge acetonitrile/pH 10 buffer with ammonium bicarbonate) to provide <b>13</b> (25 mg, 23%). <sup>1</sup>H NMR (CD<sub>3</sub>OD, 400 MHz) δ 1.32 (s, 9H), 2.95 (dd, <i>J</i> = 15.6, 10.6 Hz, 2H), 3.51 (dd, <i>J</i> = 15.8, 7.5 Hz, 2H), 4.09 (s, 2H), 4.63 (s, 2H), 5.00 (s, br, 2H), 6.74–6.83 (m, 1H), 7.07 (dd, <i>J</i> = 16.4, 7.6 Hz, 1H), 7.15–7.37 (m, 6H), 7.46 (s, 1H), 8.07 (s, 1H), 8.87 (s, 1H). UPLC-MS (long basic) <sup><i>t</i></sup>R 1.83 (513 [M + H]<sup>+</sup>).</div></div><div id="sec5_1_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> Ethyl 2-((2-(Morpholinomethyl)benzyl)amino)acetate</h4><div class="NLM_p last"><b>18A</b> (100 mg, 0.48 mmol) was dissolved in dry DMF (2.5 mL) and <i>N</i>,<i>N</i>-diisopropylethylamine (0.47 mL, 2.58 mmol). Ethyl bromoacetate (72 mg, 0.43 mmol) was added dropwise at 0 °C. The mixture was stirred at rt for 5 h. The reaction mixture was poured into water and extracted three times with ethyl acetate. The organic layer was washed twice with ammonium chloride, dried over sodium sulfate, filtered, and evaporated to provide <b>18B</b> (70 mg) that was used directly in the next step. UPLC-MS (short basic) <sup><i>t</i></sup>R 0.73 (293 [M + H]<sup>+</sup>).</div></div><div id="sec5_1_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> Ethyl 2-(<i>N</i>-(2-(Morpholinomethyl)benzyl)pivalamido)acetate</h4><div class="NLM_p last"><b>18B</b> (70 mg, 0.24 mmol) was dissolved in dichloromethane (3 mL) under an argon atmosphere and then <i>N</i>,<i>N</i>-diisopropylethylamine (62 mg, 0.48 mmol) was added, and the mixture was stirred at 5 °C (ice/water). Trimethylacetyl chloride (110 μL, 0.89 mmol) was added dropwise, and then the mixture was stirred at rt over the weekend. The reaction mixture was diluted in dichloromethane, washed with brine and saturated ammonium chloride, dried over magnesium sulfate, filtered, and the filtrate was evaporated. The residue was purified via reverse phase chromatography (SP4 30 g, C18 cartridge acetonitrile/pH 10 buffer with ammonium bicarbonate) to provide the intermediate of <b>18C</b> (40 mg, 44%). UPLC-MS (short basic) <sup><i>t</i></sup>R 0.87 (377 [M + H]<sup>+</sup>).</div></div><div id="sec5_1_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> 2-(<i>N</i>-(2-(Morpholinomethyl)benzyl)pivalamido)acetic Acid</h4><div class="NLM_p last">An intermediate of <b>18C</b> (40 mg, 0.17 mmol) was dissolved in methanol (2 mL) and 2.0 M sodium hydroxide (159 μL, 0.318 mmol) was added, and the mixture was stirred at rt overnight. The volatiles were removed, and then the residue was dissolved in water. The pH was adjusted carefully to 4 by the addition of 2 M HCl, and the crude material was extracted with ethyl acetate. The aqueous pH was again adjusted to 4, and the product was extracted with ethyl acetate. The organics were washed with brine, dried over magnesium sulfate, filtered, and the filtrate was evaporated to provide <b>18C</b> (59 mg, quant.) that was used directly in the next step. UPLC-MS (short basic) <sup><i>t</i></sup>R 0.50 (349 [M + H]<sup>+</sup>).</div></div><div id="sec5_1_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> <i>N</i>-(2-(Morpholinomethyl)benzyl)-<i>N</i>-(2-oxo-2-((2′-oxo-1,1′,2′,3-tetrahydrospiro[indene-2,3′-pyrrolo[2,3-<i>b</i>]pyridin]-5-yl)amino)ethyl)pivalamide (<b>18</b>)</h4><div class="NLM_p last"><b>18C</b> (40 mg, 0.11 mmol), EDCI·HCl (33 mg, 0.17 mmol), and HOAt (22 mg, 0.17 mmol) were dissolved in dry DMF (3 mL). <i>N</i>,<i>N</i>-Diisopropylethylamine (89 mg, 0.68 mmol) and <b>18D</b> (35 mg, 0.14 mmol) were added, and the mixture was stirred at rt for 5 h. The mixture was poured into saturated ammonium chloride, and the aqueous layer was extracted twice with ethyl acetate. The organic extract was dried over sodium sulfate, filtered, and the filtrate was evaporated. The residue was purified via reverse phase chromatography (SP4 30 g, C18 cartridge acetonitrile/pH 10 buffer with ammonium bicarbonate) to provide <b>18</b> (44 mg, 66%). <sup>1</sup>H NMR (CD<sub>3</sub>OD, 300 MHz) δ 1.32 (s, 9H), 2.38 (s, br, 4H), 3.05 (dd, <i>J</i> = 15.8, 5.6 Hz, 2H), 3.48 (dd, <i>J</i> = 15.6, 10.5 Hz, 2H), 3.52–3.61 (m, 4H), 4.05 (s, 2H), 5.21 (s, 2H), 6.86 (dd, <i>J</i> = 7.4, 5.4 Hz, 1H), 7.10 (dd, <i>J</i> = 7.4, 1.6 Hz, 1H), 7.17–7.25 (m, 4H), 7.32 (s, br, 1H), 7.37 (d, <i>J</i> = 8.4 Hz, 1H), 7.55 (s, 1H), 8.03 (dd, <i>J</i> = 5.4, 1.6 Hz, 1H). UPLC-MS (long basic) <sup><i>t</i></sup>R 2.27 (582 [M + H]<sup>+</sup>).</div></div><div id="sec5_1_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> (2-(1-Benzylpyrrolidin-3-yl)phenyl)methanamine (<b>9A</b>)</h4><div class="NLM_p last">NaBH<sub>4</sub> (0.75 g, 20 mmol) was carefully added to a solution of the corresponding nitrile <b>9E</b> (1 g, 3.82 mmol) and CoCl<sub>2</sub> (25 mg, 0.19 mmol) in methanol (40 mL) at room temperature. The mixture was stirred at rt for 4 h. The reaction mixture was slowly quenched with saturated ammonium chloride (4 mL), diluted with ethyl acetate, and filtered through celite. The aqueous layer was extracted three times with ethyl acetate. The organic layer was washed with ammonium chloride, dried over sodium sulfate, filtered, and evaporated. The crude was purified using a Biotage Isolera (18 g, C18 Ultra cartridge, 30–60% acetonitrile/water with pH 10 buffer) to provide <b>9A</b> (356 mg, 35%). UPLC-MS (short basic) <sup><i>t</i></sup>R 0.48 (267 [M + H]<sup>+</sup>).</div></div><div id="sec5_1_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> Ethyl 2-((2-(1-Benzylpyrrolidin-3-yl)benzyl)amino)acetate (<b>9B</b>)</h4><div class="NLM_p last"><b>9A</b> (40 mg, 0.15 mmol) was dissolved in dry DMF (2 mL), and triethylamine (74 mg, 0.57 mmol) and ethyl bromoacetate (27 mg, 0.16 mmol) were added. The mixture was stirred at rt overnight. The mixture was poured into saturated sodium bicarbonate, and the aqueous layer was extracted three times with ethyl acetate. The organic layer was washed twice with ammonium chloride, dried over sodium sulfate, filtered, and evaporated to provide <b>9B</b> (63 mg). UPLC-MS (short basic) <sup><i>t</i></sup>R 0.62 (353 [M + H]<sup>+</sup>).</div></div><div id="sec5_1_25" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> Ethyl 2-(<i>N</i>-(2-(1-Benzylpyrrolidin-3-yl)benzyl)pivalamido)acetate</h4><div class="NLM_p last"><b>9B</b> (63 mg, 0.178 mmol) was dissolved in dichloromethane (3 mL) under an argon atmosphere and <i>N</i>,<i>N</i>-diisopropylethylamine (0.40 μL, 0.45 mmol) was added, and the mixture was stirred at 5 °C (ice/water). Trimethylacetyl chloride (25 μL, 0.20 mmol) was added dropwise, and the mixture was stirred at rt for 4 h. The reaction mixture was diluted in dichloromethane, washed with brine and saturated sodium bicarbonate, dried over magnesium sulfate, filtered, and the filtrate was evaporated. The residue was purified via flash silica chromatography (5:1–1:1 heptane/EtOAc) to provide methyl 2-(<i>N</i>-(2-(1-benzylpyrrolidin-3-yl)benzyl)pivalamido)acetate (52 mg, 67%). UPLC-MS (short basic) <sup><i>t</i></sup>R 1.05 (437 [M + H]<sup>+</sup>).</div></div><div id="sec5_1_26" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> 2-(<i>N</i>-(2-(1-Benzylpyrrolidin-3-yl)benzyl)pivalamido)acetic Acid (<b>9C</b>)</h4><div class="NLM_p last">Methyl 2-(<i>N</i>-(2-(1-benzylpyrrolidin-3-yl)benzyl)pivalamido)acetate (52 mg, 0.13 mmol) was dissolved in a mixture of methanol (2 mL), tetrahydrofuran (2 mL), and water (1 mL), and lithium hydroxide monohydrate (16 mg, 0.65 mmol) was added. The reaction mixture was stirred overnight before the pH was adjusted carefully to 4 by the addition of 2 M HCl and volatiles were removed. The crude product was directly purified via flash silica chromatography (5–30% methanol/dichloromethane) to provide the desired <b>9C</b> as a colorless solid (50 mg, 95%). UPLC-MS (short basic) <sup><i>t</i></sup>R 0.51 (409 [M + H]<sup>+</sup>).</div></div><div id="sec5_1_27" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> <i>N</i>-(2-(1-Benzylpyrrolidin-3-yl)benzyl)-<i>N</i>-(2-oxo-2-((2′-oxo-1,1′,2′,3-tetrahydrospiro[indene-2,3′-pyrrolo[2,3-<i>b</i>]pyridin]-5-yl)amino)ethyl)pivalamide (<b>9F</b>)</h4><div class="NLM_p last"><b>9C</b> (50 mg, 0.12 mmol), <b>9D</b> (30 mg, 0.12 mmol), and HATU (54 mg, 0.14 mmol) were dissolved in dry DMF (2.5 mL). <i>N</i>-Methylmorpholine (0.25 mL) was added, and the mixture was stirred at room temperature for 10 min. The mixture was diluted with ethyl acetate and washed with brine, dried over magnesium sulfate, filtered, and the filtrate was evaporated. The residue was purified via flash silica chromatography (70–100% ethyl acetate/petrol ether) to provide <b>9F</b> (64 mg, 83%) as a colorless glass. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) δ 1.30 (s, 9H), 1.76–1.85 (m, 1H), 2.30–2.39 (m, 1H), 2.62–2.79 (m, 3H), 2.91 (t, <i>J</i> = 8.6 Hz, 1H), 3.03 (dd, <i>J</i> = 15.8, 6.2 Hz, 2H), 3.45–3.51 (m, 1H), 3.56–3.73 (m, 4H), 4.03 (s, 2H), 4.93 (s, 2H), 6.80 (dd, <i>J</i> = 7.1, 5.5 Hz, 1H), 7.02–7.07 (m, 2H), 7.15–7.37 (m, 8H), 7.48 (d, <i>J</i> = 7.6 Hz, 1H), 7.52 (s, 1H), 8.11 (d, <i>J</i> = 5.3, 1.5 Hz, 1H), 8.43 (s, 1H). UPLC-MS (short basic) <sup><i>t</i></sup>R 0.91 (642 [M + H]<sup>+</sup>), 99% pure.</div></div><div id="sec5_1_28" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> <i>N</i>-(2-Oxo-2-((2′-oxo-1,1′,2′,3-tetrahydrospiro[indene-2,3′-pyrrolo[2,3-<i>b</i>]pyridin]-5-yl)amino)ethyl)-<i>N</i>-(2-(pyrrolidin-3-yl)benzyl)pivalamide (<b>9</b>)</h4><div class="NLM_p last"><b>9F</b> (59 mg, 0.09 mmol) and Pd/C (10 mg) were dissolved in methanol (5 mL) followed by the addition of NH<sub>4</sub>COOH (57 mg, 0.9 mmol), and the mixture was refluxed for 4 h. The reaction mixture was diluted with ethyl acetate and filtered. The solvent was evaporated under reduced pressure, and the residue was purified (500 mg SCX-2 MeOH to ammonia in MeOH) to provide <b>9</b> (28 mg, 55%) as a colorless solid. <sup>1</sup>H NMR (CD<sub>3</sub>OD, 300 MHz) δ 1.33 (s, 9H), 2.02–2.15 (m, 1H), 2.32–2.43 (m, 1H), 3.00–3.12 (m, 3H), 3.14–3.25 (m, 1H), 3.30–3.38 (m, 1H), 3.40–3.59 (m, 3H), 3.61–3.76 (m, 2H), 4.17 (s, 2H), 4.90 (br s, 2H), 6.87 (d, <i>J</i> = 7.3, 5.4 Hz, 1H), 7.12 (dd, <i>J</i> = 7.4, 1.3 Hz, 1H), 7.17–7.24 (m, 2H), 7.28–7.38 (m, 3H), 7.40–7.45 (m, 1H), 7.51–7.55 (m, 1H), 8.02 (dd, <i>J</i> = 5.3, 1.4 Hz, 1H). UPLC-MS (short basic) <sup><i>t</i></sup>R 0.66 (552 [M + H]<sup>+</sup>), 97% pure.</div></div><div id="sec5_1_29" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> Ethyl 2-((3-(((<i>tert</i>-Butoxycarbonyl)amino)methyl)benzyl)amino)acetate (<b>14B</b>)</h4><div class="NLM_p last"><b>14A</b> (150 mg, 0.635 mmol) was dissolved in THF (4 mL), and triethylamine (0.13 mL, 0.825 mmol) and ethyl bromoacetate (63 μL, 0.571 mmol) were added. The mixture was stirred at rt for 2 h. The mixture was poured into saturated sodium bicarbonate, and the aqueous layer was extracted three times with ethyl acetate. The combined organic layers were dried over magnesium sulfate, filtered, and evaporated. The residue was purified via reverse phase chromatography (SP4 30 g, C18 cartridge acetonitrile/pH 10 buffer with ammonium bicarbonate) to provide <b>14B</b> (90 mg, 44%). <sup>1</sup>H NMR (CD<sub>3</sub>OD, 300 MHz) δ 1.24 (t, <i>J</i> = 7.1 Hz, 3H), 1.44 (s, 9H), 3.33 (s, 2H), 3.74 (s, 2H), 4.16 (q, <i>J</i> = 6.9 Hz, 2H), 4.21 (s, 2H), 7.15–7.31 (m, 4H). UPLC-MS (short basic) <sup><i>t</i></sup>R 0.73 (323 [M + H]<sup>+</sup>).</div></div><div id="sec5_1_30" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> Ethyl 2-(<i>N</i>-(3-(((<i>tert</i>-Butoxycarbonyl)amino)methyl)benzyl)pivalamido)acetate</h4><div class="NLM_p last"><b>14B</b> (90 mg, 0.279 mmol) was dissolved in dichloromethane (2 mL) under an argon atmosphere and <i>N</i>,<i>N</i>-diisopropylethylamine (0.72 μL, 0.42 mmol) was added, and the mixture was stirred at 5 °C (ice/water). Trimethylacetyl chloride (34 μL, 0.28 mmol) was added dropwise, and the mixture was stirred at rt over the weekend. The reaction mixture was diluted in dichloromethane, washed with brine and saturated sodium bicarbonate, dried over magnesium sulfate, filtered, and the filtrate was evaporated. The residue was purified via flash silica chromatography (1:1 heptane/EtOAc) to provide ethyl 2-(<i>N</i>-(3-(((<i>tert</i>-butoxycarbonyl)amino)methyl)benzyl)pivalamido)acetate (95 mg, 84%). LC-MS <sup><i>t</i></sup>R 2.19 (407 [M + H]<sup>+</sup>).</div></div><div id="sec5_1_31" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> 2-(<i>N</i>-(3-(((<i>tert</i>-Butoxycarbonyl)amino)methyl)benzyl)pivalamido)acetic Acid (<b>14C</b>)</h4><div class="NLM_p last">Ethyl 2-(<i>N</i>-(3-(((<i>tert</i>-butoxycarbonyl)amino)methyl)benzyl)pivalamido)acetate (95 mg, 0.234 mmol) was dissolved in THF (1 mL) and methanol (1 mL), and lithium hydroxide monohydrate (15 mg, 0.351 mmol) was added and the mixture was stirred at rt overnight. The pH was adjusted carefully to 4 by the addition of 2 M HCl, and the product was extracted with dichloromethane. The volatiles were removed to provide <b>14C</b> (76 mg, 80%). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz) δ 1.32 (s, 9H), 1.44 (s, 9H), 3.91 (s, br, 2H), 4.20–4.33 (m, 2H), 4.80 (s, 2H), 4.97–5.06 (m, 1H), 7.06–7.10 (m, 2H), 7.15–7.23 (d, 1H), 7.27–7.35 (m, 1H). LC-MS <sup><i>t</i></sup>R 1.54 (379 [M + H]<sup>+</sup>).</div></div><div id="sec5_1_32" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> <i>tert</i>-Butyl 3-((<i>N</i>-(2-Oxo-2-((2′-oxo-1,1′,2′,3-tetrahydrospiro[indene-2,3′-pyrrolo[2,3-<i>b</i>]pyridin]-5-yl)amino)ethyl)pivalamido)methyl)benzylcarbamate (<b>14E</b>)</h4><div class="NLM_p last"><b>14C</b> (71 mg, 0.188 mmol), EDCI·HCl (43 mg, 0.226 mmol), and HOAt (30 mg, 0.226 mmol) were dissolved in dry DMF (2 mL). <i>N</i>,<i>N</i>-Diisopropylethylamine (0.11 mL, 0.678 mmol) and <b>14D</b> (47 mg, 0.188 mmol) were added, and the mixture was stirred at rt overnight. The mixture was diluted with ethyl acetate and washed with saturated sodium bicarbonate. The aqueous layer was extracted twice with ethyl acetate. The combined organics were washed three times with water and then with brine, dried over magnesium sulfate, filtered, and the filtrate was evaporated. The residue was purified via flash silica chromatography (5% methanol/dichloromethane) to provide <b>14E</b> (60 mg, 52%). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) δ 1.37 (s, 9H), 1.45 (s, 9H), 3.03 (dd, <i>J</i> = 15.7, 5.7 Hz, 2H), 3.60 (dd, <i>J</i> = 15.8, 6.0 Hz, 2H), 3.99 (s, 2H), 4.28 (d, <i>J</i> = 5.5 Hz, 2H), 4.81–4.91 (m, 2H), 6.81 (dd, <i>J</i> = 7.3, 5.3 Hz, 1H), 7.06 (dd, <i>J</i> = 7.3, 1.3 Hz, 1H), 7.10–7.23 (m, 5H), 7.32 (t, <i>J</i> = 7.8 Hz, 1H), 7.52 (s, 1H), 8.11 (d, <i>J</i> = 5.3, 1.5 Hz, 1H), 8.40–8.46 (m, 2H). UPLC-MS (long basic) <sup><i>t</i></sup>R 2.36 (612 [M + H]<sup>+</sup>), 96% pure.</div></div><div id="sec5_1_33" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> <i>N</i>-(3-(Aminomethyl)benzyl)-<i>N</i>-(2-oxo-2-((2′-oxo-1,1′,2′,3-tetrahydrospiro[indene-2,3′-pyrrolo[2,3-<i>b</i>]pyridin]-5-yl)amino)ethyl)pivalamide (<b>14</b>)</h4><div class="NLM_p last"><b>14E</b> (30 mg, 0.049 mmol) was dissolved in methanol (2 mL), and <i>p</i>-toluene sulfonic acid monohydrate (19 mg, 0.10 mmol) was added. The mixture was stirred at 50 °C for 3.5 h and poured into saturated sodium bicarbonate. The aqueous layer was extracted with ethyl acetate. The organic extract was washed with brine, dried over magnesium sulfate, filtered, and the filtrate was evaporated. The residue was purified via SPE (2 g SiO<sub>2</sub>, EtOAc and then 10% MeOH in DCM) to provide <b>14</b> (5 mg, 20%). <sup>1</sup>H NMR (CD<sub>3</sub>OD, 300 MHz) δ 1.34 (s, 9H), 3.05 (dd, <i>J</i> = 15.9, 3.7 Hz, 2H), 3.49 (dd, <i>J</i> = 15.6, 7.5 Hz, 2H), 3.88 (s, 2H), 4.06 (s, br, 2H), 4.88 (s, br, 2H), 6.87 (dd, <i>J</i> = 7.1, 1.5 Hz, 1H), 7.12 (d, <i>J</i> = 7.3 Hz, 1H), 7.21 (d, <i>J</i> = 8.0 Hz, 2H), 7.26–7.39 (m, 4H), 7.52 (s, 1H), 8.03 (d, <i>J</i> = 5.5 Hz, 1H). LC-MS <sup><i>t</i></sup>R 4.98 (512 [M + H]<sup>+</sup>), 95% pure.</div></div><div id="sec5_1_34" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> Methyl 2-(((1<i>H</i>-Indazol-4-yl)methyl)amino)acetate (<b>10B</b>)</h4><div class="NLM_p last"><b>10A</b> (124 mg, 0.85 mmol) was dissolved in methanol (2.5 mL), and then methyl glycinate hydrochloride (320 mg, 2.52 mmol) and sodium cyanoborohydride (80 mg, 1.27 mmol) were added and the mixture was stirred at rt over the weekend. The reaction mixture was poured into water, and the pH was adjusted to 4 with 2 M HCl and washed twice with dichloromethane. The aqueous layer was basified with sodium carbonate and extracted twice with dichloromethane. This organic extract was dried over magnesium sulfate, filtered, and evaporated. The residue was purified by Isolera (acetonitrile/NH<sub>4</sub>COOH buffer pH = 10) to provide <b>10B</b> (35 mg, 19%). UPLC-MS (short basic) <sup><i>t</i></sup>R 1.46 (220 [M + H]<sup>+</sup>).</div></div><div id="sec5_1_35" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> Methyl 2-(<i>N</i>-((1<i>H</i>-Indazol-4-yl)methyl)pivalamido)acetate</h4><div class="NLM_p last"><b>10B</b> (35 mg, 0.15 mmol) was dissolved in dichloromethane (2 mL) and tetrahydrofuran (2 mL) under an argon atmosphere, and <i>N</i>,<i>N</i>-diisopropylethylamine (0.08 mL, 0.5 mmol) was added and the mixture was stirred at 5 °C (ice/water). Trimethylacetyl chloride (20 μL, 0.16 mmol) was added dropwise, and the mixture was stirred at rt over the weekend. The reaction mixture was diluted in dichloromethane, washed with brine and saturated ammonium chloride, dried over magnesium sulfate, filtered, and the filtrate was evaporated to provide crude methyl 2-(<i>N</i>-((1<i>H</i>-indazol-4-yl)methyl)pivalamido)acetate (60 mg, 124%) that was used directly in the next step. UPLC-MS (short basic) <sup><i>t</i></sup>R 0.66 (302 [M + H]<sup>+</sup>).</div></div><div id="sec5_1_36" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> 2-(<i>N</i>-((1<i>H</i>-Indazol-4-yl)methyl)pivalamido)acetic Acid</h4><div class="NLM_p last">Methyl 2-(<i>N</i>-((1<i>H</i>-indazol-4-yl)methyl)pivalamido)acetate (60 mg, 0.20 mmol) was dissolved in methanol (2.2 mL), and 2.5 M sodium hydroxide (0.12 mL, 0.30 mmol) was added and the mixture was stirred at rt over the weekend. The volatiles were removed, and the residue was dissolved in water. The pH was adjusted carefully to 4 by the addition of 2 M HCl and extracted with ethyl acetate. The aqueous pH was again adjusted to 4 and extracted with ethyl acetate. The organics were washed with brine, dried over magnesium sulfate, filtered, and the filtrate was evaporated to provide <b>10C</b> (49 mg, 86%) that was used directly in the next step. UPLC-MS (short basic) <sup><i>t</i></sup>R 0.73 (323 [M + H]<sup>+</sup>). UPLC-MS (short basic) <sup><i>t</i></sup>R 0.49 (290 [M + H]<sup>+</sup>).</div></div><div id="sec5_1_37" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> <i>N</i>-((1<i>H</i>-Indazol-4-yl)methyl)-<i>N</i>-(2-oxo-2-((2′-oxo-1,1′,2′,3-tetrahydrospiro[indene-2,3′-pyrrolo[2,3-<i>b</i>]pyridin]-5-yl)amino)ethyl)pivalamide (<b>10</b>)</h4><div class="NLM_p last"><b>10C</b> (35 mg, 0.12 mmol), EDCI·HCl (32 mg, 0.16 mmol), and HOAt (27 mg, 0.20 mmol) were dissolved in dry DMF (1.1 mL). <i>N</i>,<i>N</i>-Diisopropylethylamine (62 μL, 0.63 mmol) and <b>10D</b> (29 mg, 0.12 mmol) were added, and the mixture was stirred at rt overnight. The mixture was poured into saturated ammonium chloride, and the aqueous layer was extracted twice with ethyl acetate. The organic extract was dried over sodium sulfate, filtered, and the filtrate was evaporated. The crude was directly purified using a Biotage Isolera (12 g, C18 Ultra cartridge, 20–40% acetonitrile/water with pH 10 buffer) to provide crude <b>10</b> (31 mg, 49%) as a colorless solid. <sup>1</sup>H NMR (CD<sub>3</sub>OD, 300 MHz) δ 1.24 (s, 9H), 3.03 (dd, <i>J</i> = 16.0, 10.7 Hz, 2H), 3.30 (dd, <i>J</i> = 16.0, 9.2 Hz, 2H), 4.04 (s, 2H), 5.02 (s, 2H), 6.82 (dd, <i>J</i> = 7.3, 5.3 Hz, 1H), 6.90 (d, <i>J</i> = 6.9 Hz, 1H), 7.10–7.55 (m, 7H), 8.00–8.05 (m, 2H), 9.75 (s, 1H), 10.94 (s, 1H). UPLC-MS (long basic) <sup><i>t</i></sup>R 1.81 (523 [M + H]<sup>+</sup>), 100% pure.</div></div><div id="sec5_1_38" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> Methyl 2-((2-(Pyridin-3-yl)benzyl)amino)acetate (<b>20B</b>)</h4><div class="NLM_p last"><b>20A</b> (629 mg, 3.34 mmol) was dissolved in methanol (9.8 mL), and then methyl glycinate hydrochloride (1.3 g, 10.3 mmol) and sodium cyanoborohydride (324 mg, 5.1 mmol) were added and the mixture was stirred at rt overnight. The reaction mixture was poured into water and the pH was adjusted to 4 with 2 M HCl and then washed twice with dichloromethane. The aqueous layer was basified with sodium carbonate and extracted twice with dichloromethane. This organic extract was dried over magnesium sulfate, filtered, and evaporated to provide <b>20B</b> (410 mg, 48%) as a colorless oil. UPLC-MS (short basic) <sup><i>t</i></sup>R 0.62 (257 [M + H]<sup>+</sup>), 96% pure.</div></div><div id="sec5_1_39" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> Methyl 2-(<i>N</i>-(2-(Pyridin-3-yl)benzyl)pivalamido)acetate</h4><div class="NLM_p last"><b>20B</b> (97 mg, 0.38 mmol) was dissolved in dichloromethane (4 mL) under an argon atmosphere, and <i>N</i>,<i>N</i>-diisopropylethylamine (0.2 mL, 1.1 mmol) was added and the mixture was stirred at 5 °C (ice/water). Trimethylacetyl chloride (56 μL, 0.45 mmol) was added dropwise, and the mixture was stirred at rt overnight. The reaction mixture was diluted in dichloromethane, washed with brine and saturated sodium bicarbonate, dried over magnesium sulfate, filtered, and the filtrate was evaporated. The residue was purified via flash silica chromatography (0:1–1:10 MeOH/EtOAc) to provide methyl 2-((2-(pyridin-3-yl)benzyl)amino)acetate (22 mg, 17%). UPLC-MS (short basic) <sup><i>t</i></sup>R 0.74 (341 [M + H]<sup>+</sup>).</div></div><div id="sec5_1_40" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> 2-(<i>N</i>-(2-(Pyridin-3-yl)benzyl)pivalamido)acetic Acid (<b>20C</b>)</h4><div class="NLM_p last">Methyl 2-((2-(pyridin-3-yl)benzyl)amino)acetate (22 mg, 0.06 mmol) was dissolved in methanol (1 mL), and 2.5 M sodium hydroxide (0.2 mL, 0.50 mmol) was added and the mixture was stirred at rt overnight. The volatiles were removed, and then the residue was dissolved in water. The pH was adjusted carefully to 4 by the addition of 2 M HCl and extracted with ethyl acetate. The aqueous pH was again adjusted to 4. The aqueous layer was extracted with dichloromethane (repeated three times). The organics were washed with brine, dried over magnesium sulfate, filtered, and the filtrate was evaporated to provide <b>20C</b> as a yellow oil that was used directly in the next step (8 mg, 38%). UPLC-MS (short basic) <sup><i>t</i></sup>R 0.49 (327 [M + H]<sup>+</sup>).</div></div><div id="sec5_1_41" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> <i>N</i>-(2-Oxo-2-((2′-oxo-1,1′,2′,3-tetrahydrospiro[indene-2,3′-pyrrolo[2,3-<i>b</i>]pyridin]-5-yl)amino)ethyl)-<i>N</i>-(2-(pyridin-3-yl)benzyl)pivalamide (<b>20</b>)</h4><div class="NLM_p last"><b>20C</b> (8 mg, 0.02 mmol), EDCI·HCl (7 mg, 0.03 mmol), and HOAt (5 mg, 0.08 mmol) were dissolved in dry DMF (0.5 mL). <i>N</i>,<i>N</i>-Diisopropylethylamine (13 μL, 0.07 mmol) and <b>20D</b> (7 mg, 0.03 mmol) were added, and the mixture was stirred at rt overnight. The crude was directly purified via MDAP (XBridge C18 19 × 150, 30–60% acetonitrile water with 0.1% ammonium hydroxide) to provide <b>20</b> (8 mg, 38%) as a pale yellow solid. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz) δ 1.30 (s, 9H), 3.01 (dd, <i>J</i> = 15.8, 2.0 Hz, 2H), 3.59 (dd, <i>J</i> = 15.8, 2.8 Hz, 2H), 4.00 (s, 2H), 4.78 (s, 2H), 6.80 (dd, <i>J</i> = 7.3, 5.3 Hz, 1H), 7.05 (dd, <i>J</i> = 7.4, 1.5 Hz, 1H), 7.14–7.17 (m, 2H), 7.24–7.31 (m, 2H), 7.36–7.47 (m, 4H), 7.68 (dt, <i>J</i> = 7.9, 1.9 Hz, 1H), 8.11 (dd, <i>J</i> = 5.3, 1.5 Hz, 1H), 8.42 (br, 1H), 8.57 (d, <i>J</i> = 1.6 Hz, 1H), 8.63 (dd, <i>J</i> = 4.9, 1.6 Hz, 1H), 8.84 (br, 1H). UPLC-MS (short basic) <sup><i>t</i></sup>R 2.04 (560 [M + H]<sup>+</sup>).</div></div><div id="sec5_1_42" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57"> <i>N</i>-(2-Bromobenzyl)-<i>N</i>-(2-oxo-2-((2′-oxo-1,1′,2′,3-tetrahydrospiro[indene-2,3′-pyrrolo[2,3-<i>b</i>]pyridin]-5-yl)amino)ethyl)pivalamide (<b>21E</b>)</h4><div class="NLM_p last"><b>21C</b> (3.11 g, 9.48 mmol), EDCI.HCl (2.5 g, 13.27 mmol), and HOAt (1.8 g, 13.27 mmol) were dissolved in dry DMF (60 mL). <i>N</i>,<i>N</i>-Diisopropylethylamine (5.0 mL, 28.44 mmol) and <b>21D</b> (2.38 g, 9.48 mmol) were added, and the mixture was stirred at rt for 18 h. The mixture was diluted with ethyl acetate (250 mL) and washed with saturated sodium bicarbonate and three times with brine. The organic layer was dried over magnesium sulfate, filtered, and the filtrate was evaporated. The residue was purified via flash silica chromatography (0–100% EtOAc in DCM) to provide <b>21E</b> (4.38 g, 83%) as a pale yellow solid. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz) δ 1.31 (s, 9H), 3.04 (dd, <i>J</i> = 15.7, 6.4 Hz, 2H), 3.61 (dd, <i>J</i> = 15.8, 6.0 Hz, 2H), 4.07 (s, 2H), 4.91 (s, 2H), 6.81 (dd, <i>J</i> = 7.2, 5.4 Hz, 1H), 7.07 (d, <i>J</i> = 7.1 Hz, 1H), 7.12–7.24 (m, 3H), 7.34 (t, <i>J</i> = 7.5 Hz, 1H), 7.55–7.62 (m, 2H), 8.12 (dd, <i>J</i> = 5.2 Hz, 1H), 8.49 (s, 1H), 9.29 (s, 1H). UPLC-MS (short basic) <sup><i>t</i></sup>R 0.84 (561, 563 [M + H]<sup>+</sup>).</div></div><div id="sec5_1_43" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58"> <i>N</i>-(2-Cyanobenzyl)-<i>N</i>-(2-oxo-2-((2′-oxo-1,1′,2′,3-tetrahydrospiro[indene-2,3′-pyrrolo[2,3-<i>b</i>]pyridin]-5-yl)amino)ethyl)pivalamide (<b>21</b>)</h4><div class="NLM_p last"><b>21E</b> (4.40 g, 7.84 mmol) was dissolved in dry DMF (88 mL) and was degassed by bubbling argon through the solution. Zinc(II) cyanide (1.66 g, 14.12 mmol) and tetrakis(triphenylphosphine)palladium(0) (1.8 g, 1.57 mmol) were added, and the mixture was stirred at 130 °C for 2 h. UPLC-MS indicated complete conversion. The heat was removed, and the mixture was stirred at rt for 18 h. The mixture was then diluted with ethyl acetate (400 mL) and washed twice with saturated sodium bicarbonate and three times with brine. The organic layer was dried over magnesium sulfate, filtered, and the filtrate was evaporated. The residue was triturated with diethyl ether to provide <b>21</b> (3.85 g, 96%) as an off-white solid. <sup>1</sup>H NMR (CD<sub>3</sub>OD, 300 MHz) δ 1.24 (s, 9H), 3.03 (dd, <i>J</i> = 16.0, 10.7 Hz, 2H), 3.30 (dd, <i>J</i> = 16.0, 9.2 Hz, 2H), 4.04 (s, 2H), 5.02 (s, 2H), 6.82 (dd, <i>J</i> = 7.3, 5.3 Hz, 1H), 6.90 (d, <i>J</i> = 6.9 Hz, 1H), 7.10–7.55 (m, 7H), 8.00–8.05 (m, 2H), 9.75 (s, 1H), 10.94 (s, 1H).</div></div><div id="sec5_1_44" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> <i>N</i>-(2-(Aminomethyl)benzyl)-<i>N</i>-(2-oxo-2-((2′-oxo-1,1′,2′,3-tetrahydrospiro[indene-2,3′-pyrrolo[2,3-<i>b</i>]pyridin]-5-yl)amino)ethyl)pivalamide (<b>12</b>)</h4><div class="NLM_p last"><b>21</b> (2.3 g, 4.53 mmol) was dissolved in 15% ammonia in methanol (180 mL) under an argon atmosphere in an autoclave. Raney nickel (250 mg, 0.45 mmol) was added, and hydrogen was introduced to 500 psi. The vessel was stirred at 60 °C for 6 h and then at rt for 18 h. UPLC-MS showed 20% conversion, so extra Raney nickel (400 mg, 0.72 mmol) was added and hydrogen was reintroduced to 500 psi. The vessel was stirred at 60 °C for 6.5 h. UPLC-MS analysis showed 58% conversion. The mixture was decanted (from the nickel solids) and filtered through celite, washing with 15% ammonia in methanol, and the filtrate was evaporated. The residue was dissolved in 15% ammonia in methanol (180 mL) under an argon atmosphere in an autoclave. Raney nickel (400 mg, 0.72 mmol) was added, and hydrogen was reintroduced to 500 psi. The vessel was stirred at 50 °C for 6 h, then rt for 18 h, 55 °C for 6 h, rt for 42 h, and 55 °C for 8 h. The mixture was decanted (from the nickel solids) and filtered through celite, washing with 15% ammonia in methanol, and the filtrate was evaporated. The residue was purified via flash silica chromatography (EtOAc and then 5% MeOH in DCM, then 10–15% MeOH with ammonia in DCM) to provide <b>12</b> (240 mg, 10%) as a white powder after freeze-drying from an aqueous solution. <sup>1</sup>H NMR (CD<sub>3</sub>OD, 300 MHz) δ 1.32 (s, 9H), 3.04 (dd, <i>J</i> = 15.9, 5.4 Hz, 2H), 3.49 (dd, <i>J</i> = 15.8, 9.8 Hz, 2H), 3.81 (s, 2H), 4.06 (br s, 2H), 4.93 (br s, 2H), 6.86 (dd, <i>J</i> = 7.3, 5.4 Hz, 1H), 7.09–7.41 (m, 7H), 7.53 (s, br, 1H), 8.03 (dd, <i>J</i> = 5.3, 1.5 Hz, 1H). UPLC-MS (long basic) <sup><i>t</i></sup>R 1.79 (512 [M + H]<sup>+</sup>), 84% pure—contains 6% mono-<i>N-</i>methyl and 3% di-<i>N</i>-methylamine byproducts.</div></div><div id="sec5_1_45" class="NLM_sec NLM_sec_level_3"><div id="ac_i60" class="anchor-spacer"></div><h4 class="article-section__title" id="_i60"> 2-((<i>N</i>-(2-Oxo-2-((2′-oxo-1,1′,2′,3-tetrahydrospiro[indene-2,3′-pyrrolo[2,3-<i>b</i>]pyridin]-5-yl)amino)ethyl)pivalamido)methyl)benzamide (<b>15</b>)</h4><div class="NLM_p last"><b>21</b> (17 mg, 0.033 mmol) was dissolved in DMSO (1 mL). Water (0.17 mL) was added, followed by hydrogen peroxide solution (3 drops) and NaOH (2.8 mg, 0.07 mmol), and the mixture was stirred at rt for 2 h. The reaction mixture was quenched with ethyl acetate and water. The aqueous layer was extracted with ethyl acetate (repeated twice). The organics were washed with brine, dried over magnesium sulfate, filtered, and the filtrate was evaporated. The residue was purified twice via column chromatography (1:0 ethyl acetate/methanol to 15:1 ethyl acetate/methanol) to provide <b>15</b> (10.6 mg, 60%) as a pale yellow solid. <sup>1</sup>H NMR (CD<sub>3</sub>OD, 300 MHz) δ 1.31 (s, 9H), 3.04 (dd, <i>J</i> = 15.8, 5.2 Hz, 2H), 3.48 (dd, <i>J</i> = 15.9, 7.5 Hz, 2H), 4.11 (s, 2H), 5.06 (s, 2H), 6.86 (dd, <i>J</i> = 7.3, 5.3 Hz, 1H), 7.11 (dd, <i>J</i> = 7.3, 1.6 Hz, 1H), 7.20 (d, <i>J</i> = 8.2 Hz, 2H), 7.30–7.39 (m, 3H), 7.44–7.55 (m, 3H), 8.03 (dd, <i>J</i> = 5.4, 1.6 Hz, 1H). UPLC-MS (short basic) <sup><i>t</i></sup>R 1.65 (526 [M + H]<sup>+</sup>).</div></div><div id="sec5_1_46" class="NLM_sec NLM_sec_level_3"><div id="ac_i61" class="anchor-spacer"></div><h4 class="article-section__title" id="_i61"> Methyl 2-((2-(2-(Diallylamino)ethyl)benzyl)amino)acetate (<b>16B</b>)</h4><div class="NLM_p last"><b>16A</b> (116 mg, 0.516 mmol) was dissolved in methanol (2 mL), and then methyl glycinate hydrochloride (191 mg, 1.52 mmol) and sodium cyanoborohydride (55 mg, 0.88 mmol) were added and the mixture was stirred at rt for 18 h. The reaction mixture was poured into water, and the pH was adjusted to 4 with 2 M HCl before the mixture was washed twice with dichloromethane. The aqueous layer was basified with sodium carbonate and extracted twice with dichloromethane. This organic extract was dried over magnesium sulfate, filtered, and evaporated to provide <b>16B</b> (53 mg, 35%) as a colorless oil. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz) δ 2.63–2.88 (m, 4H), 3.19 (d, <i>J</i> = 6.5 Hz, 4H), 3.44 (s, 2H), 3.73 (s, 3H), 3.79 (s, 2H), 5.11–5.24 (m, 4H), 5.80–5.95 (m, 2H), 7.12–7.32 (m, 4H). UPLC-MS (short basic) <sup><i>t</i></sup>R 0.84 (303 [M + H]<sup>+</sup>), 80% pure.</div></div><div id="sec5_1_47" class="NLM_sec NLM_sec_level_3"><div id="ac_i62" class="anchor-spacer"></div><h4 class="article-section__title" id="_i62"> Methyl 2-(<i>N</i>-(2-(2-(Diallylamino)ethyl)benzyl)pivalamido)acetate</h4><div class="NLM_p last"><b>16B</b> (54 mg, 0.18 mmol) was dissolved in dichloromethane (1 mL) under an argon atmosphere, and <i>N</i>,<i>N</i>-diisopropylethylamine (93 μL, 0.53 mmol) was added. Trimethylacetyl chloride (26 μL, 0.21 mmol) was added dropwise, and the mixture was stirred at rt for 4 days. The mixture was poured into saturated sodium bicarbonate and extracted three times with dichloromethane. The organic extracts were evaporated to provide methyl 2-(<i>N</i>-(2-(2-(diallylamino)ethyl)benzyl)pivalamido)acetate (68 mg, 99%) as a colorless oil. UPLC-MS (short basic) <sup><i>t</i></sup>R 0.96 (387 [M + H]<sup>+</sup>), 89% pure.</div></div><div id="sec5_1_48" class="NLM_sec NLM_sec_level_3"><div id="ac_i63" class="anchor-spacer"></div><h4 class="article-section__title" id="_i63"> 2-(<i>N</i>-(2-(2-(Diallylamino)ethyl)benzyl)pivalamido)acetic Acid (<b>16C</b>)</h4><div class="NLM_p last">Methyl 2-(<i>N</i>-(2-(2-(diallylamino)ethyl)benzyl)pivalamido)acetate (68 mg, 0.176 mmol) was dissolved in methanol (1 mL), and then 2.5 M sodium hydroxide (0.22 mL, 0.55 mmol) was added and the mixture was stirred at rt for 18 h. The volatiles were removed, the material was diluted with water, and the pH was adjusted to 5 with 2 M HCl. This was then concentrated to dryness to provide <b>16C</b> (assume 0.176 mmol) as a glass that was used directly in the next step.</div></div><div id="sec5_1_49" class="NLM_sec NLM_sec_level_3"><div id="ac_i64" class="anchor-spacer"></div><h4 class="article-section__title" id="_i64"> <i>N</i>-(2-(2-(Diallylamino)ethyl)benzyl)-<i>N</i>-(2-oxo-2-((2′-oxo-1,1′,2′,3-tetrahydrospiro[indene-2,3′-pyrrolo[2,3-<i>b</i>]pyridin]-5-yl)amino)ethyl)pivalamide (<b>16E</b>)</h4><div class="NLM_p last"><b>16C</b> (∼0.176 mmol), EDCI.HCl (53 mg, 0.28 mmol), and HOAt (38 mg, 0.28 mmol) were dissolved in dry DMF (1 mL). <i>N</i>,<i>N</i>-Diisopropylethylamine (0.11 mL, 0.64 mmol) and <b>16D</b> (44.5 mg, 0.177 mmol) were added, and the mixture was stirred at rt for 18 h. The mixture was poured into saturated sodium bicarbonate and extracted three times with ethyl acetate. The combined organic layers were washed with brine, dried over magnesium sulfate, filtered, and the filtrate was evaporated. The residue was purified via flash silica chromatography (EtOAc) to provide <b>16E</b> (77 mg, 72%) as a pale yellow glass. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) δ 1.32 (s, 9H), 2.61–2.79 (m, 4H), 3.03 (dd, <i>J</i> = 15.8, 8.8 Hz, 2H), 3.17 (d, <i>J</i> = 6.1 Hz, 4H), 3.61 (dd, <i>J</i> = 15.5, 8.3 Hz, 2H), 4.02 (br s, 2H), 4.90 (s, 2H), 5.07–5.23 (m, 4H), 5.78–5.90 (m, 2H), 6.80 (dd, <i>J</i> = 7.3, 5.4 Hz, 1H), 7.03–7.27 (m, 7H), 7.56 (s, 1H), 8.15 (br s, 1H), 8.45 (s, 1H). UPLC-MS (long basic) <sup><i>t</i></sup>R 2.65 (606 [M + H]<sup>+</sup>), 98% pure.</div></div><div id="sec5_1_50" class="NLM_sec NLM_sec_level_3"><div id="ac_i65" class="anchor-spacer"></div><h4 class="article-section__title" id="_i65"> <i>N</i>-(2-(2-Aminoethyl)benzyl)-<i>N</i>-(2-oxo-2-((2′-oxo-1,1′,2′,3-tetrahydrospiro[indene-2,3′-pyrrolo[2,3-<i>b</i>]pyridin]-5-yl)amino)ethyl)pivalamide (<b>16</b>)</h4><div class="NLM_p last"><b>16E</b> (77 mg, 0.127 mmol) and <i>N</i>,<i>N</i>′-dimethylbarbituric acid (125 mg, 0.801 mmol) were dissolved in dry degassed dichloromethane (2 mL) and degassed again. Tetrakis(triphenylphosphine)palladium(0) (11.4 mg, 0.010 mmol) was added, and the mixture was stirred at 35 °C for 2 h and at rt for 18 h. UPLC-MS analysis showed incomplete reaction. Tetrakis(triphenylphosphine)palladium(0) (13 mg, 0.011 mmol) was added, and the mixture was stirred at 35 °C for 3.5 h. UPLC-MS still showed incomplete conversion. The mixture was diluted with dichloromethane and saturated sodium bicarbonate, and layers were separated. The aqueous layer was extracted with dichloromethane. The combined organic layers were dried over magnesium sulfate, filtered, and the filtrate was evaporated. The aqueous layer was back-extracted twice with ethyl acetate, the combined organic layers were dried over magnesium sulfate, filtered, and the filtrate was evaporated. The extracted residues were combined and shown to contain monoallyl byproduct. The product was still in the aqueous layer, which was evaporated and purified using a Biotage Isolera (18 g, C18 Ultra cartridge, 60–80% acetonitrile/water with pH 10 buffer) to provide crude <b>16</b>. This was further purified via MDAP (XBridge C18 19 × 150, 35–50% acetonitrile water with 0.1% ammonium hydroxide) to provide <b>16</b> (19.4 mg, 29%) as a pale yellow glass. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz) δ 1.33 (s, 9H), 2.78 (t, <i>J</i> = 6.9 Hz, 2H), 2.93–3.07 (m, 4H), 3.59 (d, <i>J</i> = 15.5 Hz, 2H), 4.05 (br s, 2H), 4.97 (br s, 2H), 6.80 (dd, <i>J</i> = 7.3, 5.3 Hz, 1H), 7.03–7.26 (m, 8H), 7.53 (s, 1H), 8.11 (dd, <i>J</i> = 5.3, 1.4 Hz, 1H), 8.62 (s, 1H). UPLC-MS (long basic) <sup><i>t</i></sup>R 1.79 (526 [M + H]<sup>+</sup>), 94% pure.</div></div><div id="sec5_1_51" class="NLM_sec NLM_sec_level_3"><div id="ac_i66" class="anchor-spacer"></div><h4 class="article-section__title" id="_i66"> <i>tert</i>-Butyl 8-(((2-Methoxy-2-oxoethyl)amino)methyl)-3,4-dihydroisoquinoline-2(1<i>H</i>)-carboxylate (<b>17B</b>)</h4><div class="NLM_p last"><b>17A</b> (80 mg, 0.306 mmol) was dissolved in dichloromethane (5 mL), and <i>N</i>,<i>N</i>-diisopropylethylamine (0.20 mL, 1.22 mmol) and glycine methyl ester hydrochloride (115 mg, 0.918 mmol) were added, followed by magnesium sulfate. The mixture was stirred at rt for 4 h. Sodium triacetoxyborohydride (97 mg, 0.46 mmol) was added, and stirring was continued at rt for 72 h. The reaction mixture was poured into saturated sodium bicarbonate and extracted with dichloromethane. The organic extract was dried over sodium sulfate, filtered, and evaporated. UPLC-MS indicated a 1:1 mixture of imine and amine. Repeating conditions with sodium triacetoxyborohydride in dichloromethane did not improve the ratio. The residue was dissolved in methanol (10 mL), cooled on ice/water, and sodium borohydride (7 mg, 0.18 mmol) was added, and the mixture was stirred at rt for 1.5 h. The mixture was diluted with ethyl acetate and washed with saturated sodium bicarbonate. The aqueous layer was extracted with ethyl acetate, and the organic extracts were washed with water, dried over sodium sulfate, filtered, and evaporated to provide <b>17B</b> (150 mg, quantitative yield) as a yellow oil that was used directly in the next step. UPLC-MS (short basic) <sup><i>t</i></sup>R 0.83 (335 [M + H]<sup>+</sup>).</div></div><div id="sec5_1_52" class="NLM_sec NLM_sec_level_3"><div id="ac_i67" class="anchor-spacer"></div><h4 class="article-section__title" id="_i67"> <i>tert</i>-Butyl 8-((<i>N</i>-(2-Methoxy-2-oxoethyl)pivalamido)methyl)-3,4-dihydroisoquinoline-2(1<i>H</i>)-carboxylate</h4><div class="NLM_p last"><b>17B</b> (148 mg, ∼0.407 mmol) was dissolved in dichloromethane (3 mL) under an argon atmosphere, and <i>N</i>,<i>N</i>-diisopropylethylamine (140 μL, 0.80 mmol) was added. Trimethylacetyl chloride (50 μL, 0.40 mmol) was added dropwise, and the mixture was stirred at rt for 3 h after which time UPLC-MS indicated that amine had been completely consumed. The mixture was poured into saturated sodium bicarbonate and extracted three times with dichloromethane. The organic extracts were dried over sodium sulfate, filtered, and the filtrate was evaporated. The residue was purified via flash silica SPE (5 g SiO<sub>2</sub> SPE, 15% EtOAc in DCM) to provide <i>tert</i>-butyl 8-((<i>N</i>-(2-methoxy-2-oxoethyl)pivalamido)methyl)-3,4-dihydroisoquinoline-2(1<i>H</i>)-carboxylate (35 mg, 20%) as a colorless gum. UPLC-MS (short basic) <sup><i>t</i></sup>R 0.93 (419 [M + H]<sup>+</sup>), 80% pure.</div></div><div id="sec5_1_53" class="NLM_sec NLM_sec_level_3"><div id="ac_i68" class="anchor-spacer"></div><h4 class="article-section__title" id="_i68"> 2-(<i>N</i>-((2-(<i>tert</i>-Butoxycarbonyl)-1,2,3,4-tetrahydroisoquinolin-8-yl)methyl)pivalamido)-acetic Acid (<b>17C</b>)</h4><div class="NLM_p last"><i>tert</i>-Butyl 8-((<i>N</i>-(2-methoxy-2-oxoethyl)pivalamido)methyl)-3,4-dihydroisoquinoline-2(1<i>H</i>)-carboxylate (35 mg, 0.084 mmol) was dissolved in methanol (3 mL), and 2.5 M sodium hydroxide (50 μL, 0.125 mmol) was added and the mixture was stirred at rt for 18 h. UPLC-MS indicated incomplete hydrolysis, so a further 2.5 M sodium hydroxide (50 μL, 0.125 mmol) was added, and the mixture was stirred at rt for 72 h. The reaction was diluted with ethyl acetate and washed with saturated ammonium chloride. The aqueous layer was extracted twice with ethyl acetate. The organic extracts were dried over sodium sulfate, filtered, and the filtrate was evaporated to provide <b>17C</b> (∼0.084 mmol) as a glass, which was used directly in the next step. UPLC-MS (short basic) <sup><i>t</i></sup>R 0.59 (405 [M + H]<sup>+</sup>).</div></div><div id="sec5_1_54" class="NLM_sec NLM_sec_level_3"><div id="ac_i69" class="anchor-spacer"></div><h4 class="article-section__title" id="_i69"> <i>tert</i>-Butyl 8-((<i>N</i>-(2-Oxo-2-((2′-oxo-1,1′,2′,3-tetrahydrospiro[indene-2,3′-pyrrolo[2,3-<i>b</i>]pyridin]-5-yl)amino)ethyl)pivalamido)methyl)-3,4-dihydroisoquinoline-2(1<i>H</i>)-carboxylate (<b>17E</b>)</h4><div class="NLM_p last"><b>17C</b> (35 mg, 0.084 mmol), EDCI.HCl (19 mg, 0.101 mmol), and HOAt (14 mg, 0.101 mmol) were dissolved in dry DMF (2 mL). <i>N</i>,<i>N</i>-Diisopropylethylamine (35 μL, 0.20 mmol) and <b>17D</b> (21 mg, 0.084 mmol) were added, and the mixture was stirred at rt for 18 h. The mixture was poured into saturated sodium bicarbonate, and the aqueous layer was extracted three times with ethyl acetate. The organic extract was washed three times with water, dried over sodium sulfate, filtered, and the filtrate was evaporated. The residue was purified via SPE (2 g SiO<sub>2</sub> EtOAc) to provide <b>17E</b> (30 mg, 56%) as a colorless glass. UPLC-MS (short basic) <sup><i>t</i></sup>R 0.86 (638 [M + H]<sup>+</sup>).</div></div><div id="sec5_1_55" class="NLM_sec NLM_sec_level_3"><div id="ac_i70" class="anchor-spacer"></div><h4 class="article-section__title" id="_i70"> <i>N</i>-(2-Oxo-2-((2′-oxo-1,1′,2′,3-tetrahydrospiro[indene-2,3′-pyrrolo[2,3-<i>b</i>]pyridin]-5-yl)amino)ethyl)-<i>N</i>-((1,2,3,4-tetrahydroisoquinolin-8-yl)methyl)pivalamide (<b>17</b>)</h4><div class="NLM_p last"><b>17E</b> (30 mg, 0.047 mmol) was dissolved in dichloromethane (3 mL). Trifluoroacetic acid (0.3 mL) was added, and the solution was stirred at rt for 45 min. The mixture was poured into saturated sodium bicarbonate, and the aqueous layer was extracted three times with dichloromethane. The organic extract was dried over sodium sulfate, filtered, and the filtrate was evaporated. The residue was purified via SPE (2 g SiO<sub>2</sub> 10% MeOH in EtOAc and then 10–20% MeOH in DCM) to provide <b>17</b> (12 mg, 48%) as a colorless glass. <sup>1</sup>H NMR (CD<sub>3</sub>OD, 300 MHz) δ 1.31 (s, 9H), 2.88 (t, <i>J</i> = 5.9 Hz, 2H), 3.01–3.12 (m, 4H), 3.49 (dd, <i>J</i> = 15.8, 7.6 Hz, 2H), 3.94 (s, 2H), 4.10 (br s, 2H), 4.74 (br s, 2H), 6.86 (dd, <i>J</i> = 7.3, 5.4 Hz, 1H), 6.99 (d, <i>J</i> = 7.0 Hz, 1H), 7.04–7.23 (m, 4H), 7.34 (dd, <i>J</i> = 8.2, 1.5 Hz, 1H), 7.52 (s, 1H), 8.03 (dd, <i>J</i> = 5.3, 1.6 Hz, 1H). UPLC-MS (short basic) <sup><i>t</i></sup>R 0.66 (538 [M + H]<sup>+</sup>), 99% pure.</div></div><div id="sec5_1_56" class="NLM_sec NLM_sec_level_3"><div id="ac_i71" class="anchor-spacer"></div><h4 class="article-section__title" id="_i71"> Ethyl 2-((2-((<i>tert</i>-Butoxycarbonyl)amino)benzyl)amino)acetate (<b>11B</b>)</h4><div class="NLM_p last"><b>11A</b> (100 mg, 0.45 mmol), ethyl bromoacetate (38 μL, 0.34 mmol), and <i>N</i>,<i>N</i>-diisopropylethylamine (157 μL, 0.90 mmol) were mixed in DMF (1 mL) and stirred at rt for 2 h, after which the reaction was complete by UPLC-MS. The mixture was diluted with ethyl acetate and washed with water. The aqueous layer was extracted with ethyl acetate. The organics were washed with brine, dried over magnesium sulfate, filtered, and the filtrate was evaporated to provide <b>11B</b> (119 mg, 86%) as a yellow gum. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz) δ 1.26 (t, <i>J</i> = 4.6 Hz, 3H), 1.52 (s, 9H), 3.36 (s, 2H), 3.84 (s, 2H), 4.21 (q, <i>J</i> = 7.2 Hz, 2H), 6.93 (dt, <i>J</i> = 5.8, 1.4 Hz, 1H), 7.06 (dd, <i>J</i> = 7.7, 1.6 Hz, 1H), 7.23–7.31 (m, 1H), 7.98 (br d, 1H), 9.14 (br s, 1H).</div></div><div id="sec5_1_57" class="NLM_sec NLM_sec_level_3"><div id="ac_i72" class="anchor-spacer"></div><h4 class="article-section__title" id="_i72"> Ethyl 2-(<i>N</i>-(2-((<i>tert</i>-Butoxycarbonyl)amino)benzyl)pivalamido)acetate</h4><div class="NLM_p last"><b>11B</b> (119 mg, 0.39 mmol) was dissolved in dichloromethane (5 mL), and <i>N</i>,<i>N</i>-diisopropylethylamine (204 μL, 1.17 mmol) and trimethylacetyl chloride (58 μL, 0.47 mmol) were added and the mixture was stirred at rt for 2 h. UPLC-MS showed little reaction, so further <i>N</i>,<i>N</i>-diisopropylethylamine (204 μL, 1.17 mmol) and trimethylacetyl chloride (58 μL, 0.47 mmol) were added. After an additional 2 h, UPLC-MS showed complete reaction. The mixture was poured into water, and the aqueous layer was extracted with dichloromethane. The organics were dried over magnesium sulfate, filtered, and evaporated. The residue was purified via flash chromatography (4:1 heptane/ethyl acetate) to provide the intermediate of <b>11C</b> (99 mg, 65%) as a colorless oil. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz) δ 1.25 (t, <i>J</i> = 7.1 Hz, 3H), 1.30 (s, 9H), 1.51 (s, 9H), 4.00 (s, 2H), 4.18 (q, <i>J</i> = 7.1 Hz, 2H), 4.72 (s, 2H), 6.96–7.10 (m, 2H), 7.26–7.33 (m, 1H), 7.99 (br s, 1H). UPLC-MS (short CSH 2–50%) <sup><i>t</i></sup>R 1.50 (415 [M + Na]<sup>+</sup>), 95% pure.</div></div><div id="sec5_1_58" class="NLM_sec NLM_sec_level_3"><div id="ac_i73" class="anchor-spacer"></div><h4 class="article-section__title" id="_i73"> 2-(<i>N</i>-(2-((<i>tert</i>-Butoxycarbonyl)amino)benzyl)pivalamido)acetic Acid <b>11C</b></h4><div class="NLM_p last">An intermediate of <b>7C</b> (99 mg, 0.25 mmol) was dissolved in methanol (1.5 mL), and 2.5 M sodium hydroxide (0.25 mL, 0.625 mmol) was added and the mixture was heated at reflux for 2 h. The mixture was poured into water, and the pH was adjusted carefully to 4 by the addition of 2 M HCl, and the mixture was extracted with ethyl acetate. The aqueous pH was again adjusted to 4, and the mixture was extracted with ethyl acetate. The organics were washed with brine, dried over magnesium sulfate, filtered, and the filtrate was evaporated to provide <b>11C</b> (80 mg, 88%) as a colorless solid. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz) δ 1.31 (s, 9H), 1.50 (s, 9H), 4.03 (s, 2H), 4.75 (s, 2H), 7.05–7.14 (m, 2H), 7.26–7.34 (m, 2H), 7.82 (br s, 1H). UPLC-MS (short CSH 2–50%) <sup><i>t</i></sup>R 1.28 (363 [M + Na]<sup>+</sup>), 95% pure.</div></div><div id="sec5_1_59" class="NLM_sec NLM_sec_level_3"><div id="ac_i74" class="anchor-spacer"></div><h4 class="article-section__title" id="_i74"> <i>tert</i>-Butyl (2-((<i>N</i>-(2-Oxo-2-((2′-oxo-1,1′,2′,3-tetrahydrospiro[indene-2,3′-pyrrolo[2,3-<i>b</i>]pyridin]-5-yl)amino)ethyl)pivalamido)methyl)phenyl)carbamate (<b>11E</b>)</h4><div class="NLM_p last"><b>11C</b> (80 mg, 0.22 mmol), EDCI.HCl (50 mg, 0.26 mmol), and HOAt (35 mg, 0.26 mmol) were dissolved in dry DMF (4 mL). <i>N</i>,<i>N</i>-Diisopropylethylamine (115 μL, 0.66 mmol) and <b>11D</b> (55 mg, 0.22 mmol) were added, and the mixture was stirred at rt for 4 h. The mixture was diluted with ethyl acetate and washed with saturated sodium bicarbonate. The aqueous layer was extracted twice with ethyl acetate. The combined organics were washed with brine, dried over magnesium sulfate, filtered, and the filtrate was evaporated. The residue was purified via flash silica chromatography (1:1 heptane/acetone) to provide <b>11E</b> (110 mg, 84%) as a colorless solid. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz) δ 1.36 (s, 9H), 1.51 (s, 9H), 3.03 (dd, <i>J</i> = 15.8, 2.3 Hz, 2H), 3.60 (dd, <i>J</i> = 16.0, 3.6 Hz, 2H), 4.06 (br s, 2H), 4.83 (s, 2H), 6.81 (dd, <i>J</i> = 7.4, 5.3 Hz, 1H), 7.04–7.21 (m, 5H), 7.26–7.34 (m, 1H), 7.51 (s, 1H), 7.75 (br, s, 1H), 8.12 (dd, <i>J</i> = 5.3, 1.6 Hz, 2H). UPLC-MS (short CSH 2–50%) <sup><i>t</i></sup>R 1.31 (498 [M-Boc + H]<sup>+</sup>), 88% pure.</div></div><div id="sec5_1_60" class="NLM_sec NLM_sec_level_3"><div id="ac_i75" class="anchor-spacer"></div><h4 class="article-section__title" id="_i75"> <i>N</i>-(2-Aminobenzyl)-<i>N</i>-(2-oxo-2-((2′-oxo-1,1′,2′,3-tetrahydrospiro[indene-2,3′-pyrrolo[2,3-<i>b</i>]pyridin]-5-yl)amino)ethyl)pivalamide (<b>11</b>)</h4><div class="NLM_p last"><b>11E</b> (20 mg, 0.033 mmol) was dissolved in dichloromethane (1 mL). Trifluoroacetic acid (0.05 mL) was added, and the solution was stirred at rt for 7 h. The mixture was poured into water, and the aqueous layer was extracted three times with dichloromethane. The organic extract was dried over magnesium sulfate, filtered, and the filtrate was evaporated. The residue was purified via prep-HPLC (HP C18, ID 22 mm, length 150 mm, flow rate 16 mL/min: 5–50% MeCN/water/0.1% trifluoroacetyl (TFA) over 20 min) to provide <b>11</b> (10.3 mg, 48%) as a colorless glass (TFA salt). <sup>1</sup>H NMR (CD<sub>3</sub>OD, 400 MHz) δ 1.34 (s, 9H), 3.09 (dd, <i>J</i> = 15.8, 6.6 Hz, 2H), 3.53 (dd, <i>J</i> = 15.8, 2.8 Hz, 2H), 4.17 (br s, 2H), 4.61 (br s, 1H), 4.75 (br s, 2H), 6.72 (t, <i>J</i> = 7.3 Hz, 1H), 6.77 (d, <i>J</i> = 7.9 Hz, 1H), 6.91 (dd, <i>J</i> = 7.4, 5.4 Hz, 1H), 7.00 (d, <i>J</i> = 7.5 Hz, 1H), 7.06–7.11 (m, 1H), 7.16 (dd, <i>J</i> = 7.4, 1.5 Hz, 1H), 7.25 (d, <i>J</i> = 8.2 Hz, 1H), 7.39 (dd, <i>J</i> = 8.1, 1.6 Hz, 1H), 7.57 (br s, 1H), 8.07 (dd, <i>J</i> = 5.3, 1.4 Hz, 1H). HPLC (25 min acidic) <sup><i>t</i></sup>R 12.28, 99% pure. MS 498 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_61" class="NLM_sec NLM_sec_level_3"><div id="ac_i76" class="anchor-spacer"></div><h4 class="article-section__title" id="_i76"> <i>N</i>-(2-(Guanidinomethyl)benzyl)-<i>N</i>-(2-oxo-2-((2′-oxo-1,1′,2′,3-tetrahydrospiro[indene-2,3′-pyrrolo[2,3-<i>b</i>]pyridin]-5-yl)amino)ethyl)pivalamide (<b>24</b>)</h4><div class="NLM_p last"><b>12</b> (15 mg, 0.03 mmol) and 4-benzyl-3,5-dimethyl-1<i>H</i>-pyrazole-1-carboximidamide hydrochloride (prepared according to the literature;<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> 30 mg, 0.117 mmol) and triethylamine (15 mg, 0.15 mmol) were added to tetrahydrofuran (0.3 mL) and acetonitrile (0.3 mL), and the mixture was heated at 90 °C under microwave irradiation for 1 h. The mixture was diluted with methanol and purified directly by prep-HPLC (HP C18, ID 22 mm, length 150 mm, flow 16 mL/min: 5–45% MeCN water/acetonitrile 0.1% TFA over 20 min) to provide the desired <b>24</b> (8.9 mg, 55%) as a colorless glass (TFA salt). <sup>1</sup>H NMR (CD<sub>3</sub>OD, 400 MHz) δ 1.36 (s, 9H), 3.11 (dd, <i>J</i> = 15.9, 2.8 Hz, 2H), 3.53 (dd, <i>J</i> = 15.9, 8.9 Hz, 2H), 4.29 (br s, 2H), 4.45–4.50 (m, 2H), 4.85 (br s, 2H), 6.93 (dd, <i>J</i> = 7.3, 5.4 Hz, 1H), 7.19 (dd, <i>J</i> = 7.4, 1.5 Hz, 1H), 7.24 (d, <i>J</i> = 8.2 Hz, 1H), 7.28–7.42 (m, 5H), 7.52 (br s, 1H), 7.80–7.85 (m, 1H), 8.08 (dd, <i>J</i> = 5.4, 1.5 Hz, 1H). HPLC: 98% pure. MS: 554 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_62" class="NLM_sec NLM_sec_level_3"><div id="ac_i77" class="anchor-spacer"></div><h4 class="article-section__title" id="_i77"> 2-(1,1-Dimethoxyethyl)benzaldehyde (<b>29E</b>)</h4><div class="NLM_p last"><b>29A</b> (830 mg, 3.39 mmol) was dissolved in dry tetrahydrofuran (10 mL) under an argon atmosphere and cooled on dry ice/acetone. To this was added a solution of <i>n</i>-butyllithium (2.04 mL, 5.09 mmol, 2.5 M in hexanes) dropwise so that the internal temperature stayed below −60 °C (10 min addition). The reaction was stirred on dry ice/acetone for 60 min. To this was added DMF (0.525 mL, 6.78 mmol) in one portion. The mixture was stirred on dry ice/acetone for 60 min before being allowed to warm to rt over 18 h. Water was added, and the mixture was extracted three times with ethyl acetate. The combined organic extracts were washed with brine, dried over magnesium sulfate, filtered, and the filtrate was evaporated to provide <b>29E</b> (634 mg, 96%) as a straw-colored oil. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz) δ 1.70 (s, 3H), 3.23 (s, 6H), 7.36–7.44 (m, 1H), 7.50–7.57 (m, 1H), 7.64 (dd, <i>J</i> = 7.9, 1.3 Hz, 1H), 7.86 (dd, <i>J</i> = 7.7, 1.4 Hz, 1H), 10.64 (s, 1H).</div></div><div id="sec5_1_63" class="NLM_sec NLM_sec_level_3"><div id="ac_i78" class="anchor-spacer"></div><h4 class="article-section__title" id="_i78"> Methyl 2-((2-(1,1-Dimethoxyethyl)benzyl)amino)acetate (<b>29B</b>)</h4><div class="NLM_p last"><b>29E</b> (634 mg, 3.26 mmol) was dissolved in dichloromethane (25 mL) under an argon atmosphere. <i>N</i>,<i>N</i>-Diisopropylethylamine (1.14 mL, 6.52 mmol) was added followed by methyl glycinate hydrochloride (777 mg, 6.19 mmol) and magnesium sulfate (excess). The mixture was stirred at rt for 1 h. Sodium triacetoxyborohydride (1.1 g, 5.2 mmol) was added, and the mixture was stirred at rt for 18 h. The mixture was poured into water, and the aqueous layer was extracted three times with dichloromethane. The combined organic extracts were washed with brine, dried over magnesium sulfate, filtered, and the filtrate was evaporated to provide <b>29B</b> (717 g, 82%) as a pale straw-colored gum. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz) δ 1.58 (s, 3H), 3.23 (s, 6H), 3.50 (s, 2H), 3.72 (s, 3H), 3.98 (s, 2H), 7.26–7.30 (m, 2H), 7.37–7.42 (m, 1H), 7.52–7.57 (m, 1H).</div></div><div id="sec5_1_64" class="NLM_sec NLM_sec_level_3"><div id="ac_i79" class="anchor-spacer"></div><h4 class="article-section__title" id="_i79"> Methyl 2-(<i>N</i>-(2-(1,1-Dimethoxyethyl)benzyl)pivalamido)acetate</h4><div class="NLM_p last"><b>29B</b> (685 mg, 2.56 mmol) was dissolved in dichloromethane (40 mL) under an argon atmosphere, and <i>N</i>,<i>N</i>-diisopropylethylamine (1.34 mL, 7.68 mmol) was added. Trimethylacetyl chloride (0.38 mL, 3.07 mmol) was added dropwise. The mixture was stirred at rt for 3 h after which the reaction had reached completion, as judged by TLC analysis. The mixture was poured into water, and the aqueous layer was extracted three times with dichloromethane. The combined organic extracts were washed with brine, dried over magnesium sulfate, filtered, and the filtrate was evaporated to provide methyl 2-(<i>N</i>-(2-(1-aminoethyl)benzyl)pivalamido)acetate (1.012 g, quantitative yield) as a yellow gum. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz) δ 1.32 (s, 9H), 1.52 (s, 3H), 3.20 (s, 6H), 3.72 (s, 3H), 5.02 (br s, 2H), 7.25–7.32 (m, 3H), 7.60 (dd, <i>J</i> = 7.0, 2.2 Hz, 1H), one signal collapsed, not visible.</div></div><div id="sec5_1_65" class="NLM_sec NLM_sec_level_3"><div id="ac_i80" class="anchor-spacer"></div><h4 class="article-section__title" id="_i80"> 2-(<i>N</i>-(2-(1,1-Dimethoxyethyl)benzyl)pivalamido)acetic Acid (<b>29C</b>)</h4><div class="NLM_p last">Methyl 2-(<i>N</i>-(2-(1-aminoethyl)benzyl)pivalamido)acetate (500 mg, 1.40 mmol) was dissolved in methanol (5 mL), and 2.5 M sodium hydroxide (0.84 mL, 2.1 mmol) was added. The mixture was stirred at rt for 3 h, after which the reaction had reached completion, as judged by TLC analysis. The mixture was diluted with water, and the pH was adjusted very carefully to pH 4 with 10% potassium hydrogen sulfate. Once at pH 4, the aqueous layer was extracted twice with ethyl acetate. The combined organic extracts were washed with brine, dried over magnesium sulfate, filtered, and evaporated carefully (30 °C water bath, not to dryness). <b>29C</b> was used directly in the next step as the compound is not stable.</div></div><div id="sec5_1_66" class="NLM_sec NLM_sec_level_3"><div id="ac_i81" class="anchor-spacer"></div><h4 class="article-section__title" id="_i81"> <i>N</i>-(2-(1,1-Dimethoxyethyl)benzyl)-<i>N</i>-(2-oxo-2-((2′-oxo-1,1′,2′,3-tetrahydrospiro[indene-2,3′-pyrrolo[2,3-<i>b</i>]pyridin]-5-yl)amino)ethyl)pivalamide (<b>29F</b>)</h4><div class="NLM_p last"><b>29C</b> (∼1.40 mmol) was dissolved in DMF (15 mL) under an argon atmosphere, and <i>N</i>,<i>N</i>-diisopropylethylamine (0.73 mL, 4.2 mmol) was added. EDCI.HCl (322 mg, 1.68 mmol) and HOAt (229 mg, 1.68 mmol) were added, followed by <b>29D</b> (387 mg, 1.54 mmol). The mixture was stirred at rt for 3 days. The mixture was poured into saturated sodium bicarbonate. The aqueous layer was extracted three times with ethyl acetate. The combined organic extracts were washed three times with water, dried over sodium sulfate, filtered, and the filtrate was evaporated. The residue was purified via column chromatography (300 mL silica, 2:1 heptane/acetone) to provide <b>29F</b> (247 mg, 31%) as a colorless glass. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz) δ 1.34 (s, 9H), 1.59 (s, 3H), 2.94–3.08 (m, 2H), 3.22 (s, 6H), 3.53–3.67 (m, 4H), 5.10 (br s, 2H), 6.58–6.63 (m, 1H), 6.75–6.84 (m, 1H), 7.02–7.07 (m, 2H), 7.15–7.23 (m, 1H), 7.26–7.37 (m, 3H), 8.05 (br s, 1H), 8.07–8.12 (m, 1H), 8.62 (br s, 1H).</div></div><div id="sec5_1_67" class="NLM_sec NLM_sec_level_3"><div id="ac_i82" class="anchor-spacer"></div><h4 class="article-section__title" id="_i82"> <i>N</i>-(2-Acetylbenzyl)-<i>N</i>-(2-oxo-2-((2′-oxo-1,1′,2′,3-tetrahydrospiro[indene-2,3′-pyrrolo[2,3-<i>b</i>]pyridin]-5-yl)amino)ethyl)pivalamide (<b>29G</b>)</h4><div class="NLM_p last"><b>29F</b> (247 mg, 0.43 mmol) was dissolved in acetone (15 mL), and <i>p</i>-toluene sulfonic acid monohydrate (89 mg, 0.47 mmol) was added. The mixture was stirred at rt for 4 h, at which point further <i>p</i>-toluene sulfonic acid monohydrate (33 mg, 0.17 mmol) was added and the reaction was stirred for a further 1 h. The mixture was poured into saturated sodium bicarbonate. The aqueous layer was extracted three times with ethyl acetate. The combined organic extracts were washed with brine, dried over sodium sulfate, filtered, and the filtrate was evaporated to provide <b>29G</b> (89 mg, 39%) as a colorless solid. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz) δ 1.31 (s, 9H), 2.64 (s, 3H), 3.04 (dd, <i>J</i> = 15.8, 7.4, 2H), 3.62 (dd, <i>J</i> = 15.7, 6.2 Hz, 2H), 4.05 (s, 2H), 5.23 (s, 2H), 6.82 (dd, <i>J</i> = 7.3, 5.3 Hz, 1H), 7.07 (dd, <i>J</i> = 7.3, 1.6 Hz, 1H), 7.16–7.31 (m, 3H), 7.42 (t, <i>J</i> = 7.2 Hz, 1H), 7.52–7.56 (m, 2H), 7.89 (d, <i>J</i> = 7.5 Hz, 1H), 8.11 (dd, <i>J</i> = 5.3, 1.5 Hz, 1H), 8.63 (br s, 1H). UPLC-MS <sup><i>t</i></sup>R 0.75 (524 [M + H]<sup>+</sup>), 90% pure.</div></div><div id="sec5_1_68" class="NLM_sec NLM_sec_level_3"><div id="ac_i83" class="anchor-spacer"></div><h4 class="article-section__title" id="_i83"> <i>N</i>-(2-(1-Aminoethyl)benzyl)-<i>N</i>-(2-oxo-2-((2′-oxo-1,1′,2′,3-tetrahydrospiro[indene-2,3′-pyrrolo[2,3-<i>b</i>]pyridin]-5-yl)amino)ethyl)pivalamide (<b>29</b>)</h4><div class="NLM_p"><b>29G</b> (83 mg, 0.17 mmol) was dissolved in methanol (3.5 mL), and ammonium acetate (131 mg, 1.7 mmol) and sodium cyanoborohydride (21 mg, 0.34 mmol) were added. The mixture was stirred at reflux for 18 h. Extra ammonium acetate (131 mg, 1.7 mmol) and sodium cyanoborohydride (21 mg, 0.34 mmol) were added, and the mixture was stirred at 50 °C for 72 h. The mixture was poured into water, and the aqueous layer was extracted with dichloromethane. The organic extract was evaporated, and the residue was purified via prep-HPLC (XBridge C18, ID 19 mm, length 150 mm, flow rate 20 mL/min: 40–60% MeCN in pH 10 [NH<sub>4</sub>HCO<sub>3</sub> with NH<sub>4</sub>OH] over 8 min) to provide <b>29</b> (15 mg, 17%) as a colorless solid. <sup>1</sup>H NMR (CD<sub>3</sub>OD, 300 MHz) δ 1.29–1.37 (m, 12H), 3.05 (dd, <i>J</i> = 15.6, 6.1 Hz, 2H), 3.49 (dd, <i>J</i> = 15.5, 10.6 Hz, 2H), 3.38–4.37 (m, 2H), 4.86–5.00 (m, 2H), 6.84–6.89 (m, 1H), 7.09–7.16 (m, 2H), 7.18–7.27 (m, 2H), 7.29–7.35 (m, 2H), 7.49–7.56 (m, 2H), 8.01–8.05 (m, 1H). UPLC-MS (long run) <sup><i>t</i></sup>R 1.86 (526 [M + H]<sup>+</sup>), 99% pure  (<a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a>).</div><figure id="sch5" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02191/20210408/images/medium/jm0c02191_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02191/20210408/images/large/jm0c02191_0010.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of <b>28</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02191/20210408/images/large/jm0c02191_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02191&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec5_1_69" class="NLM_sec NLM_sec_level_3"><div id="ac_i85" class="anchor-spacer"></div><h4 class="article-section__title" id="_i85"> Methyl 2-((1-(2-Bromophenyl)ethyl)amino)acetate (<b>28B</b>)</h4><div class="NLM_p last"><b>28A</b> (5 g, 25 mmol) was dissolved in methanol (9.8 mL), and then methyl glycinate hydrochloride (15.69 g, 125 mmol) and sodium cyanoborohydride (3.14 g, 62.84 mmol) were added and the mixture was stirred at rt over the weekend. The reaction mixture was poured into water, and the pH was adjusted to 4 with 2 M HCl before the mixture was washed twice with dichloromethane. The aqueous layer was basified with sodium carbonate and extracted twice with dichloromethane. This organic extract was dried over magnesium sulfate, filtered, and evaporated. The residue was purified by Isolera (acetonitrile/NH<sub>4</sub>COOH buffer pH =10) to provide <b>28B</b> (1.857 g, 27%). UPLC-MS (short basic) <sup><i>t</i></sup>R 0.88 (273 [M + H]<sup>+</sup>).</div></div><div id="sec5_1_70" class="NLM_sec NLM_sec_level_3"><div id="ac_i86" class="anchor-spacer"></div><h4 class="article-section__title" id="_i86"> Methyl 2-(<i>N</i>-(1-(2-Bromophenyl)ethyl)pivalamido)acetate <b>28C</b></h4><div class="NLM_p last"><b>28B</b> (1.86 g, 6.8 mmol) was dissolved in dichloromethane (50 mL) under an argon atmosphere, and <i>N</i>,<i>N</i>-diisopropylethylamine (3.55 mL, 20.4 mmol) was added and the mixture was stirred at 5 °C (ice/water). Trimethylacetyl chloride (1 mL, 8.16 mmol) was added dropwise, and the mixture was stirred at rt for 4 h. The reaction mixture was diluted in dichloromethane, washed with brine and saturated sodium bicarbonate, dried over magnesium sulfate, filtered, and the filtrate was evaporated. The residue was purified by flash chromatography eluting with heptane/acetone = 4:1 to provide the intermediate of <b>28C</b> (2.2 g, 91%). UPLC-MS (short basic) <sup><i>t</i></sup>R 0.98 (357 [M + H]<sup>+</sup>).</div></div><div id="sec5_1_71" class="NLM_sec NLM_sec_level_3"><div id="ac_i87" class="anchor-spacer"></div><h4 class="article-section__title" id="_i87"> Methyl 2-(<i>N</i>-(1-(2-Cyanophenyl)ethyl)pivalamido)acetate</h4><div class="NLM_p last"><b>28C</b> (100 mg, 0.28 mmol) was dissolved in dry DMF (3 mL) and was degassed by bubbling argon through the solution. Zinc(II) cyanide (59 mg, 0.5 mmol) and tetrakis(triphenylphosphine)palladium(0) (65 mg, 0.056 mmol) were added, and the mixture was stirred at 130 °C for 1 h. The mixture was diluted with ethyl acetate and washed twice with saturated sodium bicarbonate and three times with brine. The organic layer was dried over magnesium sulfate, filtered, and the filtrate was evaporated. The crude was directly purified using a Biotage Isolera (C18 Ultra cartridge, 0–20% acetone/heptane) to provide the intermediate of <b>28D</b> (67 mg, 79%). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz) δ 1.24 (s, 9H), 1.68 (s, 3H), 3.74 (s, 3H), 4.52 (d, <i>J</i> = 17.3 Hz, 1H), 7.31–7.45 (m, 2H), 7.58 (t, <i>J</i> = 7.6 Hz, 1H), 7.67 (d, <i>J</i> = 7.9 Hz, 1H). UPLC-MS (short basic) <sup><i>t</i></sup>R 0.79 (303.2 [M + H]<sup>+</sup>).</div></div><div id="sec5_1_72" class="NLM_sec NLM_sec_level_3"><div id="ac_i88" class="anchor-spacer"></div><h4 class="article-section__title" id="_i88"> Methyl 2-(<i>N</i>-(1-(2-(Aminomethyl)phenyl)ethyl)pivalamido)acetate (<b>28D</b>)</h4><div class="NLM_p last">An intermediate of <b>28D</b> (67 mg, 0.22 mmol) was dissolved in a mixture of methanol (4.5 mL) and TFA (0.5 mL). Palladium-on-carbon (10% wet, 30 mg) was added, the vessel was sealed, and an atmosphere of hydrogen was introduced using a balloon. The mixture was stirred at rt for 5 h. The reaction was filtered through celite, washed with methanol, and the filtrate was evaporated to provide <b>28D</b>. UPLC-MS (long basic) <sup><i>t</i></sup>R 0.68 (307 [M + H]<sup>+</sup>), 84% pure.</div></div><div id="sec5_1_73" class="NLM_sec NLM_sec_level_3"><div id="ac_i89" class="anchor-spacer"></div><h4 class="article-section__title" id="_i89"> Methyl 2-(<i>N</i>-(1-(2-((((Benzyloxy)carbonyl)amino)methyl)phenyl)ethyl)pivalamido)acetate</h4><div class="NLM_p last"><b>28D</b> (67 mg, 0.22 mmol) in dichloromethane (2 mL) and triethylamine (92 μL, 0.66 mmol) was added to benzyl chloroformate (34 μL, 0.24 mmol). The mixture was stirred at rt for 4 h, quenched by adding water, and extracted with dichloromethane. The combined organic phases were dried over sodium sulfate. After filtration and concentration, the residue was purified by silica gel column chromatography, eluting with heptane/acetone = 4:1 to provide the intermediate of <b>28E</b> (62 mg, 64% yield). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz) δ 1.21 (s, 9H), 1.42 (d, <i>J</i> = 6.5 Hz, 3H), 3.34 (s, 3H), 4.01 (d, <i>J</i> = 18.0 Hz, 1H), 4.20 (d, <i>J</i> = 18.0 Hz), 4.39 (d, <i>J</i> = 5.5 Hz, 2H), 5.12 (s, 2H), 5.95 (s, 1H), 6.18 (s, 1H), 7.23–7.38 (m, 9H). UPLC-MS (short basic) <sup><i>t</i></sup>R 0.89 (441 [M + H]<sup>+</sup>).</div></div><div id="sec5_1_74" class="NLM_sec NLM_sec_level_3"><div id="ac_i90" class="anchor-spacer"></div><h4 class="article-section__title" id="_i90"> 2-(<i>N</i>-(1-(2-((((Benzyloxy)carbonyl)amino)methyl)phenyl)ethyl)pivalamido)acetic Acid (<b>28E</b>)</h4><div class="NLM_p last">An intermediate of <b>28E</b> (62 mg, 0.14 mmol) was dissolved in methanol (1 mL), and 2.5 M sodium hydroxide (168 μL, 0.42 mmol) was added and the mixture was stirred at rt over the weekend. The volatiles were removed, and the residue was dissolved in water. The pH was adjusted carefully to 4 by the addition of 2 M HCl, and the mixture was extracted with ethyl acetate. The aqueous pH was again adjusted to 4, and the mixture was extracted with ethyl acetate. The organics were washed with brine, dried over magnesium sulfate, filtered, and the filtrate was evaporated to provide <b>28E</b> (68 mg, quantitative yield) that was used directly in the next step. UPLC-MS (short basic) <sup><i>t</i></sup>R 0.51 (427 [M + H]<sup>+</sup>).</div></div><div id="sec5_1_75" class="NLM_sec NLM_sec_level_3"><div id="ac_i91" class="anchor-spacer"></div><h4 class="article-section__title" id="_i91"> Benzyl 2-(1-(<i>N</i>-(2-Oxo-2-((2′-oxo-1,1′,2′,3-tetrahydrospiro[indene-2,3′-pyrrolo[2,3-<i>b</i>]pyridin]-5-yl)amino)ethyl)pivalamido)ethyl)benzylcarbamate</h4><div class="NLM_p last"><b>28E</b> (60 mg, 0.14 mmol) was dissolved in DMF (1.5 mL) under an argon atmosphere, and <i>N</i>,<i>N</i>-diisopropylethylamine (73 μL, 0.42 mmol) was added. EDCI·HCl (33 mg, 0.17 mmol) and HOAt (23 mg, 0.17 mmol) were added followed by <b>28F</b> (38 mg, 0.15 mmol). The mixture was stirred at rt overnight. The reaction mixture was poured into saturated sodium bicarbonate and extracted three times with ethyl acetate and brine, dried over magnesium sulfate, filtered, and the filtrate was evaporated. The residue was purified by column chromatography (4:1 heptane/acetone) to provide benzyl 2-(1-(<i>N</i>-(2-oxo-2-((2′-oxo-1,1′,2′,3-tetrahydrospiro[indene-2,3′-pyrrolo[2,3-<i>b</i>]pyridin]-5-yl)amino)ethyl)pivalamido)ethyl)benzylcarbamate (90 mg, 97%). UPLC-MS (short basic) <sup><i>t</i></sup>R 0.80 (658 [M + H]<sup>+</sup>).</div></div><div id="sec5_1_76" class="NLM_sec NLM_sec_level_3"><div id="ac_i92" class="anchor-spacer"></div><h4 class="article-section__title" id="_i92"> <i>N</i>-(1-(2-(Aminomethyl)phenyl)ethyl)-<i>N</i>-(2-oxo-2-((2′-oxo-1,1′,2′,3-tetrahydrospiro[indene-2,3′-pyrrolo[2,3-<i>b</i>]pyridin]-5-yl)amino)ethyl)pivalamide</h4><div class="NLM_p">To a solution of benzyl 2-(1-(<i>N</i>-(2-oxo-2-((2′-oxo-1,1′,2′,3-tetrahydrospiro[indene-2,3′-pyrrolo[2,3-<i>b</i>]pyridin]-5-yl)amino)ethyl)pivalamido)ethyl)benzylcarbamate (90 mg, 0.14 mmol) in ethanol (2 mL) was added 10% Pd/C (9 mg) under a nitrogen atmosphere. The suspension was degassed under vacuum and purged with hydrogen three times. The resulting mixture was stirred under 700 psi of hydrogen pressure at 50 °C for 9 h. The mixture was filtered through celite, and the filter liquid was concentrated and purified by preparative HPLC (acetonitrile/NH<sub>4</sub>COOH buffer over 8 min) to provide <b>28</b> (33 mg, 45% yield). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz) δ 1.28 (s, 9H), 1.49 (d, <i>J</i> = 6.7 Hz, 3H), 3.03 (s, 2H), 3.47 (dd, <i>J</i> = 15.5, 4.0 Hz, 2H), 3.82 (d, <i>J</i> = 14.1 Hz, 1H), 3.99 (d, <i>J</i> = 14.1 Hz, 1H), 4.28 (s, 1H), 6.10 (s, 1H), 6.83–6.91 (m, 1H), 7.03–7.48 (m, 8H), 8.02–8.05 (m, 1H). UPLC-MS (short basic) <sup><i>t</i></sup>R 1.80 (526 [M + H]<sup>+</sup>)(<a class="ref internalNav" href="#sch6" aria-label="Scheme 6">Scheme 6</a>).</div><figure id="sch6" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02191/20210408/images/medium/jm0c02191_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02191/20210408/images/large/jm0c02191_0011.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Synthesis of <b>7</b>, <b>8</b>, <b>23</b>, <b>26</b>, and <b>27</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02191/20210408/images/large/jm0c02191_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02191&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec5_1_77" class="NLM_sec NLM_sec_level_3"><div id="ac_i94" class="anchor-spacer"></div><h4 class="article-section__title" id="_i94"> <i>N</i>-(2-((((1<i>H</i>-Imidazol-2-yl)methyl)amino)methyl)benzyl)-<i>N</i>-(2-oxo-2-((2′-oxo-1,1′,2′,3-tetrahydrospiro[indene-2,3′-pyrrolo[2,3-<i>b</i>]pyridine]-5-yl)amino)ethyl)pivalamide (<b>23</b>)</h4><div class="NLM_p last"><b>23A</b> (30 mg, 0.059 mmol) was dissolved in dichloromethane (3 mL), and <b>23B</b> (12 mg, 0.076 mmol) was added. <i>N</i>,<i>N</i>-Diisopropylethylamine (0.028 mL, 0.15 mmol) and magnesium sulfate were added, and the mixture was stirred at rt. After 20 h, sodium triacetoxyborohydride (20 mg, 0.094 mmol) was added, and the reaction was stirred at room temperature, monitoring by UPLC-MS. Extra sodium triacetoxyborohydride (20 mg, 0.094 mmol) was added as required. Once complete, the reaction was poured into saturated sodium bicarbonate and the mixture was extracted three times with dichloromethane. The combined organics were dried over sodium sulfate, filtered, and evaporated. The crude was purified via SPE (2 g STMAd MeOH and then NH<sub>3</sub> in MeOH, followed by 2 g SiO<sub>2</sub> 0–10% MeOH in EtOAc and then 10% MeOH in DCM) to provide <b>23</b> (13 mg, 37%) as a pale yellow solid. <sup>1</sup>H NMR (CD<sub>3</sub>OD, 400 MHz) δ 1.29 (s, 9H), 3.04 (dd, <i>J</i> = 15.9, 4.1 Hz, 2H), 3.48 (dd, <i>J</i> = 15.9, 9.2 Hz, 2H), 3.63 (br d, 1H), 3.70 (br d, 1H), 3.78 (s, 2H), 3.90 (s, 2H), 4.97 (br s, 2H), 6.84 (dd, <i>J</i> = 7.4, 5.4 Hz, 1H), 6.98 (s, 2H), 7.09 (d, 1H), 7.20 (dd, <i>J</i> = 7.4, 1.5 Hz, 1H), 7.17–7.37 (m, 5H), 7.52 (s, 1H), 8.03 (d, <i>J</i> = 5.3, 1.5 Hz, 1H). UPLC-MS <sup><i>t</i></sup>R 0.64 (592 [M + H]<sup>+</sup>), 92% pure.</div></div><div id="sec5_1_78" class="NLM_sec NLM_sec_level_3"><div id="ac_i95" class="anchor-spacer"></div><h4 class="article-section__title" id="_i95"> <i>N</i>-(2-((Cyclopropylamino)methyl)benzyl)-<i>N</i>-(2-oxo-2-((2′-oxo-1,1′,2′,3-tetrahydrospiro[indene-2,3′-pyrrolo[2,3-<i>b</i>]pyridin]-5-yl)amino)ethyl)pivalamide (<b>26</b>)</h4><div class="NLM_p last"><b>26A</b> (30 mg, 0.059 mmol) was dissolved in dichloromethane (3 mL), and <b>26B</b> (8.3 μL, 0.12 mmol) was added. <i>N</i>,<i>N</i>-Diisopropylethylamine (0.028 mL, 0.15 mmol) and magnesium sulfate were added, and the mixture was stirred at rt. After 6 h, sodium triacetoxyborohydride (20 mg, 0.094 mmol) was added and the reaction was stirred at rt for 48 h. The reaction was poured into saturated sodium bicarbonate and extracted three times with dichloromethane. The combined organics were dried over sodium sulfate, filtered, and evaporated. The crude was purified via SPE (2 g SiO<sub>2</sub> 0–12% MeOH in EtOAc) and trituration in diethyl ether to provide <b>26</b> (9 mg, 28%) as a colorless solid. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz) δ 0.27–0.33 (m, 2H), 0.40–0.46 (m, 2H), 1.30 (s, 9H), 2.14–2.22 (m, 1H), 3.05 (dd, <i>J</i> = 15.9, 7.1 Hz, 2H), 3.61 (dd, <i>J</i> = 16.0, 6.8 Hz, 2H), 3.85 (s, 2H), 4.08 (br s, 2H), 5.05 (br s, 2H), 6.82 (dd, <i>J</i> = 7.3, 5.3 Hz, 1H), 7.05–7.13 (m, 2H), 7.27–7.33 (m, 5H), 7.55 (s, 1H), 8.11 (d, <i>J</i> = 5.3, 1.6 Hz, 1H), 8.20 (br s, 1H), 8.58 (br s, 1H). UPLC-MS <sup><i>t</i></sup>R 0.78 (552 [M + H]<sup>+</sup>), 95% pure.</div></div><div id="sec5_1_79" class="NLM_sec NLM_sec_level_3"><div id="ac_i96" class="anchor-spacer"></div><h4 class="article-section__title" id="_i96"> <i>N</i>-(2-(Azetidin-1-ylmethyl)benzyl)-<i>N</i>-(2-oxo-2-((2′-oxo-1,1′,2′,3-tetrahydrospiro[indene-2,3′-pyrrolo[2,3-<i>b</i>]pyridine]-5-yl)amino)ethyl)pivalamide (<b>27</b>)</h4><div class="NLM_p last"><b>27A</b> (30 mg, 0.059 mmol) was dissolved in dichloromethane (3 mL), and <b>27B</b> (11 mg, 0.12 mmol) was added. <i>N</i>,<i>N</i>-Diisopropylethylamine (0.028 mL, 0.15 mmol) and magnesium sulfate were added, and the mixture was stirred at rt. After 6 h, sodium triacetoxyborohydride (20 mg, 0.094 mmol) was added and the reaction was stirred at rt for 30 h. The reaction was poured into saturated sodium bicarbonate and extracted three times with dichloromethane. The combined organics were dried over sodium sulfate, filtered, and evaporated. The crude was purified via SPE (2 g SiO<sub>2</sub> 0–10% MeOH in EtOAc and then 10% MeOH in DCM) to provide <b>27</b> (21 mg, 65%) as a colorless glass. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz) δ 1.33 (s, 9H), 1.97–2.10 (m, 2H), 3.02 (dd, <i>J</i> = 15.8, 3.5 Hz, 2H), 3.08–3.20 (m, 4H), 3.52–3.66 (m, 4H), 4.07–4.17 (m, 2H), 5.11 (br s, 2H), 6.81 (dd, <i>J</i> = 7.3, 5.3 Hz, 1H), 7.02–7.30 (m, 7H), 7.53 (br s, 1H), 8.13 (d, <i>J</i> = 5.3, 1.4 Hz, 1H), 8.68 (br d, 2H). UPLC-MS <sup><i>t</i></sup>R 0.78 (552 [M + H]<sup>+</sup>), 95% pure.</div></div><div id="sec5_1_80" class="NLM_sec NLM_sec_level_3"><div id="ac_i97" class="anchor-spacer"></div><h4 class="article-section__title" id="_i97"> <i>tert</i>-Butyl (2-Oxo-2-((2′-oxo-1,1′,2′,3-tetrahydrospiro[indene-2,3′-pyrrolo[2,3-<i>b</i>]pyridine]-5-yl)amino)ethyl)carbamate (<b>7E</b>/<b>8E</b>)</h4><div class="NLM_p last"><i>N</i>,<i>N</i>-Diisopropylethylamine (6.24 mL, 35.8 mmol) was added to a solution of Boc-glycine-OH (2.4 g, 13.7 mmol), EDCI.HCl (2.52 g, 13.2 mmol), and HOAt (1.8 g, 13.2 mmol) in DMF (25 mL) under an argon atmosphere. Amine <b>D</b> (3.0 g, 11.9 mmol) was added, washing in with DMF (10 mL). The mixture was stirred at rt for 18 h, after which time the reaction was complete as assessed by UPLC-MS. The mixture was poured into saturated sodium bicarbonate. The aqueous layer was extracted three times with ethyl acetate. The combined organic extracts were washed three times with water, 20% aqueous citric acid, three more times with water, dried over magnesium sulfate, filtered, and the filtrate was evaporated to provide the intermediate of <b>7E</b>/<b>8E</b> (4.84 mg, 99%) as a pale yellow glass. <sup>1</sup>H NMR (CD<sub>3</sub>OD, 300 MHz) δ 1.45 (s, 9H), 3.06 (dd, <i>J</i> = 15.7, 6.1 Hz, 2H), 3.50 (dd, <i>J</i> = 16.0, 8.2 Hz, 2H), 3.84 (br s, 2H), 6.87 (dd, <i>J</i> = 7.3, 5.3 Hz, 1H), 7.13 (d, <i>J</i> = 7.9 Hz, 1H), 7.22 (d, <i>J</i> = 7.5 Hz, 1H), 7.38 (d, <i>J</i> = 7.8 Hz, 1H), 7.55 (s, 1H), 8.03 (d, <i>J</i> = 3.8 Hz, 1H). UPLC-MS (CSH 2–50%) <sup><i>t</i></sup>R 0.93 (409 [M + H]<sup>+</sup>).</div></div><div id="sec5_1_81" class="NLM_sec NLM_sec_level_3"><div id="ac_i98" class="anchor-spacer"></div><h4 class="article-section__title" id="_i98"> 2-Amino-<i>N</i>-(2′-oxo-1,1′,2′,3-tetrahydrospiro[indene-2,3′-pyrrolo[2,3-<i>b</i>]pyridine]-5-yl)acetamide Dihydrochloride (<b>7E</b>/<b>8E</b>)</h4><div class="NLM_p last">An intermediate of <b>7E</b>/<b>8E</b> (4.84 mL, 11.9 mmol) was triturated in 3 M HCl in cyclopentyl methyl ether (20 mL, 60 mmol) until a flowing suspension was obtained. The mixture was stirred at rt for 3 h after which the reaction was judged complete by UPLC-MS. The solid was isolated by decanting the solvent and then washed and decanted three times with diethyl ether. The solid was dried to provide <b>7E</b>/<b>8E</b> (4.62 mg, quantitative yield) as a beige powder. UPLC-MS (short basic) <sup><i>t</i></sup>R 0.43 (309 [M + H]<sup>+</sup>), 93% pure.</div></div><div id="sec5_1_82" class="NLM_sec NLM_sec_level_3"><div id="ac_i99" class="anchor-spacer"></div><h4 class="article-section__title" id="_i99"> <i>N</i>-(2-Oxo-2-((2′-oxo-1,1′,2′,3-tetrahydrospiro[indene-2,3′-pyrrolo[2,3-<i>b</i>]pyridin]-5-yl)amino)ethyl)-<i>N</i>-((1-phenyl-1<i>H</i>-pyrazol-5-yl)methyl)pivalamide (<b>7</b>)</h4><div class="NLM_p last"><b>7E</b> (52 mg, 0.14 mmol) was dissolved in dichloromethane (1.4 mL) and tetrahydrofuran (1.4 mL) and then <i>N</i>,<i>N</i>-diisopropylethylamine (0.065 mL, 0.37 mmol). 1-Phenyl-1<i>H</i>-pyrazole-5-carbaldehyde (27 mg, 0.16 mmol), sodium triacetoxyborohydride (100 mg, 0.47 mmol), and magnesium sulfate were added, and the mixture was stirred at rt overnight. The reaction mixture was filtered, poured into water, and the pH was adjusted to 4 with 2 M HCl and washed twice with dichloromethane. The aqueous layer was basified with sodium carbonate and extracted twice with dichloromethane. This organic extract was dried over magnesium sulfate, filtered, and evaporated to provide the intermediate of <b>7</b>. This compound was dissolved in dichloromethane (2 mL) under an argon atmosphere, and <i>N</i>,<i>N</i>-diisopropylethylamine (70 μL, 0.41 mmol) was added and the mixture was stirred at 5 °C (ice/water). Trimethylacetyl chloride (258 μL, 0.21 mmol) was added dropwise, and the mixture was stirred at rt overnight. The reaction mixture was diluted in dichloromethane, washed with brine and saturated sodium bicarbonate, dried over magnesium sulfate, filtered, and the filtrate was evaporated. The residue was purified via MDAP (XBridge C18 19 × 150, 30–60% acetonitrile water with 0.1% ammonium hydroxide) to provide <b>7</b> (11 mg, 14%). <sup>1</sup>H NMR (CD<sub>3</sub>OD, 300 MHz) δ 1.21 (s, 9H), 3.05 (dd, <i>J</i> = 15.9, 2.0 Hz, 2H), 3.48 (dd, <i>J</i> = 15.8, 5.8 Hz, 2H), 4.15 (s, 2H), 4.82 (s, 2H), 6.40 (s, br, 1H), 6.87 (dd, <i>J</i> = 7.1, 5.1 Hz, 1H), 7.12 (dd, <i>J</i> = 7.3, 1.5 Hz, 1H), 7.20 (d, <i>J</i> = 8.1 Hz, 1H), 7.29 (dd, <i>J</i> = 8.1, 1.7 Hz, 1H), 7.41–7.54 (m, 6H), 7.66 (s, 1H), 8.03 (dd, <i>J</i> = 5.4, 1.5 Hz, 1H). UPLC-MS (short basic) <sup><i>t</i></sup>R 1.99 (549 [M + H]<sup>+</sup>).</div></div><div id="sec5_1_83" class="NLM_sec NLM_sec_level_3"><div id="ac_i100" class="anchor-spacer"></div><h4 class="article-section__title" id="_i100"> <i>N</i>-(2-Oxo-2-((2′-oxo-1,1′,2′,3-tetrahydrospiro[indene-2,3′-pyrrolo[2,3-<i>b</i>]pyridin]-5-yl)amino)ethyl)-<i>N</i>-(thiazol-2-ylmethyl)pivalamide (<b>8</b>)</h4><div class="NLM_p last"><b>8E</b> (52 mg, 0.14 mmol) was dissolved in dichloromethane (1.4 mL) and tetrahydrofuran (1.4 mL) and <i>N</i>,<i>N</i>-diisopropylethylamine (0.065 mL, 0.37 mmol). Thiazole-2-carbaldehyde (15 mg, 0.14 mmol), sodium triacetoxyborohydride (100 mg, 0.47 mmol), and magnesium sulfate were added, and the mixture was stirred at rt overnight. The reaction mixture was filtered, poured into water, and the pH was adjusted to 4 with 2 M HCl before being washed twice with dichloromethane. The aqueous layer was basified with sodium carbonate and extracted twice with dichloromethane. This organic extract was dried over magnesium sulfate, filtered, and evaporated to provide an intermediate of <b>8</b>. This compound was dissolved in dichloromethane (2.5 mL) under an argon atmosphere, and <i>N</i>,<i>N</i>-diisopropylethylamine (70 μL, 0.41 mmol) was added and the mixture was stirred at 5 °C (ice/water). Trimethylacetyl chloride (221 μL, 0.18 mmol) was added dropwise, and the mixture was stirred at rt overnight. The reaction mixture was diluted in dichloromethane, washed with brine and saturated sodium bicarbonate, dried over magnesium sulfate, filtered, and the filtrate was evaporated. The residue was purified via MDAP (XBridge C18 19 × 150, 30–60% acetonitrile water with 0.1% ammonium hydroxide) to provide <b>8</b> (14 mg, 20%). <sup>1</sup>H NMR (CD<sub>3</sub>OD, 300 MHz) δ 1.29 (s, 9H), 3.10 (dd, <i>J</i> = 15.8, 6.5 Hz, 2H), 3.51 (dd, <i>J</i> = 15.9, 8.2 Hz, 2H), 4.31 (s, 2H), 5.06 (s, 2H), 6.87 (dd, <i>J</i> = 7.4, 5.5 Hz, 1H), 7.12 (dd, <i>J</i> = 7.4, 1.9 Hz, 1H), 7.20–7.25 (m, 1H), 7.35–7.40 (m, 1H), 7.55–7.59 (m, 2H), 7.72–7.75 (m, 1H), 8.03 (dd, <i>J</i> = 5.5, 1.9 Hz, 1H). UPLC-MS (short basic) <sup><i>t</i></sup>R 1.80 (490 [M + H]<sup>+</sup>).</div></div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i101" class="anchor-spacer"></div><h3 class="article-section__title" id="_i101"> Synthesis of <b>30</b> (See <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>)</h3><div id="sec5_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i102" class="anchor-spacer"></div><h4 class="article-section__title" id="_i102"> (<i>R</i>)-1′-(<i>tert</i>-Butyl)-5-(dibenzylamino)-1,3-dihydrospiro[indene-2,3′-pyrrolo[2,3-<i>b</i>]pyridin]-2′(1<i>′H</i>)-one (<b>33</b>)</h4><div class="NLM_p last">To a solution of sodium hydroxide (72 g) in water (60 mL) at room temperature were added toluene (130 mL) and [2-(chloromethyl)-4-(dibenzylamino)phenyl]methanol hydrochloride (4.7 g, 12.1 mmol). The reaction mixture was stirred at room temperature, while bubbling with argon, for 5 min. Methyl 1-<i>tert</i>-butyl-2-hydroxy-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine-3-carboxylate (3.0 g, 12.1 mmol) was added in three portions over 10 min. Argon continued to be bubbled through the stirring solution for 15 min, and (9<i>R</i>)-1-[3,5-bis(trifluoromethyl)benzyl]cinchonan-1-ium-9-ol bromide (0.7 g, 1.2 mmol) was added in one portion at room temperature. This mixture was stirred at room temperature for 3 h under bubbling argon. Water (∼300 mL) was added [note: exothermic reaction], and the mixture was stirred for ∼15 min while warming to room temperature. The two layers were separated, and the aqueous layer was extracted by ethyl acetate. The combined extracts were washed with water, dried over magnesium sulfate, filtered, and evaporated to give the crude product of ∼90% purity, 83% <i>ee</i>. This product was dissolved in toluene (60 mL) at 60 °C. Once totally dissolved, the mixture was warmed to room temperature and methanol (180 mL) was added. The mixture was stirred at room temperature for 16 h, and the resulting crystals were collected by filtration and washed with methanol to give <b>33</b> (61%, 96% <i>ee</i>). The product was further recrystallized using toluene (50 mL) and methanol (120 mL) to give 3.1 g (52%, >99% <i>ee</i>) of the product. <sup>1</sup>H NMR (CD<sub>3</sub>OD, 400 MHz) δ 1.82 (s, 9H), 2.88 (dd, <i>J</i> = 15.2, 11.8 Hz, 2H), 3.48 (t, <i>J</i> = 15.3 Hz, 2H), 4.67 (s, br, 4H), 6.67 (s, br, 1H), 6.78 (dd, <i>J</i> = 7.1, 5.3 Hz, 1H), 7.01–7.14 (m, 2H), 7.25–7.40 (m, 11H), 8.15 (dd, <i>J</i> = 5.2, 1.7 Hz, 1H); LC-MS (488.27 [M + H]<sup>+</sup>). Chiral HPLC: Phenomenex Lux 3μ Cellulose-1 column; <sup><i>n</i></sup>hexane/isopropanol, 95:5; flow rate = 1.0 mL/min; detection at 254 nm.</div></div><div id="sec5_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i103" class="anchor-spacer"></div><h4 class="article-section__title" id="_i103"> (<i>R</i>)-5-Amino-1,3-dihydrospiro[indene-2,3′-pyrrolo[2,3-<i>b</i>]pyridin]-2′(1<i>′H</i>)-one (<b>30</b>)</h4><div class="NLM_p last">To a solution of <b>33</b> (3.1 g, 6.36 mmol) in methanol (120 mL) was added methanesulfonic acid (11 mL) at room temperature. The mixture was stirred at reflux for 4 h. The methanol was removed under vacuum, and water (∼100 mL) was added to the mixture, and pH was adjusted to ∼ 10 by adding a 50% aqueous solution of sodium hydroxide. The aqueous layer was extracted with ethyl acetate, and the combined extracts were dried over magnesium sulfate, filtered, and evaporated to give the crude product. The crude product was dissolved in methanol (∼80 mL), and Pd/C (0.1 g) was added to the solution followed by concentrated HCl (7 mL). The mixture was stirred at room temperature under a balloon of H<sub>2</sub> overnight. Volatiles were removed to dryness, and the crude material was then dissolved in dichloromethane. Water followed by saturated aqueous potassium carbonate was added to pH ∼ 10. The mixture was extracted by dichloromethane, dried over magnesium sulfate, filtered, and evaporated to give 1.2 g (77%, >99% <i>ee</i>) of the desired product <b>30</b>. This compound was used directly in the next step without further purification. <sup>1</sup>H NMR (CD<sub>3</sub>OD, 400 MHz) δ 2.94 (dd, <i>J</i> = 15.3, 4.4 Hz, 2H), 3.46 (t, <i>J</i> = 14.0 Hz, 2H), 6.65 (d, <i>J</i> = 8.1 Hz, 1H), 6.69 (s, br, 1H), 6.88 (dd, <i>J</i> = 8.9, 3.8 Hz, 1H), 7.02 (d, <i>J</i> = 8.1 Hz, 1H), 7.13 (d, <i>J</i> = 7.3 Hz, 1H), 8.02–8.06 (m, 1H); LC-MS (252.11 [M + H]<sup>+</sup>); [α]<sub>D</sub><sup>22</sup> = +63.6 (<i>c</i> 1.1, MeOH). Chiral HPLC<b>:</b> Phenomenex Lux 3μ Cellulose-1 column; <sup><i>n</i></sup>hexane/isopropanol, 40:60; flow rate = 0.5 mL/min; detection at 220 nm.</div></div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i104" class="anchor-spacer"></div><h3 class="article-section__title" id="_i104"> Synthesis of (<i>R</i>)-<b>25</b></h3><div class="NLM_p last">This compound was synthesized according to the experimental procedure described for <b>25</b> using <b>30</b> instead of D (see <a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>).<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> Analytical data for (<i>R</i>)<b>-25</b>: <sup>1</sup>H NMR (CD<sub>3</sub>OD, 300 MHz) δ 1.32 (s, 9H), 2.41 (s, 3H), 3.04 (dd, <i>J</i> = 15.9, 3.9 Hz, 2H), 3.50 (dd, <i>J</i> = 15.8, 7.4 Hz, 2H), 3.72 (s, 2H), 4.11 (br s, 2H), 4.96 (br s, 2H), 6.86 (dd, <i>J</i> = 7.4, 5.4 Hz, 1H), 7.08–7.14 (m, 1H), 7.17–7.23 (m, 2H), 7.26–7.37 (m, 4H), 7.52 (s, 1H), 8.03 (d, <i>J</i> = 5.4, 1.6 Hz, 1H); [α]<sub>D</sub><sup>22</sup> = +40.8 (<i>c</i> 1.0, MeOH).</div></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i105" class="anchor-spacer"></div><h3 class="article-section__title" id="_i105"> Cell Lines and Culture Conditions</h3><div class="NLM_p last">All cell lines were purchased from ATCC, Cell Applications, Inc., or DiscoverX with proof of authentication, unless stated. All cell lines were maintained at 37 °C in a humidified atmosphere with 5% CO<sub>2</sub>. Human breast cancer cells MDA-MB-231 (ATCC, HTB-26) were cultured in RPMI 1640 medium, GlutaMAX supplement (Thermo Fisher Scientific, 61870-036) containing 10% (v/v) fetal bovine serum (FBS, Thermo Fisher Scientific, 10500-064), and 1% (v/v) penicillin–streptomycin (Sigma-Aldrich, P4333). CGRP (95-0164C6) receptor- and AM<sub>2</sub> (95-0169C6) receptor-overexpressing cell lines were obtained from DiscoverX and cultured in AssayComplete Cell Culture Kit 105 (92-3105G) supplemented with 800 μg/mL G418 and 2.5 μg/mL puromycin. The receptor component expression of these cells was validated in-house previously.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a></div></div><div id="sec5_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i106" class="anchor-spacer"></div><h3 class="article-section__title" id="_i106"> Time-Resolved Fluorescence Resonance Energy-Transfer (TR-FRET) cAMP Accumulation</h3><div class="NLM_p">The ability of the compounds to inhibit cAMP production induced by an EC<sub>50</sub> concentration of the maximum agonist activation (information previously published<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a>) in GPCR/RAMP-overexpressing cells (i.e., AM<sub>2</sub>, CGRP cells) was evaluated using cAMP accumulation assays. Each compound was tested at 8 full-log concentrations (10<sup>–11</sup>–10<sup>–5</sup> M) including a negative control (blank). The total cAMP was measured using the TR-FRET LANCE cAMP detection kit (PerkinElmer, AD0264), as described previously.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> Briefly, frozen cells (2 × 10<sup>6</sup> in each well) were thawed and prepared in warm stimulation buffer (1× HBSS, 5 mM <i>N</i>-(2-hydroxyethyl)piperazine-<i>N</i>′-ethanesulfonic acid (HEPES), 0.5 mM IBMX, and 0.1% bovine serum albumin (BSA)). Alexa Fluor conjugated anti-cAMP (1:100 concentration) was then added to the cell suspension, and cells were plated (2500 cells, 6 μL) in a 384-well white opaque microtiter plate (OptiPlates, PerkinElmer, 6007299). Cells were first preincubated with serial dilutions (3 μL) of the antagonists for 30 min at room temperature prior to their stimulation with the EC<sub>50</sub> value of agonist (3 μL) for 15 min at room temperature. Subsequently, a 12 μL detection mix (Europium-Chelate streptavidin/biotinylated cAMP) was added to stop the reaction and induce cell lysis. TR-FRET was detected after an hour of incubation by an EnSight multimode Plate reader (PerkinElmer) at 320/340 nm excitation and 615/665 nm emission. Data were normalized to agonist only and blank (stimulation buffer only) wells as 0 and 100% cAMP inhibition, respectively.</div><div class="NLM_p last">The final DMSO concentration was below 0.5%, and this was kept consistent in all of the wells, including agonist alone and blank. The same methodology including the number of cells was used for all cell lines. Concentration–response curves were analyzed using three-parameter logistic curve fitting to determine IC<sub>50</sub> values (Graphpad Prism 7 and 8). No further constraints in any parameters of the curves were used.</div></div><div id="sec5_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i107" class="anchor-spacer"></div><h3 class="article-section__title" id="_i107"> Real-Time-Glo MT Viability Assay</h3><div class="NLM_p last">Cell viability in human breast cancer cells (MDA-MB-231) was quantified using Real-Time-Glo MT Cell Viability Assay (Promega, G9712) as previously described.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> Cells (2000 cells) were seeded into 96-well white clear-bottom plates (Corning, 3903) in full serum media overnight before washing and changing to suboptimal media (RPMI + 5% FBS + 1% P/S) containing Real-Time-Glo reagents according to the Promega protocol. A baseline luminescence read (prior to treatment) was taken using an EnSight Multimode Plate Reader (PerkinElmer) after an hour of incubation at 37 °C. Cells were then treated with compounds or vehicle control (PBS + 0.05% DMSO) daily. Results were normalized to vehicle-treated controls as 100% viable (Graphpad Prism 7 and 8).</div></div><div id="sec5_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i108" class="anchor-spacer"></div><h3 class="article-section__title" id="_i108"> Ethical Statement for <i>In Vivo</i> Studies</h3><div class="NLM_p last">The <i>in vivo</i> study plans were assessed by a local research ethics committee before submission for Home Office approval. All <i>in vivo</i> experiments were carried out under the authority of project and personal licenses granted by the U.K. Home Office under the U.K. Animals (Scientific Procedures) Act 1986 (ASPA).</div></div><div id="sec5_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i109" class="anchor-spacer"></div><h3 class="article-section__title" id="_i109"> <i>In Vivo</i> Efficacy Model</h3><div class="NLM_p last">The study was performed using 6–7 week old BALB/c nude female mice, with a weight range of 15–20 g. Animals were provided by Envigo Corporation (Cambridgeshire, U.K.) or Charles River Laboratories (Massachusetts) depending on availability. Each experiment started with 10 mice (experimental units) in each experimental/control group. Subsequent analysis (tumor growth and histology) was only performed in animals where tumors had established and were palpable within 3 days of implantation. This was in accordance with the power calculation performed to ensure robust statistical analysis by the University of Sheffield Statistical Service. The animals were housed in individually ventilated cages (with the appropriate bedding and flooring conditions) in environmentally controlled conditions with a 12 h light/dark cycles at ∼26 °C. Mice had access to an adequate amount of water and a 2018 Teklad Global 18% Protein Rodent Diet containing 1.01% calcium (Harlan Laboratories, U.K.). The day-to-day care of the animals was carried out by the technicians in the Biological Services (The University of Sheffield, U.K.). All scientific procedures on animals were carried under the U.K. Home Office Project Licenses (40/3499) and Procedure Individual Licenses.</div></div><div id="sec5_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i110" class="anchor-spacer"></div><h3 class="article-section__title" id="_i110"> Compound Preparation for <i>In Vivo</i> Studies</h3><div class="NLM_p last">Compounds were dissolved in DMSO (Sigma-Aldrich, D4540) and sonicated at 37 °C for 10 min. The appropriate volume of solvent (Kolliphor HS15 (1 part, grams), Kollisolv PEG E 400 (3 parts, mL), and PBS (6 parts, mL)) was then added to yield a 6% DMSO/94% solvent solution. These working stocks (8 mg/mL) were further sonicated at 37 °C for 10 min before storing at −20 °C. To make treatment aliquots, equal amounts of the working stock (or vehicle control) and solvent were mixed and sonicated at 37 °C for 10 min (4 mg/mL, equivalent to 20 mg/kg, 3% DMSO/97% solvent). Vehicle control and compounds were sonicated at 37 °C for 10 min prior to ip injections (200 μL per mouse).</div></div><div id="sec5_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i111" class="anchor-spacer"></div><h3 class="article-section__title" id="_i111"> Cell Preparation and Tumor Inoculation</h3><div class="NLM_p last">Cells were prepared according to standard cell culture techniques. Cell pellets were resuspended in 50% PBS/50% Matrigel (Corning, 354234). Matrigel/PBS cell suspension, needles (25G), and syringes (1 mL) were kept on ice before and during tumor inoculation into mice. Cell suspension (100 μL, 5 × 10<sup>6</sup> cells) was injected subcutaneously into the left flank of 6–7 weeks old female immunodeficient nude athymic mice (BALB/c nude). Once the tumors became palpable (around 100 mm<sup>3</sup>), mice were randomized into treatment groups. Mice were treated daily at the same time of the day with an ip injection of 20 mg/kg of compound or vehicle control (200 μL per mouse) until humane end point. Mice were observed for at least 30 min post treatment to detect any acute adverse effects. Tumor size and mouse weights were measured twice a week. At the end of each study, the animals were euthanized following the appropriate procedures listed in the ASPA Act 1986. Vital organs and tumors were stored in 10% neutral-buffered formalin for further histological analysis. The primary experimental outcome was tumor volume. The percentage tumor volume was calculated by normalizing measured tumor volumes to the initial tumor volume prior to the start of treatment on day 5. Simple linear regression was done to compare the line of best fit between the growth curves. Blinding was not used for the <i>in vivo</i> studies.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i112"><a href="/doi/suppl/10.1021/acs.jmedchem.0c02191" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_87288" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_87288" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.0c02191?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c02191</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">AM<sub>2</sub> hybrid model (<a href="/doi/suppl/10.1021/acs.jmedchem.0c02191/suppl_file/jm0c02191_si_001.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">Telcagepant docking (<a href="/doi/suppl/10.1021/acs.jmedchem.0c02191/suppl_file/jm0c02191_si_002.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">Compound <b>1</b> docking (<a href="/doi/suppl/10.1021/acs.jmedchem.0c02191/suppl_file/jm0c02191_si_003.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">Compound (<i>R</i>)-<b>25</b> docking (<a href="/doi/suppl/10.1021/acs.jmedchem.0c02191/suppl_file/jm0c02191_si_004.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.0c02191/suppl_file/jm0c02191_si_005.csv" class="ext-link">CSV</a>)</p></li><li><p class="inline">X-ray crystal structure analysis of (<i>R</i>)-CLR-binding unit <b>30</b> and key compounds <b>12</b>, <b>14</b>, (±)-<b>25</b>, and (<i>R</i>)-<b>25</b> chemical data (<sup>1</sup>H NMR, HPLC, LC-MS) (<a href="/doi/suppl/10.1021/acs.jmedchem.0c02191/suppl_file/jm0c02191_si_006.pdf" class="ext-link">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c02191/suppl_file/jm0c02191_liveslides.mp4">jm0c02191_liveslides.mp4 (8.14 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c02191/suppl_file/jm0c02191_si_001.pdb">jm0c02191_si_001.pdb (105.62 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c02191/suppl_file/jm0c02191_si_002.pdb">jm0c02191_si_002.pdb (3.45 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c02191/suppl_file/jm0c02191_si_003.pdb">jm0c02191_si_003.pdb (3.09 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c02191/suppl_file/jm0c02191_si_004.pdb">jm0c02191_si_004.pdb (2.7 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c02191/suppl_file/jm0c02191_si_005.csv">jm0c02191_si_005.csv (2.74 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c02191/suppl_file/jm0c02191_si_006.pdf">jm0c02191_si_006.pdf (1.33 MB)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.0c02191" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_35140" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_35140" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Joseph P. A. Harrity</span> - <span class="hlFld-Affiliation affiliation">Department
of Chemistry, University of Sheffield, Sheffield S10 2TN, U.K.</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-5038-5699" title="Orcid link">http://orcid.org/0000-0001-5038-5699</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#63094d0b0211110a171a23100b0605050a060f074d02004d1608"><span class="__cf_email__" data-cfemail="e78dc98f8695958e939ea7948f8281818e828b83c98684c9928c">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jean-Olivier Zirimwabagabo</span> - <span class="hlFld-Affiliation affiliation">Department
of Chemistry, University of Sheffield, Sheffield S10 2TN, U.K.</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-4303-2139" title="Orcid link">http://orcid.org/0000-0002-4303-2139</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ameera B. A. Jailani</span> - <span class="hlFld-Affiliation affiliation">Department
of Oncology and Metabolism, University of
Sheffield, Sheffield S10 2TN, U.K.</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-9837-6062" title="Orcid link">http://orcid.org/0000-0001-9837-6062</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Paris Avgoustou</span> - <span class="hlFld-Affiliation affiliation">Department
of Oncology and Metabolism, University of
Sheffield, Sheffield S10 2TN, U.K.</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-1642-1083" title="Orcid link">http://orcid.org/0000-0002-1642-1083</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Matthew J. Tozer</span> - <span class="hlFld-Affiliation affiliation">Matt
Tozer Consultancy, Bognor Regis PO21 1DY, U.K.</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-9046-4065" title="Orcid link">http://orcid.org/0000-0002-9046-4065</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Karl R. Gibson</span> - <span class="hlFld-Affiliation affiliation">Sandexis
Medicinal Chemistry Ltd., Sandwich, Kent CT13 9ND, U.K.</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-7967-8476" title="Orcid link">http://orcid.org/0000-0002-7967-8476</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Paul A. Glossop</span> - <span class="hlFld-Affiliation affiliation">Sandexis
Medicinal Chemistry Ltd., Sandwich, Kent CT13 9ND, U.K.</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-6567-5648" title="Orcid link">http://orcid.org/0000-0001-6567-5648</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">James E. J. Mills</span> - <span class="hlFld-Affiliation affiliation">Sandexis
Medicinal Chemistry Ltd., Sandwich, Kent CT13 9ND, U.K.</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-2567-3872" title="Orcid link">http://orcid.org/0000-0002-2567-3872</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Roderick A. Porter</span> - <span class="hlFld-Affiliation affiliation">Rod
Porter Consultancy, Ashwell, Hertfordshire SG7 5PG, U.K.</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-8252-0429" title="Orcid link">http://orcid.org/0000-0001-8252-0429</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Paul Blaney</span> - <span class="hlFld-Affiliation affiliation">Concept
Life Sciences, High Peak SK23 0PG, U.K.</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-8121-8594" title="Orcid link">http://orcid.org/0000-0001-8121-8594</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ning Wang</span> - <span class="hlFld-Affiliation affiliation">Department
of Oncology and Metabolism, University of
Sheffield, Sheffield S10 2TN, U.K.</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-2663-7515" title="Orcid link">http://orcid.org/0000-0002-2663-7515</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Timothy M. Skerry</span> - <span class="hlFld-Affiliation affiliation">Department
of Oncology and Metabolism, University of
Sheffield, Sheffield S10 2TN, U.K.</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-1319-5575" title="Orcid link">http://orcid.org/0000-0003-1319-5575</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gareth O. Richards</span> - <span class="hlFld-Affiliation affiliation">Department
of Oncology and Metabolism, University of
Sheffield, Sheffield S10 2TN, U.K.</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-7984-6882" title="Orcid link">http://orcid.org/0000-0001-7984-6882</a></span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>J.-O.Z., A.B.A.J., P.A., T.M.S., G.O.R., and J.P.A.H contributed equally to this work. J.-O.Z., A.B.A.J., P.A., M.J.T., K.R.G., P.A.G., J.E.J.M., R.A.P., P.B., N.W., T.M.S., J.P.A.H., and G.O.R. designed research; J.-O.Z., A.B.A.J., P.A., J.E.J.M., and N.W. performed research; J.-O.Z. and P.B. contributed new reagents/analytic tools; J.-O.Z., A.B.A.J., P.A., M.J.T., K.R.G., P.A.G., J.E.J.M., R.A.P., P.B., N.W., T.M.S., J.P.A.H., and G.O.R. analyzed data; J.-O.Z., A.B.A.J., P.A., M.J.T., K.R.G., P.A.G., J.E.J.M., R.A.P., T.M.S., J.P.A.H., and G.O.R. wrote and reviewed the manuscript.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare the following competing financial interest(s): Results and reagents arising from this study are currently the subject of patent filings. The University of Sheffield is exploring the possibility of commercialising AM2 receptor antagonists as therapeutics. If this occurs, Timothy M. Skerry, Joseph P. A. Harrity, Gareth O. Richards, Paris Avgoustou, Ameera B. A. Jailani, and Jean-Olivier Zirimwabagabo may benefit financially from stock or other rewards for invention. If the research is commercialized, the following may receive payment for work to be performed during the commercialization process: Matthew J. Tozer, Karl R. Gibson, Paul A. Glossop, James E. J. Mills, Roderick A. Porter.<br /></br><p class="inlineNote">All data generated or analyzed during this study are either included in this published article (and its <a href="/doi/suppl/10.1021/acs.jmedchem.0c02191/suppl_file/jm0c02191_si_006.pdf" class="ext-link">Supporting Information</a>) or are available from the corresponding authors on reasonable request.</p></div></li></ul></div><div class="ack" id="ACK-d7e5075-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i115">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_08333" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_08333" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We would like to thank the following for their assistance with these studies: Prostate Cancer UK (Grant PA12–12), Wellcome Trust (Grants 104046/Z/14/1 and 205291/Z/16/Z), and the University of Sheffield for funding support for target validation, drug discovery research, and proof of concept studies, respectively; Drs. Richard Seabrook, Alan Naylor, Graham Showell, and Georgios Trichas for support and advice during the research; Drs. Zaixu Xu and Genfu Chen of Wuxi AppTec for chemical synthesis and ADME studies, respectively; and the reviewers of this article, whose constructive comments improved the clarity and focus of our original manuscript.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations</td></tr><tr><td class="NLM_term">AM</td><td class="NLM_def"><p class="first last">adrenomedullin</p></td></tr><tr><td class="NLM_term">AM<sub>1</sub></td><td class="NLM_def"><p class="first last">adrenomedullin-1</p></td></tr><tr><td class="NLM_term">AM<sub>2</sub></td><td class="NLM_def"><p class="first last">adrenomedullin-2</p></td></tr><tr><td class="NLM_term">CLR</td><td class="NLM_def"><p class="first last">calcitonin receptor-like receptor</p></td></tr><tr><td class="NLM_term">CSH</td><td class="NLM_def"><p class="first last">charged surface hybrid</p></td></tr><tr><td class="NLM_term">CTR</td><td class="NLM_def"><p class="first last">calcitonin receptor</p></td></tr><tr><td class="NLM_term">DIPEA</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-diisopropylethylamine</p></td></tr><tr><td class="NLM_term">EDCI.HCl</td><td class="NLM_def"><p class="first last">1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride salt</p></td></tr><tr><td class="NLM_term">HATU</td><td class="NLM_def"><p class="first last">hexafluorophosphate azabenzotriazole tetramethyl uranium</p></td></tr><tr><td class="NLM_term">HBSS</td><td class="NLM_def"><p class="first last">Hanks balanced salt solution</p></td></tr><tr><td class="NLM_term">HEPES</td><td class="NLM_def"><p class="first last">4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid</p></td></tr><tr><td class="NLM_term">HOAt</td><td class="NLM_def"><p class="first last">1-hydroxy-7-azabenzotriazole</p></td></tr><tr><td class="NLM_term">IBMX</td><td class="NLM_def"><p class="first last">3-isobutyl-1-methylxanthine</p></td></tr><tr><td class="NLM_term">LC-MS</td><td class="NLM_def"><p class="first last">liquid chromatography-mass spectrometry</p></td></tr><tr><td class="NLM_term">MDAP</td><td class="NLM_def"><p class="first last">mass directed autopurification</p></td></tr><tr><td class="NLM_term">MW</td><td class="NLM_def"><p class="first last">microwave</p></td></tr><tr><td class="NLM_term">NMM</td><td class="NLM_def"><p class="first last"><i>N</i>-methylmorpholine</p></td></tr><tr><td class="NLM_term">PDA</td><td class="NLM_def"><p class="first last">photodiode array</p></td></tr><tr><td class="NLM_term"><i>p</i>TSA</td><td class="NLM_def"><p class="first last"><i>p</i>-toluene sulfonic acid</p></td></tr><tr><td class="NLM_term">QDA</td><td class="NLM_def"><p class="first last">quadrupole dalton</p></td></tr><tr><td class="NLM_term">RAMP</td><td class="NLM_def"><p class="first last">receptor activity-modifying proteins</p></td></tr><tr><td class="NLM_term"><sup><i>t</i></sup>R</td><td class="NLM_def"><p class="first last">retention time</p></td></tr><tr><td class="NLM_term">rt</td><td class="NLM_def"><p class="first last">room temperature</p></td></tr><tr><td class="NLM_term">SCX2</td><td class="NLM_def"><p class="first last">strong cation-exchange 2 (SPE from Biotage)</p></td></tr><tr><td class="NLM_term">SEM</td><td class="NLM_def"><p class="first last">trimethylsilylethoxymethyl</p></td></tr><tr><td class="NLM_term">SPE</td><td class="NLM_def"><p class="first last">solid-phase extraction</p></td></tr><tr><td class="NLM_term">UPLC</td><td class="NLM_def"><p class="first last">ultraperformance liquid chromatography</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i117">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_06216" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_06216" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 47 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alexander, S. P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christopoulos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davenport, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathie, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peters, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veale, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armstrong, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faccenda, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harding, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pawson, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharman, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Southan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arumugam, T. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sjogren, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sobey, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abbracchio, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alexander, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-hosaini, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Back, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaulieu, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernstein, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bettler, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birdsall, N. J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blaho, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bousquet, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brauner-Osborne, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burnstock, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castano, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Catt, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ceruti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chazot, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiang, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cianciulli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clapp, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Couture, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Csaba, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dent, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Douglas, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dournaud, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eguchi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Escher, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Filardo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fong, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fumagalli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gainetdinov, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Gasparo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gershengorn, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gobeil, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodfriend, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goudet, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gregory, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gundlach, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamann, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hauger, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hay, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heinemann, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollenberg, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holliday, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horiuchi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoyer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunyady, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Husain, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ijzerman, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inagami, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jockers, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jonnalagadda, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karnik, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaupmann, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kemp, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kennedy, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kihara, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozielewicz, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kreienkamp, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kukkonen, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langenhan, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leach, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lecca, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leeman, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leprince, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lolait, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lupp, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macrae, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maguire, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazella, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McArdle, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melmed, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michel, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitolo, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mouillac, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nahon, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norel, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nyimanu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Carroll, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Offermanns, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panaro, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pertwee, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pin, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prossnitz, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramachandran, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reinscheid, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rondard, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rovati, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruzza, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanger, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schoneberg, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schulte, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schulz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Segaloff, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serhan, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoddart, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugimoto, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Summers, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timmermans, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tirupula, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tulipano, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unal, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unger, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanderheyden, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaudry, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaudry, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vilardaga, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wester, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willars, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodruff, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aldrich, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Becirovic, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Catterall, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conner, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delling, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Virgilio, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Falzoni, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">George, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldstein, S. A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grissmer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ha, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammelmann, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanukoglu, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jarvis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaczmarek, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kellenberger, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lynch, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez-Reyes, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plant, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rash, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sivilotti, L. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smart, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snutch, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van den
Eynde, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vriens, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winn, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wulff, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, H. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yue, L. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coons, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuller, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korach, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bryant, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farndale, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hobbs, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jarvis, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacEwan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monie, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waldman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beuve, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boison, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brouckaert, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burnett, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burns, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dessauer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friebe, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garthwaite, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gertsch, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helsby, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Izzo, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koesling, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuhn, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ostrom, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papapetropoulos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potter, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pyne, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pyne, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russwurm, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seifert, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stasch, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szabo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Stelt, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Vliet, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watts, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, C. M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dawson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagenbuch, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammond, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hancox, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inui, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kemp, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thwaites, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verri, T.</span></span>; <span class="NLM_contrib-group">CGTP Collaborators</span> <span> </span><span class="NLM_article-title">The concise guide to pharmacology 2019/20: G protein-coupled receptors</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>176</i></span>,  <span class="NLM_fpage">S21</span>– <span class="NLM_lpage">S141</span>, <span class="refDoi"> DOI: 10.1111/bph.14748</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=10.1111%2Fbph.14748" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=31710717" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=176&publication_year=2019&pages=S21-S141&author=S.+P.+H.+Alexanderauthor=A.+Christopoulosauthor=A.+P.+Davenportauthor=E.+Kellyauthor=A.+Mathieauthor=J.+A.+Petersauthor=E.+L.+Vealeauthor=J.+F.+Armstrongauthor=E.+Faccendaauthor=S.+D.+Hardingauthor=A.+J.+Pawsonauthor=J.+L.+Sharmanauthor=C.+Southanauthor=J.+A.+Daviesauthor=T.+V.+Arumugamauthor=A.+Bennettauthor=B.+Sjogrenauthor=C.+Sobeyauthor=S.+S.+Wongauthor=M.+P.+Abbracchioauthor=W.+Alexanderauthor=K.+Al-hosainiauthor=M.+Backauthor=J.+M.+Beaulieuauthor=K.+E.+Bernsteinauthor=B.+Bettlerauthor=N.+J.+M.+Birdsallauthor=V.+Blahoauthor=C.+Bousquetauthor=H.+Brauner-Osborneauthor=G.+Burnstockauthor=G.+Caloauthor=J.+P.+Castanoauthor=K.+J.+Cattauthor=S.+Cerutiauthor=P.+Chazotauthor=N.+Chiangauthor=J.+Chunauthor=A.+Cianciulliauthor=L.+H.+Clappauthor=R.+Coutureauthor=Z.+Csabaauthor=G.+Dentauthor=K.+D.+Singhauthor=S.+D.+Douglasauthor=P.+Dournaudauthor=S.+Eguchiauthor=E.+Escherauthor=E.+Filardoauthor=T.+M.+Fongauthor=M.+Fumagalliauthor=R.+R.+Gainetdinovauthor=M.+de+Gasparoauthor=M.+Gershengornauthor=F.+Gobeilauthor=T.+L.+Goodfriendauthor=C.+Goudetauthor=K.+J.+Gregoryauthor=A.+L.+Gundlachauthor=J.+Hamannauthor=J.+Hansonauthor=R.+L.+Haugerauthor=D.+Hayauthor=A.+Heinemannauthor=M.+D.+Hollenbergauthor=N.+D.+Hollidayauthor=M.+Horiuchiauthor=D.+Hoyerauthor=L.+Hunyadyauthor=A.+Husainauthor=A.+P.+Ijzermanauthor=T.+Inagamiauthor=K.+A.+Jacobsonauthor=R.+T.+Jensenauthor=R.+Jockersauthor=D.+Jonnalagaddaauthor=S.+Karnikauthor=K.+Kaupmannauthor=J.+Kempauthor=C.+Kennedyauthor=Y.+Kiharaauthor=P.+Kozielewiczauthor=H.+J.+Kreienkampauthor=J.+P.+Kukkonenauthor=T.+Langenhanauthor=K.+Leachauthor=D.+Leccaauthor=J.+D.+Leeauthor=S.+E.+Leemanauthor=J.+Leprinceauthor=S.+J.+Lolaitauthor=A.+Luppauthor=R.+Macraeauthor=J.+Maguireauthor=J.+Mazellaauthor=C.+A.+McArdleauthor=S.+Melmedauthor=M.+C.+Michelauthor=L.+Millerauthor=V.+Mitoloauthor=B.+Mouillacauthor=P.+M.+Murphyauthor=J.+L.+Nahonauthor=X.+Norelauthor=D.+Nyimanuauthor=A.+M.+O%E2%80%99Carrollauthor=S.+Offermannsauthor=M.+A.+Panaroauthor=R.+G.+Pertweeauthor=J.+P.+Pinauthor=E.+Prossnitzauthor=R.+Ramachandranauthor=R.+K.+Reinscheidauthor=P.+Rondardauthor=G.+E.+Rovatiauthor=C.+Ruzzaauthor=G.+Sangerauthor=T.+Schonebergauthor=G.+Schulteauthor=S.+Schulzauthor=D.+L.+Segaloffauthor=C.+N.+Serhanauthor=L.+A.+Stoddartauthor=Y.+Sugimotoauthor=R.+Summersauthor=V.+Tanauthor=W.+Thomasauthor=P.+Timmermansauthor=K.+Tirupulaauthor=G.+Tulipanoauthor=H.+Unalauthor=T.+Ungerauthor=P.+Vanderheydenauthor=D.+Vaudryauthor=H.+Vaudryauthor=J.+P.+Vilardagaauthor=C.+S.+Walkerauthor=D.+T.+Wardauthor=H.+J.+Westerauthor=G.+B.+Willarsauthor=T.+L.+Williamsauthor=T.+M.+Woodruffauthor=C.+C.+Yaoauthor=R.+W.+Aldrichauthor=E.+Becirovicauthor=M.+Bielauthor=W.+A.+Catterallauthor=A.+C.+Connerauthor=P.+Daviesauthor=M.+Dellingauthor=F.+Di+Virgilioauthor=S.+Falzoniauthor=C.+Georgeauthor=S.+A.+N.+Goldsteinauthor=S.+Grissmerauthor=K.+Haauthor=V.+Hammelmannauthor=I.+Hanukogluauthor=M.+Jarvisauthor=A.+A.+Jensenauthor=L.+K.+Kaczmarekauthor=S.+Kellenbergerauthor=B.+Kingauthor=J.+W.+Lynchauthor=E.+Perez-Reyesauthor=L.+D.+Plantauthor=L.+D.+Rashauthor=D.+J.+Renauthor=L.+G.+Sivilottiauthor=T.+G.+Smartauthor=T.+P.+Snutchauthor=J.+B.+Tianauthor=C.+Van+den%0AEyndeauthor=J.+Vriensauthor=A.+D.+Weiauthor=B.+T.+Winnauthor=H.+Wulffauthor=H.+X.+Xuauthor=L.+X.+Yueauthor=X.+L.+Zhangauthor=M.+Zhuauthor=L.+Coonsauthor=P.+Fullerauthor=K.+S.+Korachauthor=M.+Youngauthor=C.+Bryantauthor=R.+W.+Farndaleauthor=A.+Hobbsauthor=G.+E.+Jarvisauthor=D.+MacEwanauthor=T.+P.+Monieauthor=S.+Waldmanauthor=A.+Beuveauthor=D.+Boisonauthor=P.+Brouckaertauthor=J.+C.+Burnettauthor=K.+Burnsauthor=C.+Dessauerauthor=A.+Friebeauthor=J.+Garthwaiteauthor=J.+Gertschauthor=N.+Helsbyauthor=A.+A.+Izzoauthor=D.+Koeslingauthor=M.+Kuhnauthor=R.+Ostromauthor=A.+Papapetropoulosauthor=L.+R.+Potterauthor=N.+J.+Pyneauthor=S.+Pyneauthor=M.+Russwurmauthor=H.+Schmidtauthor=R.+Seifertauthor=J.+P.+Staschauthor=C.+Szaboauthor=M.+van+der+Steltauthor=A.+van+der+Vlietauthor=V.+Wattsauthor=C.+M.+H.+Andersonauthor=S.+Broerauthor=P.+Dawsonauthor=B.+Hagenbuchauthor=J.+R.+Hammondauthor=J.+Hancoxauthor=K.+Inuiauthor=Y.+Kanaiauthor=S.+Kempauthor=D.+T.+Thwaitesauthor=T.+Verriauthor=CGTP+Collaborators&title=The+concise+guide+to+pharmacology+2019%2F20%3A+G+protein-coupled+receptors&doi=10.1111%2Fbph.14748"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1111%2Fbph.14748&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.14748%26sid%3Dliteratum%253Aachs%26aulast%3DAlexander%26aufirst%3DS.%2BP.%2BH.%26aulast%3DChristopoulos%26aufirst%3DA.%26aulast%3DDavenport%26aufirst%3DA.%2BP.%26aulast%3DKelly%26aufirst%3DE.%26aulast%3DMathie%26aufirst%3DA.%26aulast%3DPeters%26aufirst%3DJ.%2BA.%26aulast%3DVeale%26aufirst%3DE.%2BL.%26aulast%3DArmstrong%26aufirst%3DJ.%2BF.%26aulast%3DFaccenda%26aufirst%3DE.%26aulast%3DHarding%26aufirst%3DS.%2BD.%26aulast%3DPawson%26aufirst%3DA.%2BJ.%26aulast%3DSharman%26aufirst%3DJ.%2BL.%26aulast%3DSouthan%26aufirst%3DC.%26aulast%3DDavies%26aufirst%3DJ.%2BA.%26aulast%3DArumugam%26aufirst%3DT.%2BV.%26aulast%3DBennett%26aufirst%3DA.%26aulast%3DSjogren%26aufirst%3DB.%26aulast%3DSobey%26aufirst%3DC.%26aulast%3DWong%26aufirst%3DS.%2BS.%26aulast%3DAbbracchio%26aufirst%3DM.%2BP.%26aulast%3DAlexander%26aufirst%3DW.%26aulast%3DAl-hosaini%26aufirst%3DK.%26aulast%3DBack%26aufirst%3DM.%26aulast%3DBeaulieu%26aufirst%3DJ.%2BM.%26aulast%3DBernstein%26aufirst%3DK.%2BE.%26aulast%3DBettler%26aufirst%3DB.%26aulast%3DBirdsall%26aufirst%3DN.%2BJ.%2BM.%26aulast%3DBlaho%26aufirst%3DV.%26aulast%3DBousquet%26aufirst%3DC.%26aulast%3DBrauner-Osborne%26aufirst%3DH.%26aulast%3DBurnstock%26aufirst%3DG.%26aulast%3DCalo%26aufirst%3DG.%26aulast%3DCastano%26aufirst%3DJ.%2BP.%26aulast%3DCatt%26aufirst%3DK.%2BJ.%26aulast%3DCeruti%26aufirst%3DS.%26aulast%3DChazot%26aufirst%3DP.%26aulast%3DChiang%26aufirst%3DN.%26aulast%3DChun%26aufirst%3DJ.%26aulast%3DCianciulli%26aufirst%3DA.%26aulast%3DClapp%26aufirst%3DL.%2BH.%26aulast%3DCouture%26aufirst%3DR.%26aulast%3DCsaba%26aufirst%3DZ.%26aulast%3DDent%26aufirst%3DG.%26aulast%3DSingh%26aufirst%3DK.%2BD.%26aulast%3DDouglas%26aufirst%3DS.%2BD.%26aulast%3DDournaud%26aufirst%3DP.%26aulast%3DEguchi%26aufirst%3DS.%26aulast%3DEscher%26aufirst%3DE.%26aulast%3DFilardo%26aufirst%3DE.%26aulast%3DFong%26aufirst%3DT.%2BM.%26aulast%3DFumagalli%26aufirst%3DM.%26aulast%3DGainetdinov%26aufirst%3DR.%2BR.%26aulast%3Dde%2BGasparo%26aufirst%3DM.%26aulast%3DGershengorn%26aufirst%3DM.%26aulast%3DGobeil%26aufirst%3DF.%26aulast%3DGoodfriend%26aufirst%3DT.%2BL.%26aulast%3DGoudet%26aufirst%3DC.%26aulast%3DGregory%26aufirst%3DK.%2BJ.%26aulast%3DGundlach%26aufirst%3DA.%2BL.%26aulast%3DHamann%26aufirst%3DJ.%26aulast%3DHanson%26aufirst%3DJ.%26aulast%3DHauger%26aufirst%3DR.%2BL.%26aulast%3DHay%26aufirst%3DD.%26aulast%3DHeinemann%26aufirst%3DA.%26aulast%3DHollenberg%26aufirst%3DM.%2BD.%26aulast%3DHolliday%26aufirst%3DN.%2BD.%26aulast%3DHoriuchi%26aufirst%3DM.%26aulast%3DHoyer%26aufirst%3DD.%26aulast%3DHunyady%26aufirst%3DL.%26aulast%3DHusain%26aufirst%3DA.%26aulast%3DIjzerman%26aufirst%3DA.%2BP.%26aulast%3DInagami%26aufirst%3DT.%26aulast%3DJacobson%26aufirst%3DK.%2BA.%26aulast%3DJensen%26aufirst%3DR.%2BT.%26aulast%3DJockers%26aufirst%3DR.%26aulast%3DJonnalagadda%26aufirst%3DD.%26aulast%3DKarnik%26aufirst%3DS.%26aulast%3DKaupmann%26aufirst%3DK.%26aulast%3DKemp%26aufirst%3DJ.%26aulast%3DKennedy%26aufirst%3DC.%26aulast%3DKihara%26aufirst%3DY.%26aulast%3DKozielewicz%26aufirst%3DP.%26aulast%3DKreienkamp%26aufirst%3DH.%2BJ.%26aulast%3DKukkonen%26aufirst%3DJ.%2BP.%26aulast%3DLangenhan%26aufirst%3DT.%26aulast%3DLeach%26aufirst%3DK.%26aulast%3DLecca%26aufirst%3DD.%26aulast%3DLee%26aufirst%3DJ.%2BD.%26aulast%3DLeeman%26aufirst%3DS.%2BE.%26aulast%3DLeprince%26aufirst%3DJ.%26aulast%3DLolait%26aufirst%3DS.%2BJ.%26aulast%3DLupp%26aufirst%3DA.%26aulast%3DMacrae%26aufirst%3DR.%26aulast%3DMaguire%26aufirst%3DJ.%26aulast%3DMazella%26aufirst%3DJ.%26aulast%3DMcArdle%26aufirst%3DC.%2BA.%26aulast%3DMelmed%26aufirst%3DS.%26aulast%3DMichel%26aufirst%3DM.%2BC.%26aulast%3DMiller%26aufirst%3DL.%26aulast%3DMitolo%26aufirst%3DV.%26aulast%3DMouillac%26aufirst%3DB.%26aulast%3DMurphy%26aufirst%3DP.%2BM.%26aulast%3DNahon%26aufirst%3DJ.%2BL.%26aulast%3DNorel%26aufirst%3DX.%26aulast%3DNyimanu%26aufirst%3DD.%26aulast%3DO%25E2%2580%2599Carroll%26aufirst%3DA.%2BM.%26aulast%3DOffermanns%26aufirst%3DS.%26aulast%3DPanaro%26aufirst%3DM.%2BA.%26aulast%3DPertwee%26aufirst%3DR.%2BG.%26aulast%3DPin%26aufirst%3DJ.%2BP.%26aulast%3DProssnitz%26aufirst%3DE.%26aulast%3DRamachandran%26aufirst%3DR.%26aulast%3DReinscheid%26aufirst%3DR.%2BK.%26aulast%3DRondard%26aufirst%3DP.%26aulast%3DRovati%26aufirst%3DG.%2BE.%26aulast%3DRuzza%26aufirst%3DC.%26aulast%3DSanger%26aufirst%3DG.%26aulast%3DSchoneberg%26aufirst%3DT.%26aulast%3DSchulte%26aufirst%3DG.%26aulast%3DSchulz%26aufirst%3DS.%26aulast%3DSegaloff%26aufirst%3DD.%2BL.%26aulast%3DSerhan%26aufirst%3DC.%2BN.%26aulast%3DStoddart%26aufirst%3DL.%2BA.%26aulast%3DSugimoto%26aufirst%3DY.%26aulast%3DSummers%26aufirst%3DR.%26aulast%3DTan%26aufirst%3DV.%26aulast%3DThomas%26aufirst%3DW.%26aulast%3DTimmermans%26aufirst%3DP.%26aulast%3DTirupula%26aufirst%3DK.%26aulast%3DTulipano%26aufirst%3DG.%26aulast%3DUnal%26aufirst%3DH.%26aulast%3DUnger%26aufirst%3DT.%26aulast%3DVanderheyden%26aufirst%3DP.%26aulast%3DVaudry%26aufirst%3DD.%26aulast%3DVaudry%26aufirst%3DH.%26aulast%3DVilardaga%26aufirst%3DJ.%2BP.%26aulast%3DWalker%26aufirst%3DC.%2BS.%26aulast%3DWard%26aufirst%3DD.%2BT.%26aulast%3DWester%26aufirst%3DH.%2BJ.%26aulast%3DWillars%26aufirst%3DG.%2BB.%26aulast%3DWilliams%26aufirst%3DT.%2BL.%26aulast%3DWoodruff%26aufirst%3DT.%2BM.%26aulast%3DYao%26aufirst%3DC.%2BC.%26aulast%3DAldrich%26aufirst%3DR.%2BW.%26aulast%3DBecirovic%26aufirst%3DE.%26aulast%3DBiel%26aufirst%3DM.%26aulast%3DCatterall%26aufirst%3DW.%2BA.%26aulast%3DConner%26aufirst%3DA.%2BC.%26aulast%3DDavies%26aufirst%3DP.%26aulast%3DDelling%26aufirst%3DM.%26aulast%3DDi%2BVirgilio%26aufirst%3DF.%26aulast%3DFalzoni%26aufirst%3DS.%26aulast%3DGeorge%26aufirst%3DC.%26aulast%3DGoldstein%26aufirst%3DS.%2BA.%2BN.%26aulast%3DGrissmer%26aufirst%3DS.%26aulast%3DHa%26aufirst%3DK.%26aulast%3DHammelmann%26aufirst%3DV.%26aulast%3DHanukoglu%26aufirst%3DI.%26aulast%3DJarvis%26aufirst%3DM.%26aulast%3DJensen%26aufirst%3DA.%2BA.%26aulast%3DKaczmarek%26aufirst%3DL.%2BK.%26aulast%3DKellenberger%26aufirst%3DS.%26aulast%3DKing%26aufirst%3DB.%26aulast%3DLynch%26aufirst%3DJ.%2BW.%26aulast%3DPerez-Reyes%26aufirst%3DE.%26aulast%3DPlant%26aufirst%3DL.%2BD.%26aulast%3DRash%26aufirst%3DL.%2BD.%26aulast%3DRen%26aufirst%3DD.%2BJ.%26aulast%3DSivilotti%26aufirst%3DL.%2BG.%26aulast%3DSmart%26aufirst%3DT.%2BG.%26aulast%3DSnutch%26aufirst%3DT.%2BP.%26aulast%3DTian%26aufirst%3DJ.%2BB.%26aulast%3DVan%2Bden%2BEynde%26aufirst%3DC.%26aulast%3DVriens%26aufirst%3DJ.%26aulast%3DWei%26aufirst%3DA.%2BD.%26aulast%3DWinn%26aufirst%3DB.%2BT.%26aulast%3DWulff%26aufirst%3DH.%26aulast%3DXu%26aufirst%3DH.%2BX.%26aulast%3DYue%26aufirst%3DL.%2BX.%26aulast%3DZhang%26aufirst%3DX.%2BL.%26aulast%3DZhu%26aufirst%3DM.%26aulast%3DCoons%26aufirst%3DL.%26aulast%3DFuller%26aufirst%3DP.%26aulast%3DKorach%26aufirst%3DK.%2BS.%26aulast%3DYoung%26aufirst%3DM.%26aulast%3DBryant%26aufirst%3DC.%26aulast%3DFarndale%26aufirst%3DR.%2BW.%26aulast%3DHobbs%26aufirst%3DA.%26aulast%3DJarvis%26aufirst%3DG.%2BE.%26aulast%3DMacEwan%26aufirst%3DD.%26aulast%3DMonie%26aufirst%3DT.%2BP.%26aulast%3DWaldman%26aufirst%3DS.%26aulast%3DBeuve%26aufirst%3DA.%26aulast%3DBoison%26aufirst%3DD.%26aulast%3DBrouckaert%26aufirst%3DP.%26aulast%3DBurnett%26aufirst%3DJ.%2BC.%26aulast%3DBurns%26aufirst%3DK.%26aulast%3DDessauer%26aufirst%3DC.%26aulast%3DFriebe%26aufirst%3DA.%26aulast%3DGarthwaite%26aufirst%3DJ.%26aulast%3DGertsch%26aufirst%3DJ.%26aulast%3DHelsby%26aufirst%3DN.%26aulast%3DIzzo%26aufirst%3DA.%2BA.%26aulast%3DKoesling%26aufirst%3DD.%26aulast%3DKuhn%26aufirst%3DM.%26aulast%3DOstrom%26aufirst%3DR.%26aulast%3DPapapetropoulos%26aufirst%3DA.%26aulast%3DPotter%26aufirst%3DL.%2BR.%26aulast%3DPyne%26aufirst%3DN.%2BJ.%26aulast%3DPyne%26aufirst%3DS.%26aulast%3DRusswurm%26aufirst%3DM.%26aulast%3DSchmidt%26aufirst%3DH.%26aulast%3DSeifert%26aufirst%3DR.%26aulast%3DStasch%26aufirst%3DJ.%2BP.%26aulast%3DSzabo%26aufirst%3DC.%26aulast%3Dvan%2Bder%2BStelt%26aufirst%3DM.%26aulast%3Dvan%2Bder%2BVliet%26aufirst%3DA.%26aulast%3DWatts%26aufirst%3DV.%26aulast%3DAnderson%26aufirst%3DC.%2BM.%2BH.%26aulast%3DBroer%26aufirst%3DS.%26aulast%3DDawson%26aufirst%3DP.%26aulast%3DHagenbuch%26aufirst%3DB.%26aulast%3DHammond%26aufirst%3DJ.%2BR.%26aulast%3DHancox%26aufirst%3DJ.%26aulast%3DInui%26aufirst%3DK.%26aulast%3DKanai%26aufirst%3DY.%26aulast%3DKemp%26aufirst%3DS.%26aulast%3DThwaites%26aufirst%3DD.%2BT.%26aulast%3DVerri%26aufirst%3DT.%26aulast%3D%26atitle%3DThe%2520concise%2520guide%2520to%2520pharmacology%25202019%252F20%253A%2520G%2520protein-coupled%2520receptors%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2019%26volume%3D176%26spage%3DS21%26epage%3DS141%26doi%3D10.1111%2Fbph.14748" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sriram, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Insel, P. A.</span></span> <span> </span><span class="NLM_article-title">G protein-coupled receptors as targets for approved drugs: how many targets and how many drugs?</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>93</i></span>,  <span class="NLM_fpage">251</span>– <span class="NLM_lpage">258</span>, <span class="refDoi"> DOI: 10.1124/mol.117.111062</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=10.1124%2Fmol.117.111062" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=29298813" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs12qsr3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=2018&pages=251-258&author=K.+Sriramauthor=P.+A.+Insel&title=G+protein-coupled+receptors+as+targets+for+approved+drugs%3A+how+many+targets+and+how+many+drugs%3F&doi=10.1124%2Fmol.117.111062"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">G protein-coupled receptors as targets for approved drugs: how many targets and how many drugs?</span></div><div class="casAuthors">Sriram, Krishna; Insel, Paul A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">251-258</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">1521-0111</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Ests. vary regarding the no. of G protein-coupled receptors (GPCRs), the largest family of membrane receptors that are targeted by approved drugs, and the no. of such drugs that target GPCRs.  We review current knowledge regarding GPCRs as drug targets by integrating data from public databases (ChEMBL, Guide to PHARMACOl., and DrugBank) and from the Broad Institute Drug Repurposing Hub.  To account for discrepancies among these sources, we curated a list of GPCRs currently targeted by approved drugs.  As of Nov. 2017, 134 GPCRs are targets for drugs approved in the United States or European Union; 128 GPCRs are targets for drugs listed in the Food and Drug Administration Orange Book.  We est. that ∼700 approved drugs target GPCRs, implying that approx. 35% of approved drugs target GPCRs.  GPCRs and GPCR-related proteins, i.e., those upstream of or downstream from GPCRs, represent ∼17% of all protein targets for approved drugs, with GPCRs themselves accounting for ∼12%.  As such, GPCRs constitute the largest family of proteins targeted by approved drugs.  Drugs that currently target GPCRs and GPCRrelated proteins are primarily small mols. and peptides.  Since ∼100 of the ∼360 human endo-GPCRs (other than olfactory, taste, and visual GPCRs) are orphan receptors (lacking known physiol. agonists), the no. of GPCR targets, the no. of GPCR-targeted drugs, and perhaps the types of drugs will likely increase, thus further expanding this GPCR repertoire and the many roles of GPCR drugs in therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIvH0Lu99b3rVg90H21EOLACvtfcHk0liSeUtLUff5lg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs12qsr3O&md5=ee1a26a2fcdbe66eeb1a864d168d787b</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1124%2Fmol.117.111062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.117.111062%26sid%3Dliteratum%253Aachs%26aulast%3DSriram%26aufirst%3DK.%26aulast%3DInsel%26aufirst%3DP.%2BA.%26atitle%3DG%2520protein-coupled%2520receptors%2520as%2520targets%2520for%2520approved%2520drugs%253A%2520how%2520many%2520targets%2520and%2520how%2520many%2520drugs%253F%26jtitle%3DMol.%2520Pharmacol.%26date%3D2018%26volume%3D93%26spage%3D251%26epage%3D258%26doi%3D10.1124%2Fmol.117.111062" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weston, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winfield, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodgson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowell, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mobarec, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodlock, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reynolds, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poyner, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ladds, G.</span></span> <span> </span><span class="NLM_article-title">Receptor activity-modifying protein-directed G protein signaling specificity for the calcitonin gene-related peptide family of receptors</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>291</i></span>,  <span class="NLM_fpage">21925</span>– <span class="NLM_lpage">21944</span>, <span class="refDoi"> DOI: 10.1074/jbc.M116.751362</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=10.1074%2Fjbc.M116.751362" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=27566546" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1OgsbbK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=291&publication_year=2016&pages=21925-21944&author=C.+Westonauthor=I.+Winfieldauthor=M.+Harrisauthor=R.+Hodgsonauthor=A.+Shahauthor=S.+J.+Dowellauthor=J.+C.+Mobarecauthor=D.+A.+Woodlockauthor=C.+A.+Reynoldsauthor=D.+R.+Poynerauthor=H.+A.+Watkinsauthor=G.+Ladds&title=Receptor+activity-modifying+protein-directed+G+protein+signaling+specificity+for+the+calcitonin+gene-related+peptide+family+of+receptors&doi=10.1074%2Fjbc.M116.751362"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Receptor Activity-modifying Protein-directed G Protein Signaling Specificity for the Calcitonin Gene-related Peptide Family of Receptors</span></div><div class="casAuthors">Weston, Cathryn; Winfield, Ian; Harris, Matthew; Hodgson, Rose; Shah, Archna; Dowell, Simon J.; Mobarec, Juan Carlos; Woodlock, David A.; Reynolds, Christopher A.; Poyner, David R.; Watkins, Harriet A.; Ladds, Graham</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">291</span>
        (<span class="NLM_cas:issue">42</span>),
    <span class="NLM_cas:pages">21925-21944</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The calcitonin gene-related peptide (CGRP) family of G protein-coupled receptors (GPCRs) is formed through the assocn. of the calcitonin receptor-like receptor (CLR) and one of three receptor activity-modifying proteins (RAMPs).  Binding of one of the three peptide ligands, CGRP, adrenomedullin (AM), and intermedin/adrenomedullin 2 (AM2), is well known to result in a Gαs-mediated increase in cAMP.  Here we used modified yeast strains that couple receptor activation to cell growth, via chimeric yeast/Gα subunits, and HEK-293 cells to characterize the effect of different RAMP and ligand combinations on this pathway.  We not only demonstrate functional couplings to both Gαs and Gαq but also identify a Gαi component to CLR signaling in both yeast and HEK-293 cells, which is absent in HEK-293S cells.  We show that the CGRP family of receptors displays both ligand- and RAMP-dependent signaling bias among the Gαs, Gαi, and Gαq/11 pathways.  The results are discussed in the context of RAMP interactions probed through mol. modeling and mol. dynamics simulations of the RAMP-GPCR-G protein complexes.  This study further highlights the importance of RAMPs to CLR pharmacol. and to bias in general, as well as identifying the importance of choosing an appropriate model system for the study of GPCR pharmacol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-ksJs_JFeYbVg90H21EOLACvtfcHk0lgNLSE3Z5mAbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1OgsbbK&md5=32e2c6c34928aa8fbe52325b7a36e78a</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M116.751362&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M116.751362%26sid%3Dliteratum%253Aachs%26aulast%3DWeston%26aufirst%3DC.%26aulast%3DWinfield%26aufirst%3DI.%26aulast%3DHarris%26aufirst%3DM.%26aulast%3DHodgson%26aufirst%3DR.%26aulast%3DShah%26aufirst%3DA.%26aulast%3DDowell%26aufirst%3DS.%2BJ.%26aulast%3DMobarec%26aufirst%3DJ.%2BC.%26aulast%3DWoodlock%26aufirst%3DD.%2BA.%26aulast%3DReynolds%26aufirst%3DC.%2BA.%26aulast%3DPoyner%26aufirst%3DD.%2BR.%26aulast%3DWatkins%26aufirst%3DH.%2BA.%26aulast%3DLadds%26aufirst%3DG.%26atitle%3DReceptor%2520activity-modifying%2520protein-directed%2520G%2520protein%2520signaling%2520specificity%2520for%2520the%2520calcitonin%2520gene-related%2520peptide%2520family%2520of%2520receptors%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2016%26volume%3D291%26spage%3D21925%26epage%3D21944%26doi%3D10.1074%2Fjbc.M116.751362" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hay, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pioszak, A. A.</span></span> <span> </span><span class="NLM_article-title">Receptor activity-modifying proteins (RAMPs): new insights and roles</span>. <i>Annu. Rev. Pharmacol. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">469</span>– <span class="NLM_lpage">487</span>, <span class="refDoi"> DOI: 10.1146/annurev-pharmtox-010715-103120</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=10.1146%2Fannurev-pharmtox-010715-103120" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=26514202" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslGmsbbE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2016&pages=469-487&author=D.+L.+Hayauthor=A.+A.+Pioszak&title=Receptor+activity-modifying+proteins+%28RAMPs%29%3A+new+insights+and+roles&doi=10.1146%2Fannurev-pharmtox-010715-103120"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Receptor Activity-Modifying Proteins (RAMPs): New Insights and Roles</span></div><div class="casAuthors">Hay, Debbie L.; Pioszak, Augen A.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Pharmacology and Toxicology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">469-487</span>CODEN:
                <span class="NLM_cas:coden">ARPTDI</span>;
        ISSN:<span class="NLM_cas:issn">0362-1642</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews</span>)
        </div><div class="casAbstract">It is now recognized that G protein-coupled receptors (GPCRs), once considered largely independent functional units, have a far more diverse mol. architecture.  Receptor activity-modifying proteins (RAMPs) provide an important example of proteins that interact with GPCRs to modify their function.  RAMPs are able to act as pharmacol. switches and chaperones, and they can regulate signaling and/or trafficking in a receptor-dependent manner.  This review covers recent discoveries in the RAMP field and summarizes the known GPCR partners and functions of RAMPs.  We also discuss the first peptide-bound structures of RAMP-GPCR complexes, which give insight into the mol. mechanisms that enable RAMPs to alter the pharmacol. and signaling of GPCRs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlK5LE240AvrVg90H21EOLACvtfcHk0lgNLSE3Z5mAbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslGmsbbE&md5=a943f1f936ba9354111ca0dfb16a6e67</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1146%2Fannurev-pharmtox-010715-103120&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev-pharmtox-010715-103120%26sid%3Dliteratum%253Aachs%26aulast%3DHay%26aufirst%3DD.%2BL.%26aulast%3DPioszak%26aufirst%3DA.%2BA.%26atitle%3DReceptor%2520activity-modifying%2520proteins%2520%2528RAMPs%2529%253A%2520new%2520insights%2520and%2520roles%26jtitle%3DAnnu.%2520Rev.%2520Pharmacol.%2520Toxicol.%26date%3D2016%26volume%3D56%26spage%3D469%26epage%3D487%26doi%3D10.1146%2Fannurev-pharmtox-010715-103120" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hay, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garelja, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poyner, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, C. S.</span></span> <span> </span><span class="NLM_article-title">Update on the pharmacology of calcitonin/CGRP family of peptides: IUPHAR Review 25</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>175</i></span>,  <span class="NLM_fpage">3</span>– <span class="NLM_lpage">17</span>, <span class="refDoi"> DOI: 10.1111/bph.14075</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=10.1111%2Fbph.14075" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=29059473" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvVOjsrzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=175&publication_year=2018&pages=3-17&author=D.+L.+Hayauthor=M.+L.+Gareljaauthor=D.+R.+Poynerauthor=C.+S.+Walker&title=Update+on+the+pharmacology+of+calcitonin%2FCGRP+family+of+peptides%3A+IUPHAR+Review+25&doi=10.1111%2Fbph.14075"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Update on the pharmacology of calcitonin/CGRP family of peptides: IUPHAR Review 25</span></div><div class="casAuthors">Hay, Debbie L.; Garelja, Michael L.; Poyner, David R.; Walker, Christopher S.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">175</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3-17</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The calcitonin/CGRP family of peptides includes calcitonin, α and β CGRP, amylin, adrenomedullin (AM) and adrenomedullin 2/intermedin (AM2/IMD).  Their receptors consist of one of two GPCRs, the calcitonin receptor (CTR) or the calcitonin receptor-like receptor (CLR).  Further diversity arises from heterodimerization of these GPCRs with one of three receptor activity-modifying proteins (RAMPs).  This gives the CGRP receptor (CLR/RAMP1), the AM1 and AM2 receptors (CLR/RAMP2 or RAMP3) and the AMY1, AMY2 and AMY3 receptors (CTR/RAMPs1-3 complexes, resp.).  Apart from the CGRP receptor, there are only peptide antagonists widely available for these receptors, and these have limited selectivity, thus defining the function of each receptor in vivo remains challenging.  Further challenges arise from the probable co-expression of CTR with the CTR/RAMP complexes and species-dependent splice variants of the CTR (CT(a) and CT(b)).  Furthermore, the AMY1(a) receptor is activated equally well by both amylin and CGRP, and the preferred receptor for AM2/IMD has been unclear.  However, there are clear therapeutic rationales for developing agents against the various receptors for these peptides.  For example, many agents targeting the CGRP system are in clin. trials, and pramlintide, an amylin analog, is an approved therapy for insulin-requiring diabetes.  This review provides an update on the pharmacol. of the calcitonin family of peptides by members of the corresponding subcommittee of the International Union of Basic and Clin. Pharmacol. and colleagues.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpuzfzqMhXcSbVg90H21EOLACvtfcHk0lgNLSE3Z5mAbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvVOjsrzJ&md5=ff10d0f78ca78127c11bd4fe8c71b86a</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1111%2Fbph.14075&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.14075%26sid%3Dliteratum%253Aachs%26aulast%3DHay%26aufirst%3DD.%2BL.%26aulast%3DGarelja%26aufirst%3DM.%2BL.%26aulast%3DPoyner%26aufirst%3DD.%2BR.%26aulast%3DWalker%26aufirst%3DC.%2BS.%26atitle%3DUpdate%2520on%2520the%2520pharmacology%2520of%2520calcitonin%252FCGRP%2520family%2520of%2520peptides%253A%2520IUPHAR%2520Review%252025%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2018%26volume%3D175%26spage%3D3%26epage%3D17%26doi%3D10.1111%2Fbph.14075" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bortolato, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dore, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollenstein, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tehan, B. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mason, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marshall, F. H.</span></span> <span> </span><span class="NLM_article-title">Structure of class B GPCRs: new horizons for drug discovery</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>171</i></span>,  <span class="NLM_fpage">3132</span>– <span class="NLM_lpage">3145</span>, <span class="refDoi"> DOI: 10.1111/bph.12689</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=10.1111%2Fbph.12689" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=24628305" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=1%3ACAS%3A528%3ADC%252BC2cXpsVKrtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=171&publication_year=2014&pages=3132-3145&author=A.+Bortolatoauthor=A.+S.+Doreauthor=K.+Hollensteinauthor=B.+G.+Tehanauthor=J.+S.+Masonauthor=F.+H.+Marshall&title=Structure+of+class+B+GPCRs%3A+new+horizons+for+drug+discovery&doi=10.1111%2Fbph.12689"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of Class B GPCRs: new horizons for drug discovery</span></div><div class="casAuthors">Bortolato, Andrea; Dore, Andrew S.; Hollenstein, Kaspar; Tehan, Benjamin G.; Mason, Jonathan S.; Marshall, Fiona H.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">171</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3132-3145</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Class B GPCRs of the secretin family are important drug targets in many human diseases including diabetes, neurodegeneration, cardiovascular disease and psychiatric disorders.  X-ray crystal structures for the glucagon receptor and corticotropin-releasing factor receptor 1 have now been published.  In this review, we analyze the new structures and how they compare with each other and with Class A and F receptors.  We also consider the differences in druggability and possible similarity in the activation mechanisms.  Finally, we discuss the potential for the design of small-mol. modulators for these important targets in drug discovery.  This new structural insight allows, for the first time, structure-based drug design methods to be applied to Class B GPCRs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprqe_GGLyHcbVg90H21EOLACvtfcHk0ljrQOrQmrEtoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXpsVKrtr0%253D&md5=3e08525e9309b28bc3a7a268fd83067e</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1111%2Fbph.12689&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.12689%26sid%3Dliteratum%253Aachs%26aulast%3DBortolato%26aufirst%3DA.%26aulast%3DDore%26aufirst%3DA.%2BS.%26aulast%3DHollenstein%26aufirst%3DK.%26aulast%3DTehan%26aufirst%3DB.%2BG.%26aulast%3DMason%26aufirst%3DJ.%2BS.%26aulast%3DMarshall%26aufirst%3DF.%2BH.%26atitle%3DStructure%2520of%2520class%2520B%2520GPCRs%253A%2520new%2520horizons%2520for%2520drug%2520discovery%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2014%26volume%3D171%26spage%3D3132%26epage%3D3145%26doi%3D10.1111%2Fbph.12689" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de
Graaf, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, R. C.</span></span> <span> </span><span class="NLM_article-title">Extending the structural view of class B GPCRs</span>. <i>Trends Biochem. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">946</span>– <span class="NLM_lpage">960</span>, <span class="refDoi"> DOI: 10.1016/j.tibs.2017.10.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=10.1016%2Fj.tibs.2017.10.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=29132948" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslSktb7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2017&pages=946-960&author=C.+de%0AGraafauthor=G.+J.+Songauthor=C.+Caoauthor=Q.+Zhaoauthor=M.+W.+Wangauthor=B.+L.+Wuauthor=R.+C.+Stevens&title=Extending+the+structural+view+of+class+B+GPCRs&doi=10.1016%2Fj.tibs.2017.10.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Extending the Structural View of Class B GPCRs</span></div><div class="casAuthors">de Graaf, Chris; Song, Gaojie; Cao, Can; Zhao, Qiang; Wang, Ming-Wei; Wu, Beili; Stevens, Raymond C.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Biochemical Sciences</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">946-960</span>CODEN:
                <span class="NLM_cas:coden">TBSCDB</span>;
        ISSN:<span class="NLM_cas:issn">0968-0004</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The secretin-like class B family of G protein-coupled receptors (GPCRs) are key players in hormonal homeostasis.  Recent structures of various receptors in complex with a variety of orthosteric and allosteric ligands provide fundamental new insights into the function and mechanism of class B GPCRs, including: (i) ligand-induced changes in the relative orientation of the extracellular and transmembrane receptor domains; (ii) intramol. interaction networks that stabilize conformational changes to accommodate intracellular G protein binding; and (iii) allosteric modulation of receptor activation.  This review provides a comprehensive anal. of the structural, biochem., and pharmacol. data on class B GPCRs for understanding ligand-receptor interaction and modulation mechanisms and assessing the potential implications for drug discovery for the secretin-like GPCR family.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoB3zzE8S9kfrVg90H21EOLACvtfcHk0ljrQOrQmrEtoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslSktb7E&md5=3e0c0b52f9078a329d3eb80290a44c97</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2Fj.tibs.2017.10.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tibs.2017.10.003%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BGraaf%26aufirst%3DC.%26aulast%3DSong%26aufirst%3DG.%2BJ.%26aulast%3DCao%26aufirst%3DC.%26aulast%3DZhao%26aufirst%3DQ.%26aulast%3DWang%26aufirst%3DM.%2BW.%26aulast%3DWu%26aufirst%3DB.%2BL.%26aulast%3DStevens%26aufirst%3DR.%2BC.%26atitle%3DExtending%2520the%2520structural%2520view%2520of%2520class%2520B%2520GPCRs%26jtitle%3DTrends%2520Biochem.%2520Sci.%26date%3D2017%26volume%3D42%26spage%3D946%26epage%3D960%26doi%3D10.1016%2Fj.tibs.2017.10.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liang, Y.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khoshouei, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deganutti, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glukhova, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koole, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peat, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radjainia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plitzko, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baumeister, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hay, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christopoulos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reynolds, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wootten, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sexton, P. M.</span></span> <span> </span><span class="NLM_article-title">Cryo-EM structure of the active, G(s)- protein complexed, human CGRP receptor</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>561</i></span>,  <span class="NLM_fpage">492</span>– <span class="NLM_lpage">497</span>, <span class="refDoi"> DOI: 10.1038/s41586-018-0535-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=10.1038%2Fs41586-018-0535-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=30209400" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslSnu7jL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=561&publication_year=2018&pages=492-497&author=Y.-L.+Liangauthor=M.+Khoshoueiauthor=G.+Deganuttiauthor=A.+Glukhovaauthor=C.+Kooleauthor=T.+S.+Peatauthor=M.+Radjainiaauthor=J.+M.+Plitzkoauthor=W.+Baumeisterauthor=L.+J.+Millerauthor=D.+L.+Hayauthor=A.+Christopoulosauthor=C.+A.+Reynoldsauthor=D.+Woottenauthor=P.+M.+Sexton&title=Cryo-EM+structure+of+the+active%2C+G%28s%29-+protein+complexed%2C+human+CGRP+receptor&doi=10.1038%2Fs41586-018-0535-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Cryo-EM structure of the active, Gs-protein complexed, human CGRP receptor</span></div><div class="casAuthors">Liang, Yi-Lynn; Khoshouei, Maryam; Deganutti, Giuseppe; Glukhova, Alisa; Koole, Cassandra; Peat, Thomas S.; Radjainia, Mazdak; Plitzko, Jurgen M.; Baumeister, Wolfgang; Miller, Laurence J.; Hay, Deborah L.; Christopoulos, Arthur; Reynolds, Christopher A.; Wootten, Denise; Sexton, Patrick M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">561</span>
        (<span class="NLM_cas:issue">7724</span>),
    <span class="NLM_cas:pages">492-497</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Calcitonin gene-related peptide (CGRP) is a widely expressed neuropeptide that plays a major role in sensory neurotransmission.  The CGRP receptor is a heterodimer of the calcitonin receptor-like receptor (CLR) class B G-protein-coupled receptor and a type 1 transmembrane domain protein, receptor activity-modifying protein 1 (RAMP1).  Here, we report the structure of the human CGRP receptor in complex with CGRP and the Gs-protein heterotrimer at 3.3 Å global resoln., detd. by Volta phase-plate cryo-electron microscopy.  The receptor activity-modifying protein transmembrane domain sits at the interface between transmembrane domains 3, 4, and 5 of CLR, and stabilizes CLR extracellular loop 2.  RAMP1 makes only limited direct contact with CGRP, consistent with its function in allosteric modulation of CLR.  Mol. dynamics simulations indicated that RAMP1 provides stability to the receptor complex, particularly in the positioning of the extracellular domain of CLR.  This work provides insights into the control of G-protein-coupled receptor function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxOm13jzoHHbVg90H21EOLACvtfcHk0ljjzfyDRHzDlg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslSnu7jL&md5=ed535627358ee097dacc0be9ef4d8d96</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2Fs41586-018-0535-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41586-018-0535-y%26sid%3Dliteratum%253Aachs%26aulast%3DLiang%26aufirst%3DY.-L.%26aulast%3DKhoshouei%26aufirst%3DM.%26aulast%3DDeganutti%26aufirst%3DG.%26aulast%3DGlukhova%26aufirst%3DA.%26aulast%3DKoole%26aufirst%3DC.%26aulast%3DPeat%26aufirst%3DT.%2BS.%26aulast%3DRadjainia%26aufirst%3DM.%26aulast%3DPlitzko%26aufirst%3DJ.%2BM.%26aulast%3DBaumeister%26aufirst%3DW.%26aulast%3DMiller%26aufirst%3DL.%2BJ.%26aulast%3DHay%26aufirst%3DD.%2BL.%26aulast%3DChristopoulos%26aufirst%3DA.%26aulast%3DReynolds%26aufirst%3DC.%2BA.%26aulast%3DWootten%26aufirst%3DD.%26aulast%3DSexton%26aufirst%3DP.%2BM.%26atitle%3DCryo-EM%2520structure%2520of%2520the%2520active%252C%2520G%2528s%2529-%2520protein%2520complexed%252C%2520human%2520CGRP%2520receptor%26jtitle%3DNature%26date%3D2018%26volume%3D561%26spage%3D492%26epage%3D497%26doi%3D10.1038%2Fs41586-018-0535-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liang, Y.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belousoff, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khoshouei, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deganutti, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koole, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furness, S. G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hay, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christopoulos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reynolds, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danev, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wootten, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sexton, P. M.</span></span> <span> </span><span class="NLM_article-title">Structure and dynamics of adrenomedullin receptors AM1 and AM2 reveal key mechanisms in the control of receptor phenotype by receptor activity-modifying proteins</span>. <i>ACS Pharmacol. Transl. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">263</span>– <span class="NLM_lpage">284</span>, <span class="refDoi"> DOI: 10.1021/acsptsci.9b00080</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsptsci.9b00080" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=1%3ACAS%3A528%3ADC%252BB3cXlt1WnsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2020&pages=263-284&author=Y.-L.+Liangauthor=M.+J.+Belousoffauthor=M.+M.+Fletcherauthor=X.+Zhangauthor=M.+Khoshoueiauthor=G.+Deganuttiauthor=C.+Kooleauthor=S.+G.+B.+Furnessauthor=L.+J.+Millerauthor=D.+L.+Hayauthor=A.+Christopoulosauthor=C.+A.+Reynoldsauthor=R.+Danevauthor=D.+Woottenauthor=P.+M.+Sexton&title=Structure+and+dynamics+of+adrenomedullin+receptors+AM1+and+AM2+reveal+key+mechanisms+in+the+control+of+receptor+phenotype+by+receptor+activity-modifying+proteins&doi=10.1021%2Facsptsci.9b00080"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Structure and Dynamics of Adrenomedullin Receptors AM1 and AM2 Reveal Key Mechanisms in the Control of Receptor Phenotype by Receptor Activity-Modifying Proteins</span></div><div class="casAuthors">Liang, Yi-Lynn; Belousoff, Matthew J.; Fletcher, Madeleine M.; Zhang, Xin; Khoshouei, Maryam; Deganutti, Giuseppe; Koole, Cassandra; Furness, Sebastian G. B.; Miller, Laurence J.; Hay, Debbie L.; Christopoulos, Arthur; Reynolds, Christopher A.; Danev, Radostin; Wootten, Denise; Sexton, Patrick M.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Pharmacology & Translational Science</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">263-284</span>CODEN:
                <span class="NLM_cas:coden">APTSFN</span>;
        ISSN:<span class="NLM_cas:issn">2575-9108</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Adrenomedullin (AM) and calcitonin gene-related peptide (CGRP) receptors are critically important for metab., vascular tone, and inflammatory response.  AM receptors are also required for normal lymphatic and blood vascular development and angiogenesis.  They play a pivotal role in embryo implantation and fertility and can provide protection against hypoxic and oxidative stress.  CGRP and AM receptors are heterodimers of the calcitonin receptor-like receptor (CLR) and receptor activity-modifying protein 1 (RAMP1) (CGRPR), as well as RAMP2 or RAMP3 (AM1R and AM2R, resp.).  However, the mechanistic basis for RAMP modulation of CLR phenotype is unclear.  In this study, we report the cryo-EM structure of the AM1R in complex with AM and Gs at a global resoln. of 3.0 Å, and structures of the AM2R in complex with either AM or intermedin/adrenomedullin 2 (AM2) and Gs at 2.4 and 2.3 Å, resp.  The structures reveal distinctions in the primary orientation of the extracellular domains (ECDs) relative to the receptor core and distinct positioning of extracellular loop 3 (ECL3) that are receptor-dependent.  Anal. of dynamic data present in the cryo-EM micrographs revealed addnl. distinctions in the extent of mobility of the ECDs.  Chimeric exchange of the linker region of the RAMPs connecting the TM helix and the ECD supports a role for this segment in controlling receptor phenotype.  Moreover, a subset of the motions of the ECD appeared coordinated with motions of the G protein relative to the receptor core, suggesting that receptor ECD dynamics could influence G protein interactions.  This work provides fundamental advances in our understanding of GPCR function and how this can be allosterically modulated by accessory proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpB5Q0D37yiZLVg90H21EOLACvtfcHk0ljjzfyDRHzDlg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXlt1WnsL4%253D&md5=77a9ed6c15298b83e282ec160e0b9ca0</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1021%2Facsptsci.9b00080&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsptsci.9b00080%26sid%3Dliteratum%253Aachs%26aulast%3DLiang%26aufirst%3DY.-L.%26aulast%3DBelousoff%26aufirst%3DM.%2BJ.%26aulast%3DFletcher%26aufirst%3DM.%2BM.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DKhoshouei%26aufirst%3DM.%26aulast%3DDeganutti%26aufirst%3DG.%26aulast%3DKoole%26aufirst%3DC.%26aulast%3DFurness%26aufirst%3DS.%2BG.%2BB.%26aulast%3DMiller%26aufirst%3DL.%2BJ.%26aulast%3DHay%26aufirst%3DD.%2BL.%26aulast%3DChristopoulos%26aufirst%3DA.%26aulast%3DReynolds%26aufirst%3DC.%2BA.%26aulast%3DDanev%26aufirst%3DR.%26aulast%3DWootten%26aufirst%3DD.%26aulast%3DSexton%26aufirst%3DP.%2BM.%26atitle%3DStructure%2520and%2520dynamics%2520of%2520adrenomedullin%2520receptors%2520AM1%2520and%2520AM2%2520reveal%2520key%2520mechanisms%2520in%2520the%2520control%2520of%2520receptor%2520phenotype%2520by%2520receptor%2520activity-modifying%2520proteins%26jtitle%3DACS%2520Pharmacol.%2520Transl.%2520Sci.%26date%3D2020%26volume%3D3%26spage%3D263%26epage%3D284%26doi%3D10.1021%2Facsptsci.9b00080" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Garelja, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Au, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brimble, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gingell, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendrikse, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lovell, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prodan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sexton, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siow, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wootten, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, P. W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hay, D. L.</span></span> <span> </span><span class="NLM_article-title">Molecular mechanisms of class B GPCR activation: insights from adrenomedullin receptors</span>. <i>ACS Pharmacol. Transl. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">246</span>– <span class="NLM_lpage">262</span>, <span class="refDoi"> DOI: 10.1021/acsptsci.9b00083</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsptsci.9b00083" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=1%3ACAS%3A528%3ADC%252BB3cXjslSqs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2020&pages=246-262&author=M.+L.+Gareljaauthor=M.+Auauthor=M.+A.+Brimbleauthor=J.+J.+Gingellauthor=E.+R.+Hendrikseauthor=A.+Lovellauthor=N.+Prodanauthor=P.+M.+Sextonauthor=A.+Siowauthor=C.+S.+Walkerauthor=H.+A.+Watkinsauthor=G.+M.+Williamsauthor=D.+Woottenauthor=S.+H.+Yangauthor=P.+W.+R.+Harrisauthor=D.+L.+Hay&title=Molecular+mechanisms+of+class+B+GPCR+activation%3A+insights+from+adrenomedullin+receptors&doi=10.1021%2Facsptsci.9b00083"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Mechanisms of Class B GPCR Activation: Insights from Adrenomedullin Receptors</span></div><div class="casAuthors">Garelja, Michael L.; Au, Maggie; Brimble, Margaret A.; Gingell, Joseph J.; Hendrikse, Erica R.; Lovell, Annie; Prodan, Nicole; Sexton, Patrick M.; Siow, Andrew; Walker, Christopher S.; Watkins, Harriet A.; Williams, Geoffrey M.; Wootten, Denise; Yang, Sung H.; Harris, Paul W. R.; Hay, Debbie L.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Pharmacology & Translational Science</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">246-262</span>CODEN:
                <span class="NLM_cas:coden">APTSFN</span>;
        ISSN:<span class="NLM_cas:issn">2575-9108</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Adrenomedullin (AM) is a 52 amino acid peptide that plays a regulatory role in the vasculature.  Receptors for AM are comprised of the class B G protein-coupled receptor, the calcitonin-like receptor (CLR), in complex with one of three receptor activity-modifying proteins (RAMPs).  The C-terminus of AM is involved in binding to the extracellular domain of the receptor, while the N-is proposed to interact with the juxtamembranous portion of the receptor to activate signaling.  There is currently limited information on the mol. determinants involved in AM signaling, thus we set out to define the importance of the AM N-terminus through five signaling pathways (cAMP prodn., ERK phosphorylation, CREB phosphorylation, Akt phosphorylation, and IP1 prodn.).  We characterized the three CLR:RAMP complexes through the five pathways, finding that each had a distinct repertoire of intracellular signaling pathways that it is able to regulate.  We then performed an alanine scan of AM from residues 15-31 and found that most residues could be substituted with only small effects on signaling, and that most substitutions affected signaling through all receptors and pathways in a similar manner.  We identify F18, T20, L26, and I30 as being crit. for AM function, while also identifying an analog (AM15-52 G19A) which has unique signaling properties relative to the unmodified AM.  We interpret our findings in the context of new structural information, highlighting the complementary nature of structural biol. and functional assays.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9HQAGPU8XlLVg90H21EOLACvtfcHk0ljjzfyDRHzDlg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXjslSqs7c%253D&md5=3b11e7f7b4de93ddfa71f0304c7a4320</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1021%2Facsptsci.9b00083&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsptsci.9b00083%26sid%3Dliteratum%253Aachs%26aulast%3DGarelja%26aufirst%3DM.%2BL.%26aulast%3DAu%26aufirst%3DM.%26aulast%3DBrimble%26aufirst%3DM.%2BA.%26aulast%3DGingell%26aufirst%3DJ.%2BJ.%26aulast%3DHendrikse%26aufirst%3DE.%2BR.%26aulast%3DLovell%26aufirst%3DA.%26aulast%3DProdan%26aufirst%3DN.%26aulast%3DSexton%26aufirst%3DP.%2BM.%26aulast%3DSiow%26aufirst%3DA.%26aulast%3DWalker%26aufirst%3DC.%2BS.%26aulast%3DWatkins%26aufirst%3DH.%2BA.%26aulast%3DWilliams%26aufirst%3DG.%2BM.%26aulast%3DWootten%26aufirst%3DD.%26aulast%3DYang%26aufirst%3DS.%2BH.%26aulast%3DHarris%26aufirst%3DP.%2BW.%2BR.%26aulast%3DHay%26aufirst%3DD.%2BL.%26atitle%3DMolecular%2520mechanisms%2520of%2520class%2520B%2520GPCR%2520activation%253A%2520insights%2520from%2520adrenomedullin%2520receptors%26jtitle%3DACS%2520Pharmacol.%2520Transl.%2520Sci.%26date%3D2020%26volume%3D3%26spage%3D246%26epage%3D262%26doi%3D10.1021%2Facsptsci.9b00083" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hoare, S. R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grigoriadis, D. E.</span></span> <span> </span><span class="NLM_article-title">Non-peptide translation to CRF-receptor antagonists:allosterism, kinetics’ and efficacy in human disease</span>. <i>Curr. Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">282</span>– <span class="NLM_lpage">295</span>, <span class="refDoi"> DOI: 10.2174/1874467210666170110124539</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=10.2174%2F1874467210666170110124539" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=28103785" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1Kgs7bJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2017&pages=282-295&author=S.+R.+J.+Hoareauthor=D.+E.+Grigoriadis&title=Non-peptide+translation+to+CRF-receptor+antagonists%3Aallosterism%2C+kinetics%E2%80%99+and+efficacy+in+human+disease&doi=10.2174%2F1874467210666170110124539"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Non-peptide CRF-Receptor Antagonists: Allosterism, Kinetics and Translation to Efficacy in Human Disease</span></div><div class="casAuthors">Hoare, Samuel R. J.; Grigoriadis, Dimitri E.</div><div class="citationInfo"><span class="NLM_cas:title">Current Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">282-295</span>CODEN:
                <span class="NLM_cas:coden">CMPUB6</span>;
        ISSN:<span class="NLM_cas:issn">1874-4702</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  G-Protein coupled receptors (GPCRs) have been, and remain a key target of drug discovery programs for human disease.  While many drugs have been developed that interact with these proteins in the simple classic manner - that is - phys. blocking the cognate ligand from simply binding to its target receptor, drug discovery approaches have elucidated alternative more complex methods by which small mols. can interact with these receptors and block their function.  This is most evident in the Class B GPCRs where the cognate ligands are relatively large peptides with multiple points of contact on the GPCR spanning both hydrophilic and hydrophobic domains on the same protein to elicit function.  It has therefore been difficult to precisely det. not only the mechanism by which a small mol. can inhibit the function of a large peptide but also the nature of that mechanism that drives the differences in efficacy.  This review will examine in detail the nature of small mol. inhibition of corticotropin-releasing factor receptors and illustrate the role that allosteric binding and kinetics play in the functional inhibition of this Class B GPCR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJZQo8LWBxsLVg90H21EOLACvtfcHk0liyUJ1wdhzYiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1Kgs7bJ&md5=bc36be25744a4f405957eb2516e25bc3</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.2174%2F1874467210666170110124539&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1874467210666170110124539%26sid%3Dliteratum%253Aachs%26aulast%3DHoare%26aufirst%3DS.%2BR.%2BJ.%26aulast%3DGrigoriadis%26aufirst%3DD.%2BE.%26atitle%3DNon-peptide%2520translation%2520to%2520CRF-receptor%2520antagonists%253Aallosterism%252C%2520kinetics%25E2%2580%2599%2520and%2520efficacy%2520in%2520human%2520disease%26jtitle%3DCurr.%2520Mol.%2520Pharmacol.%26date%3D2017%26volume%3D10%26spage%3D282%26epage%3D295%26doi%3D10.2174%2F1874467210666170110124539" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thal, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glukhova, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sexton, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christopoulos, A.</span></span> <span> </span><span class="NLM_article-title">Structural insights into G-protein-coupled receptor allostery</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>559</i></span>,  <span class="NLM_fpage">45</span>– <span class="NLM_lpage">53</span>, <span class="refDoi"> DOI: 10.1038/s41586-018-0259-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=10.1038%2Fs41586-018-0259-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=29973731" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1Ojt7rF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=559&publication_year=2018&pages=45-53&author=D.+M.+Thalauthor=A.+Glukhovaauthor=P.+M.+Sextonauthor=A.+Christopoulos&title=Structural+insights+into+G-protein-coupled+receptor+allostery&doi=10.1038%2Fs41586-018-0259-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Structural insights into G-protein-coupled receptor allostery</span></div><div class="casAuthors">Thal, David M.; Glukhova, Alisa; Sexton, Patrick M.; Christopoulos, Arthur</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">559</span>
        (<span class="NLM_cas:issue">7712</span>),
    <span class="NLM_cas:pages">45-53</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  G-protein-coupled receptors (GPCRs) are key cell-surface proteins that transduce external environmental cues into biochem. signals across the membrane.  GPCRs are intrinsically allosteric proteins; they interact via spatially distinct yet conformationally linked domains with both endogenous and exogenous proteins, nutrients, metabolites, hormones, small mols., and biol. agents.  Here, we explore recent high-resoln. structural studies, which are beginning to unravel the at. details of allosteric transitions that govern GPCR biol., as well as highlighting how the wide diversity of druggable allosteric sites across these receptors present opportunities for developing new classes of therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpe7mS11VNWXbVg90H21EOLACvtfcHk0liyUJ1wdhzYiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1Ojt7rF&md5=6bb61606ab4c32db2a96c9e283b11b09</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1038%2Fs41586-018-0259-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41586-018-0259-z%26sid%3Dliteratum%253Aachs%26aulast%3DThal%26aufirst%3DD.%2BM.%26aulast%3DGlukhova%26aufirst%3DA.%26aulast%3DSexton%26aufirst%3DP.%2BM.%26aulast%3DChristopoulos%26aufirst%3DA.%26atitle%3DStructural%2520insights%2520into%2520G-protein-coupled%2520receptor%2520allostery%26jtitle%3DNature%26date%3D2018%26volume%3D559%26spage%3D45%26epage%3D53%26doi%3D10.1038%2Fs41586-018-0259-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hendrikse, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liew, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bower, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonnet, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jamaluddin, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prodan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richards, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pairaudeau, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rujan, R.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sudra, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reynolds, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Booe, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pioszak, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flanagan, J. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hay, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hay, D. L.</span></span> <span> </span><span class="NLM_article-title">Identification of small-molecule positive modulators of calcitonin-like receptor-based receptors</span>. <i>ACS Pharmacol. Transl. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">305</span>– <span class="NLM_lpage">320</span>, <span class="refDoi"> DOI: 10.1021/acsptsci.9b00108</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsptsci.9b00108" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=1%3ACAS%3A528%3ADC%252BB3cXkslWrsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2020&pages=305-320&author=E.+R.+Hendrikseauthor=L.+P.+Liewauthor=R.+L.+Bowerauthor=M.+Bonnetauthor=M.+A.+Jamaluddinauthor=N.+Prodanauthor=K.+D.+Richardsauthor=C.+S.+Walkerauthor=G.+Pairaudeauauthor=D.+M.+Smithauthor=R.-M.+Rujanauthor=R.+Sudraauthor=C.+A.+Reynoldsauthor=J.+M.+Booeauthor=A.+A.+Pioszakauthor=J.+U.+Flanaganauthor=M.+P.+Hayauthor=D.+L.+Hay&title=Identification+of+small-molecule+positive+modulators+of+calcitonin-like+receptor-based+receptors&doi=10.1021%2Facsptsci.9b00108"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of Small-Molecule Positive Modulators of Calcitonin-like Receptor-Based Receptors</span></div><div class="casAuthors">Hendrikse, Erica R.; Liew, Lydia P.; Bower, Rebekah L.; Bonnet, Muriel; Jamaluddin, Muhammad A.; Prodan, Nicole; Richards, Keith D.; Walker, Christopher S.; Pairaudeau, Garry; Smith, David M.; Rujan, Roxana-Maria; Sudra, Risha; Reynolds, Christopher A.; Booe, Jason M.; Pioszak, Augen A.; Flanagan, Jack U.; Hay, Michael P.; Hay, Debbie L.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Pharmacology & Translational Science</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">305-320</span>CODEN:
                <span class="NLM_cas:coden">APTSFN</span>;
        ISSN:<span class="NLM_cas:issn">2575-9108</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Class B G protein-coupled receptors are highly therapeutically relevant but challenges remain in identifying suitable small-mol. drugs.  The calcitonin-like receptor (CLR) in particular is linked to conditions such as migraine, cardiovascular disease, and inflammatory bowel disease.  The CLR cannot act as a cell-surface receptor alone but rather must couple to one of three receptor activity-modifying proteins (RAMPs), forming heterodimeric receptors for the peptides adrenomedullin and calcitonin gene-related peptide.  These peptides have extended binding sites across their receptors.  This is one reason why there are few small-mol. ligands that can modulate these receptors.  Here we describe small mols. that are able to pos. modulate the signaling of the CLR with all three RAMPs but are not active at the related calcitonin receptor.  These compds. were selected from a β-arrestin recruitment screen, coupled with rounds of medicinal chem. to improve their activity.  Translational potential is shown as the compds. can pos. modulate cAMP signaling in a vascular cell line model.  Binding expts. do not support an extracellular domain binding site; however, mol. modeling reveals potential allosteric binding sites in multiple receptor regions.  These are the first small-mol. pos. modulators described for the CLR:RAMP complexes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEjIWD6ELg67Vg90H21EOLACvtfcHk0liyUJ1wdhzYiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXkslWrsL0%253D&md5=72f27ffa368066df40ff4c1329254dac</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1021%2Facsptsci.9b00108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsptsci.9b00108%26sid%3Dliteratum%253Aachs%26aulast%3DHendrikse%26aufirst%3DE.%2BR.%26aulast%3DLiew%26aufirst%3DL.%2BP.%26aulast%3DBower%26aufirst%3DR.%2BL.%26aulast%3DBonnet%26aufirst%3DM.%26aulast%3DJamaluddin%26aufirst%3DM.%2BA.%26aulast%3DProdan%26aufirst%3DN.%26aulast%3DRichards%26aufirst%3DK.%2BD.%26aulast%3DWalker%26aufirst%3DC.%2BS.%26aulast%3DPairaudeau%26aufirst%3DG.%26aulast%3DSmith%26aufirst%3DD.%2BM.%26aulast%3DRujan%26aufirst%3DR.-M.%26aulast%3DSudra%26aufirst%3DR.%26aulast%3DReynolds%26aufirst%3DC.%2BA.%26aulast%3DBooe%26aufirst%3DJ.%2BM.%26aulast%3DPioszak%26aufirst%3DA.%2BA.%26aulast%3DFlanagan%26aufirst%3DJ.%2BU.%26aulast%3DHay%26aufirst%3DM.%2BP.%26aulast%3DHay%26aufirst%3DD.%2BL.%26atitle%3DIdentification%2520of%2520small-molecule%2520positive%2520modulators%2520of%2520calcitonin-like%2520receptor-based%2520receptors%26jtitle%3DACS%2520Pharmacol.%2520Transl.%2520Sci.%26date%3D2020%26volume%3D3%26spage%3D305%26epage%3D320%26doi%3D10.1021%2Facsptsci.9b00108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hewitt, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aurora, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dodick, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goadsby, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bachman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taraborelli, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, X. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Assaid, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lines, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, T. W.</span></span> <span> </span><span class="NLM_article-title">Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine</span>. <i>Cephalalgia</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">712</span>– <span class="NLM_lpage">722</span>, <span class="refDoi"> DOI: 10.1177/0333102411398399</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=10.1177%2F0333102411398399" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=21383045" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=1%3ACAS%3A280%3ADC%252BC3Mvjs1aktg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2011&pages=712-722&author=D.+J.+Hewittauthor=S.+K.+Auroraauthor=D.+W.+Dodickauthor=P.+J.+Goadsbyauthor=Y.+Geauthor=R.+Bachmanauthor=D.+Taraborelliauthor=X.+Y.+Fanauthor=C.+Assaidauthor=C.+Linesauthor=T.+W.+Ho&title=Randomized+controlled+trial+of+the+CGRP+receptor+antagonist+MK-3207+in+the+acute+treatment+of+migraine&doi=10.1177%2F0333102411398399"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine</span></div><div class="casAuthors">Hewitt David J; Aurora Sheena K; Dodick David W; Goadsby Peter J; Ge Yang Joy; Bachman Robert; Taraborelli Donna; Fan Xiaoyin; Assaid Christopher; Lines Christopher; Ho Tony W</div><div class="citationInfo"><span class="NLM_cas:title">Cephalalgia : an international journal of headache</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">712-22</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  This study evaluated the CGRP receptor antagonist MK-3207 for acute treatment of migraine.  METHODS:  Multicenter, double-blind, randomized, placebo-controlled, parallel-group, two-stage adaptive study with two interim efficacy analyses to facilitate optimal dose selection.  Migraine patients were initially randomized to MK-3207 2.5, 5, 10, 20, 50 and 100 mg or placebo to treat a moderate/severe migraine.  One or more doses were to be discontinued based on the first interim analysis and a lower or higher dose could be added based on the second interim analysis.  The primary endpoint was two-hour pain freedom.  RESULTS:  A total of 547 patients took study medication.  After the first interim analysis, the two lowest MK-3207 doses (2.5, 5 mg) were identified as showing insufficient efficacy.  Per the pre-specified adaptive design decision rule, only the 2.5-mg group was discontinued and the five highest doses (5, 10, 20, 50, 100 mg) were continued into the second stage.  After the second interim efficacy analysis, a 200 mg dose was added due to insufficient efficacy at the top three (20, 50, 100 mg) doses.  A positive dose-response trend was demonstrated when data were combined across all MK-3207 doses for two-hour pain freedom (p < .001).  The pairwise difference versus placebo for two-hour pain freedom was significant for 200 mg (p < .001) and nominally significant for 100 mg and 10 mg (p < .05).  The incidence of adverse events appeared comparable between active treatment groups and placebo, and did not appear to increase with increasing dose.  CONCLUSIONS:  MK-3207 was effective and generally well tolerated in the acute treatment of migraine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTWH3T54_BmWO-MdeMhXAHkfW6udTcc2ebH4iK6_q7CUbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3Mvjs1aktg%253D%253D&md5=4a0e3bcb7010b04b2812d10f0ad9f57f</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1177%2F0333102411398399&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0333102411398399%26sid%3Dliteratum%253Aachs%26aulast%3DHewitt%26aufirst%3DD.%2BJ.%26aulast%3DAurora%26aufirst%3DS.%2BK.%26aulast%3DDodick%26aufirst%3DD.%2BW.%26aulast%3DGoadsby%26aufirst%3DP.%2BJ.%26aulast%3DGe%26aufirst%3DY.%26aulast%3DBachman%26aufirst%3DR.%26aulast%3DTaraborelli%26aufirst%3DD.%26aulast%3DFan%26aufirst%3DX.%2BY.%26aulast%3DAssaid%26aufirst%3DC.%26aulast%3DLines%26aufirst%3DC.%26aulast%3DHo%26aufirst%3DT.%2BW.%26atitle%3DRandomized%2520controlled%2520trial%2520of%2520the%2520CGRP%2520receptor%2520antagonist%2520MK-3207%2520in%2520the%2520acute%2520treatment%2520of%2520migraine%26jtitle%3DCephalalgia%26date%3D2011%26volume%3D31%26spage%3D712%26epage%3D722%26doi%3D10.1177%2F0333102411398399" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ho, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connor, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearlman, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koppenhaver, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, X. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lines, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edvinsson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goadsby, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michelson, D.</span></span> <span> </span><span class="NLM_article-title">Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention</span>. <i>Neurology</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>83</i></span>,  <span class="NLM_fpage">958</span>– <span class="NLM_lpage">966</span>, <span class="refDoi"> DOI: 10.1212/WNL.0000000000000771</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=10.1212%2FWNL.0000000000000771" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=25107879" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFert7bJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=2014&pages=958-966&author=T.+W.+Hoauthor=K.+M.+Connorauthor=Y.+Zhangauthor=E.+Pearlmanauthor=J.+Koppenhaverauthor=X.+Y.+Fanauthor=C.+Linesauthor=L.+Edvinssonauthor=P.+J.+Goadsbyauthor=D.+Michelson&title=Randomized+controlled+trial+of+the+CGRP+receptor+antagonist+telcagepant+for+migraine+prevention&doi=10.1212%2FWNL.0000000000000771"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention</span></div><div class="casAuthors">Ho, Tony W.; Connor, Kathryn M.; Zhang, Ying; Pearlman, Eric; Koppenhaver, Janelle; Fan, Xiaoyin; Lines, Christopher; Edvinsson, Lars; Goadsby, Peter J.; Michelson, David</div><div class="citationInfo"><span class="NLM_cas:title">Neurology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">83</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">958-966</span>CODEN:
                <span class="NLM_cas:coden">NEURAI</span>;
        ISSN:<span class="NLM_cas:issn">0028-3878</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Objective: To evaluate whether the calcitonin gene-related peptide (CGRP) receptor antagonist telcagepant might be effective for migraine prevention.  Methods: In this randomized, double-blind, placebo-controlled, multicenter trial (ClinicalTrials.gov NCT00797667), patients experiencing 3-14 migraine days during a 4-wk baseline were randomized to telcagepant 140 mg, telcagepant 280 mg, or placebo twice daily for 12 wk.  Efficacy was assessed by mean monthly headache days and migraine/probable migraine days (headache plus ≥1 assocd. symptom).  Results: The trial was terminated following a recommendation from the Safety Monitoring Board due to hepatotoxicity concerns.  At termination, the planned 660 patients had been randomized, 656 had been treated with ≥1 dose of study medication, and 14 had completed the trial.  The mean treatment duration was 48-50 days.  Thirteen patients, all in the telcagepant groups, had an alanine aminotransferase (ALT) elevation ≥3× the upper limit of normal and 7 of these also had an aspartate aminotransferase elevation ≥3× the upper limit of normal.  Two patients had very high symptomatic transaminase elevations that occurred within 2-6 wk of treatment initiation and resolved after treatment discontinuation.  The originally planned efficacy anal. over 12 wk was not performed due to limited data at later time points, but there was evidence that telcagepant resulted in a larger redn. from baseline than placebo for mean monthly headache days (month 1: 140 mg = -2.9, 280 mg = -3.1, placebo = -1.7; p < 0.05) and migraine/probable migraine days (month 1: 140 mg = -2.7, 280 mg = -3.0, placebo = -1.6; p < 0.05).  Conclusions: These data suggest a potential role for CGRP receptor antagonism in migraine prophylaxis.  However, the obsd. aminotransferase elevations do not support the use of telcagepant for daily administration.  Classification of evidence: This study provides Class II evidence that in patients with migraine, telcagepant taken daily reduces headache days by 1.4 days per mo compared to placebo and causes 2.5% of patients to have elevations of serum ALT levels.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNEH1T2nja2bVg90H21EOLACvtfcHk0ljSrpGBMVBCKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFert7bJ&md5=66d4abf9a3373373a1f18c3bd56487f5</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1212%2FWNL.0000000000000771&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1212%252FWNL.0000000000000771%26sid%3Dliteratum%253Aachs%26aulast%3DHo%26aufirst%3DT.%2BW.%26aulast%3DConnor%26aufirst%3DK.%2BM.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DPearlman%26aufirst%3DE.%26aulast%3DKoppenhaver%26aufirst%3DJ.%26aulast%3DFan%26aufirst%3DX.%2BY.%26aulast%3DLines%26aufirst%3DC.%26aulast%3DEdvinsson%26aufirst%3DL.%26aulast%3DGoadsby%26aufirst%3DP.%2BJ.%26aulast%3DMichelson%26aufirst%3DD.%26atitle%3DRandomized%2520controlled%2520trial%2520of%2520the%2520CGRP%2520receptor%2520antagonist%2520telcagepant%2520for%2520migraine%2520prevention%26jtitle%3DNeurology%26date%3D2014%26volume%3D83%26spage%3D958%26epage%3D966%26doi%3D10.1212%2FWNL.0000000000000771" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bell, I. M.</span></span> <span> </span><span class="NLM_article-title">Calcitonin gene-related peptide receptor antagonists: new therapeutic agents for migraine</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">7838</span>– <span class="NLM_lpage">7858</span>, <span class="refDoi"> DOI: 10.1021/jm500364u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500364u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVentb7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=7838-7858&author=I.+M.+Bell&title=Calcitonin+gene-related+peptide+receptor+antagonists%3A+new+therapeutic+agents+for+migraine&doi=10.1021%2Fjm500364u"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Calcitonin Gene-Related Peptide Receptor Antagonists: New Therapeutic Agents for Migraine</span></div><div class="casAuthors">Bell, Ian M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">7838-7858</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Calcitonin gene-related peptide (CGRP) is a potent neuromodulator and vasodilator.  It has been implicated in the pathogenesis of migraine by a no. of lines of evidence, although its precise role has yet to be fully defined.  Compelling evidence for the importance of CGRP in migraine has been provided by clin. trials with multiple small mol. CGRP receptor antagonists.  These clin. studies have shown that blockade of the CGRP receptor can produce antimigraine efficacy comparable to that of the gold std. triptan class of drugs with an incidence of adverse events that appears to be relatively low.  The present review describes the discovery and development of these new antimigraine agents and highlights the challenges of identifying orally acting drugs that target a family B G-protein-coupled receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqyCZ6aYV8RgbVg90H21EOLACvtfcHk0liRZ8B5QrgIxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVentb7O&md5=ef228d3b829dd642d50eb00e6868ac82</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Fjm500364u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500364u%26sid%3Dliteratum%253Aachs%26aulast%3DBell%26aufirst%3DI.%2BM.%26atitle%3DCalcitonin%2520gene-related%2520peptide%2520receptor%2520antagonists%253A%2520new%2520therapeutic%2520agents%2520for%2520migraine%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D7838%26epage%3D7858%26doi%3D10.1021%2Fjm500364u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Karsan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goadsby, P. J.</span></span> <span> </span><span class="NLM_article-title">Calcitonin gene-related peptide and migraine</span>. <i>Curr. Opin. Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">250</span>– <span class="NLM_lpage">254</span>, <span class="refDoi"> DOI: 10.1097/WCO.0000000000000191</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=10.1097%2FWCO.0000000000000191" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=25887765" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=1%3ACAS%3A528%3ADC%252BC2MXns1Ggsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2015&pages=250-254&author=N.+Karsanauthor=P.+J.+Goadsby&title=Calcitonin+gene-related+peptide+and+migraine&doi=10.1097%2FWCO.0000000000000191"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Calcitonin gene-related peptide and migraine</span></div><div class="casAuthors">Karsan, Nazia; Goadsby, Peter J.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Neurology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">250-254</span>CODEN:
                <span class="NLM_cas:coden">CONEEX</span>;
        ISSN:<span class="NLM_cas:issn">1350-7540</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">A review.  Purpose of review: Migraine is a common, complex disorder of the brain with significant morbidity.  As the pathophysiol. of the disorder has become better appreciated, the role of neuropeptides has been explored.  Calcitonin gene-related peptide (CGRP) has emerged as a promising therapeutic target.  Recent findings: CGRP is widely distributed in the nervous system, particularly at anatomical areas thought to be involved with migraine, including the trigeminovascular nociceptive system.  In studies, CGRP has been shown to be released during severe migraine attacks, and effective triptan treatment of an attack normalizes these levels.  CGRP administration triggers migraine in patients and CGRP receptor antagonists can abort migraine.  Moreover, recent data demonstrate that CGRP mechanism blockade either by small mol. receptor antagonists or by monoclonal antibodies can have a preventive effect in migraine.  Summary: This article highlights the evidence behind the role of CGRP in migraine and the state of CGRP-based mechanism treatment development.  We present a summary of the evidence base behind CGRP in migraine pathophysiol. and the novel CGRP mechanism drugs and their potential future contribution to migraine management in our clin. practice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-3EyuX74g5bVg90H21EOLACvtfcHk0liRZ8B5QrgIxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXns1Ggsbc%253D&md5=fb23b2333e4417b3789bfe27f604ef4d</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1097%2FWCO.0000000000000191&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FWCO.0000000000000191%26sid%3Dliteratum%253Aachs%26aulast%3DKarsan%26aufirst%3DN.%26aulast%3DGoadsby%26aufirst%3DP.%2BJ.%26atitle%3DCalcitonin%2520gene-related%2520peptide%2520and%2520migraine%26jtitle%3DCurr.%2520Opin.%2520Neurol.%26date%3D2015%26volume%3D28%26spage%3D250%26epage%3D254%26doi%3D10.1097%2FWCO.0000000000000191" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ho, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Assaid, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gottwald, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacGregor, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mannix, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Oosterhout, W. P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koppenhaver, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lines, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrari, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michelson, D.</span></span> <span> </span><span class="NLM_article-title">Randomized controlled trial of the CGRP receptor antagonist telcagepant for prevention of headache in women with perimenstrual migraine</span>. <i>Cephalalgia</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">148</span>– <span class="NLM_lpage">161</span>, <span class="refDoi"> DOI: 10.1177/0333102415584308</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=10.1177%2F0333102415584308" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=25926620" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=1%3ACAS%3A280%3ADC%252BC2MjptVyqug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2016&pages=148-161&author=T.+W.+Hoauthor=A.+P.+Hoauthor=Y.+Geauthor=C.+Assaidauthor=R.+Gottwaldauthor=E.+A.+MacGregorauthor=L.+K.+Mannixauthor=W.+P.+J.+van+Oosterhoutauthor=J.+Koppenhaverauthor=C.+Linesauthor=M.+D.+Ferrariauthor=D.+Michelson&title=Randomized+controlled+trial+of+the+CGRP+receptor+antagonist+telcagepant+for+prevention+of+headache+in+women+with+perimenstrual+migraine&doi=10.1177%2F0333102415584308"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Randomized controlled trial of the CGRP receptor antagonist telcagepant for prevention of headache in women with perimenstrual migraine</span></div><div class="casAuthors">Ho Tony W; Ho Andrew P; Ge Yang Joy; Assaid Christopher; Gottwald Regina; Koppenhaver Janelle; Lines Christopher; Michelson David; MacGregor E Anne; Mannix Lisa K; van Oosterhout Willebrordus P J; Ferrari Michel D</div><div class="citationInfo"><span class="NLM_cas:title">Cephalalgia : an international journal of headache</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">148-61</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">AIM:  The aim of this article is to evaluate the safety and efficacy of perimenstrual telcagepant, a CGRP receptor antagonist, for headache prophylaxis.  METHODS:  We conducted a randomized, double-blind, placebo-controlled, six-month trial in women with migraine for ≥ 3 months who experienced perimenstrual headaches.  Women were randomized to telcagepant 140 mg or placebo (2:1 ratio) for seven consecutive days perimenstrually.  Safety was assessed by adverse events and laboratory tests.  The primary efficacy endpoint was mean monthly headache days in the subset of women reporting perimenstrual migraine (-2 days to +3 days of menses onset) and ≥ 5 moderate or severe migraines per month prior to entering the trial.  RESULTS:  Telcagepant was generally well tolerated: 66/2660 (2.5%) on telcagepant and 36/1326 (2.7%) on placebo discontinued because of a clinical adverse event.  The percentages of patients with clinical adverse events, laboratory adverse events, or discontinuation because of a laboratory adverse event were also similar between treatments.  Alanine aminotransferase elevations ≥ 3x normal occurred in 0.6% of women on telcagepant and 0.4% on placebo.  Three women on telcagepant vs none on placebo had alanine aminotransferase elevations ≥ 8× normal.  In the efficacy subset there was no significant effect of telcagepant (n = 887) vs placebo (n = 447) in mean monthly headache days (treatment difference -0.5 day (95% CI: -1.1, 0.1)).  However, telcagepant was associated with a reduction in on-drug headache days (treatment difference -0.4 day (95% CI: -0.5, -0.2), nominal p < 0.001).  CONCLUSIONS:  Telcagepant 140 mg taken perimenstrually for seven days was generally well tolerated, but was associated with transaminase elevations.  Telcagepant did not reduce monthly headache frequency, but did reduce perimenstrual headaches.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcREYn0dkl_4ba__Jf7-eMvJfW6udTcc2ebrm_0wDQGZjrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MjptVyqug%253D%253D&md5=7dc9df49ef57fb7afd44af098814468a</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1177%2F0333102415584308&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0333102415584308%26sid%3Dliteratum%253Aachs%26aulast%3DHo%26aufirst%3DT.%2BW.%26aulast%3DHo%26aufirst%3DA.%2BP.%26aulast%3DGe%26aufirst%3DY.%26aulast%3DAssaid%26aufirst%3DC.%26aulast%3DGottwald%26aufirst%3DR.%26aulast%3DMacGregor%26aufirst%3DE.%2BA.%26aulast%3DMannix%26aufirst%3DL.%2BK.%26aulast%3Dvan%2BOosterhout%26aufirst%3DW.%2BP.%2BJ.%26aulast%3DKoppenhaver%26aufirst%3DJ.%26aulast%3DLines%26aufirst%3DC.%26aulast%3DFerrari%26aufirst%3DM.%2BD.%26aulast%3DMichelson%26aufirst%3DD.%26atitle%3DRandomized%2520controlled%2520trial%2520of%2520the%2520CGRP%2520receptor%2520antagonist%2520telcagepant%2520for%2520prevention%2520of%2520headache%2520in%2520women%2520with%2520perimenstrual%2520migraine%26jtitle%3DCephalalgia%26date%3D2016%26volume%3D36%26spage%3D148%26epage%3D161%26doi%3D10.1177%2F0333102415584308" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Croop, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goadsby, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stock, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conway, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forshaw, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stock, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coric, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lipton, R. B.</span></span> <span> </span><span class="NLM_article-title">Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>394</i></span>,  <span class="NLM_fpage">737</span>– <span class="NLM_lpage">745</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(19)31606-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=10.1016%2FS0140-6736%2819%2931606-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=31311674" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlOjtrvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=394&publication_year=2019&pages=737-745&author=R.+Croopauthor=P.+J.+Goadsbyauthor=D.+A.+Stockauthor=C.+M.+Conwayauthor=M.+Forshawauthor=E.+G.+Stockauthor=V.+Coricauthor=R.+B.+Lipton&title=Efficacy%2C+safety%2C+and+tolerability+of+rimegepant+orally+disintegrating+tablet+for+the+acute+treatment+of+migraine%3A+a+randomised%2C+phase+3%2C+double-blind%2C+placebo-controlled+trial&doi=10.1016%2FS0140-6736%2819%2931606-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial</span></div><div class="casAuthors">Croop, Robert; Goadsby, Peter J.; Stock, David A.; Conway, Charles M.; Forshaw, Micaela; Stock, Elyse G.; Coric, Vladimir; Lipton, Richard B.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">394</span>
        (<span class="NLM_cas:issue">10200</span>),
    <span class="NLM_cas:pages">737-745</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">In this double-blind, randomised, placebo-controlled, multicentre phase 3 trial, adults aged 18 years or older with history of migraine of at least 1 yr were recruited to 69 study centers in the USA.  This study is registered with ClinicalTrials.gov, no. NCT03461757, and is closed to accrual.  Between Feb 27 and Aug 28, 2018, 1811 participants were recruited and assessed for eligibility. 1466 participants were randomly assigned to the rimegepant (n=732) or placebo (n=734) groups, of whom 1375 received treatment with rimegepant (n=682) or placebo (n=693), and 1351 were evaluated for efficacy (rimegepant n=669, placebo n=682).  At 2 h postdose, rimegepant orally disintegrating tablet was superior to placebo for freedom from pain (21% vs 11%, p<0·0001; risk difference 10, 95% CI 6-14) and freedom from the most bothersome symptom (35% vs 27%, p=0·0009; risk difference 8, 95% CI 3-13).  The most common adverse events were nausea (rimegepant n=11 [2%]; placebo n=3 [<1%]) and UTI (rimegepant n=10 [1%]; placebo n=4 [1%]).  Each treatment group had a transaminase concn. of more than 3 × the upper limit of normal; neither was related to study medication, and no elevations in bilirubin greater than 2 × the upper limit of normal were reported.  In the acute treatment of migraine, a single 75 mg dose of rimegepant in an orally disintegrating tablet formulation was more effective than placebo.  Tolerability was similar to placebo, with no safety concerns.Biohaven Pharmaceuticals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoidQI9-1-aZLVg90H21EOLACvtfcHk0liRZ8B5QrgIxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlOjtrvL&md5=37885d5210b0c9bf3da45d477bc27c8e</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2819%2931606-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252819%252931606-X%26sid%3Dliteratum%253Aachs%26aulast%3DCroop%26aufirst%3DR.%26aulast%3DGoadsby%26aufirst%3DP.%2BJ.%26aulast%3DStock%26aufirst%3DD.%2BA.%26aulast%3DConway%26aufirst%3DC.%2BM.%26aulast%3DForshaw%26aufirst%3DM.%26aulast%3DStock%26aufirst%3DE.%2BG.%26aulast%3DCoric%26aufirst%3DV.%26aulast%3DLipton%26aufirst%3DR.%2BB.%26atitle%3DEfficacy%252C%2520safety%252C%2520and%2520tolerability%2520of%2520rimegepant%2520orally%2520disintegrating%2520tablet%2520for%2520the%2520acute%2520treatment%2520of%2520migraine%253A%2520a%2520randomised%252C%2520phase%25203%252C%2520double-blind%252C%2520placebo-controlled%2520trial%26jtitle%3DLancet%26date%3D2019%26volume%3D394%26spage%3D737%26epage%3D745%26doi%3D10.1016%2FS0140-6736%2819%2931606-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scott, L. J.</span></span> <span> </span><span class="NLM_article-title">Ubrogepant: first approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>80</i></span>,  <span class="NLM_fpage">323</span>– <span class="NLM_lpage">328</span>, <span class="refDoi"> DOI: 10.1007/s40265-020-01264-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=10.1007%2Fs40265-020-01264-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=32020557" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=1%3ACAS%3A280%3ADC%252BB38%252FotlKlsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2020&pages=323-328&author=L.+J.+Scott&title=Ubrogepant%3A+first+approval&doi=10.1007%2Fs40265-020-01264-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Ubrogepant: First Approval</span></div><div class="casAuthors">Scott Lesley J</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">80</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">323-328</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Ubrogepant (Ubrelvy®) is an orally administered, small molecule, highly-selective, calcitonin gene-related peptide (CGRP) antagonist that was developed by Allergan under license to Merck & Co. as an acute treatment for migraine.  In December 2019, ubrogepant received its first global approval in the USA for the acute treatment of migraine (± aura) in adults.  This article summarizes the milestones in the development of ubrogepant leading to its first global approval for the acute treatment of migraine (± aura) in adults.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTbpElibNSrFMvLc4ARHEmzfW6udTcc2eaj8c4qJYipM7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB38%252FotlKlsA%253D%253D&md5=dee277e0c6d6835ea105dbb4024f8a92</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1007%2Fs40265-020-01264-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-020-01264-5%26sid%3Dliteratum%253Aachs%26aulast%3DScott%26aufirst%3DL.%2BJ.%26atitle%3DUbrogepant%253A%2520first%2520approval%26jtitle%3DDrugs%26date%3D2020%26volume%3D80%26spage%3D323%26epage%3D328%26doi%3D10.1007%2Fs40265-020-01264-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ornello, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casalena, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frattale, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabriele, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Affaitati, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giamberardino, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Assetta, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maddestra, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marzoli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viola, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cerone, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marini, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pistoia, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sacco, S.</span></span> <span> </span><span class="NLM_article-title">Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy</span>. <i>J. Headache Pain</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>21</i></span>, <span class="NLM_elocation-id">32</span> <span class="refDoi"> DOI: 10.1186/s10194-020-01102-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=10.1186%2Fs10194-020-01102-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=32264820" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=1%3ACAS%3A528%3ADC%252BB3cXms1Srtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2020&author=R.+Ornelloauthor=A.+Casalenaauthor=I.+Frattaleauthor=A.+Gabrieleauthor=G.+Affaitatiauthor=M.+A.+Giamberardinoauthor=M.+Assettaauthor=M.+Maddestraauthor=F.+Marzoliauthor=S.+Violaauthor=D.+Ceroneauthor=C.+Mariniauthor=F.+Pistoiaauthor=S.+Sacco&title=Real-life+data+on+the+efficacy+and+safety+of+erenumab+in+the+Abruzzo+region%2C+central+Italy&doi=10.1186%2Fs10194-020-01102-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy</span></div><div class="casAuthors">Ornello, Raffaele; Casalena, Alfonsina; Frattale, Ilaria; Gabriele, Amleto; Affaitati, Giannapia; Giamberardino, Maria Adele; Assetta, Maurizio; Maddestra, Maurizio; Marzoli, Fabio; Viola, Stefano; Cerone, Davide; Marini, Carmine; Pistoia, Francesca; Sacco, Simona</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Headache and Pain</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">32</span>CODEN:
                <span class="NLM_cas:coden">JHPOAT</span>;
        ISSN:<span class="NLM_cas:issn">1129-2369</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">We aimed to assess the efficacy and safety of erenumab, a fully human monoclonal antibody inhibiting the calcitonin gene-related peptide receptor (CGRPr), for the prevention of migraine in a real-life setting.  We included in our observational study all patients with episodic or chronic migraine treated with erenumab during the year 2019 in the Abruzzo region, central Italy, and with a 6-mo follow-up.  We included 89 patients; 76 (85.4%) received 6 doses of erenumab, 11 (12.4%) autonomously withdrew the drug due to perceived inefficacy, and 2 (2.2%) due to adverse events.  Seventy-eight patients (87.6%) were female, with a mean age of 46.8 ± 11.2 years; 84 (94.4%) had chronic migraine, and 64 (71.9%) medication overuse.  Fifty-three patients had a 50% decrease in monthly migraine days (MMDs) within the first three doses; 46 of 64 patients withdrew medication overuse.  In the 76 patients who completed a 6-dose treatment, erenumab decreased median MMDs from 19 (interquartile range [IQR] 12-27.5) to 4 (IQR 2-9.5; P < 0.001), median monthly days of analgesic use from 10, and median monthly days of triptan use from 5 (IQR 0-15.5) to 1 (IQR 0-4; P < 0.001).  We recorded 27 adverse events in 20 (22.5%) patients, the most common being constipation (13.5%).  Our real-life data confirm the efficacy and tolerability of erenumab for the prevention of migraine in a difficult-to-treat population of patients with a high prevalence of chronic migraine and medication overuse.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmOonB2vGajLVg90H21EOLACvtfcHk0ljGQwYf-fLyTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXms1Srtr8%253D&md5=898468bba5d28a0cb07d3626c7ddd9c6</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1186%2Fs10194-020-01102-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs10194-020-01102-9%26sid%3Dliteratum%253Aachs%26aulast%3DOrnello%26aufirst%3DR.%26aulast%3DCasalena%26aufirst%3DA.%26aulast%3DFrattale%26aufirst%3DI.%26aulast%3DGabriele%26aufirst%3DA.%26aulast%3DAffaitati%26aufirst%3DG.%26aulast%3DGiamberardino%26aufirst%3DM.%2BA.%26aulast%3DAssetta%26aufirst%3DM.%26aulast%3DMaddestra%26aufirst%3DM.%26aulast%3DMarzoli%26aufirst%3DF.%26aulast%3DViola%26aufirst%3DS.%26aulast%3DCerone%26aufirst%3DD.%26aulast%3DMarini%26aufirst%3DC.%26aulast%3DPistoia%26aufirst%3DF.%26aulast%3DSacco%26aufirst%3DS.%26atitle%3DReal-life%2520data%2520on%2520the%2520efficacy%2520and%2520safety%2520of%2520erenumab%2520in%2520the%2520Abruzzo%2520region%252C%2520central%2520Italy%26jtitle%3DJ.%2520Headache%2520Pain%26date%3D2020%26volume%3D21%26doi%3D10.1186%2Fs10194-020-01102-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lipton, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goadsby, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaeffler, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biondi, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pederson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cady, R.</span></span> <span> </span><span class="NLM_article-title">Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2</span>. <i>Neurology</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>94</i></span>,  <span class="NLM_fpage">E1365</span>– <span class="NLM_lpage">E1377</span>, <span class="refDoi"> DOI: 10.1212/WNL.0000000000009169</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=10.1212%2FWNL.0000000000009169" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=32209650" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=1%3ACAS%3A528%3ADC%252BB3cXlvVGns7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=2020&pages=E1365-E1377&author=R.+B.+Liptonauthor=P.+J.+Goadsbyauthor=J.+Smithauthor=B.+A.+Schaefflerauthor=D.+M.+Biondiauthor=J.+Hirmanauthor=S.+Pedersonauthor=B.+Allanauthor=R.+Cady&title=Efficacy+and+safety+of+eptinezumab+in+patients+with+chronic+migraine%3A+PROMISE-2&doi=10.1212%2FWNL.0000000000009169"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2</span></div><div class="casAuthors">Lipton, Richard B.; Goadsby, Peter J.; Smith, Jeff; Schaeffler, Barbara A.; Biondi, David M.; Hirman, Joe; Pederson, Susan; Allan, Brent; Cady, Roger</div><div class="citationInfo"><span class="NLM_cas:title">Neurology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">e1365-e1377</span>CODEN:
                <span class="NLM_cas:coden">NEURAI</span>;
        ISSN:<span class="NLM_cas:issn">0028-3878</span>.
    
            (<span class="NLM_cas:orgname">Wolters Kluwer</span>)
        </div><div class="casAbstract">Objective: To evaluate the efficacy and safety of eptinezumab, a humanized anti-calcitonin gene-related peptide monoclonal antibody, in the preventive treatment of chronic migraine (CM).  Methods: The Prevention of Migraine via I.v. ALD403 Safety and Efficacy-2 (PROMISE-2) study was a phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.  Adults with CM were randomly assigned to receive IV eptinezumab 100 mg, eptinezumab 300 mg, or placebo administered on day 0 and week 12.  The primary endpoint was change from baseline in mean monthly migraine days (MMDs) over weeks 1 to 12.  Results: Among treated participants (n = 1,072), baseline mean no. of MMDs was ≈16.1 across groups.  Treatment with eptinezumab 100 and 300 mg was assocd. with significant redns. in MMDs across weeks 1 to 12 compared with placebo (placebo -5.6, 100 mg -7.7, p < 0.0001 vs placebo; 300 mg -8.2, p < 0.0001 vs placebo).  Treatment-emergent adverse events (TEAEs) were reported by 43.5% (100 mg), 52.0% (300 mg), and 46.7% (placebo) of patients.  Nasopharyngitis was the only TEAE reported for >2% of eptinezumab-treated patients at an incidence of >2% over placebo; it occurred in the 300 mg eptinezumab arm (eptinezumab 9.4%, placebo 6.0%).  Conclusion: In patients with CM, eptinezumab 100 and 300 mg was assocd. with a significant redn. in MMDs from the day after IV administration through week 12, was well tolerated, and demonstrated an acceptable safety profile.  Classification of evidence: This study provides Class I evidence that for patients with CM, a single dose of eptinezumab reduces MMDs over 12 wk of treatment.  CLINICALTRIALS.GOV Identifier: NCT02974153.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6BTPomCLBR7Vg90H21EOLACvtfcHk0ljGQwYf-fLyTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXlvVGns7Y%253D&md5=a9373129ed07d44034c0662b3c9abeaf</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1212%2FWNL.0000000000009169&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1212%252FWNL.0000000000009169%26sid%3Dliteratum%253Aachs%26aulast%3DLipton%26aufirst%3DR.%2BB.%26aulast%3DGoadsby%26aufirst%3DP.%2BJ.%26aulast%3DSmith%26aufirst%3DJ.%26aulast%3DSchaeffler%26aufirst%3DB.%2BA.%26aulast%3DBiondi%26aufirst%3DD.%2BM.%26aulast%3DHirman%26aufirst%3DJ.%26aulast%3DPederson%26aufirst%3DS.%26aulast%3DAllan%26aufirst%3DB.%26aulast%3DCady%26aufirst%3DR.%26atitle%3DEfficacy%2520and%2520safety%2520of%2520eptinezumab%2520in%2520patients%2520with%2520chronic%2520migraine%253A%2520PROMISE-2%26jtitle%3DNeurology%26date%3D2020%26volume%3D94%26spage%3DE1365%26epage%3DE1377%26doi%3D10.1212%2FWNL.0000000000009169" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bangs, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kudrow, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oakes, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terwindt, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magis, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yunes-Medina, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stauffer, V. L.</span></span> <span> </span><span class="NLM_article-title">Safety and tolerability of monthly galcanezumab injections in patients with migraine: integrated results from migraine clinical studies</span>. <i>BMC Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>20</i></span>, <span class="NLM_elocation-id">25</span> <span class="refDoi"> DOI: 10.1186/s12883-020-1609-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=10.1186%2Fs12883-020-1609-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=31952501" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=1%3ACAS%3A528%3ADC%252BB3cXkslCns78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2020&author=M.+E.+Bangsauthor=D.+Kudrowauthor=S.+Wangauthor=T.+M.+Oakesauthor=G.+M.+Terwindtauthor=D.+Magisauthor=L.+Yunes-Medinaauthor=V.+L.+Stauffer&title=Safety+and+tolerability+of+monthly+galcanezumab+injections+in+patients+with+migraine%3A+integrated+results+from+migraine+clinical+studies&doi=10.1186%2Fs12883-020-1609-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Safety and tolerability of monthly galcanezumab injections in patients with migraine: integrated results from migraine clinical studies</span></div><div class="casAuthors">Bangs, Mark E.; Kudrow, David; Wang, Shufang; Oakes, Tina M.; Terwindt, Gisela M.; Magis, Delphine; Yunes-Medina, Laura; Stauffer, Virginia L.</div><div class="citationInfo"><span class="NLM_cas:title">BMC Neurology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">25</span>CODEN:
                <span class="NLM_cas:coden">BNMEC8</span>;
        ISSN:<span class="NLM_cas:issn">1471-2377</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Abstr.: Background: Galcanezumab, a humanized monoclonal antibody that selectively binds to calcitonin gene-related peptide, has demonstrated a significant redn. in monthly migraine headache days in phase 2 and 3 trials.  In these analyses, we aimed to evaluate the safety and tolerability of galcanezumab compared with placebo for prevention of episodic or chronic migraine.  Methods: Data were integrated from three double-blind clin. studies for the up to 6-mo galcanezumab exposure group (N = 1435), and from five clin. studies for the up to 1-yr all-galcanezumab exposure group (N = 2276).  Patients received a monthly 120 mg s.c. injection of galcanezumab (with a 240 mg loading dose in month 1), 240 mg galcanezumab, or placebo.  Outcomes measured were treatment-emergent adverse events (TEAEs), serious AEs (SAEs), and discontinuation due to AEs (DCAEs).  Lab. results, vital signs, ECG (ECG), suicidal ideation and behavior results were evaluated.  Results: TEAEs that occurred more frequently in galcanezumab-treated patients included injection site pain, injection site reactions excluding pain, constipation, vertigo, and pruritus.  The proportion of DCAEs among galcanezumab-treated patients ranged between 1.8 and 3.0%, and differed from placebo group for galcanezumab 240 mg (P < 0.05).  Fewer than 2.0% of patients in either galcanezumab dose-group compared with 1.0% of placebo-treated patients reported a SAE.  There were no clin. meaningful differences between galcanezumab and placebo in lab. measures, vital signs including blood pressure, ECGs, cardiovascular-related AEs, or suicidal ideation and behavior.  Conclusions: Galcanezumab demonstrated a favorable safety and tolerability profile for up to 1 yr of treatment for the prevention of migraine.  Trial registration: Clin. Trials CGAB = NCT02163993, EVOLVE-1 = NCT02614183, EVOLVE-2 = NCT02614196, REGAIN = NCT02614261, and CGAJ = NCT02614287.  All were first posted on 25 Nov. 2015, except CGAB posted on 16 June 2014, and before enrolling the first patient.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpej1FhW5OZdrVg90H21EOLACvtfcHk0lgG2FS94EtqQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXkslCns78%253D&md5=7228272780e5c059cba1c533a97fe011</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1186%2Fs12883-020-1609-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12883-020-1609-7%26sid%3Dliteratum%253Aachs%26aulast%3DBangs%26aufirst%3DM.%2BE.%26aulast%3DKudrow%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DOakes%26aufirst%3DT.%2BM.%26aulast%3DTerwindt%26aufirst%3DG.%2BM.%26aulast%3DMagis%26aufirst%3DD.%26aulast%3DYunes-Medina%26aufirst%3DL.%26aulast%3DStauffer%26aufirst%3DV.%2BL.%26atitle%3DSafety%2520and%2520tolerability%2520of%2520monthly%2520galcanezumab%2520injections%2520in%2520patients%2520with%2520migraine%253A%2520integrated%2520results%2520from%2520migraine%2520clinical%2520studies%26jtitle%3DBMC%2520Neurol.%26date%3D2020%26volume%3D20%26doi%3D10.1186%2Fs12883-020-1609-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Archbold, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flanagan, J. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gingell, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hay, D. L.</span></span> <span> </span><span class="NLM_article-title">Structural insights into RAMP modification of secretin family G protein-coupled receptors: implications for drug development</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">591</span>– <span class="NLM_lpage">600</span>, <span class="refDoi"> DOI: 10.1016/j.tips.2011.05.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=10.1016%2Fj.tips.2011.05.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=21722971" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1Gkur7N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2011&pages=591-600&author=J.+K.+Archboldauthor=J.+U.+Flanaganauthor=H.+A.+Watkinsauthor=J.+J.+Gingellauthor=D.+L.+Hay&title=Structural+insights+into+RAMP+modification+of+secretin+family+G+protein-coupled+receptors%3A+implications+for+drug+development&doi=10.1016%2Fj.tips.2011.05.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Structural insights into RAMP modification of secretin family G protein-coupled receptors: implications for drug development</span></div><div class="casAuthors">Archbold, Julia K.; Flanagan, Jack U.; Watkins, Harriet A.; Gingell, Joseph J.; Hay, Debbie L.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">591-600</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Secretin family G protein-coupled receptors (GPCRs) are important therapeutic targets for migraine, diabetes, bone disorders, inflammatory disorders and cardiovascular disease.  They possess a large N-terminal extracellular domain (ECD) known to be the primary ligand-binding determinant.  Structural detn. of several secretin family GPCR ECDs in complex with peptide ligands has been achieved recently, providing insight into the mol. determinants of hormone binding.  Some secretin family GPCRs assoc. with receptor activity-modifying proteins (RAMPs), resulting in changes to receptor pharmacol.  Recently, the first crystal structure of a RAMP ECD in complex with a secretin family GPCR was solved, revealing the elegant mechanism governing receptor selectivity of small mol. antagonists of the calcitonin gene-related peptide (CGRP) receptor.  Here we review the structural basis of ligand binding to secretin family GPCRs, concg. on recent progress made on the structural basis of RAMP-modified GPCR pharmacol. and its implications for rational drug design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYsel-YOVbvrVg90H21EOLACvtfcHk0lgG2FS94EtqQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1Gkur7N&md5=b47c3f513ed3bb3e24558860b8341869</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2011.05.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2011.05.007%26sid%3Dliteratum%253Aachs%26aulast%3DArchbold%26aufirst%3DJ.%2BK.%26aulast%3DFlanagan%26aufirst%3DJ.%2BU.%26aulast%3DWatkins%26aufirst%3DH.%2BA.%26aulast%3DGingell%26aufirst%3DJ.%2BJ.%26aulast%3DHay%26aufirst%3DD.%2BL.%26atitle%3DStructural%2520insights%2520into%2520RAMP%2520modification%2520of%2520secretin%2520family%2520G%2520protein-coupled%2520receptors%253A%2520implications%2520for%2520drug%2520development%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2011%26volume%3D32%26spage%3D591%26epage%3D600%26doi%3D10.1016%2Fj.tips.2011.05.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brain, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grant, A. D.</span></span> <span> </span><span class="NLM_article-title">Vascular actions of calcitonin gene-related peptide and adrenomedullin</span>. <i>Physiol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>84</i></span>,  <span class="NLM_fpage">903</span>– <span class="NLM_lpage">934</span>, <span class="refDoi"> DOI: 10.1152/physrev.00037.2003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=10.1152%2Fphysrev.00037.2003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=15269340" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmtlCnu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=2004&pages=903-934&author=S.+D.+Brainauthor=A.+D.+Grant&title=Vascular+actions+of+calcitonin+gene-related+peptide+and+adrenomedullin&doi=10.1152%2Fphysrev.00037.2003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Vascular actions of calcitonin gene-related peptide and adrenomedullin</span></div><div class="casAuthors">Brain, Susan D.; Grant, Andrew D.</div><div class="citationInfo"><span class="NLM_cas:title">Physiological Reviews</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">84</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">903-934</span>CODEN:
                <span class="NLM_cas:coden">PHREA7</span>;
        ISSN:<span class="NLM_cas:issn">0031-9333</span>.
    
            (<span class="NLM_cas:orgname">American Physiological Society</span>)
        </div><div class="casAbstract">This review summarizes the receptor-mediated vascular activities of calcitonin gene-related peptide (CGRP) and the structurally related peptide adrenomedullin (AM).  CGRP is a 37-amino acid neuropeptide, primarily released from sensory nerves, while AM is produced by stimulated vascular cells, and amylin is secreted from the pancreas.  They share vasodilator activity, albeit to varying extents depending on species and tissue.  In particular, CGRP has potent activity in the cerebral circulation, which is possibly relevant to the pathol. of migraine, while vascular sources of AM contribute to dysfunction in cardiovascular disease.  Both peptides exhibit potent activity in microvascular beds.  All 3 peptides can act on a family of CGRP receptors that consist of calcitonin receptor-like receptor (CL) linked to one of 3 receptor activity-modifying proteins (RAMPs) that are essential for functional activity.  The assocn. of CL with RAMP1 produces a CGRP receptor, with RAMP2 an AM receptor and with RAMP3 a CGRP/AM receptor.  Evidence for the selective activity of the first nonpeptide CGRP antagonist BIBN4096BS for the CGRP receptor is presented.  The cardiovascular activity of these peptides in a range of species and in human clin. conditions is detailed, and potential therapeutic applications based on use of antagonists and gene targeting of agonists are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_Jum9315jsrVg90H21EOLACvtfcHk0lgG2FS94EtqQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmtlCnu7w%253D&md5=1912eea830cd128022bd2468cb4f31eb</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1152%2Fphysrev.00037.2003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fphysrev.00037.2003%26sid%3Dliteratum%253Aachs%26aulast%3DBrain%26aufirst%3DS.%2BD.%26aulast%3DGrant%26aufirst%3DA.%2BD.%26atitle%3DVascular%2520actions%2520of%2520calcitonin%2520gene-related%2520peptide%2520and%2520adrenomedullin%26jtitle%3DPhysiol.%2520Rev.%26date%3D2004%26volume%3D84%26spage%3D903%26epage%3D934%26doi%3D10.1152%2Fphysrev.00037.2003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shindo, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakurai, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamiyoshi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ichikawa-Shindo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimoyama, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iinuma, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arai, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyagawa, S.</span></span> <span> </span><span class="NLM_article-title">Regulation of adrenomedullin and its family peptide by RAMP system - lessons from genetically engineered mice</span>. <i>Curr. Protein Pept. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">347</span>– <span class="NLM_lpage">357</span>, <span class="refDoi"> DOI: 10.2174/13892037113149990052</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=10.2174%2F13892037113149990052" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=23745699" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1Gmu7fO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2013&pages=347-357&author=T.+Shindoauthor=T.+Sakuraiauthor=A.+Kamiyoshiauthor=Y.+Ichikawa-Shindoauthor=N.+Shimoyamaauthor=N.+Iinumaauthor=T.+Araiauthor=S.+Miyagawa&title=Regulation+of+adrenomedullin+and+its+family+peptide+by+RAMP+system+-+lessons+from+genetically+engineered+mice&doi=10.2174%2F13892037113149990052"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of Adrenomedullin and its Family Peptide by RAMP System - Lessons from Genetically Engineered Mice</span></div><div class="casAuthors">Shindo, Takayuki; Sakurai, Takayuki; Kamiyoshi, Akiko; Ichikawa-Shindo, Yuka; Shimoyama, Natsumi; Iinuma, Nobuyoshi; Arai, Takuma; Miyagawa, Shinichi</div><div class="citationInfo"><span class="NLM_cas:title">Current Protein and Peptide Science</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">347-357</span>CODEN:
                <span class="NLM_cas:coden">CPPSCM</span>;
        ISSN:<span class="NLM_cas:issn">1389-2037</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Adrenomedullin (ADM), originally identified as a vasodilating peptide, is now recognized to be a pleiotropic mol. involved in both the pathogenesis of cardiovascular diseases and circulatory homeostasis.  Homozygotes of ADM knockout mice (ADM-/-) were lethal at mid-gestation with abnormalities of vascular development and this finding clarified the angiogenic potency of ADM.  Calcitonin gene-related peptide (CGRP), which has a structure and function similar to that of ADM, has been identified as a family peptide of ADM.  Unlike ADM-/-, CGRP-/- were apparently normal.  Therefore, the study of knockout mice first clarified the distinctly different physiol. roles between ADM and CGRP.  In contrast, heterozygotes of ADM knockout mice (ADM+/-) were alive but showed blood pressure elevation, reduced neovascularization, and enhanced neointimal formation by arterial injury.  Based on these observations, there was hope ADM would have a therapeutic use.  However, ADM has a short half-life in the blood stream and its application in chronic disease has limitations.  Therefore, we focused on the ADM receptor system.  The calcitonin-receptor-like receptor (CLR), which is the ADM receptor, assocs. with one of the accessory proteins, called receptor activity-modifying proteins (RAMPs).  By interacting with RAMP1, CLR exhibits a high affinity for CGRP, whereas by interacting with either RAMP2 or -3, CLR exhibits a high affinity for ADM.  We generated RAMP knockout mice and found that vascular phenotypes similar to ADM-/- were reproduced only in RAMP2-/-.  This shows that RAMP2 is the key determinant of the vascular functions of ADM.  RAMP2 could be an attractive therapeutic target in cardiovascular diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpE847bSXcnx7Vg90H21EOLACvtfcHk0lj-UqTDw5M7Cg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1Gmu7fO&md5=a4bea647953bafbea570a7f02366009e</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.2174%2F13892037113149990052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F13892037113149990052%26sid%3Dliteratum%253Aachs%26aulast%3DShindo%26aufirst%3DT.%26aulast%3DSakurai%26aufirst%3DT.%26aulast%3DKamiyoshi%26aufirst%3DA.%26aulast%3DIchikawa-Shindo%26aufirst%3DY.%26aulast%3DShimoyama%26aufirst%3DN.%26aulast%3DIinuma%26aufirst%3DN.%26aulast%3DArai%26aufirst%3DT.%26aulast%3DMiyagawa%26aufirst%3DS.%26atitle%3DRegulation%2520of%2520adrenomedullin%2520and%2520its%2520family%2520peptide%2520by%2520RAMP%2520system%2520-%2520lessons%2520from%2520genetically%2520engineered%2520mice%26jtitle%3DCurr.%2520Protein%2520Pept.%2520Sci.%26date%3D2013%26volume%3D14%26spage%3D347%26epage%3D357%26doi%3D10.2174%2F13892037113149990052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Larráyoz, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martínez-Herrero, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">García-Sanmartín, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ochoa-Callejero, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martínez, A.</span></span> <span> </span><span class="NLM_article-title">Adrenomedullin and tumour microenvironment</span>. <i>J. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>12</i></span>, <span class="NLM_elocation-id">339</span> <span class="refDoi"> DOI: 10.1186/s12967-014-0339-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=10.1186%2Fs12967-014-0339-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=25475159" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=1%3ACAS%3A528%3ADC%252BC2MXit1OitLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2014&author=I.+M.+Larr%C3%A1yozauthor=S.+Mart%C3%ADnez-Herreroauthor=J.+Garc%C3%ADa-Sanmart%C3%ADnauthor=L.+Ochoa-Callejeroauthor=A.+Mart%C3%ADnez&title=Adrenomedullin+and+tumour+microenvironment&doi=10.1186%2Fs12967-014-0339-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Adrenomedullin and tumour microenvironment</span></div><div class="casAuthors">Larrayoz, Ignacio M.; Martinez-Herrero, Sonia; Garcia-Sanmartin, Josune; Ochoa-Callejero, Laura; Martinez, Alfredo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Translational Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">339/1-339/33, 33 pp.</span>CODEN:
                <span class="NLM_cas:coden">JTMOBV</span>;
        ISSN:<span class="NLM_cas:issn">1479-5876</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">A review.  Adrenomedullin (AM) is a regulatory peptide whose involvement in tumor progression is becoming more relevant with recent studies.  AM is produced and secreted by the tumor cells but also by numerous stromal cells including macrophages, mast cells, endothelial cells, and vascular smooth muscle cells.  Most cancer patients present high levels of circulating AM and in some cases these higher levels correlate with a worst prognosis.  In some cases it has been shown that the high AM levels return to normal following surgical removal of the tumor, thus indicating the tumor as the source of this excessive prodn. of AM.  Expression of this peptide is a good investment for the tumor cell since AM acts as an autocrine/paracrine growth factor, prevents apoptosis-mediated cell death, increases tumor cell motility and metastasis, induces angiogenesis, and blocks immunosurveillance by inhibiting the immune system.  In addn., AM expression gets rapidly activated by hypoxia through a HIF-1α mediated mechanism, thus characterizing AM as a major survival factor for tumor cells.  Accordingly, a no. of studies have shown that inhibition of this peptide or its receptors results in a significant redn. in tumor progression.  In conclusion, AM is a great target for drug development and new drugs interfering with this system are being developed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr03Zy8I9oN27Vg90H21EOLACvtfcHk0lj-UqTDw5M7Cg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXit1OitLY%253D&md5=4f1143a6a72d68da71b3ee062bcb9fd2</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1186%2Fs12967-014-0339-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12967-014-0339-2%26sid%3Dliteratum%253Aachs%26aulast%3DLarr%25C3%25A1yoz%26aufirst%3DI.%2BM.%26aulast%3DMart%25C3%25ADnez-Herrero%26aufirst%3DS.%26aulast%3DGarc%25C3%25ADa-Sanmart%25C3%25ADn%26aufirst%3DJ.%26aulast%3DOchoa-Callejero%26aufirst%3DL.%26aulast%3DMart%25C3%25ADnez%26aufirst%3DA.%26atitle%3DAdrenomedullin%2520and%2520tumour%2520microenvironment%26jtitle%3DJ.%2520Transl.%2520Med.%26date%3D2014%26volume%3D12%26doi%3D10.1186%2Fs12967-014-0339-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hay, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poyner, D. R.</span></span> <span> </span><span class="NLM_article-title">Adrenomedullin and calcitonin gene-related peptide receptors in endocrine-related cancers: opportunities and challenges</span>. <i>Endocr.-Relat. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">C1</span>– <span class="NLM_lpage">C14</span>, <span class="refDoi"> DOI: 10.1677/ERC-10-0244</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=10.1677%2FERC-10-0244" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=21051558" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjsFWqtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2011&pages=C1-C14&author=D.+L.+Hayauthor=C.+S.+Walkerauthor=D.+R.+Poyner&title=Adrenomedullin+and+calcitonin+gene-related+peptide+receptors+in+endocrine-related+cancers%3A+opportunities+and+challenges&doi=10.1677%2FERC-10-0244"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Adrenomedullin and calcitonin gene-related peptide receptors in endocrine-related cancers: opportunities and challenges</span></div><div class="casAuthors">Hay, Debbie L.; Walker, Christopher S.; Poyner, David R.</div><div class="citationInfo"><span class="NLM_cas:title">Endocrine-Related Cancer</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">C1-C14</span>CODEN:
                <span class="NLM_cas:coden">ERCAE9</span>;
        ISSN:<span class="NLM_cas:issn">1351-0088</span>.
    
            (<span class="NLM_cas:orgname">BioScientifica Ltd.</span>)
        </div><div class="casAbstract">A review.  Adrenomedullin (AM), adrenomedullin 2 (AM2/intermedin) and calcitonin gene-related peptide (CGRP) are members of the calcitonin family of peptides.  They can act as growth or survival factors for a no. of tumors, including those that are endocrine-related.  One mechanism through which this occurs is stimulating angiogenesis and lymphangiogenesis.  AM is expressed by numerous tumor types and for some cancers, plasma AM levels can be correlated with the severity of the disease.  In cancer models, lowering AM content or blocking AM receptors can reduce tumor mass.  AM receptors are complexes formed between a seven transmembrane protein, calcitonin receptor-like receptor and one of the two accessory proteins, receptor activity-modifying proteins (RAMPs) 2 or 3 to give the AM1 and AM2 receptors resp.  AM also has affinity at the CGRP receptor, which uses RAMP1.  Unfortunately, due to a lack of selective pharmacol. tools or antibodies to distinguish AM and CGRP receptors, the precise receptors and signal transduction pathways used by the peptides are often uncertain.  Two other membrane proteins, RDC1 and L1/G10D (the 'ADMR'), are not currently considered to be genuine CGRP or AM receptors.  In order to properly evaluate whether AM or CGRP receptor inhibition has a role in cancer therapy, it is important to identify which receptors mediate the effects of these peptides.  To effectively distinguish AM1 and AM2 receptors, selective receptor antagonists need to be developed.  The development of specific CGRP receptor antagonists suggests that this is now feasible.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVRGmWq_pGxrVg90H21EOLACvtfcHk0lj-UqTDw5M7Cg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjsFWqtLY%253D&md5=0b7543a7b04991ae89eb351493b65c43</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1677%2FERC-10-0244&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1677%252FERC-10-0244%26sid%3Dliteratum%253Aachs%26aulast%3DHay%26aufirst%3DD.%2BL.%26aulast%3DWalker%26aufirst%3DC.%2BS.%26aulast%3DPoyner%26aufirst%3DD.%2BR.%26atitle%3DAdrenomedullin%2520and%2520calcitonin%2520gene-related%2520peptide%2520receptors%2520in%2520endocrine-related%2520cancers%253A%2520opportunities%2520and%2520challenges%26jtitle%3DEndocr.-Relat.%2520Cancer%26date%3D2011%26volume%3D18%26spage%3DC1%26epage%3DC14%26doi%3D10.1677%2FERC-10-0244" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qiao, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ni, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akuo, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, S.</span></span> <span> </span><span class="NLM_article-title">The role of adrenomedullin in the pathogenesis of gastric cancer</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">88464</span>– <span class="NLM_lpage">88474</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.18881</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=10.18632%2Foncotarget.18881" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=29179449" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=1%3ACAS%3A280%3ADC%252BC1M3ltlOntw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=88464-88474&author=F.+Qiaoauthor=J.+Fangauthor=J.+Xuauthor=W.+Zhaoauthor=Y.+Niauthor=B.+A.+Akuoauthor=W.+Zhangauthor=Y.+Liuauthor=F.+Dingauthor=G.+Liauthor=B.+Liuauthor=H.+Wangauthor=S.+Shao&title=The+role+of+adrenomedullin+in+the+pathogenesis+of+gastric+cancer&doi=10.18632%2Foncotarget.18881"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">The role of adrenomedullin in the pathogenesis of gastric cancer</span></div><div class="casAuthors">Qiao Fuhao; Fang Jian; Xu Jinfeng; Zhao Wenqiu; Ni Ying; Akuo Bufugdi Andreas; Zhang Wei; Liu Yun; Ding Fangfang; Wang Hua; Shao Shihe; Qiao Fuhao; Li Guanlin; Liu Baoguo</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">51</span>),
    <span class="NLM_cas:pages">88464-88474</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Adrenomedullin has been shown to be overexpressed in many tumors, including gastric cancer tumors; however, its mechanism of action remains unclear.  In this study, we examined the role of adrenomedullin in the pathogenesis of gastric cancer.  Using clinical specimens and immunohistochemistry, we found that the expression levels of adrenomedullin and its receptors are inordinately elevated as compared to the adjacent non-tumor gastric tissues.  We used siRNA gene silencing, in BGC-823 gastric cancer cell lines, to target adrenomedullin genes, and found that increased adrenomedullin expression results in the proliferation of tumor cells, tumor invasion, and metastasis.  Furthermore, we found that under hypoxic conditions, gastric cancer BGC-823 cells exhibit higher expression levels of adrenomedullin and various other related proteins.  Our results indicate the involvement of adrenomedullin in microvessel proliferation and partially in the release of hypoxia in solid tumors.  Knockdown of adrenomedullin expression, at the protein level, reduced the levels of phosphoprotein kinase B and B-cell lymphoma 2 but increased the levels of cleaved-caspase3 and Bcl 2 associated x protein (Bax).  Therefore, we hypothesized siRNA targeting of adrenomedullin genes inhibits various serine/threonine kinases via a signaling pathway that induces cell apoptosis.  SiRNA targeting of adrenomedullin genes and green fluorescent control vectors were used to transfect BGC-823 cells, and western blot analyses were used to detect changes in the rates of autophagy in related proteins using confocal laser scanning microscopy.  No significant changes were detected.  Therefore, the knockdown of adrenomedullin and its receptors may represent a novel treatment strategy for gastric cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR5yvT6h5Erjs-crCu0nI_sfW6udTcc2ebSv-HJ-iLi0bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M3ltlOntw%253D%253D&md5=92fd0f166620f05fdd61748b9f1a4886</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.18881&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.18881%26sid%3Dliteratum%253Aachs%26aulast%3DQiao%26aufirst%3DF.%26aulast%3DFang%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DW.%26aulast%3DNi%26aufirst%3DY.%26aulast%3DAkuo%26aufirst%3DB.%2BA.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DDing%26aufirst%3DF.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DShao%26aufirst%3DS.%26atitle%3DThe%2520role%2520of%2520adrenomedullin%2520in%2520the%2520pathogenesis%2520of%2520gastric%2520cancer%26jtitle%3DOncotarget%26date%3D2017%26volume%3D8%26spage%3D88464%26epage%3D88474%26doi%3D10.18632%2Foncotarget.18881" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dai, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamiyoshi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakurai, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ichikawa-Shindo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawate, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kakihara, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsui, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shindo, T.</span></span> <span> </span><span class="NLM_article-title">Deficiency of the adrenomedullin-RAMP3 system suppresses metastasis through the modification of cancer-associated fibroblasts</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">1914</span>– <span class="NLM_lpage">1930</span>, <span class="refDoi"> DOI: 10.1038/s41388-019-1112-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=10.1038%2Fs41388-019-1112-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=31754214" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=1%3ACAS%3A528%3ADC%252BC1MXit1Smt7nO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2020&pages=1914-1930&author=K.+Daiauthor=M.+Tanakaauthor=A.+Kamiyoshiauthor=T.+Sakuraiauthor=Y.+Ichikawa-Shindoauthor=H.+Kawateauthor=N.+Cuiauthor=Y.+Weiauthor=M.+Tanakaauthor=S.+Kakiharaauthor=S.+Matsuiauthor=T.+Shindo&title=Deficiency+of+the+adrenomedullin-RAMP3+system+suppresses+metastasis+through+the+modification+of+cancer-associated+fibroblasts&doi=10.1038%2Fs41388-019-1112-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Deficiency of the adrenomedullin-RAMP3 system suppresses metastasis through the modification of cancer-associated fibroblasts</span></div><div class="casAuthors">Dai, Kun; Tanaka, Megumu; Kamiyoshi, Akiko; Sakurai, Takayuki; Ichikawa-Shindo, Yuka; Kawate, Hisaka; Cui, Nanqi; Wei, Yangxuan; Tanaka, Masaaki; Kakihara, Shinji; Matsui, Shuhei; Shindo, Takayuki</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1914-1930</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Tumor metastasis is a primary source of morbidity and mortality in cancer.  Adrenomedullin (AM) is a multifunctional peptide regulated by receptor activity-modifying proteins (RAMPs).  We previously reported that the AM-RAMP2 system is involved in tumor angiogenesis, but the function of the AM-RAMP3 system remains largely unknown.  Here, we investigated the actions of the AM-RAMP2 and 3 systems in the tumor microenvironment and their impact on metastasis.  PAN02 pancreatic cancer cells were injected into the spleens of mice, leading to spontaneous liver metastasis.  Tumor metastasis was enhanced in vascular endothelial cell-specific RAMP2 knockout mice (DI-E-RAMP2-/-).  By contrast, metastasis was suppressed in RAMP3-/- mice, where the no. of podoplanin (PDPN)-pos. cancer-assocd. fibroblasts (CAFs) was reduced in the periphery of tumors at metastatic sites.  Because PDPN-pos. CAFs are a hallmark of tumor malignancy, we assessed the regulation of PDPN and found that Src/Cas/PDPN signaling is mediated by RAMP3.  In fact, RAMP3 deficiency CAFs suppressed migration, proliferation, and metastasis in co-cultures with tumor cells in vitro and in vivo.  Moreover, the activation of RAMP2 in RAMP3-/- mice suppressed both tumor growth and metastasis.  Based on these results, we suggest that the upregulation of PDPN in DI-E-RAMP2-/- mice increases malignancy, while the downregulation of PDPN in RAMP3-/- mice reduces it.  Selective activation of RAMP2 and inhibition of RAMP3 would therefore be expected to suppress tumor metastasis.  This study provides the first evidence that understanding and targeting to AM-RAMP systems could contribute to the development of novel therapeutics against metastasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGop648nEd65s7Vg90H21EOLACvtfcHk0lh0BUtfjrgs5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXit1Smt7nO&md5=84853e55ce395d762292b803ce571a9a</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1038%2Fs41388-019-1112-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41388-019-1112-z%26sid%3Dliteratum%253Aachs%26aulast%3DDai%26aufirst%3DK.%26aulast%3DTanaka%26aufirst%3DM.%26aulast%3DKamiyoshi%26aufirst%3DA.%26aulast%3DSakurai%26aufirst%3DT.%26aulast%3DIchikawa-Shindo%26aufirst%3DY.%26aulast%3DKawate%26aufirst%3DH.%26aulast%3DCui%26aufirst%3DN.%26aulast%3DWei%26aufirst%3DY.%26aulast%3DTanaka%26aufirst%3DM.%26aulast%3DKakihara%26aufirst%3DS.%26aulast%3DMatsui%26aufirst%3DS.%26aulast%3DShindo%26aufirst%3DT.%26atitle%3DDeficiency%2520of%2520the%2520adrenomedullin-RAMP3%2520system%2520suppresses%2520metastasis%2520through%2520the%2520modification%2520of%2520cancer-associated%2520fibroblasts%26jtitle%3DOncogene%26date%3D2020%26volume%3D39%26spage%3D1914%26epage%3D1930%26doi%3D10.1038%2Fs41388-019-1112-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Greillier, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tounsi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berenguer-Daize, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dussault, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delfino, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benyahia, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cayol, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mabrouk, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barlesi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouafik, L.</span></span> <span> </span><span class="NLM_article-title">Functional analysis of the adrenomedullin pathway in malignant pleural mesothelioma</span>. <i>J. Thorac. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">94</span>– <span class="NLM_lpage">107</span>, <span class="refDoi"> DOI: 10.1016/j.jtho.2015.09.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=10.1016%2Fj.jtho.2015.09.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=26762744" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=1%3ACAS%3A280%3ADC%252BC28ngsVaqtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=94-107&author=L.+Greillierauthor=A.+Tounsiauthor=C.+Berenguer-Daizeauthor=N.+Dussaultauthor=C.+Delfinoauthor=Z.+Benyahiaauthor=M.+Cayolauthor=K.+Mabroukauthor=S.+Garciaauthor=P.+M.+Martinauthor=F.+Barlesiauthor=L.+Ouafik&title=Functional+analysis+of+the+adrenomedullin+pathway+in+malignant+pleural+mesothelioma&doi=10.1016%2Fj.jtho.2015.09.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Functional Analysis of the Adrenomedullin Pathway in Malignant Pleural Mesothelioma</span></div><div class="casAuthors">Greillier Laurent; Tounsi Asma; Berenguer-Daize Caroline; Dussault Nadege; Delfino Christine; Benyahia Zohra; Cayol Mylene; Mabrouk Kamel; Garcia Stephane; Martin Pierre-Marie; Ouafik L'Houcine; Barlesi Fabrice</div><div class="citationInfo"><span class="NLM_cas:title">Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">94-107</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">INTRODUCTION:  Malignant pleural mesothelioma (MPM) grows aggressively within the thoracic cavity and has a very low cure rate, thus highlighting the need for identification of new therapeutic targets.  Adrenomedullin (AM) is a multifunctional peptide that is highly expressed in several tumors and plays an important role in angiogenesis and tumor growth after binding to its receptors, calcitonin receptor-like receptor/receptor activity-modifying protein 2 (CLR/RAMP2) and calcitonin receptor-like receptor/receptor activity-modifying protein 3 (CLR/RAMP3).  METHODS:  Real time quantitative reverse transcriptase polymerase chain reaction (RT-PCR) was used to assess the steady-state levels of AM, CLR, RAMP2 and RAMP3 messenger RNA (mRNA) transcripts in normal pleural tissue (n=5) and MPM (n=24).  The expression of these candidates at protein level was revealed by immunohistochemistry.  We also characterized the expression and regulation by hypoxia of AM system in MPM cell lines and MeT-5A cells.  In vitro and in vivo studies were performed to determine the functional role of AM system in MPM.  RESULTS:  In this study, real-time quantitative reverse transcriptase polymerase chain reaction showed twofold to 10-fold higher levels of AM messenger RNA in MPM tissue than in normal pleural tissue.  The MPM cell lines H2452, H2052, and human mesothelioma cell line MSTO-211H showed a significant increase in expression of AM messenger RNA under hypoxic conditions.  Our results also show that AM stimulates cell proliferation in vitro through the Raf1 proto-oncogene, serine/threonine kinase (CRAF)/ Mitogen-activated protein kinase kinase 1 (MEK)/Extracellular regulated MAPKinase (ERK) pathway.  Furthermore, the proliferation, migration, and invasion of MPM cells were decreased after treatment with anti-AM (αAM) and anti-AM receptor antibodies, thus indicating that MPM cells are regulated by AM.  The action of AM was specific and mediated by CLR/RAMP2 and CLR/RAMP3 receptors.  In vivo, αAM and AM22-52 antagonist therapies blocked angiogenesis and induced apoptosis in MSTO-211H xenografts, thereby resulting in tumor regression.  Histologic examination of tumors treated with AM22-52 and αAM antibody showed evidence of disruption of tumor vasculature with depletion of vascular endothelial cells and a significant decrease in lymphatic endothelial cells.  CONCLUSIONS:  Our findings highlight the importance of the AM pathway in growth of MPM and in neovascularization by supplying and amplifying signals that are essential for pathologic neoangiogenesis and lymphangiogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRXL591qi4wo7P3FVUi_gf8fW6udTcc2ebSv-HJ-iLi0bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28ngsVaqtA%253D%253D&md5=39b2547c1c0da50a93e005fcba25ee6e</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2Fj.jtho.2015.09.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jtho.2015.09.004%26sid%3Dliteratum%253Aachs%26aulast%3DGreillier%26aufirst%3DL.%26aulast%3DTounsi%26aufirst%3DA.%26aulast%3DBerenguer-Daize%26aufirst%3DC.%26aulast%3DDussault%26aufirst%3DN.%26aulast%3DDelfino%26aufirst%3DC.%26aulast%3DBenyahia%26aufirst%3DZ.%26aulast%3DCayol%26aufirst%3DM.%26aulast%3DMabrouk%26aufirst%3DK.%26aulast%3DGarcia%26aufirst%3DS.%26aulast%3DMartin%26aufirst%3DP.%2BM.%26aulast%3DBarlesi%26aufirst%3DF.%26aulast%3DOuafik%26aufirst%3DL.%26atitle%3DFunctional%2520analysis%2520of%2520the%2520adrenomedullin%2520pathway%2520in%2520malignant%2520pleural%2520mesothelioma%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2016%26volume%3D11%26spage%3D94%26epage%3D107%26doi%3D10.1016%2Fj.jtho.2015.09.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brekhman, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lugassie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaffryar-Eilot, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kessler, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golding, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neufeld, G.</span></span> <span> </span><span class="NLM_article-title">Receptor activity modifying protein-3 mediates the protumorigenic activity of lysyl oxidase-like protein-2</span>. <i>FASEB J.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">55</span>– <span class="NLM_lpage">65</span>, <span class="refDoi"> DOI: 10.1096/fj.10-162677</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=10.1096%2Ffj.10-162677" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=20802105" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=1%3ACAS%3A528%3ADC%252BC3MXls1GnsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2011&pages=55-65&author=V.+Brekhmanauthor=J.+Lugassieauthor=S.+Zaffryar-Eilotauthor=E.+Saboauthor=O.+Kesslerauthor=V.+Smithauthor=H.+Goldingauthor=G.+Neufeld&title=Receptor+activity+modifying+protein-3+mediates+the+protumorigenic+activity+of+lysyl+oxidase-like+protein-2&doi=10.1096%2Ffj.10-162677"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Receptor activity modifying protein-3 mediates the protumorigenic activity of lysyl oxidase-like protein-2</span></div><div class="casAuthors">Brekhman, Vera; Lugassie, Jennie; Zaffryar-Eilot, Shelly; Sabo, Edmond; Kessler, Ofra; Smith, Victoria; Golding, Hana; Neufeld, Gera</div><div class="citationInfo"><span class="NLM_cas:title">FASEB Journal</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">55-65, 10.1096/fj.10-162677</span>CODEN:
                <span class="NLM_cas:coden">FAJOEC</span>;
        ISSN:<span class="NLM_cas:issn">0892-6638</span>.
    
            (<span class="NLM_cas:orgname">Federation of American Societies for Experimental Biology</span>)
        </div><div class="casAbstract">Lysyl oxidase-like protein-2 (LOXL2) induces epithelial to mesenchymal transition and promotes invasiveness.  To understand the mechanisms involved, we examd. the effect of LOXL2 overexpression in MCF-7 cells on gene expression.  We found that LOXL2 up-regulated the expression of receptor activity modifying protein-3 (RAMP3).  Expression of RAMP3 in MDA-MB-231 cells in which LOXL2 expression was inhibited restored vimentin expression, invasiveness, and tumor development.  Inhibition of RAMP3 expression in MDA-MB-231 cells mimicked the effects produced by inhibition of LOXL2 expression and was accompanied by inhibition of p38 phosphorylation.  LOXL2 overexpression in these cells did not restore invasiveness, suggesting that RAMP3 functions downstream to LOXL2.  LOXL2 and RAMP3 are strongly coexpressed in human colon, breast, and gastric carcinomas but not in normal colon or gastric epithelial cells.  RAMP3 assocs. with several G-protein-coupled receptors forming receptors for peptides, such as adrenomedullin and amylin.  We hypothesized that RAMP3 could function as a transducer of autocrine signals induced by such peptides.  However, the proinvasive effects of RAMP3 could not be abrogated following inhibition of the expression or activity of these peptides.  Our expts. suggest that the protumorigenic effects of LOXL2 are partially mediated by RAMP3 and that RAMP3 inhibitors may function as antitumorigenic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXWC73S7YgtbVg90H21EOLACvtfcHk0lgFaZ1ZSkg6qg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXls1GnsQ%253D%253D&md5=bd999d5fb9816056ef51844b2327509d</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1096%2Ffj.10-162677&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1096%252Ffj.10-162677%26sid%3Dliteratum%253Aachs%26aulast%3DBrekhman%26aufirst%3DV.%26aulast%3DLugassie%26aufirst%3DJ.%26aulast%3DZaffryar-Eilot%26aufirst%3DS.%26aulast%3DSabo%26aufirst%3DE.%26aulast%3DKessler%26aufirst%3DO.%26aulast%3DSmith%26aufirst%3DV.%26aulast%3DGolding%26aufirst%3DH.%26aulast%3DNeufeld%26aufirst%3DG.%26atitle%3DReceptor%2520activity%2520modifying%2520protein-3%2520mediates%2520the%2520protumorigenic%2520activity%2520of%2520lysyl%2520oxidase-like%2520protein-2%26jtitle%3DFASEB%2520J.%26date%3D2011%26volume%3D25%26spage%3D55%26epage%3D65%26doi%3D10.1096%2Ffj.10-162677" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Siclari, V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohammad, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tompkins, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKenna, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wessner, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niewolna, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guise, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suvannasankha, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chirgwin, J. M.</span></span> <span> </span><span class="NLM_article-title">Tumor-expressed adrenomedullin accelerates breast cancer bone metastasis</span>. <i>Breast Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>16</i></span>, <span class="NLM_elocation-id">458</span> <span class="refDoi"> DOI: 10.1186/s13058-014-0458-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=10.1186%2Fs13058-014-0458-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=25439669" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjtVCrtrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2014&author=V.+A.+Siclariauthor=K.+S.+Mohammadauthor=D.+R.+Tompkinsauthor=H.+Davisauthor=C.+R.+McKennaauthor=X.+Pengauthor=L.+L.+Wessnerauthor=M.+Niewolnaauthor=T.+A.+Guiseauthor=A.+Suvannasankhaauthor=J.+M.+Chirgwin&title=Tumor-expressed+adrenomedullin+accelerates+breast+cancer+bone+metastasis&doi=10.1186%2Fs13058-014-0458-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Tumor-expressed adrenomedullin accelerates breast cancer bone metastasis</span></div><div class="casAuthors">Siclari, Valerie A.; Mohammad, Khalid S.; Tompkins, Douglas R.; Davis, Holly; McKenna, C. Ryan; Peng, Xianghong; Wessner, Lisa L.; Niewolna, Maria; Guise, Theresa A.; Suvannasankha, Attaya; Chirgwin, John M.</div><div class="citationInfo"><span class="NLM_cas:title">Breast Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">458/1-458/14, 14 pp.</span>CODEN:
                <span class="NLM_cas:coden">BRCRFS</span>;
        ISSN:<span class="NLM_cas:issn">1465-542X</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Introduction: Adrenomedullin (AM) is secreted by breast cancer cells and increased by hypoxia.  It is a multifunctional peptide that stimulates angiogenesis and proliferation.  The peptide is also a potent paracrine stimulator of osteoblasts and bone formation, suggesting a role in skeletal metastases-a major site of treatment-refractory tumor growth in patients with advanced disease.  Methods: The role of adrenomedullin in bone metastases was tested by stable overexpression in MDA-MB-231 breast cancer cells, which cause osteolytic bone metastases in a std. animal model.  Cells with fivefold increased expression of AM were characterized in vitro, inoculated into immunodeficient mice and compared for their ability to form bone metastases vs. control subclones.  Bone destruction was monitored by X-ray, and tumor burden and osteoclast nos. were detd. by quant. histomorphometry.  The effects of AM overexpression on tumor growth and angiogenesis in the mammary fat pad were detd.  The effects of AM peptide on osteoclast-like multinucleated cell formation were tested in vitro.  A small-mol. AM antagonist was tested for its effects on AM-stimulated ex vivo bone cell cultures and co-cultures with tumor cells, where responses of tumor and bone were distinguished by species-specific real-time PCR.  Results: Overexpression of AM mRNA did not alter cell proliferation in vitro, expression of tumor-secreted factors or cell cycle progression.  AM-overexpressing cells caused osteolytic bone metastases to develop more rapidly, which was accompanied by decreased survival.  In the mammary fat pad, tumors grew more rapidly with unchanged blood vessel formation.  Tumor growth in the bone was also more rapid, and osteoclasts were increased.  AM peptide potently stimulated bone cultures ex vivo; responses that were blocked by small-mol. adrenomedullin antagonists in the absence of cellular toxicity.  Antagonist treatment dramatically suppressed tumor growth in bone and decreased markers of osteoclast activity.  Conclusions: The results identify AM as a target for therapeutic intervention against bone metastases.  Adrenomedullin potentiates osteolytic responses in bone to metastatic breast cancer cells.  Small-mol. antagonists can effectively block bone-mediated responses to tumor-secreted adrenomedullin, and such agents warrant development for testing in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlXnDtx05gIrVg90H21EOLACvtfcHk0lgFaZ1ZSkg6qg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjtVCrtrg%253D&md5=821749d2bc9e4947351a044f21c63960</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1186%2Fs13058-014-0458-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13058-014-0458-y%26sid%3Dliteratum%253Aachs%26aulast%3DSiclari%26aufirst%3DV.%2BA.%26aulast%3DMohammad%26aufirst%3DK.%2BS.%26aulast%3DTompkins%26aufirst%3DD.%2BR.%26aulast%3DDavis%26aufirst%3DH.%26aulast%3DMcKenna%26aufirst%3DC.%2BR.%26aulast%3DPeng%26aufirst%3DX.%26aulast%3DWessner%26aufirst%3DL.%2BL.%26aulast%3DNiewolna%26aufirst%3DM.%26aulast%3DGuise%26aufirst%3DT.%2BA.%26aulast%3DSuvannasankha%26aufirst%3DA.%26aulast%3DChirgwin%26aufirst%3DJ.%2BM.%26atitle%3DTumor-expressed%2520adrenomedullin%2520accelerates%2520breast%2520cancer%2520bone%2520metastasis%26jtitle%3DBreast%2520Cancer%2520Res.%26date%3D2014%26volume%3D16%26doi%3D10.1186%2Fs13058-014-0458-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Avgoustou, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jailani, A. B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zirimwabagabo, J.-O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tozer, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibson, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glossop, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mills, J. E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porter, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blaney, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bungay, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bigos, K. J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holmes, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warrington, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skerry, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrity, J. P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richards, G. O.</span></span> <span> </span><span class="NLM_article-title">Discovery of a first-in-class potent small molecule antagonist against the adrenomedullin-2 receptor</span>. <i>ACS Pharmacol. Transl. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">706</span>– <span class="NLM_lpage">719</span>, <span class="refDoi"> DOI: 10.1021/acsptsci.0c00032</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsptsci.0c00032" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=1%3ACAS%3A528%3ADC%252BB3cXht1CltLvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2020&pages=706-719&author=P.+Avgoustouauthor=A.+B.+A.+Jailaniauthor=J.-O.+Zirimwabagaboauthor=M.+J.+Tozerauthor=K.+R.+Gibsonauthor=P.+A.+Glossopauthor=J.+E.+J.+Millsauthor=R.+A.+Porterauthor=P.+Blaneyauthor=P.+Bungayauthor=N.+Wangauthor=A.+Shawauthor=K.+J.+A.+Bigosauthor=J.+L.+Holmesauthor=J.+I.+Warringtonauthor=T.+M.+Skerryauthor=J.+P.+A.+Harrityauthor=G.+O.+Richards&title=Discovery+of+a+first-in-class+potent+small+molecule+antagonist+against+the+adrenomedullin-2+receptor&doi=10.1021%2Facsptsci.0c00032"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a First-in-Class Potent Small Molecule Antagonist against the Adrenomedullin-2 Receptor</span></div><div class="casAuthors">Avgoustou, Paris; Jailani, Ameera B. A.; Zirimwabagabo, Jean-Olivier; Tozer, Matthew J.; Gibson, Karl R.; Glossop, Paul A.; Mills, James E. J.; Porter, Roderick A.; Blaney, Paul; Bungay, Peter J.; Wang, Ning; Shaw, Alice P.; Bigos, Kamilla J. A.; Holmes, Joseph L.; Warrington, Jessica I.; Skerry, Timothy M.; Harrity, Joseph P. A.; Richards, Gareth O.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Pharmacology & Translational Science</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">706-719</span>CODEN:
                <span class="NLM_cas:coden">APTSFN</span>;
        ISSN:<span class="NLM_cas:issn">2575-9108</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The hormone adrenomedullin has both physiol. and pathol. roles in biol.  As a potent vasodilator, adrenomedullin is critically important in the regulation of blood pressure, but it also has several roles in disease, of which its actions in cancer are becoming recognized to have clin. importance.  Reduced circulating adrenomedullin causes increased blood pressure but also reduces tumor progression, so drugs blocking all effects of adrenomedullin would be unacceptable clin.  However, there are two distinct receptors for adrenomedullin, each comprising the same G protein-coupled receptor (GPCR), the calcitonin receptor-like receptor (CLR), together with a different accessory protein known as a receptor activity-modifying protein (RAMP).  The CLR with RAMP2 forms an adrenomedullin-1 receptor, and the CLR with RAMP3 forms an adrenomedullin-2 receptor.  Recent research suggests that a selective blockade of adrenomedullin-2 receptors would be therapeutically valuable.  Here we describe the design, synthesis, and characterization of potent small-mol. adrenomedullin-2 receptor antagonists with 1000-fold selectivity over the adrenomedullin-1 receptor, although retaining activity against the CGRP receptor.  These mols. have clear effects on markers of pancreatic cancer progression in vitro, drug-like pharmacokinetic properties, and inhibit xenograft tumor growth and extend life in a mouse model of pancreatic cancer.  Taken together, our data support the promise of a new class of anticancer therapeutics as well as improved understanding of the pharmacol. of the adrenomedullin receptors and other GPCR/RAMP heteromers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqag5PL8Hif27Vg90H21EOLACvtfcHk0lgFaZ1ZSkg6qg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXht1CltLvI&md5=cd030e8fd531b0773e2c32ed89655ea2</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Facsptsci.0c00032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsptsci.0c00032%26sid%3Dliteratum%253Aachs%26aulast%3DAvgoustou%26aufirst%3DP.%26aulast%3DJailani%26aufirst%3DA.%2BB.%2BA.%26aulast%3DZirimwabagabo%26aufirst%3DJ.-O.%26aulast%3DTozer%26aufirst%3DM.%2BJ.%26aulast%3DGibson%26aufirst%3DK.%2BR.%26aulast%3DGlossop%26aufirst%3DP.%2BA.%26aulast%3DMills%26aufirst%3DJ.%2BE.%2BJ.%26aulast%3DPorter%26aufirst%3DR.%2BA.%26aulast%3DBlaney%26aufirst%3DP.%26aulast%3DBungay%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DN.%26aulast%3DShaw%26aufirst%3DA.%26aulast%3DBigos%26aufirst%3DK.%2BJ.%2BA.%26aulast%3DHolmes%26aufirst%3DJ.%2BL.%26aulast%3DWarrington%26aufirst%3DJ.%2BI.%26aulast%3DSkerry%26aufirst%3DT.%2BM.%26aulast%3DHarrity%26aufirst%3DJ.%2BP.%2BA.%26aulast%3DRichards%26aufirst%3DG.%2BO.%26atitle%3DDiscovery%2520of%2520a%2520first-in-class%2520potent%2520small%2520molecule%2520antagonist%2520against%2520the%2520adrenomedullin-2%2520receptor%26jtitle%3DACS%2520Pharmacol.%2520Transl.%2520Sci.%26date%3D2020%26volume%3D3%26spage%3D706%26epage%3D719%26doi%3D10.1021%2Facsptsci.0c00032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kusano, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kukimoto-Niino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hino, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohsawa, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okuda, K.-i.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakamoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shirouzu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shindo, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yokoyama, S.</span></span> <span> </span><span class="NLM_article-title">Structural basis for extracellular interactions between calcitonin receptor-like receptor and receptor activity-modifying protein 2 for adrenomedullin-specific binding</span>. <i>Protein Sci.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">199</span>– <span class="NLM_lpage">210</span>, <span class="refDoi"> DOI: 10.1002/pro.2003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=10.1002%2Fpro.2003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=22102369" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=1%3ACAS%3A528%3ADC%252BC38Xpslyqtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2012&pages=199-210&author=S.+Kusanoauthor=M.+Kukimoto-Niinoauthor=N.+Hinoauthor=N.+Ohsawaauthor=K.-i.+Okudaauthor=K.+Sakamotoauthor=M.+Shirouzuauthor=T.+Shindoauthor=S.+Yokoyama&title=Structural+basis+for+extracellular+interactions+between+calcitonin+receptor-like+receptor+and+receptor+activity-modifying+protein+2+for+adrenomedullin-specific+binding&doi=10.1002%2Fpro.2003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis for extracellular interactions between calcitonin receptor-like receptor and receptor activity-modifying protein 2 for adrenomedullin-specific binding</span></div><div class="casAuthors">Kusano, Seisuke; Kukimoto-Niino, Mutsuko; Hino, Nobumasa; Ohsawa, Noboru; Okuda, Ken-ichi; Sakamoto, Kensaku; Shirouzu, Mikako; Shindo, Takayuki; Yokoyama, Shigeyuki</div><div class="citationInfo"><span class="NLM_cas:title">Protein Science</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">199-210</span>CODEN:
                <span class="NLM_cas:coden">PRCIEI</span>;
        ISSN:<span class="NLM_cas:issn">1469-896X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The calcitonin receptor-like receptor (CRLR), a class B GPCR, forms a heterodimer with receptor activity-modifying protein 2 (RAMP2), and serves as the adrenomedullin (AM) receptor to control neovascularization, while CRLR and RAMP1 form the calcitonin gene-related peptide (CGRP) receptor.  Here, the authors report the crystal structures of the RAMP2 extracellular domain alone and in the complex with the CRLR extracellular domain.  The CRLR-RAMP2 complex exhibits several intermol. interactions that were not obsd. in the previously reported CRLR-RAMP1 complex, and thus the shape of the putative ligand-binding pocket of CRLR-RAMP2 is distinct from that of CRLR-RAMP1.  The CRLR-RAMP2 interactions were confirmed for the full-length proteins on the cell surface by site-specific photo-crosslinking.  Mutagenesis revealed that AM binding requires RAMP2 residues that are not conserved in RAMP1.  Therefore, the differences in both the shapes and the key residues of the binding pocket are essential for the ligand specificity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiC362DktsB7Vg90H21EOLACvtfcHk0ljsVvYX0-24FQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xpslyqtw%253D%253D&md5=91a86ba3ae2e23dfb12fc7e0f91c4eeb</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1002%2Fpro.2003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpro.2003%26sid%3Dliteratum%253Aachs%26aulast%3DKusano%26aufirst%3DS.%26aulast%3DKukimoto-Niino%26aufirst%3DM.%26aulast%3DHino%26aufirst%3DN.%26aulast%3DOhsawa%26aufirst%3DN.%26aulast%3DOkuda%26aufirst%3DK.-i.%26aulast%3DSakamoto%26aufirst%3DK.%26aulast%3DShirouzu%26aufirst%3DM.%26aulast%3DShindo%26aufirst%3DT.%26aulast%3DYokoyama%26aufirst%3DS.%26atitle%3DStructural%2520basis%2520for%2520extracellular%2520interactions%2520between%2520calcitonin%2520receptor-like%2520receptor%2520and%2520receptor%2520activity-modifying%2520protein%25202%2520for%2520adrenomedullin-specific%2520binding%26jtitle%3DProtein%2520Sci.%26date%3D2012%26volume%3D21%26spage%3D199%26epage%3D210%26doi%3D10.1002%2Fpro.2003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">ter
Haar, E.</span></span> <span> </span><span class="NLM_article-title">Crystal structure of the ectodomain complex of the CGRP receptor, a Class-B GPCR, reveals the site of drug antagonism</span>. <i>Structure</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">1083</span>– <span class="NLM_lpage">1093</span>, <span class="refDoi"> DOI: 10.1016/j.str.2010.05.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=10.1016%2Fj.str.2010.05.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=20826335" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFalsLnM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2010&pages=1083-1093&author=E.+ter%0AHaar&title=Crystal+structure+of+the+ectodomain+complex+of+the+CGRP+receptor%2C+a+Class-B+GPCR%2C+reveals+the+site+of+drug+antagonism&doi=10.1016%2Fj.str.2010.05.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal Structure of the Ectodomain Complex of the CGRP Receptor, a Class-B GPCR, Reveals the Site of Drug Antagonism</span></div><div class="casAuthors">ter Haar, Ernst; Koth, Christopher M.; Abdul-Manan, Norzehan; Swenson, Lora; Coll, Joyce T.; Lippke, Judith A.; Lepre, Christopher A.; Garcia-Guzman, Miguel; Moore, Jonathan M.</div><div class="citationInfo"><span class="NLM_cas:title">Structure (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1083-1093</span>CODEN:
                <span class="NLM_cas:coden">STRUE6</span>;
        ISSN:<span class="NLM_cas:issn">0969-2126</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Dysregulation of the calcitonin gene-related peptide (CGRP), a potent vasodilator, is directly implicated in the pathogenesis of migraine.  CGRP binds to and signals through the CGRP receptor (CGRP-R), a heterodimer contg. the calcitonin receptor-like receptor (CLR), a class B GPCR, and RAMP1, a receptor activity-modifying protein.  We have solved the crystal structure of the CLR/RAMP1 N-terminal ectodomain heterodimer, revealing how RAMPs bind to and potentially modulate the activities of the CLR GPCR subfamily.  We also report the structures of CLR/RAMP1 in complex with the clin. receptor antagonists olcegepant (BIBN4096BS) and telcagepant (MK0974).  Both drugs act by blocking access to the peptide-binding cleft at the interface of CLR and RAMP1.  These structures illustrate, for the first time, how small mols. bind to and modulate the activity of a class B GPCR, and highlight the challenges of designing potent receptor antagonists for the treatment of migraine and other class B GPCR-related diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJl19cAutQ5rVg90H21EOLACvtfcHk0ljsVvYX0-24FQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFalsLnM&md5=2b17356889336fafc9a6ec2a965e3db3</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2Fj.str.2010.05.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.str.2010.05.014%26sid%3Dliteratum%253Aachs%26aulast%3Dter%2BHaar%26aufirst%3DE.%26atitle%3DCrystal%2520structure%2520of%2520the%2520ectodomain%2520complex%2520of%2520the%2520CGRP%2520receptor%252C%2520a%2520Class-B%2520GPCR%252C%2520reveals%2520the%2520site%2520of%2520drug%2520antagonism%26jtitle%3DStructure%26date%3D2010%26volume%3D18%26spage%3D1083%26epage%3D1093%26doi%3D10.1016%2Fj.str.2010.05.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Boyle, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banck, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morley, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vandermeersch, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutchison, G. R.</span></span> <span> </span><span class="NLM_article-title">Open babel: an open chemical toolbox</span>. <i>J. Cheminf.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>3</i></span>, <span class="NLM_elocation-id">33</span> <span class="refDoi"> DOI: 10.1186/1758-2946-3-33</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=10.1186%2F1758-2946-3-33" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=21982300" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVWjurbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2011&author=N.+M.+O%E2%80%99Boyleauthor=M.+Banckauthor=C.+A.+Jamesauthor=C.+Morleyauthor=T.+Vandermeerschauthor=G.+R.+Hutchison&title=Open+babel%3A+an+open+chemical+toolbox&doi=10.1186%2F1758-2946-3-33"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Open Babel: an open chemical toolbox</span></div><div class="casAuthors">O'Boyle, Noel M.; Banck, Michael; James, Craig A.; Morley, Chris; Vandermeersch, Tim; Hutchison, Geoffrey R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cheminformatics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">33</span>CODEN:
                <span class="NLM_cas:coden">JCOHB3</span>;
        ISSN:<span class="NLM_cas:issn">1758-2946</span>.
    
            (<span class="NLM_cas:orgname">Chemistry Central Ltd.</span>)
        </div><div class="casAbstract">Background: A frequent problem in computational modeling is the interconversion of chem. structures between different formats.  While std. interchange formats exist (for example, Chem. Markup Language) and de facto stds. have arisen (for example, SMILES format), the need to interconvert formats is a continuing problem due to the multitude of different application areas for chem. data, differences in the data stored by different formats (0D vs. 3D, for example), and competition between software along with a lack of vendor-neutral formats.  Results: We discuss, for the first time, Open Babel, an open-source chem. toolbox that speaks the many languages of chem. data.  Open Babel version 2.3 interconverts over 110 formats.  The need to represent such a wide variety of chem. and mol. data requires a library that implements a wide range of cheminformatics algorithms, from partial charge assignment and aromaticity detection, to bond order perception and canonicalization.  We detail the implementation of Open Babel, describe key advances in the 2.3 release, and outline a variety of uses both in terms of software products and scientific research, including applications far beyond simple format interconversion.  Conclusions: Open Babel presents a soln. to the proliferation of multiple chem. file formats.  In addn., it provides a variety of useful utilities from conformer searching and 2D depiction, to filtering, batch conversion, and substructure and similarity searching.  For developers, it can be used as a programming library to handle chem. data in areas such as org. chem., drug design, materials science, and computational chem.  It is freely available under an open-source license.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfQ1lvaS5767Vg90H21EOLACvtfcHk0ljsVvYX0-24FQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVWjurbF&md5=74e4f19b7f87417f916d57f7abcfb761</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1186%2F1758-2946-3-33&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1758-2946-3-33%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Boyle%26aufirst%3DN.%2BM.%26aulast%3DBanck%26aufirst%3DM.%26aulast%3DJames%26aufirst%3DC.%2BA.%26aulast%3DMorley%26aufirst%3DC.%26aulast%3DVandermeersch%26aufirst%3DT.%26aulast%3DHutchison%26aufirst%3DG.%2BR.%26atitle%3DOpen%2520babel%253A%2520an%2520open%2520chemical%2520toolbox%26jtitle%3DJ.%2520Cheminf.%26date%3D2011%26volume%3D3%26doi%3D10.1186%2F1758-2946-3-33" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Crowley, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stump, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, D. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potteiger, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McWherter, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paone, D. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quigley, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruno, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Culberson, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danziger, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fandozzi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gauvreau, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kemmerer, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menzel, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mosser, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salvatore, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kane, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selnick, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fraley, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burgey, C. S.</span></span> <span> </span><span class="NLM_article-title">Novel oxazolidinone calcitonin gene-related peptide (CGRP) receptor antagonists for the acute treatment of migraine</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">4777</span>– <span class="NLM_lpage">4781</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2015.07.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=10.1016%2Fj.bmcl.2015.07.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=26231160" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFOktL7N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=4777-4781&author=B.+M.+Crowleyauthor=C.+A.+Stumpauthor=D.+N.+Nguyenauthor=C.+M.+Potteigerauthor=M.+A.+McWherterauthor=D.+V.+Paoneauthor=A.+G.+Quigleyauthor=J.+G.+Brunoauthor=D.+Cuiauthor=J.+C.+Culbersonauthor=A.+Danzigerauthor=C.+Fandozziauthor=D.+Gauvreauauthor=A.+L.+Kemmererauthor=K.+Menzelauthor=E.+L.+Mooreauthor=S.+D.+Mosserauthor=V.+Reddyauthor=R.+B.+Whiteauthor=C.+A.+Salvatoreauthor=S.+A.+Kaneauthor=I.+M.+Bellauthor=H.+G.+Selnickauthor=M.+E.+Fraleyauthor=C.+S.+Burgey&title=Novel+oxazolidinone+calcitonin+gene-related+peptide+%28CGRP%29+receptor+antagonists+for+the+acute+treatment+of+migraine&doi=10.1016%2Fj.bmcl.2015.07.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Novel oxazolidinone calcitonin gene-related peptide (CGRP) receptor antagonists for the acute treatment of migraine</span></div><div class="casAuthors">Crowley, Brendan M.; Stump, Craig A.; Nguyen, Diem N.; Potteiger, Craig M.; McWherter, Melody A.; Paone, Daniel V.; Quigley, Amy G.; Bruno, Joseph G.; Cui, Dan; Culberson, J. Christopher; Danziger, Andrew; Fandozzi, Christine; Gauvreau, Danny; Kemmerer, Amanda L.; Menzel, Karsten; Moore, Eric L.; Mosser, Scott D.; Reddy, Vijay; White, Rebecca B.; Salvatore, Christopher A.; Kane, Stefanie A.; Bell, Ian M.; Selnick, Harold G.; Fraley, Mark E.; Burgey, Christopher S.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">4777-4781</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">In the authors' efforts to develop CGRP receptor antagonists as backups to MK-3207, the authors employed a scaffold hopping approach to identify a series of novel oxazolidinone-based compds.  The development of a structurally diverse, potent ((I), cAMP + HS IC50 = 0.67 nM), and selective compd. (hERG IC50 = 19 μM) with favorable rodent pharmacokinetics (F = 100%, t1/2 = 7 h) is described.  Key to this development was identification of a 3-substituted spirotetrahydropyran ring that afforded a substantial gain in potency (10 to 35-fold).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrebgkfNpm2nrVg90H21EOLACvtfcHk0lgxXwwDBeHpMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFOktL7N&md5=1f943f701866efddce9400141a3fa6c9</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.07.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.07.021%26sid%3Dliteratum%253Aachs%26aulast%3DCrowley%26aufirst%3DB.%2BM.%26aulast%3DStump%26aufirst%3DC.%2BA.%26aulast%3DNguyen%26aufirst%3DD.%2BN.%26aulast%3DPotteiger%26aufirst%3DC.%2BM.%26aulast%3DMcWherter%26aufirst%3DM.%2BA.%26aulast%3DPaone%26aufirst%3DD.%2BV.%26aulast%3DQuigley%26aufirst%3DA.%2BG.%26aulast%3DBruno%26aufirst%3DJ.%2BG.%26aulast%3DCui%26aufirst%3DD.%26aulast%3DCulberson%26aufirst%3DJ.%2BC.%26aulast%3DDanziger%26aufirst%3DA.%26aulast%3DFandozzi%26aufirst%3DC.%26aulast%3DGauvreau%26aufirst%3DD.%26aulast%3DKemmerer%26aufirst%3DA.%2BL.%26aulast%3DMenzel%26aufirst%3DK.%26aulast%3DMoore%26aufirst%3DE.%2BL.%26aulast%3DMosser%26aufirst%3DS.%2BD.%26aulast%3DReddy%26aufirst%3DV.%26aulast%3DWhite%26aufirst%3DR.%2BB.%26aulast%3DSalvatore%26aufirst%3DC.%2BA.%26aulast%3DKane%26aufirst%3DS.%2BA.%26aulast%3DBell%26aufirst%3DI.%2BM.%26aulast%3DSelnick%26aufirst%3DH.%2BG.%26aulast%3DFraley%26aufirst%3DM.%2BE.%26aulast%3DBurgey%26aufirst%3DC.%2BS.%26atitle%3DNovel%2520oxazolidinone%2520calcitonin%2520gene-related%2520peptide%2520%2528CGRP%2529%2520receptor%2520antagonists%2520for%2520the%2520acute%2520treatment%2520of%2520migraine%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D4777%26epage%3D4781%26doi%3D10.1016%2Fj.bmcl.2015.07.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Neese, F.</span></span> <span> </span><span class="NLM_article-title">The ORCA program system</span>. <i>Wiley Interdiscip. Rev.: Comput. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">73</span>– <span class="NLM_lpage">78</span>, <span class="refDoi"> DOI: 10.1002/wcms.81</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=10.1002%2Fwcms.81" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvFGls7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2012&pages=73-78&author=F.+Neese&title=The+ORCA+program+system&doi=10.1002%2Fwcms.81"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">The ORCA program system</span></div><div class="casAuthors">Neese, Frank</div><div class="citationInfo"><span class="NLM_cas:title">Wiley Interdisciplinary Reviews: Computational Molecular Science</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">73-78</span>CODEN:
                <span class="NLM_cas:coden">WIRCAH</span>;
        ISSN:<span class="NLM_cas:issn">1759-0884</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  ORCA is a general-purpose quantum chem. program package that features virtually all modern electronic structure methods (d. functional theory, many-body perturbation and coupled cluster theories, and multireference and semiempirical methods).  It is designed with the aim of generality, extendibility, efficiency, and user friendliness.  Its main field of application is larger mols., transition metal complexes, and their spectroscopic properties.  ORCA uses std. Gaussian basis functions and is fully parallelized.  The article provides an overview of its current possibilities and documents its efficiency.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq39ez8fWMbr7Vg90H21EOLACvtfcHk0lgxXwwDBeHpMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvFGls7s%253D&md5=a753e33a6f9a326553295596f5c754e5</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1002%2Fwcms.81&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fwcms.81%26sid%3Dliteratum%253Aachs%26aulast%3DNeese%26aufirst%3DF.%26atitle%3DThe%2520ORCA%2520program%2520system%26jtitle%3DWiley%2520Interdiscip.%2520Rev.%253A%2520Comput.%2520Mol.%2520Sci.%26date%3D2012%26volume%3D2%26spage%3D73%26epage%3D78%26doi%3D10.1002%2Fwcms.81" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jones, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willett, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glen, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leach, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, R.</span></span> <span> </span><span class="NLM_article-title">Development and validation of a genetic algorithm for flexible docking</span>. <i>J. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>267</i></span>,  <span class="NLM_fpage">727</span>– <span class="NLM_lpage">748</span>, <span class="refDoi"> DOI: 10.1006/jmbi.1996.0897</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=10.1006%2Fjmbi.1996.0897" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=9126849" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=1%3ACAS%3A528%3ADyaK2sXis1KntLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=267&publication_year=1997&pages=727-748&author=G.+Jonesauthor=P.+Willettauthor=R.+C.+Glenauthor=A.+R.+Leachauthor=R.+Taylor&title=Development+and+validation+of+a+genetic+algorithm+for+flexible+docking&doi=10.1006%2Fjmbi.1996.0897"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Development and validation of a genetic algorithm for flexible docking</span></div><div class="casAuthors">Jones, Gareth; Willett, Peter; Glen, Robert C.; Leach, Andrew R.; Taylor, Robin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">267</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">727-748</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Academic</span>)
        </div><div class="casAbstract">Prediction of small mol. binding modes to macromols. of known three-dimensional structure is a problem of paramount importance in rational drug design (the "docking" problem).  We report the development and validation of the program GOLD (Genetic Optimization for Ligand Docking).  GOLD is an automated ligand docking program that uses a genetic algorithm to explore the full range of ligand conformational flexibility with partial flexibility of the protein and satisfies the fundamental requirement that the ligand must displace loosely bound water on binding.  Numerous enhancements and modifications have been applied to the original technique resulting in a substantial increase in the reliability and the applicability of the algorithm.  The advanced algorithm has been tested on a dataset of 100 complexes extd. from the Brookhaven Protein Data Bank.  When used to dock the ligand back into the binding site, GOLD achieved a 71% success rate in identifying the exptl. binding mode.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrP3I60Rl2uorVg90H21EOLACvtfcHk0lgxXwwDBeHpMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXis1KntLo%253D&md5=476a2b1d8f80f3ba418052fe29d735ca</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1006%2Fjmbi.1996.0897&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fjmbi.1996.0897%26sid%3Dliteratum%253Aachs%26aulast%3DJones%26aufirst%3DG.%26aulast%3DWillett%26aufirst%3DP.%26aulast%3DGlen%26aufirst%3DR.%2BC.%26aulast%3DLeach%26aufirst%3DA.%2BR.%26aulast%3DTaylor%26aufirst%3DR.%26atitle%3DDevelopment%2520and%2520validation%2520of%2520a%2520genetic%2520algorithm%2520for%2520flexible%2520docking%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D1997%26volume%3D267%26spage%3D727%26epage%3D748%26doi%3D10.1006%2Fjmbi.1996.0897" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wood, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schirripa, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quigley, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stump, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bednar, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fay, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruno, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mosser, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roller, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salvatore, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kane, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vacca, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selnick, H. G.</span></span> <span> </span><span class="NLM_article-title">Novel CGRP receptor antagonists through a design strategy of target simplification with addition of molecular flexibility</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">5787</span>– <span class="NLM_lpage">5790</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2009.07.134</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=10.1016%2Fj.bmcl.2009.07.134" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=19703767" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFakurrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=5787-5790&author=M.+R.+Woodauthor=K.+M.+Schirripaauthor=J.+J.+Kimauthor=A.+G.+Quigleyauthor=C.+A.+Stumpauthor=I.+M.+Bellauthor=R.+A.+Bednarauthor=J.+F.+Fayauthor=J.+G.+Brunoauthor=E.+L.+Mooreauthor=S.+D.+Mosserauthor=S.+Rollerauthor=C.+A.+Salvatoreauthor=S.+A.+Kaneauthor=J.+P.+Vaccaauthor=H.+G.+Selnick&title=Novel+CGRP+receptor+antagonists+through+a+design+strategy+of+target+simplification+with+addition+of+molecular+flexibility&doi=10.1016%2Fj.bmcl.2009.07.134"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Novel CGRP receptor antagonists through a design strategy of target simplification with addition of molecular flexibility</span></div><div class="casAuthors">Wood, Michael R.; Schirripa, Kathy M.; Kim, June J.; Quigley, Amy G.; Stump, Craig A.; Bell, Ian M.; Bednar, Rodney A.; Fay, John F.; Bruno, Joseph G.; Moore, Eric L.; Mosser, Scott D.; Roller, Shane; Salvatore, Christopher A.; Kane, Stefanie A.; Vacca, Joseph P.; Selnick, Harold G.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">5787-5790</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A novel class of CGRP receptor antagonists was rationally designed by modifying a highly potent, but structurally complex, CGRP receptor antagonist.  Initial modifications focused on simplified structures, with increased flexibility.  Subsequent to the prepn. of a less-potent but more flexible lead, classic medicinal chem. methods were applied to restore high affinity ((I), CGRP K i = 0.035 nM) while maintaining structural diversity relative to the lead.  Good selectivity against the closely related adrenomedullin-2 receptor was also achieved.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWvr7UslFgILVg90H21EOLACvtfcHk0liIZPVs0aegEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFakurrF&md5=a58c696445b1d323576990a5e824642a</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.07.134&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.07.134%26sid%3Dliteratum%253Aachs%26aulast%3DWood%26aufirst%3DM.%2BR.%26aulast%3DSchirripa%26aufirst%3DK.%2BM.%26aulast%3DKim%26aufirst%3DJ.%2BJ.%26aulast%3DQuigley%26aufirst%3DA.%2BG.%26aulast%3DStump%26aufirst%3DC.%2BA.%26aulast%3DBell%26aufirst%3DI.%2BM.%26aulast%3DBednar%26aufirst%3DR.%2BA.%26aulast%3DFay%26aufirst%3DJ.%2BF.%26aulast%3DBruno%26aufirst%3DJ.%2BG.%26aulast%3DMoore%26aufirst%3DE.%2BL.%26aulast%3DMosser%26aufirst%3DS.%2BD.%26aulast%3DRoller%26aufirst%3DS.%26aulast%3DSalvatore%26aufirst%3DC.%2BA.%26aulast%3DKane%26aufirst%3DS.%2BA.%26aulast%3DVacca%26aufirst%3DJ.%2BP.%26aulast%3DSelnick%26aufirst%3DH.%2BG.%26atitle%3DNovel%2520CGRP%2520receptor%2520antagonists%2520through%2520a%2520design%2520strategy%2520of%2520target%2520simplification%2520with%2520addition%2520of%2520molecular%2520flexibility%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D5787%26epage%3D5790%26doi%3D10.1016%2Fj.bmcl.2009.07.134" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Booe, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barwell, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuteyi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simms, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jamaluddin, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warner, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bill, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brimble, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poyner, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hay, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pioszak, A. A.</span></span> <span> </span><span class="NLM_article-title">Structural basis for receptor activity-modifying protein-dependent selective peptide recognition by a G protein-coupled receptor</span>. <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">1040</span>– <span class="NLM_lpage">1052</span>, <span class="refDoi"> DOI: 10.1016/j.molcel.2015.04.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=10.1016%2Fj.molcel.2015.04.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=25982113" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=1%3ACAS%3A528%3ADC%252BC2MXosVaqtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=1040-1052&author=J.+M.+Booeauthor=C.+S.+Walkerauthor=J.+Barwellauthor=G.+Kuteyiauthor=J.+Simmsauthor=M.+A.+Jamaluddinauthor=M.+L.+Warnerauthor=R.+M.+Billauthor=P.+W.+Harrisauthor=M.+A.+Brimbleauthor=D.+R.+Poynerauthor=D.+L.+Hayauthor=A.+A.+Pioszak&title=Structural+basis+for+receptor+activity-modifying+protein-dependent+selective+peptide+recognition+by+a+G+protein-coupled+receptor&doi=10.1016%2Fj.molcel.2015.04.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Basis for Receptor Activity-Modifying Protein-Dependent Selective Peptide Recognition by a G Protein-Coupled Receptor</span></div><div class="casAuthors">Booe, Jason M.; Walker, Christopher S.; Barwell, James; Kuteyi, Gabriel; Simms, John; Jamaluddin, Muhammad A.; Warner, Margaret L.; Bill, Roslyn M.; Harris, Paul W.; Brimble, Margaret A.; Poyner, David R.; Hay, Debbie L.; Pioszak, Augen A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1040-1052</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Assocn. of receptor activity-modifying proteins (RAMP1-3) with the G protein-coupled receptor (GPCR) calcitonin receptor-like receptor (CLR) enables selective recognition of the peptides calcitonin gene-related peptide (CGRP) and adrenomedullin (AM) that have diverse functions in the cardiovascular and lymphatic systems.  How peptides selectively bind GPCR:RAMP complexes is unknown.  We report crystal structures of CGRP analog-bound CLR:RAMP1 and AM-bound CLR:RAMP2 extracellular domain heterodimers at 2.5 and 1.8 Å resolns., resp.  The peptides similarly occupy a shared binding site on CLR with conformations characterized by a β-turn structure near their C termini rather than the α-helical structure common to peptides that bind related GPCRs.  The RAMPs augment the binding site with distinct contacts to the variable C-terminal peptide residues and elicit subtly different CLR conformations.  The structures and accompanying pharmacol. data reveal how a class of accessory membrane proteins modulate ligand binding of a GPCR and may inform drug development targeting CLR:RAMP complexes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqO56KMgeClFLVg90H21EOLACvtfcHk0liIZPVs0aegEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXosVaqtr4%253D&md5=5e38aa2169f83e1b5c46868c1cd5650b</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2015.04.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2015.04.018%26sid%3Dliteratum%253Aachs%26aulast%3DBooe%26aufirst%3DJ.%2BM.%26aulast%3DWalker%26aufirst%3DC.%2BS.%26aulast%3DBarwell%26aufirst%3DJ.%26aulast%3DKuteyi%26aufirst%3DG.%26aulast%3DSimms%26aufirst%3DJ.%26aulast%3DJamaluddin%26aufirst%3DM.%2BA.%26aulast%3DWarner%26aufirst%3DM.%2BL.%26aulast%3DBill%26aufirst%3DR.%2BM.%26aulast%3DHarris%26aufirst%3DP.%2BW.%26aulast%3DBrimble%26aufirst%3DM.%2BA.%26aulast%3DPoyner%26aufirst%3DD.%2BR.%26aulast%3DHay%26aufirst%3DD.%2BL.%26aulast%3DPioszak%26aufirst%3DA.%2BA.%26atitle%3DStructural%2520basis%2520for%2520receptor%2520activity-modifying%2520protein-dependent%2520selective%2520peptide%2520recognition%2520by%2520a%2520G%2520protein-coupled%2520receptor%26jtitle%3DMol.%2520Cell%26date%3D2015%26volume%3D58%26spage%3D1040%26epage%3D1052%26doi%3D10.1016%2Fj.molcel.2015.04.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bell, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallicchio, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quigley, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stump, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zartman, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fay, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lynch, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mosser, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prueksaritanont, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Regan, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roller, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salvatore, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kane, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vacca, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selnick, H. G.</span></span> <span> </span><span class="NLM_article-title">Discovery of MK-3207: a highly potent, orally bioavailable CGRP receptor antagonist</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">24</span>– <span class="NLM_lpage">29</span>, <span class="refDoi"> DOI: 10.1021/ml900016y</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml900016y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=1%3ACAS%3A528%3ADC%252BC3cXksFegsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2010&pages=24-29&author=I.+M.+Bellauthor=S.+N.+Gallicchioauthor=M.+R.+Woodauthor=A.+G.+Quigleyauthor=C.+A.+Stumpauthor=C.+B.+Zartmanauthor=J.+F.+Fayauthor=C.+C.+Liauthor=J.+J.+Lynchauthor=E.+L.+Mooreauthor=S.+D.+Mosserauthor=T.+Prueksaritanontauthor=C.+P.+Reganauthor=S.+Rollerauthor=C.+A.+Salvatoreauthor=S.+A.+Kaneauthor=J.+P.+Vaccaauthor=H.+G.+Selnick&title=Discovery+of+MK-3207%3A+a+highly+potent%2C+orally+bioavailable+CGRP+receptor+antagonist&doi=10.1021%2Fml900016y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of MK-3207: A Highly Potent, Orally Bioavailable CGRP Receptor Antagonist</span></div><div class="casAuthors">Bell, Ian M.; Gallicchio, Steven N.; Wood, Michael R.; Quigley, Amy G.; Stump, Craig A.; Zartman, C. Blair; Fay, John F.; Li, Chi-Chung; Lynch, Joseph J.; Moore, Eric L.; Mosser, Scott D.; Prueksaritanont, Thomayant; Regan, Christopher P.; Roller, Shane; Salvatore, Christopher A.; Kane, Stefanie A.; Vacca, Joseph P.; Selnick, Harold G.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">24-29</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Incorporation of polar functionality into a series of highly potent calcitonin gene-related peptide (CGRP) receptor antagonists was explored in an effort to improve pharmacokinetics.  This strategy identified piperazinone analogs that possessed improved soly. at acidic pH and increased oral bioavailability in monkeys.  Further optimization led to the discovery of the clin. candidate 2-[(8R)-8-(3,5-difluorophenyl)-10-oxo-6,9-diazaspiro[4.5]dec-9-yl]-N-[(2R)-2'-oxo-1,1',2',3-tetrahydrospiro[indene-2,3'-pyrrolo[2,3-b]pyridin]-5-yl]acetamide (MK-3207) (4), the most potent orally active CGRP receptor antagonist described to date.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIThxRCo8aD7Vg90H21EOLACvtfcHk0liIZPVs0aegEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXksFegsQ%253D%253D&md5=2060a1762781cce87db2263731e9d85a</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1021%2Fml900016y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml900016y%26sid%3Dliteratum%253Aachs%26aulast%3DBell%26aufirst%3DI.%2BM.%26aulast%3DGallicchio%26aufirst%3DS.%2BN.%26aulast%3DWood%26aufirst%3DM.%2BR.%26aulast%3DQuigley%26aufirst%3DA.%2BG.%26aulast%3DStump%26aufirst%3DC.%2BA.%26aulast%3DZartman%26aufirst%3DC.%2BB.%26aulast%3DFay%26aufirst%3DJ.%2BF.%26aulast%3DLi%26aufirst%3DC.%2BC.%26aulast%3DLynch%26aufirst%3DJ.%2BJ.%26aulast%3DMoore%26aufirst%3DE.%2BL.%26aulast%3DMosser%26aufirst%3DS.%2BD.%26aulast%3DPrueksaritanont%26aufirst%3DT.%26aulast%3DRegan%26aufirst%3DC.%2BP.%26aulast%3DRoller%26aufirst%3DS.%26aulast%3DSalvatore%26aufirst%3DC.%2BA.%26aulast%3DKane%26aufirst%3DS.%2BA.%26aulast%3DVacca%26aufirst%3DJ.%2BP.%26aulast%3DSelnick%26aufirst%3DH.%2BG.%26atitle%3DDiscovery%2520of%2520MK-3207%253A%2520a%2520highly%2520potent%252C%2520orally%2520bioavailable%2520CGRP%2520receptor%2520antagonist%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D1%26spage%3D24%26epage%3D29%26doi%3D10.1021%2Fml900016y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rudolf, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eberlein, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engel, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pieper, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Entzeroth, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hallermayer, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doods, H.</span></span> <span> </span><span class="NLM_article-title">Development of human calcitonin gene-related peptide (CGRP) receptor antagonists. 1. Potent and selective small molecule CGRP antagonists. 1-[<i>N</i><sup>2</sup>-[3,5-Dibromo-<i>N</i>-[[4-(3,4-dihydro-2(1<i>H</i>)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)piperazine: the first CGRP antagonist for clinical trials in acute migraine</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">5921</span>– <span class="NLM_lpage">5931</span>, <span class="refDoi"> DOI: 10.1021/jm0490641</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0490641" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=1%3ACAS%3A528%3ADC%252BD2MXpt1WhsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=5921-5931&author=K.+Rudolfauthor=W.+Eberleinauthor=W.+Engelauthor=H.+Pieperauthor=M.+Entzerothauthor=G.+Hallermayerauthor=H.+Doods&title=Development+of+human+calcitonin+gene-related+peptide+%28CGRP%29+receptor+antagonists.+1.+Potent+and+selective+small+molecule+CGRP+antagonists.+1-%5BN2-%5B3%2C5-Dibromo-N-%5B%5B4-%283%2C4-dihydro-2%281H%29-oxoquinazolin-3-yl%29-1-piperidinyl%5Dcarbonyl%5D-D-tyrosyl%5D-L-lysyl%5D-4-%284-pyridinyl%29piperazine%3A+the+first+CGRP+antagonist+for+clinical+trials+in+acute+migraine&doi=10.1021%2Fjm0490641"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Development of Human Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonists. Potent and Selective Small Molecule CGRP Antagonists. 1-[N2-[3,5-Dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1- piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)piperazine: The First CGRP Antagonist for Clinical Trials in Acute Migraine</span></div><div class="casAuthors">Rudolf, Klaus; Eberlein, Wolfgang; Engel, Wolfhard; Pieper, Helmut; Entzeroth, Michael; Hallermayer, Gerhard; Doods, Henri</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">5921-5931</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Although the triptans have greatly improved the acute treatment of migraine headache, there are yet many shortcomings.  Therefore, new strategies for the treatment of migraine are needed which offer advantages over current therapy, e.g. triptans.  Our novel approach was based on the hypothesis that the release of calcitonin gene-related peptide (CGRP) could play a causative role in migraine headache.  Thus the authors initiated a program aimed at the design and synthesis of small mol. CGRP receptor antagonists.  High throughput screening led to the identification of (R)-Tyr-(S)-Lys dipeptide-like compds. that showed weak but unequivocal binding to the human CGRP receptor.  Lead optimization afforded highly potent CGRP antagonists, the prototype being compd. (I) (BIBN4096).  This compd. exhibiting a favorable biol. profile was selected for initial clin. trials.  A proof of concept study indicated that i.v. application of I was effective in the treatment of acute migraine headache.  This finding strongly supports our initial working hypothesis that CGRP plays an important role in the pathophysiol. of migraine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTkWy0CNrVprVg90H21EOLACvtfcHk0lhySjEE-D1bnQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXpt1WhsL8%253D&md5=802a2111a5507db63f9c91cb07469449</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1021%2Fjm0490641&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0490641%26sid%3Dliteratum%253Aachs%26aulast%3DRudolf%26aufirst%3DK.%26aulast%3DEberlein%26aufirst%3DW.%26aulast%3DEngel%26aufirst%3DW.%26aulast%3DPieper%26aufirst%3DH.%26aulast%3DEntzeroth%26aufirst%3DM.%26aulast%3DHallermayer%26aufirst%3DG.%26aulast%3DDoods%26aufirst%3DH.%26atitle%3DDevelopment%2520of%2520human%2520calcitonin%2520gene-related%2520peptide%2520%2528CGRP%2529%2520receptor%2520antagonists.%25201.%2520Potent%2520and%2520selective%2520small%2520molecule%2520CGRP%2520antagonists.%25201-%255BN2-%255B3%252C5-Dibromo-N-%255B%255B4-%25283%252C4-dihydro-2%25281H%2529-oxoquinazolin-3-yl%2529-1-piperidinyl%255Dcarbonyl%255D-D-tyrosyl%255D-L-lysyl%255D-4-%25284-pyridinyl%2529piperazine%253A%2520the%2520first%2520CGRP%2520antagonist%2520for%2520clinical%2520trials%2520in%2520acute%2520migraine%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D5921%26epage%3D5931%26doi%3D10.1021%2Fjm0490641" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Belyk, K. M.</span>; <span class="NLM_string-name">Cleator, E.</span>; <span class="NLM_string-name">Kuo, S.-C.</span>; <span class="NLM_string-name">Maligres, P. E.</span>; <span class="NLM_string-name">Xiang, B.</span>; <span class="NLM_string-name">Yasuda, N.</span>; <span class="NLM_string-name">Yin, J.</span></span> <span> </span><span class="NLM_article-title">Process for Making CGRP Receptor Antagonists</span>. U.S. Patent <span class="NLM_patent">US9,487,523</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=K.+M.+Belyk&author=E.+Cleator&author=S.-C.+Kuo&author=P.+E.+Maligres&author=B.+Xiang&author=N.+Yasuda&author=J.+Yin&title=Process+for+Making+CGRP+Receptor+Antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBelyk%26aufirst%3DK.%2BM.%26atitle%3DProcess%2520for%2520Making%2520CGRP%2520Receptor%2520Antagonists%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belyk, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reamer, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yasuda, N.</span></span> <span> </span><span class="NLM_article-title">Discovery and application of doubly quaternized cinchona-alkaloid-based phase-transfer catalysts</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">8375</span>– <span class="NLM_lpage">8378</span>, <span class="refDoi"> DOI: 10.1002/anie.201404084</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=10.1002%2Fanie.201404084" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVamtrbE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2014&pages=8375-8378&author=B.+Xiangauthor=K.+M.+Belykauthor=R.+A.+Reamerauthor=N.+Yasuda&title=Discovery+and+application+of+doubly+quaternized+cinchona-alkaloid-based+phase-transfer+catalysts&doi=10.1002%2Fanie.201404084"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and application of doubly quaternized cinchona-alkaloid-based phase-transfer catalysts</span></div><div class="casAuthors">Xiang, Bangping; Belyk, Kevin M.; Reamer, Robert A.; Yasuda, Nobuyoshi</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">32</span>),
    <span class="NLM_cas:pages">8375-8378</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Novel N,N'-disubstituted cinchona alkaloids were reported as efficient phase-transfer catalysts for the assembly of stereogenic quaternary centers.  In comparison to traditional cinchona-alkaloid-based phase-transfer catalysts, these new catalysts afford substantial improvements in enantioselectivity and reaction rate for intramol. spirocyclization reactions of 3-[2-(chloromethyl)aryl]-γ-lactams with catalyst loadings as low as 0.3 mol% under mild conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqN80hfS6mXArVg90H21EOLACvtfcHk0lhySjEE-D1bnQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVamtrbE&md5=dcd37cc490895354bf52ce22784d230b</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1002%2Fanie.201404084&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201404084%26sid%3Dliteratum%253Aachs%26aulast%3DXiang%26aufirst%3DB.%26aulast%3DBelyk%26aufirst%3DK.%2BM.%26aulast%3DReamer%26aufirst%3DR.%2BA.%26aulast%3DYasuda%26aufirst%3DN.%26atitle%3DDiscovery%2520and%2520application%2520of%2520doubly%2520quaternized%2520cinchona-alkaloid-based%2520phase-transfer%2520catalysts%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2014%26volume%3D53%26spage%3D8375%26epage%3D8378%26doi%3D10.1002%2Fanie.201404084" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dräger, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solodenko, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Messinger, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schon, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirschning, A.</span></span> <span> </span><span class="NLM_article-title">A new reagent and its polymer-supported variant for the amidination of amines</span>. <i>Tetrahedron Lett.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">1401</span>– <span class="NLM_lpage">1403</span>, <span class="refDoi"> DOI: 10.1016/S0040-4039(01)02403-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=10.1016%2FS0040-4039%2801%2902403-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=1%3ACAS%3A528%3ADC%252BD38Xpsl2lsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2002&pages=1401-1403&author=G.+Dr%C3%A4gerauthor=W.+Solodenkoauthor=J.+Messingerauthor=U.+Schonauthor=A.+Kirschning&title=A+new+reagent+and+its+polymer-supported+variant+for+the+amidination+of+amines&doi=10.1016%2FS0040-4039%2801%2902403-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">A new reagent and its polymer-supported variant for the amidination of amines</span></div><div class="casAuthors">Drager, Gerald; Solodenko, Wladimir; Messinger, Josef; Schon, Uwe; Kirschning, Andreas</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron Letters</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1401-1403</span>CODEN:
                <span class="NLM_cas:coden">TELEAY</span>;
        ISSN:<span class="NLM_cas:issn">0040-4039</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">New reagents for the high yielding amidination of primary and secondary amines are described.  By attaching a benzyl substituent to the 3,5-dimethyl-1H-pyrazole-1-carboxamidine ring, a reagent I is obtained which allows easy work-up after amidination because of soly. of byproducts in org. solvents.  In addn., the polystyrene-bound analog was prepd. which allows amidination of various amines with high purity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEAeQ0BBcJD7Vg90H21EOLACvtfcHk0lhySjEE-D1bnQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xpsl2lsg%253D%253D&md5=7bca90187eb9317b641c915d42ea0eda</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1016%2FS0040-4039%2801%2902403-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0040-4039%252801%252902403-0%26sid%3Dliteratum%253Aachs%26aulast%3DDr%25C3%25A4ger%26aufirst%3DG.%26aulast%3DSolodenko%26aufirst%3DW.%26aulast%3DMessinger%26aufirst%3DJ.%26aulast%3DSchon%26aufirst%3DU.%26aulast%3DKirschning%26aufirst%3DA.%26atitle%3DA%2520new%2520reagent%2520and%2520its%2520polymer-supported%2520variant%2520for%2520the%2520amidination%2520of%2520amines%26jtitle%3DTetrahedron%2520Lett.%26date%3D2002%26volume%3D43%26spage%3D1401%26epage%3D1403%26doi%3D10.1016%2FS0040-4039%2801%2902403-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 1 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Alexander M.  Grandits</span>, <span class="hlFld-ContribAuthor ">Rotraud  Wieser</span>. </span><span class="cited-content_cbyCitation_article-title">Gene expression changes contribute to stemness and therapy resistance of relapsed acute myeloid leukemia: roles of SOCS2, CALCRL, MTSS1, and KDM6A. </span><span class="cited-content_cbyCitation_journal-name">Experimental Hematology</span><span> <strong>2021,</strong> <em>99 </em>, 1-11. <a href="https://doi.org/10.1016/j.exphem.2021.05.004" title="DOI URL">https://doi.org/10.1016/j.exphem.2021.05.004</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.exphem.2021.05.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.exphem.2021.05.004%26sid%3Dliteratum%253Aachs%26jtitle%3DExperimental%2520Hematology%26atitle%3DGene%252Bexpression%252Bchanges%252Bcontribute%252Bto%252Bstemness%252Band%252Btherapy%252Bresistance%252Bof%252Brelapsed%252Bacute%252Bmyeloid%252Bleukemia%25253A%252Broles%252Bof%252BSOCS2%25252C%252BCALCRL%25252C%252BMTSS1%25252C%252Band%252BKDM6A%26aulast%3DGrandits%26aufirst%3DAlexander%2BM.%26date%3D2021%26volume%3D99%26spage%3D1%26epage%3D11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02191/20210408/images/medium/jm0c02191_0017.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02191/20210408/images/large/jm0c02191_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02191&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02191/20210408/images/medium/jm0c02191_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02191/20210408/images/large/jm0c02191_0002.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Docking of telcagepant (magenta) and compound <b>1</b> (purple) in our pseudo (hybrid)-model of the AM<sub>2</sub> receptor-binding pocket. The Glu74 residue from RAMP3 is indicated in green. CLR is shown in yellow and RAMP3 in cyan. Hydrogen bonds are shown as dotted lines. Compound <b>1</b> has similar spatial occupancy and interactions to telcagepant (magenta) as observed in the CGRP receptor crystal structure (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3N7R">3N7R</a><a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02191/20210408/images/large/jm0c02191_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02191&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02191/20210408/images/medium/jm0c02191_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02191/20210408/images/large/jm0c02191_0003.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Compound <b>1</b> structure analysis for SAR.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02191/20210408/images/large/jm0c02191_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02191&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02191/20210408/images/medium/jm0c02191_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02191/20210408/images/large/jm0c02191_0006.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Reagents and General Conditions<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02191/20210408/images/large/jm0c02191_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02191&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>(a) Ethyl bromoacetate, <i>N</i>,<i>N</i>-diisopropylethylamine (DIPEA), dimethylformamide (DMF) or benzylbromoacetate, Et<sub>3</sub>N, tetrahydrofuran (THF; when amine was used) and glycine ethyl ester hydrochloride, NaBH<sub>3</sub>CN, MeOH (when aldehyde or ketone was used); (b) (i) PivCl, DIPEA, dichloromethane (DCM); (ii) 2.5 N NaOH, MeOH or LiOH·H<sub>2</sub>O, MeOH/THF/H<sub>2</sub>O; (c) HATU, NMM, DM or EDCI, HOAt, DIPEA, DMF.</p></p></figure><figure data-id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02191/20210408/images/medium/jm0c02191_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02191/20210408/images/large/jm0c02191_0007.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Reagents and Conditions<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02191/20210408/images/large/jm0c02191_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02191&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>(a) (i) NaOH, PTC*, toluene/H<sub>2</sub>O; (ii) recrystallized from toluene/MeOH; (b) (i) MsOH, toluene, 90 °C; (ii) ∼10% Pd/C, H<sub>2</sub>, HCl/MeOH, rt, o/n. PTC*: Chiral phase transfer catalyst. Please see <a class="ref internalNav" href="#sec5" aria-label="Experimental Section">Experimental Section</a> for details.</p></p></figure><figure data-id="fig3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02191/20210408/images/medium/jm0c02191_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02191/20210408/images/large/jm0c02191_0004.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Docking of compound (<i>R</i>)-25 in our pseudo (hybrid)-model of the AM<sub>2</sub> receptor-binding pocket. Glu74 residues from RAMP3 are indicated in green. CLR is shown in yellow and RAMP3 in cyan. Hydrogen bonds are shown as dotted lines. The protonated amine of compound (<i>R</i>)-25 forms salt bridges with the carboxylate of Glu74 and the carboxylate of Asp71 (an asparagine carboxamide in RAMP3).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02191/20210408/images/large/jm0c02191_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02191&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02191/20210408/images/medium/jm0c02191_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02191/20210408/images/large/jm0c02191_0005.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. AM<sub>2</sub> receptor antagonist inhibits <i>in vitro</i> viability of human breast cancer cell line MDA-MB-231 as well as subcutaneous MDA-MB-231 tumor growth in BALB/c nude mice. (a) Daily treatment with small molecule AM<sub>2</sub> receptor antagonists significantly decreased the viability of MDA-MB-231 cells <i>in vitro</i> by 55% after 3 days when treated with 10 μM (±)-<b>25</b>, compared to that of vehicle-treated controls (<i>p</i> < 0.01, unpaired <i>t</i>-test). Data are from three independent experiments and presented as mean ± SD. (b) Mice (<i>n</i> = 10 per group) were inoculated subcutaneously with MDA-MB-231 cells to generate tumors, and first treatment was given on the day of the first tumor volume measurement (arrow). Tumor growth rates were significantly reduced in mice treated daily with 20 mg/kg ip (±)-<b>25</b> (<i>p</i> < 0.001, simple linear regression comparing the line of best fit). Data are presented as mean ± SD.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02191/20210408/images/large/jm0c02191_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02191&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch3" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02191/20210408/images/medium/jm0c02191_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02191/20210408/images/large/jm0c02191_0008.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of <b>2</b> and <b>4</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02191/20210408/images/large/jm0c02191_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02191&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch4" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02191/20210408/images/medium/jm0c02191_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02191/20210408/images/large/jm0c02191_0009.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of <b>5</b>, <b>6</b>, <b>9</b>–<b>14</b>, <b>16</b>–<b>21</b>, <b>24</b>, <b>25</b>, and <b>29</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02191/20210408/images/large/jm0c02191_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02191&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>(a) Ethyl bromoacetate, SIPEA, DMF, rt or benzyl bromoacetate, Et<sub>3</sub>N, THF, rt (from amine) or glycine ethyl ester hydrochloride, NaBH<sub>3</sub>CN, MeOH, rt (fromaldehyde or ketone); (b) (i) PivCl, DIPEA, DCM, rt; (ii) 2.5 N NaOH, MeOH, rt; (c) <b>D</b>, HATU, NMM, DMF, rt or <b>D</b>, EDCl, HOAt, DIPEA, DMF, rt; (d) H<sub>2</sub>, Pd/C, NH<sub>4</sub>COOH, MeOH, reflux; (e) TFA, DCM, rt or TsOH, MeOH, rt; (f) (i) <i>p</i>TsOH, acetone, rt; (ii) MeNH<sub>2</sub>, HCl, DIPEA, Na<sub>2</sub>SO<sub>4</sub>, DCM, rt then NaBH(OAc)<sub>3</sub>, rt; (g) 20% Pd(PPh<sub>3</sub>)<sub>4</sub>, 1,3-dimethylbarbituric acid, DCM, 35 °C; (h) Zn(CN)<sub>2</sub>, Pd(PPh<sub>3</sub>)<sub>4</sub>, DMF, 130 °C, MW; (j) H<sub>2</sub>, Raney-Ni, 2M NH<sub>3</sub> in MeOH, 55 °C; (k) 4-benzyl-3,5-dimethyl-1<i>H</i>-pyrazole-1-carboximidamide hydrochloride, 5 equiv, Et<sub>3</sub>N, MeCN/THF, MW, 90 °C; (m) (i) <i>p</i>TsOH, acetone, rt; (ii) NH<sub>4</sub>OAc, MeOH, reflux; then NaBH<sub>3</sub>CN, rt; (n) H<sub>2</sub>O<sub>2</sub>, H<sub>2</sub>O, NaOH, DMSO, rt.</p></p></figure><figure data-id="sch5" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02191/20210408/images/medium/jm0c02191_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02191/20210408/images/large/jm0c02191_0010.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of <b>28</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02191/20210408/images/large/jm0c02191_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02191&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch6" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02191/20210408/images/medium/jm0c02191_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02191/20210408/images/large/jm0c02191_0011.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Synthesis of <b>7</b>, <b>8</b>, <b>23</b>, <b>26</b>, and <b>27</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-6/acs.jmedchem.0c02191/20210408/images/large/jm0c02191_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02191&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i117">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_26306" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_26306" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 47 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alexander, S. P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christopoulos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davenport, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathie, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peters, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veale, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armstrong, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faccenda, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harding, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pawson, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharman, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Southan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arumugam, T. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sjogren, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sobey, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abbracchio, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alexander, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-hosaini, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Back, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaulieu, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernstein, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bettler, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birdsall, N. J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blaho, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bousquet, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brauner-Osborne, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burnstock, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castano, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Catt, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ceruti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chazot, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiang, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cianciulli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clapp, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Couture, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Csaba, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dent, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Douglas, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dournaud, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eguchi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Escher, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Filardo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fong, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fumagalli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gainetdinov, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Gasparo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gershengorn, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gobeil, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodfriend, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goudet, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gregory, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gundlach, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamann, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hauger, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hay, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heinemann, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollenberg, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holliday, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horiuchi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoyer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunyady, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Husain, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ijzerman, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inagami, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jockers, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jonnalagadda, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karnik, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaupmann, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kemp, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kennedy, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kihara, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozielewicz, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kreienkamp, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kukkonen, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langenhan, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leach, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lecca, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leeman, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leprince, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lolait, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lupp, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macrae, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maguire, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazella, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McArdle, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melmed, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michel, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitolo, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mouillac, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nahon, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norel, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nyimanu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Carroll, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Offermanns, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panaro, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pertwee, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pin, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prossnitz, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramachandran, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reinscheid, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rondard, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rovati, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruzza, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanger, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schoneberg, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schulte, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schulz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Segaloff, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serhan, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoddart, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugimoto, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Summers, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timmermans, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tirupula, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tulipano, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unal, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unger, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanderheyden, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaudry, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaudry, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vilardaga, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wester, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willars, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodruff, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aldrich, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Becirovic, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Catterall, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conner, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delling, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Virgilio, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Falzoni, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">George, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldstein, S. A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grissmer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ha, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammelmann, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanukoglu, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jarvis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaczmarek, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kellenberger, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lynch, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez-Reyes, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plant, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rash, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sivilotti, L. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smart, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snutch, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van den
Eynde, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vriens, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winn, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wulff, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, H. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yue, L. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coons, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuller, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korach, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bryant, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farndale, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hobbs, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jarvis, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacEwan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monie, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waldman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beuve, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boison, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brouckaert, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burnett, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burns, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dessauer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friebe, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garthwaite, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gertsch, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helsby, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Izzo, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koesling, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuhn, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ostrom, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papapetropoulos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potter, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pyne, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pyne, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russwurm, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seifert, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stasch, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szabo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Stelt, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Vliet, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watts, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, C. M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dawson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagenbuch, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammond, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hancox, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inui, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kemp, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thwaites, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verri, T.</span></span>; <span class="NLM_contrib-group">CGTP Collaborators</span> <span> </span><span class="NLM_article-title">The concise guide to pharmacology 2019/20: G protein-coupled receptors</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>176</i></span>,  <span class="NLM_fpage">S21</span>– <span class="NLM_lpage">S141</span>, <span class="refDoi"> DOI: 10.1111/bph.14748</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=10.1111%2Fbph.14748" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=31710717" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=176&publication_year=2019&pages=S21-S141&author=S.+P.+H.+Alexanderauthor=A.+Christopoulosauthor=A.+P.+Davenportauthor=E.+Kellyauthor=A.+Mathieauthor=J.+A.+Petersauthor=E.+L.+Vealeauthor=J.+F.+Armstrongauthor=E.+Faccendaauthor=S.+D.+Hardingauthor=A.+J.+Pawsonauthor=J.+L.+Sharmanauthor=C.+Southanauthor=J.+A.+Daviesauthor=T.+V.+Arumugamauthor=A.+Bennettauthor=B.+Sjogrenauthor=C.+Sobeyauthor=S.+S.+Wongauthor=M.+P.+Abbracchioauthor=W.+Alexanderauthor=K.+Al-hosainiauthor=M.+Backauthor=J.+M.+Beaulieuauthor=K.+E.+Bernsteinauthor=B.+Bettlerauthor=N.+J.+M.+Birdsallauthor=V.+Blahoauthor=C.+Bousquetauthor=H.+Brauner-Osborneauthor=G.+Burnstockauthor=G.+Caloauthor=J.+P.+Castanoauthor=K.+J.+Cattauthor=S.+Cerutiauthor=P.+Chazotauthor=N.+Chiangauthor=J.+Chunauthor=A.+Cianciulliauthor=L.+H.+Clappauthor=R.+Coutureauthor=Z.+Csabaauthor=G.+Dentauthor=K.+D.+Singhauthor=S.+D.+Douglasauthor=P.+Dournaudauthor=S.+Eguchiauthor=E.+Escherauthor=E.+Filardoauthor=T.+M.+Fongauthor=M.+Fumagalliauthor=R.+R.+Gainetdinovauthor=M.+de+Gasparoauthor=M.+Gershengornauthor=F.+Gobeilauthor=T.+L.+Goodfriendauthor=C.+Goudetauthor=K.+J.+Gregoryauthor=A.+L.+Gundlachauthor=J.+Hamannauthor=J.+Hansonauthor=R.+L.+Haugerauthor=D.+Hayauthor=A.+Heinemannauthor=M.+D.+Hollenbergauthor=N.+D.+Hollidayauthor=M.+Horiuchiauthor=D.+Hoyerauthor=L.+Hunyadyauthor=A.+Husainauthor=A.+P.+Ijzermanauthor=T.+Inagamiauthor=K.+A.+Jacobsonauthor=R.+T.+Jensenauthor=R.+Jockersauthor=D.+Jonnalagaddaauthor=S.+Karnikauthor=K.+Kaupmannauthor=J.+Kempauthor=C.+Kennedyauthor=Y.+Kiharaauthor=P.+Kozielewiczauthor=H.+J.+Kreienkampauthor=J.+P.+Kukkonenauthor=T.+Langenhanauthor=K.+Leachauthor=D.+Leccaauthor=J.+D.+Leeauthor=S.+E.+Leemanauthor=J.+Leprinceauthor=S.+J.+Lolaitauthor=A.+Luppauthor=R.+Macraeauthor=J.+Maguireauthor=J.+Mazellaauthor=C.+A.+McArdleauthor=S.+Melmedauthor=M.+C.+Michelauthor=L.+Millerauthor=V.+Mitoloauthor=B.+Mouillacauthor=P.+M.+Murphyauthor=J.+L.+Nahonauthor=X.+Norelauthor=D.+Nyimanuauthor=A.+M.+O%E2%80%99Carrollauthor=S.+Offermannsauthor=M.+A.+Panaroauthor=R.+G.+Pertweeauthor=J.+P.+Pinauthor=E.+Prossnitzauthor=R.+Ramachandranauthor=R.+K.+Reinscheidauthor=P.+Rondardauthor=G.+E.+Rovatiauthor=C.+Ruzzaauthor=G.+Sangerauthor=T.+Schonebergauthor=G.+Schulteauthor=S.+Schulzauthor=D.+L.+Segaloffauthor=C.+N.+Serhanauthor=L.+A.+Stoddartauthor=Y.+Sugimotoauthor=R.+Summersauthor=V.+Tanauthor=W.+Thomasauthor=P.+Timmermansauthor=K.+Tirupulaauthor=G.+Tulipanoauthor=H.+Unalauthor=T.+Ungerauthor=P.+Vanderheydenauthor=D.+Vaudryauthor=H.+Vaudryauthor=J.+P.+Vilardagaauthor=C.+S.+Walkerauthor=D.+T.+Wardauthor=H.+J.+Westerauthor=G.+B.+Willarsauthor=T.+L.+Williamsauthor=T.+M.+Woodruffauthor=C.+C.+Yaoauthor=R.+W.+Aldrichauthor=E.+Becirovicauthor=M.+Bielauthor=W.+A.+Catterallauthor=A.+C.+Connerauthor=P.+Daviesauthor=M.+Dellingauthor=F.+Di+Virgilioauthor=S.+Falzoniauthor=C.+Georgeauthor=S.+A.+N.+Goldsteinauthor=S.+Grissmerauthor=K.+Haauthor=V.+Hammelmannauthor=I.+Hanukogluauthor=M.+Jarvisauthor=A.+A.+Jensenauthor=L.+K.+Kaczmarekauthor=S.+Kellenbergerauthor=B.+Kingauthor=J.+W.+Lynchauthor=E.+Perez-Reyesauthor=L.+D.+Plantauthor=L.+D.+Rashauthor=D.+J.+Renauthor=L.+G.+Sivilottiauthor=T.+G.+Smartauthor=T.+P.+Snutchauthor=J.+B.+Tianauthor=C.+Van+den%0AEyndeauthor=J.+Vriensauthor=A.+D.+Weiauthor=B.+T.+Winnauthor=H.+Wulffauthor=H.+X.+Xuauthor=L.+X.+Yueauthor=X.+L.+Zhangauthor=M.+Zhuauthor=L.+Coonsauthor=P.+Fullerauthor=K.+S.+Korachauthor=M.+Youngauthor=C.+Bryantauthor=R.+W.+Farndaleauthor=A.+Hobbsauthor=G.+E.+Jarvisauthor=D.+MacEwanauthor=T.+P.+Monieauthor=S.+Waldmanauthor=A.+Beuveauthor=D.+Boisonauthor=P.+Brouckaertauthor=J.+C.+Burnettauthor=K.+Burnsauthor=C.+Dessauerauthor=A.+Friebeauthor=J.+Garthwaiteauthor=J.+Gertschauthor=N.+Helsbyauthor=A.+A.+Izzoauthor=D.+Koeslingauthor=M.+Kuhnauthor=R.+Ostromauthor=A.+Papapetropoulosauthor=L.+R.+Potterauthor=N.+J.+Pyneauthor=S.+Pyneauthor=M.+Russwurmauthor=H.+Schmidtauthor=R.+Seifertauthor=J.+P.+Staschauthor=C.+Szaboauthor=M.+van+der+Steltauthor=A.+van+der+Vlietauthor=V.+Wattsauthor=C.+M.+H.+Andersonauthor=S.+Broerauthor=P.+Dawsonauthor=B.+Hagenbuchauthor=J.+R.+Hammondauthor=J.+Hancoxauthor=K.+Inuiauthor=Y.+Kanaiauthor=S.+Kempauthor=D.+T.+Thwaitesauthor=T.+Verriauthor=CGTP+Collaborators&title=The+concise+guide+to+pharmacology+2019%2F20%3A+G+protein-coupled+receptors&doi=10.1111%2Fbph.14748"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1111%2Fbph.14748&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.14748%26sid%3Dliteratum%253Aachs%26aulast%3DAlexander%26aufirst%3DS.%2BP.%2BH.%26aulast%3DChristopoulos%26aufirst%3DA.%26aulast%3DDavenport%26aufirst%3DA.%2BP.%26aulast%3DKelly%26aufirst%3DE.%26aulast%3DMathie%26aufirst%3DA.%26aulast%3DPeters%26aufirst%3DJ.%2BA.%26aulast%3DVeale%26aufirst%3DE.%2BL.%26aulast%3DArmstrong%26aufirst%3DJ.%2BF.%26aulast%3DFaccenda%26aufirst%3DE.%26aulast%3DHarding%26aufirst%3DS.%2BD.%26aulast%3DPawson%26aufirst%3DA.%2BJ.%26aulast%3DSharman%26aufirst%3DJ.%2BL.%26aulast%3DSouthan%26aufirst%3DC.%26aulast%3DDavies%26aufirst%3DJ.%2BA.%26aulast%3DArumugam%26aufirst%3DT.%2BV.%26aulast%3DBennett%26aufirst%3DA.%26aulast%3DSjogren%26aufirst%3DB.%26aulast%3DSobey%26aufirst%3DC.%26aulast%3DWong%26aufirst%3DS.%2BS.%26aulast%3DAbbracchio%26aufirst%3DM.%2BP.%26aulast%3DAlexander%26aufirst%3DW.%26aulast%3DAl-hosaini%26aufirst%3DK.%26aulast%3DBack%26aufirst%3DM.%26aulast%3DBeaulieu%26aufirst%3DJ.%2BM.%26aulast%3DBernstein%26aufirst%3DK.%2BE.%26aulast%3DBettler%26aufirst%3DB.%26aulast%3DBirdsall%26aufirst%3DN.%2BJ.%2BM.%26aulast%3DBlaho%26aufirst%3DV.%26aulast%3DBousquet%26aufirst%3DC.%26aulast%3DBrauner-Osborne%26aufirst%3DH.%26aulast%3DBurnstock%26aufirst%3DG.%26aulast%3DCalo%26aufirst%3DG.%26aulast%3DCastano%26aufirst%3DJ.%2BP.%26aulast%3DCatt%26aufirst%3DK.%2BJ.%26aulast%3DCeruti%26aufirst%3DS.%26aulast%3DChazot%26aufirst%3DP.%26aulast%3DChiang%26aufirst%3DN.%26aulast%3DChun%26aufirst%3DJ.%26aulast%3DCianciulli%26aufirst%3DA.%26aulast%3DClapp%26aufirst%3DL.%2BH.%26aulast%3DCouture%26aufirst%3DR.%26aulast%3DCsaba%26aufirst%3DZ.%26aulast%3DDent%26aufirst%3DG.%26aulast%3DSingh%26aufirst%3DK.%2BD.%26aulast%3DDouglas%26aufirst%3DS.%2BD.%26aulast%3DDournaud%26aufirst%3DP.%26aulast%3DEguchi%26aufirst%3DS.%26aulast%3DEscher%26aufirst%3DE.%26aulast%3DFilardo%26aufirst%3DE.%26aulast%3DFong%26aufirst%3DT.%2BM.%26aulast%3DFumagalli%26aufirst%3DM.%26aulast%3DGainetdinov%26aufirst%3DR.%2BR.%26aulast%3Dde%2BGasparo%26aufirst%3DM.%26aulast%3DGershengorn%26aufirst%3DM.%26aulast%3DGobeil%26aufirst%3DF.%26aulast%3DGoodfriend%26aufirst%3DT.%2BL.%26aulast%3DGoudet%26aufirst%3DC.%26aulast%3DGregory%26aufirst%3DK.%2BJ.%26aulast%3DGundlach%26aufirst%3DA.%2BL.%26aulast%3DHamann%26aufirst%3DJ.%26aulast%3DHanson%26aufirst%3DJ.%26aulast%3DHauger%26aufirst%3DR.%2BL.%26aulast%3DHay%26aufirst%3DD.%26aulast%3DHeinemann%26aufirst%3DA.%26aulast%3DHollenberg%26aufirst%3DM.%2BD.%26aulast%3DHolliday%26aufirst%3DN.%2BD.%26aulast%3DHoriuchi%26aufirst%3DM.%26aulast%3DHoyer%26aufirst%3DD.%26aulast%3DHunyady%26aufirst%3DL.%26aulast%3DHusain%26aufirst%3DA.%26aulast%3DIjzerman%26aufirst%3DA.%2BP.%26aulast%3DInagami%26aufirst%3DT.%26aulast%3DJacobson%26aufirst%3DK.%2BA.%26aulast%3DJensen%26aufirst%3DR.%2BT.%26aulast%3DJockers%26aufirst%3DR.%26aulast%3DJonnalagadda%26aufirst%3DD.%26aulast%3DKarnik%26aufirst%3DS.%26aulast%3DKaupmann%26aufirst%3DK.%26aulast%3DKemp%26aufirst%3DJ.%26aulast%3DKennedy%26aufirst%3DC.%26aulast%3DKihara%26aufirst%3DY.%26aulast%3DKozielewicz%26aufirst%3DP.%26aulast%3DKreienkamp%26aufirst%3DH.%2BJ.%26aulast%3DKukkonen%26aufirst%3DJ.%2BP.%26aulast%3DLangenhan%26aufirst%3DT.%26aulast%3DLeach%26aufirst%3DK.%26aulast%3DLecca%26aufirst%3DD.%26aulast%3DLee%26aufirst%3DJ.%2BD.%26aulast%3DLeeman%26aufirst%3DS.%2BE.%26aulast%3DLeprince%26aufirst%3DJ.%26aulast%3DLolait%26aufirst%3DS.%2BJ.%26aulast%3DLupp%26aufirst%3DA.%26aulast%3DMacrae%26aufirst%3DR.%26aulast%3DMaguire%26aufirst%3DJ.%26aulast%3DMazella%26aufirst%3DJ.%26aulast%3DMcArdle%26aufirst%3DC.%2BA.%26aulast%3DMelmed%26aufirst%3DS.%26aulast%3DMichel%26aufirst%3DM.%2BC.%26aulast%3DMiller%26aufirst%3DL.%26aulast%3DMitolo%26aufirst%3DV.%26aulast%3DMouillac%26aufirst%3DB.%26aulast%3DMurphy%26aufirst%3DP.%2BM.%26aulast%3DNahon%26aufirst%3DJ.%2BL.%26aulast%3DNorel%26aufirst%3DX.%26aulast%3DNyimanu%26aufirst%3DD.%26aulast%3DO%25E2%2580%2599Carroll%26aufirst%3DA.%2BM.%26aulast%3DOffermanns%26aufirst%3DS.%26aulast%3DPanaro%26aufirst%3DM.%2BA.%26aulast%3DPertwee%26aufirst%3DR.%2BG.%26aulast%3DPin%26aufirst%3DJ.%2BP.%26aulast%3DProssnitz%26aufirst%3DE.%26aulast%3DRamachandran%26aufirst%3DR.%26aulast%3DReinscheid%26aufirst%3DR.%2BK.%26aulast%3DRondard%26aufirst%3DP.%26aulast%3DRovati%26aufirst%3DG.%2BE.%26aulast%3DRuzza%26aufirst%3DC.%26aulast%3DSanger%26aufirst%3DG.%26aulast%3DSchoneberg%26aufirst%3DT.%26aulast%3DSchulte%26aufirst%3DG.%26aulast%3DSchulz%26aufirst%3DS.%26aulast%3DSegaloff%26aufirst%3DD.%2BL.%26aulast%3DSerhan%26aufirst%3DC.%2BN.%26aulast%3DStoddart%26aufirst%3DL.%2BA.%26aulast%3DSugimoto%26aufirst%3DY.%26aulast%3DSummers%26aufirst%3DR.%26aulast%3DTan%26aufirst%3DV.%26aulast%3DThomas%26aufirst%3DW.%26aulast%3DTimmermans%26aufirst%3DP.%26aulast%3DTirupula%26aufirst%3DK.%26aulast%3DTulipano%26aufirst%3DG.%26aulast%3DUnal%26aufirst%3DH.%26aulast%3DUnger%26aufirst%3DT.%26aulast%3DVanderheyden%26aufirst%3DP.%26aulast%3DVaudry%26aufirst%3DD.%26aulast%3DVaudry%26aufirst%3DH.%26aulast%3DVilardaga%26aufirst%3DJ.%2BP.%26aulast%3DWalker%26aufirst%3DC.%2BS.%26aulast%3DWard%26aufirst%3DD.%2BT.%26aulast%3DWester%26aufirst%3DH.%2BJ.%26aulast%3DWillars%26aufirst%3DG.%2BB.%26aulast%3DWilliams%26aufirst%3DT.%2BL.%26aulast%3DWoodruff%26aufirst%3DT.%2BM.%26aulast%3DYao%26aufirst%3DC.%2BC.%26aulast%3DAldrich%26aufirst%3DR.%2BW.%26aulast%3DBecirovic%26aufirst%3DE.%26aulast%3DBiel%26aufirst%3DM.%26aulast%3DCatterall%26aufirst%3DW.%2BA.%26aulast%3DConner%26aufirst%3DA.%2BC.%26aulast%3DDavies%26aufirst%3DP.%26aulast%3DDelling%26aufirst%3DM.%26aulast%3DDi%2BVirgilio%26aufirst%3DF.%26aulast%3DFalzoni%26aufirst%3DS.%26aulast%3DGeorge%26aufirst%3DC.%26aulast%3DGoldstein%26aufirst%3DS.%2BA.%2BN.%26aulast%3DGrissmer%26aufirst%3DS.%26aulast%3DHa%26aufirst%3DK.%26aulast%3DHammelmann%26aufirst%3DV.%26aulast%3DHanukoglu%26aufirst%3DI.%26aulast%3DJarvis%26aufirst%3DM.%26aulast%3DJensen%26aufirst%3DA.%2BA.%26aulast%3DKaczmarek%26aufirst%3DL.%2BK.%26aulast%3DKellenberger%26aufirst%3DS.%26aulast%3DKing%26aufirst%3DB.%26aulast%3DLynch%26aufirst%3DJ.%2BW.%26aulast%3DPerez-Reyes%26aufirst%3DE.%26aulast%3DPlant%26aufirst%3DL.%2BD.%26aulast%3DRash%26aufirst%3DL.%2BD.%26aulast%3DRen%26aufirst%3DD.%2BJ.%26aulast%3DSivilotti%26aufirst%3DL.%2BG.%26aulast%3DSmart%26aufirst%3DT.%2BG.%26aulast%3DSnutch%26aufirst%3DT.%2BP.%26aulast%3DTian%26aufirst%3DJ.%2BB.%26aulast%3DVan%2Bden%2BEynde%26aufirst%3DC.%26aulast%3DVriens%26aufirst%3DJ.%26aulast%3DWei%26aufirst%3DA.%2BD.%26aulast%3DWinn%26aufirst%3DB.%2BT.%26aulast%3DWulff%26aufirst%3DH.%26aulast%3DXu%26aufirst%3DH.%2BX.%26aulast%3DYue%26aufirst%3DL.%2BX.%26aulast%3DZhang%26aufirst%3DX.%2BL.%26aulast%3DZhu%26aufirst%3DM.%26aulast%3DCoons%26aufirst%3DL.%26aulast%3DFuller%26aufirst%3DP.%26aulast%3DKorach%26aufirst%3DK.%2BS.%26aulast%3DYoung%26aufirst%3DM.%26aulast%3DBryant%26aufirst%3DC.%26aulast%3DFarndale%26aufirst%3DR.%2BW.%26aulast%3DHobbs%26aufirst%3DA.%26aulast%3DJarvis%26aufirst%3DG.%2BE.%26aulast%3DMacEwan%26aufirst%3DD.%26aulast%3DMonie%26aufirst%3DT.%2BP.%26aulast%3DWaldman%26aufirst%3DS.%26aulast%3DBeuve%26aufirst%3DA.%26aulast%3DBoison%26aufirst%3DD.%26aulast%3DBrouckaert%26aufirst%3DP.%26aulast%3DBurnett%26aufirst%3DJ.%2BC.%26aulast%3DBurns%26aufirst%3DK.%26aulast%3DDessauer%26aufirst%3DC.%26aulast%3DFriebe%26aufirst%3DA.%26aulast%3DGarthwaite%26aufirst%3DJ.%26aulast%3DGertsch%26aufirst%3DJ.%26aulast%3DHelsby%26aufirst%3DN.%26aulast%3DIzzo%26aufirst%3DA.%2BA.%26aulast%3DKoesling%26aufirst%3DD.%26aulast%3DKuhn%26aufirst%3DM.%26aulast%3DOstrom%26aufirst%3DR.%26aulast%3DPapapetropoulos%26aufirst%3DA.%26aulast%3DPotter%26aufirst%3DL.%2BR.%26aulast%3DPyne%26aufirst%3DN.%2BJ.%26aulast%3DPyne%26aufirst%3DS.%26aulast%3DRusswurm%26aufirst%3DM.%26aulast%3DSchmidt%26aufirst%3DH.%26aulast%3DSeifert%26aufirst%3DR.%26aulast%3DStasch%26aufirst%3DJ.%2BP.%26aulast%3DSzabo%26aufirst%3DC.%26aulast%3Dvan%2Bder%2BStelt%26aufirst%3DM.%26aulast%3Dvan%2Bder%2BVliet%26aufirst%3DA.%26aulast%3DWatts%26aufirst%3DV.%26aulast%3DAnderson%26aufirst%3DC.%2BM.%2BH.%26aulast%3DBroer%26aufirst%3DS.%26aulast%3DDawson%26aufirst%3DP.%26aulast%3DHagenbuch%26aufirst%3DB.%26aulast%3DHammond%26aufirst%3DJ.%2BR.%26aulast%3DHancox%26aufirst%3DJ.%26aulast%3DInui%26aufirst%3DK.%26aulast%3DKanai%26aufirst%3DY.%26aulast%3DKemp%26aufirst%3DS.%26aulast%3DThwaites%26aufirst%3DD.%2BT.%26aulast%3DVerri%26aufirst%3DT.%26aulast%3D%26atitle%3DThe%2520concise%2520guide%2520to%2520pharmacology%25202019%252F20%253A%2520G%2520protein-coupled%2520receptors%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2019%26volume%3D176%26spage%3DS21%26epage%3DS141%26doi%3D10.1111%2Fbph.14748" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sriram, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Insel, P. A.</span></span> <span> </span><span class="NLM_article-title">G protein-coupled receptors as targets for approved drugs: how many targets and how many drugs?</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>93</i></span>,  <span class="NLM_fpage">251</span>– <span class="NLM_lpage">258</span>, <span class="refDoi"> DOI: 10.1124/mol.117.111062</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=10.1124%2Fmol.117.111062" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=29298813" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs12qsr3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=2018&pages=251-258&author=K.+Sriramauthor=P.+A.+Insel&title=G+protein-coupled+receptors+as+targets+for+approved+drugs%3A+how+many+targets+and+how+many+drugs%3F&doi=10.1124%2Fmol.117.111062"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">G protein-coupled receptors as targets for approved drugs: how many targets and how many drugs?</span></div><div class="casAuthors">Sriram, Krishna; Insel, Paul A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">251-258</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">1521-0111</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Ests. vary regarding the no. of G protein-coupled receptors (GPCRs), the largest family of membrane receptors that are targeted by approved drugs, and the no. of such drugs that target GPCRs.  We review current knowledge regarding GPCRs as drug targets by integrating data from public databases (ChEMBL, Guide to PHARMACOl., and DrugBank) and from the Broad Institute Drug Repurposing Hub.  To account for discrepancies among these sources, we curated a list of GPCRs currently targeted by approved drugs.  As of Nov. 2017, 134 GPCRs are targets for drugs approved in the United States or European Union; 128 GPCRs are targets for drugs listed in the Food and Drug Administration Orange Book.  We est. that ∼700 approved drugs target GPCRs, implying that approx. 35% of approved drugs target GPCRs.  GPCRs and GPCR-related proteins, i.e., those upstream of or downstream from GPCRs, represent ∼17% of all protein targets for approved drugs, with GPCRs themselves accounting for ∼12%.  As such, GPCRs constitute the largest family of proteins targeted by approved drugs.  Drugs that currently target GPCRs and GPCRrelated proteins are primarily small mols. and peptides.  Since ∼100 of the ∼360 human endo-GPCRs (other than olfactory, taste, and visual GPCRs) are orphan receptors (lacking known physiol. agonists), the no. of GPCR targets, the no. of GPCR-targeted drugs, and perhaps the types of drugs will likely increase, thus further expanding this GPCR repertoire and the many roles of GPCR drugs in therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIvH0Lu99b3rVg90H21EOLACvtfcHk0lhq4ejUmhGIuw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs12qsr3O&md5=ee1a26a2fcdbe66eeb1a864d168d787b</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1124%2Fmol.117.111062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.117.111062%26sid%3Dliteratum%253Aachs%26aulast%3DSriram%26aufirst%3DK.%26aulast%3DInsel%26aufirst%3DP.%2BA.%26atitle%3DG%2520protein-coupled%2520receptors%2520as%2520targets%2520for%2520approved%2520drugs%253A%2520how%2520many%2520targets%2520and%2520how%2520many%2520drugs%253F%26jtitle%3DMol.%2520Pharmacol.%26date%3D2018%26volume%3D93%26spage%3D251%26epage%3D258%26doi%3D10.1124%2Fmol.117.111062" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weston, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winfield, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodgson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowell, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mobarec, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodlock, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reynolds, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poyner, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ladds, G.</span></span> <span> </span><span class="NLM_article-title">Receptor activity-modifying protein-directed G protein signaling specificity for the calcitonin gene-related peptide family of receptors</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>291</i></span>,  <span class="NLM_fpage">21925</span>– <span class="NLM_lpage">21944</span>, <span class="refDoi"> DOI: 10.1074/jbc.M116.751362</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=10.1074%2Fjbc.M116.751362" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=27566546" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1OgsbbK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=291&publication_year=2016&pages=21925-21944&author=C.+Westonauthor=I.+Winfieldauthor=M.+Harrisauthor=R.+Hodgsonauthor=A.+Shahauthor=S.+J.+Dowellauthor=J.+C.+Mobarecauthor=D.+A.+Woodlockauthor=C.+A.+Reynoldsauthor=D.+R.+Poynerauthor=H.+A.+Watkinsauthor=G.+Ladds&title=Receptor+activity-modifying+protein-directed+G+protein+signaling+specificity+for+the+calcitonin+gene-related+peptide+family+of+receptors&doi=10.1074%2Fjbc.M116.751362"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Receptor Activity-modifying Protein-directed G Protein Signaling Specificity for the Calcitonin Gene-related Peptide Family of Receptors</span></div><div class="casAuthors">Weston, Cathryn; Winfield, Ian; Harris, Matthew; Hodgson, Rose; Shah, Archna; Dowell, Simon J.; Mobarec, Juan Carlos; Woodlock, David A.; Reynolds, Christopher A.; Poyner, David R.; Watkins, Harriet A.; Ladds, Graham</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">291</span>
        (<span class="NLM_cas:issue">42</span>),
    <span class="NLM_cas:pages">21925-21944</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The calcitonin gene-related peptide (CGRP) family of G protein-coupled receptors (GPCRs) is formed through the assocn. of the calcitonin receptor-like receptor (CLR) and one of three receptor activity-modifying proteins (RAMPs).  Binding of one of the three peptide ligands, CGRP, adrenomedullin (AM), and intermedin/adrenomedullin 2 (AM2), is well known to result in a Gαs-mediated increase in cAMP.  Here we used modified yeast strains that couple receptor activation to cell growth, via chimeric yeast/Gα subunits, and HEK-293 cells to characterize the effect of different RAMP and ligand combinations on this pathway.  We not only demonstrate functional couplings to both Gαs and Gαq but also identify a Gαi component to CLR signaling in both yeast and HEK-293 cells, which is absent in HEK-293S cells.  We show that the CGRP family of receptors displays both ligand- and RAMP-dependent signaling bias among the Gαs, Gαi, and Gαq/11 pathways.  The results are discussed in the context of RAMP interactions probed through mol. modeling and mol. dynamics simulations of the RAMP-GPCR-G protein complexes.  This study further highlights the importance of RAMPs to CLR pharmacol. and to bias in general, as well as identifying the importance of choosing an appropriate model system for the study of GPCR pharmacol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-ksJs_JFeYbVg90H21EOLACvtfcHk0lhq4ejUmhGIuw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1OgsbbK&md5=32e2c6c34928aa8fbe52325b7a36e78a</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M116.751362&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M116.751362%26sid%3Dliteratum%253Aachs%26aulast%3DWeston%26aufirst%3DC.%26aulast%3DWinfield%26aufirst%3DI.%26aulast%3DHarris%26aufirst%3DM.%26aulast%3DHodgson%26aufirst%3DR.%26aulast%3DShah%26aufirst%3DA.%26aulast%3DDowell%26aufirst%3DS.%2BJ.%26aulast%3DMobarec%26aufirst%3DJ.%2BC.%26aulast%3DWoodlock%26aufirst%3DD.%2BA.%26aulast%3DReynolds%26aufirst%3DC.%2BA.%26aulast%3DPoyner%26aufirst%3DD.%2BR.%26aulast%3DWatkins%26aufirst%3DH.%2BA.%26aulast%3DLadds%26aufirst%3DG.%26atitle%3DReceptor%2520activity-modifying%2520protein-directed%2520G%2520protein%2520signaling%2520specificity%2520for%2520the%2520calcitonin%2520gene-related%2520peptide%2520family%2520of%2520receptors%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2016%26volume%3D291%26spage%3D21925%26epage%3D21944%26doi%3D10.1074%2Fjbc.M116.751362" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hay, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pioszak, A. A.</span></span> <span> </span><span class="NLM_article-title">Receptor activity-modifying proteins (RAMPs): new insights and roles</span>. <i>Annu. Rev. Pharmacol. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">469</span>– <span class="NLM_lpage">487</span>, <span class="refDoi"> DOI: 10.1146/annurev-pharmtox-010715-103120</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=10.1146%2Fannurev-pharmtox-010715-103120" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=26514202" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslGmsbbE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2016&pages=469-487&author=D.+L.+Hayauthor=A.+A.+Pioszak&title=Receptor+activity-modifying+proteins+%28RAMPs%29%3A+new+insights+and+roles&doi=10.1146%2Fannurev-pharmtox-010715-103120"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Receptor Activity-Modifying Proteins (RAMPs): New Insights and Roles</span></div><div class="casAuthors">Hay, Debbie L.; Pioszak, Augen A.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Pharmacology and Toxicology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">469-487</span>CODEN:
                <span class="NLM_cas:coden">ARPTDI</span>;
        ISSN:<span class="NLM_cas:issn">0362-1642</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews</span>)
        </div><div class="casAbstract">It is now recognized that G protein-coupled receptors (GPCRs), once considered largely independent functional units, have a far more diverse mol. architecture.  Receptor activity-modifying proteins (RAMPs) provide an important example of proteins that interact with GPCRs to modify their function.  RAMPs are able to act as pharmacol. switches and chaperones, and they can regulate signaling and/or trafficking in a receptor-dependent manner.  This review covers recent discoveries in the RAMP field and summarizes the known GPCR partners and functions of RAMPs.  We also discuss the first peptide-bound structures of RAMP-GPCR complexes, which give insight into the mol. mechanisms that enable RAMPs to alter the pharmacol. and signaling of GPCRs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlK5LE240AvrVg90H21EOLACvtfcHk0lhq4ejUmhGIuw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslGmsbbE&md5=a943f1f936ba9354111ca0dfb16a6e67</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1146%2Fannurev-pharmtox-010715-103120&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev-pharmtox-010715-103120%26sid%3Dliteratum%253Aachs%26aulast%3DHay%26aufirst%3DD.%2BL.%26aulast%3DPioszak%26aufirst%3DA.%2BA.%26atitle%3DReceptor%2520activity-modifying%2520proteins%2520%2528RAMPs%2529%253A%2520new%2520insights%2520and%2520roles%26jtitle%3DAnnu.%2520Rev.%2520Pharmacol.%2520Toxicol.%26date%3D2016%26volume%3D56%26spage%3D469%26epage%3D487%26doi%3D10.1146%2Fannurev-pharmtox-010715-103120" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hay, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garelja, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poyner, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, C. S.</span></span> <span> </span><span class="NLM_article-title">Update on the pharmacology of calcitonin/CGRP family of peptides: IUPHAR Review 25</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>175</i></span>,  <span class="NLM_fpage">3</span>– <span class="NLM_lpage">17</span>, <span class="refDoi"> DOI: 10.1111/bph.14075</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=10.1111%2Fbph.14075" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=29059473" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvVOjsrzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=175&publication_year=2018&pages=3-17&author=D.+L.+Hayauthor=M.+L.+Gareljaauthor=D.+R.+Poynerauthor=C.+S.+Walker&title=Update+on+the+pharmacology+of+calcitonin%2FCGRP+family+of+peptides%3A+IUPHAR+Review+25&doi=10.1111%2Fbph.14075"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Update on the pharmacology of calcitonin/CGRP family of peptides: IUPHAR Review 25</span></div><div class="casAuthors">Hay, Debbie L.; Garelja, Michael L.; Poyner, David R.; Walker, Christopher S.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">175</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3-17</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The calcitonin/CGRP family of peptides includes calcitonin, α and β CGRP, amylin, adrenomedullin (AM) and adrenomedullin 2/intermedin (AM2/IMD).  Their receptors consist of one of two GPCRs, the calcitonin receptor (CTR) or the calcitonin receptor-like receptor (CLR).  Further diversity arises from heterodimerization of these GPCRs with one of three receptor activity-modifying proteins (RAMPs).  This gives the CGRP receptor (CLR/RAMP1), the AM1 and AM2 receptors (CLR/RAMP2 or RAMP3) and the AMY1, AMY2 and AMY3 receptors (CTR/RAMPs1-3 complexes, resp.).  Apart from the CGRP receptor, there are only peptide antagonists widely available for these receptors, and these have limited selectivity, thus defining the function of each receptor in vivo remains challenging.  Further challenges arise from the probable co-expression of CTR with the CTR/RAMP complexes and species-dependent splice variants of the CTR (CT(a) and CT(b)).  Furthermore, the AMY1(a) receptor is activated equally well by both amylin and CGRP, and the preferred receptor for AM2/IMD has been unclear.  However, there are clear therapeutic rationales for developing agents against the various receptors for these peptides.  For example, many agents targeting the CGRP system are in clin. trials, and pramlintide, an amylin analog, is an approved therapy for insulin-requiring diabetes.  This review provides an update on the pharmacol. of the calcitonin family of peptides by members of the corresponding subcommittee of the International Union of Basic and Clin. Pharmacol. and colleagues.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpuzfzqMhXcSbVg90H21EOLACvtfcHk0ljzka_hXyIXrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvVOjsrzJ&md5=ff10d0f78ca78127c11bd4fe8c71b86a</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1111%2Fbph.14075&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.14075%26sid%3Dliteratum%253Aachs%26aulast%3DHay%26aufirst%3DD.%2BL.%26aulast%3DGarelja%26aufirst%3DM.%2BL.%26aulast%3DPoyner%26aufirst%3DD.%2BR.%26aulast%3DWalker%26aufirst%3DC.%2BS.%26atitle%3DUpdate%2520on%2520the%2520pharmacology%2520of%2520calcitonin%252FCGRP%2520family%2520of%2520peptides%253A%2520IUPHAR%2520Review%252025%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2018%26volume%3D175%26spage%3D3%26epage%3D17%26doi%3D10.1111%2Fbph.14075" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bortolato, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dore, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollenstein, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tehan, B. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mason, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marshall, F. H.</span></span> <span> </span><span class="NLM_article-title">Structure of class B GPCRs: new horizons for drug discovery</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>171</i></span>,  <span class="NLM_fpage">3132</span>– <span class="NLM_lpage">3145</span>, <span class="refDoi"> DOI: 10.1111/bph.12689</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=10.1111%2Fbph.12689" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=24628305" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=1%3ACAS%3A528%3ADC%252BC2cXpsVKrtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=171&publication_year=2014&pages=3132-3145&author=A.+Bortolatoauthor=A.+S.+Doreauthor=K.+Hollensteinauthor=B.+G.+Tehanauthor=J.+S.+Masonauthor=F.+H.+Marshall&title=Structure+of+class+B+GPCRs%3A+new+horizons+for+drug+discovery&doi=10.1111%2Fbph.12689"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of Class B GPCRs: new horizons for drug discovery</span></div><div class="casAuthors">Bortolato, Andrea; Dore, Andrew S.; Hollenstein, Kaspar; Tehan, Benjamin G.; Mason, Jonathan S.; Marshall, Fiona H.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">171</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3132-3145</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Class B GPCRs of the secretin family are important drug targets in many human diseases including diabetes, neurodegeneration, cardiovascular disease and psychiatric disorders.  X-ray crystal structures for the glucagon receptor and corticotropin-releasing factor receptor 1 have now been published.  In this review, we analyze the new structures and how they compare with each other and with Class A and F receptors.  We also consider the differences in druggability and possible similarity in the activation mechanisms.  Finally, we discuss the potential for the design of small-mol. modulators for these important targets in drug discovery.  This new structural insight allows, for the first time, structure-based drug design methods to be applied to Class B GPCRs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprqe_GGLyHcbVg90H21EOLACvtfcHk0ljzka_hXyIXrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXpsVKrtr0%253D&md5=3e08525e9309b28bc3a7a268fd83067e</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1111%2Fbph.12689&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.12689%26sid%3Dliteratum%253Aachs%26aulast%3DBortolato%26aufirst%3DA.%26aulast%3DDore%26aufirst%3DA.%2BS.%26aulast%3DHollenstein%26aufirst%3DK.%26aulast%3DTehan%26aufirst%3DB.%2BG.%26aulast%3DMason%26aufirst%3DJ.%2BS.%26aulast%3DMarshall%26aufirst%3DF.%2BH.%26atitle%3DStructure%2520of%2520class%2520B%2520GPCRs%253A%2520new%2520horizons%2520for%2520drug%2520discovery%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2014%26volume%3D171%26spage%3D3132%26epage%3D3145%26doi%3D10.1111%2Fbph.12689" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de
Graaf, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, R. C.</span></span> <span> </span><span class="NLM_article-title">Extending the structural view of class B GPCRs</span>. <i>Trends Biochem. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">946</span>– <span class="NLM_lpage">960</span>, <span class="refDoi"> DOI: 10.1016/j.tibs.2017.10.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=10.1016%2Fj.tibs.2017.10.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=29132948" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslSktb7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2017&pages=946-960&author=C.+de%0AGraafauthor=G.+J.+Songauthor=C.+Caoauthor=Q.+Zhaoauthor=M.+W.+Wangauthor=B.+L.+Wuauthor=R.+C.+Stevens&title=Extending+the+structural+view+of+class+B+GPCRs&doi=10.1016%2Fj.tibs.2017.10.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Extending the Structural View of Class B GPCRs</span></div><div class="casAuthors">de Graaf, Chris; Song, Gaojie; Cao, Can; Zhao, Qiang; Wang, Ming-Wei; Wu, Beili; Stevens, Raymond C.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Biochemical Sciences</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">946-960</span>CODEN:
                <span class="NLM_cas:coden">TBSCDB</span>;
        ISSN:<span class="NLM_cas:issn">0968-0004</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The secretin-like class B family of G protein-coupled receptors (GPCRs) are key players in hormonal homeostasis.  Recent structures of various receptors in complex with a variety of orthosteric and allosteric ligands provide fundamental new insights into the function and mechanism of class B GPCRs, including: (i) ligand-induced changes in the relative orientation of the extracellular and transmembrane receptor domains; (ii) intramol. interaction networks that stabilize conformational changes to accommodate intracellular G protein binding; and (iii) allosteric modulation of receptor activation.  This review provides a comprehensive anal. of the structural, biochem., and pharmacol. data on class B GPCRs for understanding ligand-receptor interaction and modulation mechanisms and assessing the potential implications for drug discovery for the secretin-like GPCR family.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoB3zzE8S9kfrVg90H21EOLACvtfcHk0ljzka_hXyIXrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslSktb7E&md5=3e0c0b52f9078a329d3eb80290a44c97</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2Fj.tibs.2017.10.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tibs.2017.10.003%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BGraaf%26aufirst%3DC.%26aulast%3DSong%26aufirst%3DG.%2BJ.%26aulast%3DCao%26aufirst%3DC.%26aulast%3DZhao%26aufirst%3DQ.%26aulast%3DWang%26aufirst%3DM.%2BW.%26aulast%3DWu%26aufirst%3DB.%2BL.%26aulast%3DStevens%26aufirst%3DR.%2BC.%26atitle%3DExtending%2520the%2520structural%2520view%2520of%2520class%2520B%2520GPCRs%26jtitle%3DTrends%2520Biochem.%2520Sci.%26date%3D2017%26volume%3D42%26spage%3D946%26epage%3D960%26doi%3D10.1016%2Fj.tibs.2017.10.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liang, Y.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khoshouei, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deganutti, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glukhova, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koole, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peat, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radjainia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plitzko, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baumeister, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hay, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christopoulos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reynolds, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wootten, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sexton, P. M.</span></span> <span> </span><span class="NLM_article-title">Cryo-EM structure of the active, G(s)- protein complexed, human CGRP receptor</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>561</i></span>,  <span class="NLM_fpage">492</span>– <span class="NLM_lpage">497</span>, <span class="refDoi"> DOI: 10.1038/s41586-018-0535-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=10.1038%2Fs41586-018-0535-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=30209400" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslSnu7jL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=561&publication_year=2018&pages=492-497&author=Y.-L.+Liangauthor=M.+Khoshoueiauthor=G.+Deganuttiauthor=A.+Glukhovaauthor=C.+Kooleauthor=T.+S.+Peatauthor=M.+Radjainiaauthor=J.+M.+Plitzkoauthor=W.+Baumeisterauthor=L.+J.+Millerauthor=D.+L.+Hayauthor=A.+Christopoulosauthor=C.+A.+Reynoldsauthor=D.+Woottenauthor=P.+M.+Sexton&title=Cryo-EM+structure+of+the+active%2C+G%28s%29-+protein+complexed%2C+human+CGRP+receptor&doi=10.1038%2Fs41586-018-0535-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Cryo-EM structure of the active, Gs-protein complexed, human CGRP receptor</span></div><div class="casAuthors">Liang, Yi-Lynn; Khoshouei, Maryam; Deganutti, Giuseppe; Glukhova, Alisa; Koole, Cassandra; Peat, Thomas S.; Radjainia, Mazdak; Plitzko, Jurgen M.; Baumeister, Wolfgang; Miller, Laurence J.; Hay, Deborah L.; Christopoulos, Arthur; Reynolds, Christopher A.; Wootten, Denise; Sexton, Patrick M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">561</span>
        (<span class="NLM_cas:issue">7724</span>),
    <span class="NLM_cas:pages">492-497</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Calcitonin gene-related peptide (CGRP) is a widely expressed neuropeptide that plays a major role in sensory neurotransmission.  The CGRP receptor is a heterodimer of the calcitonin receptor-like receptor (CLR) class B G-protein-coupled receptor and a type 1 transmembrane domain protein, receptor activity-modifying protein 1 (RAMP1).  Here, we report the structure of the human CGRP receptor in complex with CGRP and the Gs-protein heterotrimer at 3.3 Å global resoln., detd. by Volta phase-plate cryo-electron microscopy.  The receptor activity-modifying protein transmembrane domain sits at the interface between transmembrane domains 3, 4, and 5 of CLR, and stabilizes CLR extracellular loop 2.  RAMP1 makes only limited direct contact with CGRP, consistent with its function in allosteric modulation of CLR.  Mol. dynamics simulations indicated that RAMP1 provides stability to the receptor complex, particularly in the positioning of the extracellular domain of CLR.  This work provides insights into the control of G-protein-coupled receptor function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxOm13jzoHHbVg90H21EOLACvtfcHk0liX3OwKxHN4uA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslSnu7jL&md5=ed535627358ee097dacc0be9ef4d8d96</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2Fs41586-018-0535-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41586-018-0535-y%26sid%3Dliteratum%253Aachs%26aulast%3DLiang%26aufirst%3DY.-L.%26aulast%3DKhoshouei%26aufirst%3DM.%26aulast%3DDeganutti%26aufirst%3DG.%26aulast%3DGlukhova%26aufirst%3DA.%26aulast%3DKoole%26aufirst%3DC.%26aulast%3DPeat%26aufirst%3DT.%2BS.%26aulast%3DRadjainia%26aufirst%3DM.%26aulast%3DPlitzko%26aufirst%3DJ.%2BM.%26aulast%3DBaumeister%26aufirst%3DW.%26aulast%3DMiller%26aufirst%3DL.%2BJ.%26aulast%3DHay%26aufirst%3DD.%2BL.%26aulast%3DChristopoulos%26aufirst%3DA.%26aulast%3DReynolds%26aufirst%3DC.%2BA.%26aulast%3DWootten%26aufirst%3DD.%26aulast%3DSexton%26aufirst%3DP.%2BM.%26atitle%3DCryo-EM%2520structure%2520of%2520the%2520active%252C%2520G%2528s%2529-%2520protein%2520complexed%252C%2520human%2520CGRP%2520receptor%26jtitle%3DNature%26date%3D2018%26volume%3D561%26spage%3D492%26epage%3D497%26doi%3D10.1038%2Fs41586-018-0535-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liang, Y.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belousoff, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khoshouei, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deganutti, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koole, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furness, S. G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hay, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christopoulos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reynolds, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danev, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wootten, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sexton, P. M.</span></span> <span> </span><span class="NLM_article-title">Structure and dynamics of adrenomedullin receptors AM1 and AM2 reveal key mechanisms in the control of receptor phenotype by receptor activity-modifying proteins</span>. <i>ACS Pharmacol. Transl. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">263</span>– <span class="NLM_lpage">284</span>, <span class="refDoi"> DOI: 10.1021/acsptsci.9b00080</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsptsci.9b00080" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=1%3ACAS%3A528%3ADC%252BB3cXlt1WnsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2020&pages=263-284&author=Y.-L.+Liangauthor=M.+J.+Belousoffauthor=M.+M.+Fletcherauthor=X.+Zhangauthor=M.+Khoshoueiauthor=G.+Deganuttiauthor=C.+Kooleauthor=S.+G.+B.+Furnessauthor=L.+J.+Millerauthor=D.+L.+Hayauthor=A.+Christopoulosauthor=C.+A.+Reynoldsauthor=R.+Danevauthor=D.+Woottenauthor=P.+M.+Sexton&title=Structure+and+dynamics+of+adrenomedullin+receptors+AM1+and+AM2+reveal+key+mechanisms+in+the+control+of+receptor+phenotype+by+receptor+activity-modifying+proteins&doi=10.1021%2Facsptsci.9b00080"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Structure and Dynamics of Adrenomedullin Receptors AM1 and AM2 Reveal Key Mechanisms in the Control of Receptor Phenotype by Receptor Activity-Modifying Proteins</span></div><div class="casAuthors">Liang, Yi-Lynn; Belousoff, Matthew J.; Fletcher, Madeleine M.; Zhang, Xin; Khoshouei, Maryam; Deganutti, Giuseppe; Koole, Cassandra; Furness, Sebastian G. B.; Miller, Laurence J.; Hay, Debbie L.; Christopoulos, Arthur; Reynolds, Christopher A.; Danev, Radostin; Wootten, Denise; Sexton, Patrick M.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Pharmacology & Translational Science</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">263-284</span>CODEN:
                <span class="NLM_cas:coden">APTSFN</span>;
        ISSN:<span class="NLM_cas:issn">2575-9108</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Adrenomedullin (AM) and calcitonin gene-related peptide (CGRP) receptors are critically important for metab., vascular tone, and inflammatory response.  AM receptors are also required for normal lymphatic and blood vascular development and angiogenesis.  They play a pivotal role in embryo implantation and fertility and can provide protection against hypoxic and oxidative stress.  CGRP and AM receptors are heterodimers of the calcitonin receptor-like receptor (CLR) and receptor activity-modifying protein 1 (RAMP1) (CGRPR), as well as RAMP2 or RAMP3 (AM1R and AM2R, resp.).  However, the mechanistic basis for RAMP modulation of CLR phenotype is unclear.  In this study, we report the cryo-EM structure of the AM1R in complex with AM and Gs at a global resoln. of 3.0 Å, and structures of the AM2R in complex with either AM or intermedin/adrenomedullin 2 (AM2) and Gs at 2.4 and 2.3 Å, resp.  The structures reveal distinctions in the primary orientation of the extracellular domains (ECDs) relative to the receptor core and distinct positioning of extracellular loop 3 (ECL3) that are receptor-dependent.  Anal. of dynamic data present in the cryo-EM micrographs revealed addnl. distinctions in the extent of mobility of the ECDs.  Chimeric exchange of the linker region of the RAMPs connecting the TM helix and the ECD supports a role for this segment in controlling receptor phenotype.  Moreover, a subset of the motions of the ECD appeared coordinated with motions of the G protein relative to the receptor core, suggesting that receptor ECD dynamics could influence G protein interactions.  This work provides fundamental advances in our understanding of GPCR function and how this can be allosterically modulated by accessory proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpB5Q0D37yiZLVg90H21EOLACvtfcHk0liX3OwKxHN4uA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXlt1WnsL4%253D&md5=77a9ed6c15298b83e282ec160e0b9ca0</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1021%2Facsptsci.9b00080&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsptsci.9b00080%26sid%3Dliteratum%253Aachs%26aulast%3DLiang%26aufirst%3DY.-L.%26aulast%3DBelousoff%26aufirst%3DM.%2BJ.%26aulast%3DFletcher%26aufirst%3DM.%2BM.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DKhoshouei%26aufirst%3DM.%26aulast%3DDeganutti%26aufirst%3DG.%26aulast%3DKoole%26aufirst%3DC.%26aulast%3DFurness%26aufirst%3DS.%2BG.%2BB.%26aulast%3DMiller%26aufirst%3DL.%2BJ.%26aulast%3DHay%26aufirst%3DD.%2BL.%26aulast%3DChristopoulos%26aufirst%3DA.%26aulast%3DReynolds%26aufirst%3DC.%2BA.%26aulast%3DDanev%26aufirst%3DR.%26aulast%3DWootten%26aufirst%3DD.%26aulast%3DSexton%26aufirst%3DP.%2BM.%26atitle%3DStructure%2520and%2520dynamics%2520of%2520adrenomedullin%2520receptors%2520AM1%2520and%2520AM2%2520reveal%2520key%2520mechanisms%2520in%2520the%2520control%2520of%2520receptor%2520phenotype%2520by%2520receptor%2520activity-modifying%2520proteins%26jtitle%3DACS%2520Pharmacol.%2520Transl.%2520Sci.%26date%3D2020%26volume%3D3%26spage%3D263%26epage%3D284%26doi%3D10.1021%2Facsptsci.9b00080" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Garelja, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Au, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brimble, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gingell, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendrikse, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lovell, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prodan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sexton, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siow, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wootten, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, P. W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hay, D. L.</span></span> <span> </span><span class="NLM_article-title">Molecular mechanisms of class B GPCR activation: insights from adrenomedullin receptors</span>. <i>ACS Pharmacol. Transl. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">246</span>– <span class="NLM_lpage">262</span>, <span class="refDoi"> DOI: 10.1021/acsptsci.9b00083</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsptsci.9b00083" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=1%3ACAS%3A528%3ADC%252BB3cXjslSqs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2020&pages=246-262&author=M.+L.+Gareljaauthor=M.+Auauthor=M.+A.+Brimbleauthor=J.+J.+Gingellauthor=E.+R.+Hendrikseauthor=A.+Lovellauthor=N.+Prodanauthor=P.+M.+Sextonauthor=A.+Siowauthor=C.+S.+Walkerauthor=H.+A.+Watkinsauthor=G.+M.+Williamsauthor=D.+Woottenauthor=S.+H.+Yangauthor=P.+W.+R.+Harrisauthor=D.+L.+Hay&title=Molecular+mechanisms+of+class+B+GPCR+activation%3A+insights+from+adrenomedullin+receptors&doi=10.1021%2Facsptsci.9b00083"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Mechanisms of Class B GPCR Activation: Insights from Adrenomedullin Receptors</span></div><div class="casAuthors">Garelja, Michael L.; Au, Maggie; Brimble, Margaret A.; Gingell, Joseph J.; Hendrikse, Erica R.; Lovell, Annie; Prodan, Nicole; Sexton, Patrick M.; Siow, Andrew; Walker, Christopher S.; Watkins, Harriet A.; Williams, Geoffrey M.; Wootten, Denise; Yang, Sung H.; Harris, Paul W. R.; Hay, Debbie L.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Pharmacology & Translational Science</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">246-262</span>CODEN:
                <span class="NLM_cas:coden">APTSFN</span>;
        ISSN:<span class="NLM_cas:issn">2575-9108</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Adrenomedullin (AM) is a 52 amino acid peptide that plays a regulatory role in the vasculature.  Receptors for AM are comprised of the class B G protein-coupled receptor, the calcitonin-like receptor (CLR), in complex with one of three receptor activity-modifying proteins (RAMPs).  The C-terminus of AM is involved in binding to the extracellular domain of the receptor, while the N-is proposed to interact with the juxtamembranous portion of the receptor to activate signaling.  There is currently limited information on the mol. determinants involved in AM signaling, thus we set out to define the importance of the AM N-terminus through five signaling pathways (cAMP prodn., ERK phosphorylation, CREB phosphorylation, Akt phosphorylation, and IP1 prodn.).  We characterized the three CLR:RAMP complexes through the five pathways, finding that each had a distinct repertoire of intracellular signaling pathways that it is able to regulate.  We then performed an alanine scan of AM from residues 15-31 and found that most residues could be substituted with only small effects on signaling, and that most substitutions affected signaling through all receptors and pathways in a similar manner.  We identify F18, T20, L26, and I30 as being crit. for AM function, while also identifying an analog (AM15-52 G19A) which has unique signaling properties relative to the unmodified AM.  We interpret our findings in the context of new structural information, highlighting the complementary nature of structural biol. and functional assays.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9HQAGPU8XlLVg90H21EOLACvtfcHk0liX3OwKxHN4uA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXjslSqs7c%253D&md5=3b11e7f7b4de93ddfa71f0304c7a4320</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1021%2Facsptsci.9b00083&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsptsci.9b00083%26sid%3Dliteratum%253Aachs%26aulast%3DGarelja%26aufirst%3DM.%2BL.%26aulast%3DAu%26aufirst%3DM.%26aulast%3DBrimble%26aufirst%3DM.%2BA.%26aulast%3DGingell%26aufirst%3DJ.%2BJ.%26aulast%3DHendrikse%26aufirst%3DE.%2BR.%26aulast%3DLovell%26aufirst%3DA.%26aulast%3DProdan%26aufirst%3DN.%26aulast%3DSexton%26aufirst%3DP.%2BM.%26aulast%3DSiow%26aufirst%3DA.%26aulast%3DWalker%26aufirst%3DC.%2BS.%26aulast%3DWatkins%26aufirst%3DH.%2BA.%26aulast%3DWilliams%26aufirst%3DG.%2BM.%26aulast%3DWootten%26aufirst%3DD.%26aulast%3DYang%26aufirst%3DS.%2BH.%26aulast%3DHarris%26aufirst%3DP.%2BW.%2BR.%26aulast%3DHay%26aufirst%3DD.%2BL.%26atitle%3DMolecular%2520mechanisms%2520of%2520class%2520B%2520GPCR%2520activation%253A%2520insights%2520from%2520adrenomedullin%2520receptors%26jtitle%3DACS%2520Pharmacol.%2520Transl.%2520Sci.%26date%3D2020%26volume%3D3%26spage%3D246%26epage%3D262%26doi%3D10.1021%2Facsptsci.9b00083" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hoare, S. R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grigoriadis, D. E.</span></span> <span> </span><span class="NLM_article-title">Non-peptide translation to CRF-receptor antagonists:allosterism, kinetics’ and efficacy in human disease</span>. <i>Curr. Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">282</span>– <span class="NLM_lpage">295</span>, <span class="refDoi"> DOI: 10.2174/1874467210666170110124539</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=10.2174%2F1874467210666170110124539" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=28103785" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1Kgs7bJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2017&pages=282-295&author=S.+R.+J.+Hoareauthor=D.+E.+Grigoriadis&title=Non-peptide+translation+to+CRF-receptor+antagonists%3Aallosterism%2C+kinetics%E2%80%99+and+efficacy+in+human+disease&doi=10.2174%2F1874467210666170110124539"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Non-peptide CRF-Receptor Antagonists: Allosterism, Kinetics and Translation to Efficacy in Human Disease</span></div><div class="casAuthors">Hoare, Samuel R. J.; Grigoriadis, Dimitri E.</div><div class="citationInfo"><span class="NLM_cas:title">Current Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">282-295</span>CODEN:
                <span class="NLM_cas:coden">CMPUB6</span>;
        ISSN:<span class="NLM_cas:issn">1874-4702</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  G-Protein coupled receptors (GPCRs) have been, and remain a key target of drug discovery programs for human disease.  While many drugs have been developed that interact with these proteins in the simple classic manner - that is - phys. blocking the cognate ligand from simply binding to its target receptor, drug discovery approaches have elucidated alternative more complex methods by which small mols. can interact with these receptors and block their function.  This is most evident in the Class B GPCRs where the cognate ligands are relatively large peptides with multiple points of contact on the GPCR spanning both hydrophilic and hydrophobic domains on the same protein to elicit function.  It has therefore been difficult to precisely det. not only the mechanism by which a small mol. can inhibit the function of a large peptide but also the nature of that mechanism that drives the differences in efficacy.  This review will examine in detail the nature of small mol. inhibition of corticotropin-releasing factor receptors and illustrate the role that allosteric binding and kinetics play in the functional inhibition of this Class B GPCR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJZQo8LWBxsLVg90H21EOLACvtfcHk0liasHGpBsY_cA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1Kgs7bJ&md5=bc36be25744a4f405957eb2516e25bc3</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.2174%2F1874467210666170110124539&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1874467210666170110124539%26sid%3Dliteratum%253Aachs%26aulast%3DHoare%26aufirst%3DS.%2BR.%2BJ.%26aulast%3DGrigoriadis%26aufirst%3DD.%2BE.%26atitle%3DNon-peptide%2520translation%2520to%2520CRF-receptor%2520antagonists%253Aallosterism%252C%2520kinetics%25E2%2580%2599%2520and%2520efficacy%2520in%2520human%2520disease%26jtitle%3DCurr.%2520Mol.%2520Pharmacol.%26date%3D2017%26volume%3D10%26spage%3D282%26epage%3D295%26doi%3D10.2174%2F1874467210666170110124539" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thal, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glukhova, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sexton, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christopoulos, A.</span></span> <span> </span><span class="NLM_article-title">Structural insights into G-protein-coupled receptor allostery</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>559</i></span>,  <span class="NLM_fpage">45</span>– <span class="NLM_lpage">53</span>, <span class="refDoi"> DOI: 10.1038/s41586-018-0259-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=10.1038%2Fs41586-018-0259-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=29973731" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1Ojt7rF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=559&publication_year=2018&pages=45-53&author=D.+M.+Thalauthor=A.+Glukhovaauthor=P.+M.+Sextonauthor=A.+Christopoulos&title=Structural+insights+into+G-protein-coupled+receptor+allostery&doi=10.1038%2Fs41586-018-0259-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Structural insights into G-protein-coupled receptor allostery</span></div><div class="casAuthors">Thal, David M.; Glukhova, Alisa; Sexton, Patrick M.; Christopoulos, Arthur</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">559</span>
        (<span class="NLM_cas:issue">7712</span>),
    <span class="NLM_cas:pages">45-53</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  G-protein-coupled receptors (GPCRs) are key cell-surface proteins that transduce external environmental cues into biochem. signals across the membrane.  GPCRs are intrinsically allosteric proteins; they interact via spatially distinct yet conformationally linked domains with both endogenous and exogenous proteins, nutrients, metabolites, hormones, small mols., and biol. agents.  Here, we explore recent high-resoln. structural studies, which are beginning to unravel the at. details of allosteric transitions that govern GPCR biol., as well as highlighting how the wide diversity of druggable allosteric sites across these receptors present opportunities for developing new classes of therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpe7mS11VNWXbVg90H21EOLACvtfcHk0liasHGpBsY_cA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1Ojt7rF&md5=6bb61606ab4c32db2a96c9e283b11b09</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1038%2Fs41586-018-0259-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41586-018-0259-z%26sid%3Dliteratum%253Aachs%26aulast%3DThal%26aufirst%3DD.%2BM.%26aulast%3DGlukhova%26aufirst%3DA.%26aulast%3DSexton%26aufirst%3DP.%2BM.%26aulast%3DChristopoulos%26aufirst%3DA.%26atitle%3DStructural%2520insights%2520into%2520G-protein-coupled%2520receptor%2520allostery%26jtitle%3DNature%26date%3D2018%26volume%3D559%26spage%3D45%26epage%3D53%26doi%3D10.1038%2Fs41586-018-0259-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hendrikse, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liew, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bower, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonnet, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jamaluddin, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prodan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richards, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pairaudeau, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rujan, R.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sudra, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reynolds, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Booe, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pioszak, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flanagan, J. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hay, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hay, D. L.</span></span> <span> </span><span class="NLM_article-title">Identification of small-molecule positive modulators of calcitonin-like receptor-based receptors</span>. <i>ACS Pharmacol. Transl. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">305</span>– <span class="NLM_lpage">320</span>, <span class="refDoi"> DOI: 10.1021/acsptsci.9b00108</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsptsci.9b00108" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=1%3ACAS%3A528%3ADC%252BB3cXkslWrsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2020&pages=305-320&author=E.+R.+Hendrikseauthor=L.+P.+Liewauthor=R.+L.+Bowerauthor=M.+Bonnetauthor=M.+A.+Jamaluddinauthor=N.+Prodanauthor=K.+D.+Richardsauthor=C.+S.+Walkerauthor=G.+Pairaudeauauthor=D.+M.+Smithauthor=R.-M.+Rujanauthor=R.+Sudraauthor=C.+A.+Reynoldsauthor=J.+M.+Booeauthor=A.+A.+Pioszakauthor=J.+U.+Flanaganauthor=M.+P.+Hayauthor=D.+L.+Hay&title=Identification+of+small-molecule+positive+modulators+of+calcitonin-like+receptor-based+receptors&doi=10.1021%2Facsptsci.9b00108"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of Small-Molecule Positive Modulators of Calcitonin-like Receptor-Based Receptors</span></div><div class="casAuthors">Hendrikse, Erica R.; Liew, Lydia P.; Bower, Rebekah L.; Bonnet, Muriel; Jamaluddin, Muhammad A.; Prodan, Nicole; Richards, Keith D.; Walker, Christopher S.; Pairaudeau, Garry; Smith, David M.; Rujan, Roxana-Maria; Sudra, Risha; Reynolds, Christopher A.; Booe, Jason M.; Pioszak, Augen A.; Flanagan, Jack U.; Hay, Michael P.; Hay, Debbie L.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Pharmacology & Translational Science</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">305-320</span>CODEN:
                <span class="NLM_cas:coden">APTSFN</span>;
        ISSN:<span class="NLM_cas:issn">2575-9108</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Class B G protein-coupled receptors are highly therapeutically relevant but challenges remain in identifying suitable small-mol. drugs.  The calcitonin-like receptor (CLR) in particular is linked to conditions such as migraine, cardiovascular disease, and inflammatory bowel disease.  The CLR cannot act as a cell-surface receptor alone but rather must couple to one of three receptor activity-modifying proteins (RAMPs), forming heterodimeric receptors for the peptides adrenomedullin and calcitonin gene-related peptide.  These peptides have extended binding sites across their receptors.  This is one reason why there are few small-mol. ligands that can modulate these receptors.  Here we describe small mols. that are able to pos. modulate the signaling of the CLR with all three RAMPs but are not active at the related calcitonin receptor.  These compds. were selected from a β-arrestin recruitment screen, coupled with rounds of medicinal chem. to improve their activity.  Translational potential is shown as the compds. can pos. modulate cAMP signaling in a vascular cell line model.  Binding expts. do not support an extracellular domain binding site; however, mol. modeling reveals potential allosteric binding sites in multiple receptor regions.  These are the first small-mol. pos. modulators described for the CLR:RAMP complexes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEjIWD6ELg67Vg90H21EOLACvtfcHk0liasHGpBsY_cA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXkslWrsL0%253D&md5=72f27ffa368066df40ff4c1329254dac</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1021%2Facsptsci.9b00108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsptsci.9b00108%26sid%3Dliteratum%253Aachs%26aulast%3DHendrikse%26aufirst%3DE.%2BR.%26aulast%3DLiew%26aufirst%3DL.%2BP.%26aulast%3DBower%26aufirst%3DR.%2BL.%26aulast%3DBonnet%26aufirst%3DM.%26aulast%3DJamaluddin%26aufirst%3DM.%2BA.%26aulast%3DProdan%26aufirst%3DN.%26aulast%3DRichards%26aufirst%3DK.%2BD.%26aulast%3DWalker%26aufirst%3DC.%2BS.%26aulast%3DPairaudeau%26aufirst%3DG.%26aulast%3DSmith%26aufirst%3DD.%2BM.%26aulast%3DRujan%26aufirst%3DR.-M.%26aulast%3DSudra%26aufirst%3DR.%26aulast%3DReynolds%26aufirst%3DC.%2BA.%26aulast%3DBooe%26aufirst%3DJ.%2BM.%26aulast%3DPioszak%26aufirst%3DA.%2BA.%26aulast%3DFlanagan%26aufirst%3DJ.%2BU.%26aulast%3DHay%26aufirst%3DM.%2BP.%26aulast%3DHay%26aufirst%3DD.%2BL.%26atitle%3DIdentification%2520of%2520small-molecule%2520positive%2520modulators%2520of%2520calcitonin-like%2520receptor-based%2520receptors%26jtitle%3DACS%2520Pharmacol.%2520Transl.%2520Sci.%26date%3D2020%26volume%3D3%26spage%3D305%26epage%3D320%26doi%3D10.1021%2Facsptsci.9b00108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hewitt, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aurora, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dodick, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goadsby, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bachman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taraborelli, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, X. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Assaid, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lines, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, T. W.</span></span> <span> </span><span class="NLM_article-title">Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine</span>. <i>Cephalalgia</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">712</span>– <span class="NLM_lpage">722</span>, <span class="refDoi"> DOI: 10.1177/0333102411398399</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=10.1177%2F0333102411398399" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=21383045" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=1%3ACAS%3A280%3ADC%252BC3Mvjs1aktg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2011&pages=712-722&author=D.+J.+Hewittauthor=S.+K.+Auroraauthor=D.+W.+Dodickauthor=P.+J.+Goadsbyauthor=Y.+Geauthor=R.+Bachmanauthor=D.+Taraborelliauthor=X.+Y.+Fanauthor=C.+Assaidauthor=C.+Linesauthor=T.+W.+Ho&title=Randomized+controlled+trial+of+the+CGRP+receptor+antagonist+MK-3207+in+the+acute+treatment+of+migraine&doi=10.1177%2F0333102411398399"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine</span></div><div class="casAuthors">Hewitt David J; Aurora Sheena K; Dodick David W; Goadsby Peter J; Ge Yang Joy; Bachman Robert; Taraborelli Donna; Fan Xiaoyin; Assaid Christopher; Lines Christopher; Ho Tony W</div><div class="citationInfo"><span class="NLM_cas:title">Cephalalgia : an international journal of headache</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">712-22</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  This study evaluated the CGRP receptor antagonist MK-3207 for acute treatment of migraine.  METHODS:  Multicenter, double-blind, randomized, placebo-controlled, parallel-group, two-stage adaptive study with two interim efficacy analyses to facilitate optimal dose selection.  Migraine patients were initially randomized to MK-3207 2.5, 5, 10, 20, 50 and 100 mg or placebo to treat a moderate/severe migraine.  One or more doses were to be discontinued based on the first interim analysis and a lower or higher dose could be added based on the second interim analysis.  The primary endpoint was two-hour pain freedom.  RESULTS:  A total of 547 patients took study medication.  After the first interim analysis, the two lowest MK-3207 doses (2.5, 5 mg) were identified as showing insufficient efficacy.  Per the pre-specified adaptive design decision rule, only the 2.5-mg group was discontinued and the five highest doses (5, 10, 20, 50, 100 mg) were continued into the second stage.  After the second interim efficacy analysis, a 200 mg dose was added due to insufficient efficacy at the top three (20, 50, 100 mg) doses.  A positive dose-response trend was demonstrated when data were combined across all MK-3207 doses for two-hour pain freedom (p < .001).  The pairwise difference versus placebo for two-hour pain freedom was significant for 200 mg (p < .001) and nominally significant for 100 mg and 10 mg (p < .05).  The incidence of adverse events appeared comparable between active treatment groups and placebo, and did not appear to increase with increasing dose.  CONCLUSIONS:  MK-3207 was effective and generally well tolerated in the acute treatment of migraine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTWH3T54_BmWO-MdeMhXAHkfW6udTcc2eaNggsFtIlSn7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3Mvjs1aktg%253D%253D&md5=4a0e3bcb7010b04b2812d10f0ad9f57f</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1177%2F0333102411398399&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0333102411398399%26sid%3Dliteratum%253Aachs%26aulast%3DHewitt%26aufirst%3DD.%2BJ.%26aulast%3DAurora%26aufirst%3DS.%2BK.%26aulast%3DDodick%26aufirst%3DD.%2BW.%26aulast%3DGoadsby%26aufirst%3DP.%2BJ.%26aulast%3DGe%26aufirst%3DY.%26aulast%3DBachman%26aufirst%3DR.%26aulast%3DTaraborelli%26aufirst%3DD.%26aulast%3DFan%26aufirst%3DX.%2BY.%26aulast%3DAssaid%26aufirst%3DC.%26aulast%3DLines%26aufirst%3DC.%26aulast%3DHo%26aufirst%3DT.%2BW.%26atitle%3DRandomized%2520controlled%2520trial%2520of%2520the%2520CGRP%2520receptor%2520antagonist%2520MK-3207%2520in%2520the%2520acute%2520treatment%2520of%2520migraine%26jtitle%3DCephalalgia%26date%3D2011%26volume%3D31%26spage%3D712%26epage%3D722%26doi%3D10.1177%2F0333102411398399" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ho, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connor, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearlman, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koppenhaver, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, X. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lines, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edvinsson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goadsby, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michelson, D.</span></span> <span> </span><span class="NLM_article-title">Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention</span>. <i>Neurology</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>83</i></span>,  <span class="NLM_fpage">958</span>– <span class="NLM_lpage">966</span>, <span class="refDoi"> DOI: 10.1212/WNL.0000000000000771</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=10.1212%2FWNL.0000000000000771" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=25107879" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFert7bJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=2014&pages=958-966&author=T.+W.+Hoauthor=K.+M.+Connorauthor=Y.+Zhangauthor=E.+Pearlmanauthor=J.+Koppenhaverauthor=X.+Y.+Fanauthor=C.+Linesauthor=L.+Edvinssonauthor=P.+J.+Goadsbyauthor=D.+Michelson&title=Randomized+controlled+trial+of+the+CGRP+receptor+antagonist+telcagepant+for+migraine+prevention&doi=10.1212%2FWNL.0000000000000771"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention</span></div><div class="casAuthors">Ho, Tony W.; Connor, Kathryn M.; Zhang, Ying; Pearlman, Eric; Koppenhaver, Janelle; Fan, Xiaoyin; Lines, Christopher; Edvinsson, Lars; Goadsby, Peter J.; Michelson, David</div><div class="citationInfo"><span class="NLM_cas:title">Neurology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">83</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">958-966</span>CODEN:
                <span class="NLM_cas:coden">NEURAI</span>;
        ISSN:<span class="NLM_cas:issn">0028-3878</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Objective: To evaluate whether the calcitonin gene-related peptide (CGRP) receptor antagonist telcagepant might be effective for migraine prevention.  Methods: In this randomized, double-blind, placebo-controlled, multicenter trial (ClinicalTrials.gov NCT00797667), patients experiencing 3-14 migraine days during a 4-wk baseline were randomized to telcagepant 140 mg, telcagepant 280 mg, or placebo twice daily for 12 wk.  Efficacy was assessed by mean monthly headache days and migraine/probable migraine days (headache plus ≥1 assocd. symptom).  Results: The trial was terminated following a recommendation from the Safety Monitoring Board due to hepatotoxicity concerns.  At termination, the planned 660 patients had been randomized, 656 had been treated with ≥1 dose of study medication, and 14 had completed the trial.  The mean treatment duration was 48-50 days.  Thirteen patients, all in the telcagepant groups, had an alanine aminotransferase (ALT) elevation ≥3× the upper limit of normal and 7 of these also had an aspartate aminotransferase elevation ≥3× the upper limit of normal.  Two patients had very high symptomatic transaminase elevations that occurred within 2-6 wk of treatment initiation and resolved after treatment discontinuation.  The originally planned efficacy anal. over 12 wk was not performed due to limited data at later time points, but there was evidence that telcagepant resulted in a larger redn. from baseline than placebo for mean monthly headache days (month 1: 140 mg = -2.9, 280 mg = -3.1, placebo = -1.7; p < 0.05) and migraine/probable migraine days (month 1: 140 mg = -2.7, 280 mg = -3.0, placebo = -1.6; p < 0.05).  Conclusions: These data suggest a potential role for CGRP receptor antagonism in migraine prophylaxis.  However, the obsd. aminotransferase elevations do not support the use of telcagepant for daily administration.  Classification of evidence: This study provides Class II evidence that in patients with migraine, telcagepant taken daily reduces headache days by 1.4 days per mo compared to placebo and causes 2.5% of patients to have elevations of serum ALT levels.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNEH1T2nja2bVg90H21EOLACvtfcHk0ljMvCya58rBFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFert7bJ&md5=66d4abf9a3373373a1f18c3bd56487f5</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1212%2FWNL.0000000000000771&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1212%252FWNL.0000000000000771%26sid%3Dliteratum%253Aachs%26aulast%3DHo%26aufirst%3DT.%2BW.%26aulast%3DConnor%26aufirst%3DK.%2BM.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DPearlman%26aufirst%3DE.%26aulast%3DKoppenhaver%26aufirst%3DJ.%26aulast%3DFan%26aufirst%3DX.%2BY.%26aulast%3DLines%26aufirst%3DC.%26aulast%3DEdvinsson%26aufirst%3DL.%26aulast%3DGoadsby%26aufirst%3DP.%2BJ.%26aulast%3DMichelson%26aufirst%3DD.%26atitle%3DRandomized%2520controlled%2520trial%2520of%2520the%2520CGRP%2520receptor%2520antagonist%2520telcagepant%2520for%2520migraine%2520prevention%26jtitle%3DNeurology%26date%3D2014%26volume%3D83%26spage%3D958%26epage%3D966%26doi%3D10.1212%2FWNL.0000000000000771" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bell, I. M.</span></span> <span> </span><span class="NLM_article-title">Calcitonin gene-related peptide receptor antagonists: new therapeutic agents for migraine</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">7838</span>– <span class="NLM_lpage">7858</span>, <span class="refDoi"> DOI: 10.1021/jm500364u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500364u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVentb7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=7838-7858&author=I.+M.+Bell&title=Calcitonin+gene-related+peptide+receptor+antagonists%3A+new+therapeutic+agents+for+migraine&doi=10.1021%2Fjm500364u"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Calcitonin Gene-Related Peptide Receptor Antagonists: New Therapeutic Agents for Migraine</span></div><div class="casAuthors">Bell, Ian M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">7838-7858</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Calcitonin gene-related peptide (CGRP) is a potent neuromodulator and vasodilator.  It has been implicated in the pathogenesis of migraine by a no. of lines of evidence, although its precise role has yet to be fully defined.  Compelling evidence for the importance of CGRP in migraine has been provided by clin. trials with multiple small mol. CGRP receptor antagonists.  These clin. studies have shown that blockade of the CGRP receptor can produce antimigraine efficacy comparable to that of the gold std. triptan class of drugs with an incidence of adverse events that appears to be relatively low.  The present review describes the discovery and development of these new antimigraine agents and highlights the challenges of identifying orally acting drugs that target a family B G-protein-coupled receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqyCZ6aYV8RgbVg90H21EOLACvtfcHk0lgaKPfRGS7ZIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVentb7O&md5=ef228d3b829dd642d50eb00e6868ac82</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Fjm500364u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500364u%26sid%3Dliteratum%253Aachs%26aulast%3DBell%26aufirst%3DI.%2BM.%26atitle%3DCalcitonin%2520gene-related%2520peptide%2520receptor%2520antagonists%253A%2520new%2520therapeutic%2520agents%2520for%2520migraine%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D7838%26epage%3D7858%26doi%3D10.1021%2Fjm500364u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Karsan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goadsby, P. J.</span></span> <span> </span><span class="NLM_article-title">Calcitonin gene-related peptide and migraine</span>. <i>Curr. Opin. Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">250</span>– <span class="NLM_lpage">254</span>, <span class="refDoi"> DOI: 10.1097/WCO.0000000000000191</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=10.1097%2FWCO.0000000000000191" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=25887765" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=1%3ACAS%3A528%3ADC%252BC2MXns1Ggsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2015&pages=250-254&author=N.+Karsanauthor=P.+J.+Goadsby&title=Calcitonin+gene-related+peptide+and+migraine&doi=10.1097%2FWCO.0000000000000191"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Calcitonin gene-related peptide and migraine</span></div><div class="casAuthors">Karsan, Nazia; Goadsby, Peter J.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Neurology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">250-254</span>CODEN:
                <span class="NLM_cas:coden">CONEEX</span>;
        ISSN:<span class="NLM_cas:issn">1350-7540</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">A review.  Purpose of review: Migraine is a common, complex disorder of the brain with significant morbidity.  As the pathophysiol. of the disorder has become better appreciated, the role of neuropeptides has been explored.  Calcitonin gene-related peptide (CGRP) has emerged as a promising therapeutic target.  Recent findings: CGRP is widely distributed in the nervous system, particularly at anatomical areas thought to be involved with migraine, including the trigeminovascular nociceptive system.  In studies, CGRP has been shown to be released during severe migraine attacks, and effective triptan treatment of an attack normalizes these levels.  CGRP administration triggers migraine in patients and CGRP receptor antagonists can abort migraine.  Moreover, recent data demonstrate that CGRP mechanism blockade either by small mol. receptor antagonists or by monoclonal antibodies can have a preventive effect in migraine.  Summary: This article highlights the evidence behind the role of CGRP in migraine and the state of CGRP-based mechanism treatment development.  We present a summary of the evidence base behind CGRP in migraine pathophysiol. and the novel CGRP mechanism drugs and their potential future contribution to migraine management in our clin. practice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-3EyuX74g5bVg90H21EOLACvtfcHk0lgaKPfRGS7ZIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXns1Ggsbc%253D&md5=fb23b2333e4417b3789bfe27f604ef4d</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1097%2FWCO.0000000000000191&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FWCO.0000000000000191%26sid%3Dliteratum%253Aachs%26aulast%3DKarsan%26aufirst%3DN.%26aulast%3DGoadsby%26aufirst%3DP.%2BJ.%26atitle%3DCalcitonin%2520gene-related%2520peptide%2520and%2520migraine%26jtitle%3DCurr.%2520Opin.%2520Neurol.%26date%3D2015%26volume%3D28%26spage%3D250%26epage%3D254%26doi%3D10.1097%2FWCO.0000000000000191" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ho, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Assaid, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gottwald, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacGregor, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mannix, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Oosterhout, W. P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koppenhaver, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lines, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrari, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michelson, D.</span></span> <span> </span><span class="NLM_article-title">Randomized controlled trial of the CGRP receptor antagonist telcagepant for prevention of headache in women with perimenstrual migraine</span>. <i>Cephalalgia</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">148</span>– <span class="NLM_lpage">161</span>, <span class="refDoi"> DOI: 10.1177/0333102415584308</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=10.1177%2F0333102415584308" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=25926620" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=1%3ACAS%3A280%3ADC%252BC2MjptVyqug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2016&pages=148-161&author=T.+W.+Hoauthor=A.+P.+Hoauthor=Y.+Geauthor=C.+Assaidauthor=R.+Gottwaldauthor=E.+A.+MacGregorauthor=L.+K.+Mannixauthor=W.+P.+J.+van+Oosterhoutauthor=J.+Koppenhaverauthor=C.+Linesauthor=M.+D.+Ferrariauthor=D.+Michelson&title=Randomized+controlled+trial+of+the+CGRP+receptor+antagonist+telcagepant+for+prevention+of+headache+in+women+with+perimenstrual+migraine&doi=10.1177%2F0333102415584308"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Randomized controlled trial of the CGRP receptor antagonist telcagepant for prevention of headache in women with perimenstrual migraine</span></div><div class="casAuthors">Ho Tony W; Ho Andrew P; Ge Yang Joy; Assaid Christopher; Gottwald Regina; Koppenhaver Janelle; Lines Christopher; Michelson David; MacGregor E Anne; Mannix Lisa K; van Oosterhout Willebrordus P J; Ferrari Michel D</div><div class="citationInfo"><span class="NLM_cas:title">Cephalalgia : an international journal of headache</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">148-61</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">AIM:  The aim of this article is to evaluate the safety and efficacy of perimenstrual telcagepant, a CGRP receptor antagonist, for headache prophylaxis.  METHODS:  We conducted a randomized, double-blind, placebo-controlled, six-month trial in women with migraine for ≥ 3 months who experienced perimenstrual headaches.  Women were randomized to telcagepant 140 mg or placebo (2:1 ratio) for seven consecutive days perimenstrually.  Safety was assessed by adverse events and laboratory tests.  The primary efficacy endpoint was mean monthly headache days in the subset of women reporting perimenstrual migraine (-2 days to +3 days of menses onset) and ≥ 5 moderate or severe migraines per month prior to entering the trial.  RESULTS:  Telcagepant was generally well tolerated: 66/2660 (2.5%) on telcagepant and 36/1326 (2.7%) on placebo discontinued because of a clinical adverse event.  The percentages of patients with clinical adverse events, laboratory adverse events, or discontinuation because of a laboratory adverse event were also similar between treatments.  Alanine aminotransferase elevations ≥ 3x normal occurred in 0.6% of women on telcagepant and 0.4% on placebo.  Three women on telcagepant vs none on placebo had alanine aminotransferase elevations ≥ 8× normal.  In the efficacy subset there was no significant effect of telcagepant (n = 887) vs placebo (n = 447) in mean monthly headache days (treatment difference -0.5 day (95% CI: -1.1, 0.1)).  However, telcagepant was associated with a reduction in on-drug headache days (treatment difference -0.4 day (95% CI: -0.5, -0.2), nominal p < 0.001).  CONCLUSIONS:  Telcagepant 140 mg taken perimenstrually for seven days was generally well tolerated, but was associated with transaminase elevations.  Telcagepant did not reduce monthly headache frequency, but did reduce perimenstrual headaches.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcREYn0dkl_4ba__Jf7-eMvJfW6udTcc2eYww_lDmskak7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MjptVyqug%253D%253D&md5=7dc9df49ef57fb7afd44af098814468a</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1177%2F0333102415584308&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0333102415584308%26sid%3Dliteratum%253Aachs%26aulast%3DHo%26aufirst%3DT.%2BW.%26aulast%3DHo%26aufirst%3DA.%2BP.%26aulast%3DGe%26aufirst%3DY.%26aulast%3DAssaid%26aufirst%3DC.%26aulast%3DGottwald%26aufirst%3DR.%26aulast%3DMacGregor%26aufirst%3DE.%2BA.%26aulast%3DMannix%26aufirst%3DL.%2BK.%26aulast%3Dvan%2BOosterhout%26aufirst%3DW.%2BP.%2BJ.%26aulast%3DKoppenhaver%26aufirst%3DJ.%26aulast%3DLines%26aufirst%3DC.%26aulast%3DFerrari%26aufirst%3DM.%2BD.%26aulast%3DMichelson%26aufirst%3DD.%26atitle%3DRandomized%2520controlled%2520trial%2520of%2520the%2520CGRP%2520receptor%2520antagonist%2520telcagepant%2520for%2520prevention%2520of%2520headache%2520in%2520women%2520with%2520perimenstrual%2520migraine%26jtitle%3DCephalalgia%26date%3D2016%26volume%3D36%26spage%3D148%26epage%3D161%26doi%3D10.1177%2F0333102415584308" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Croop, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goadsby, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stock, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conway, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forshaw, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stock, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coric, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lipton, R. B.</span></span> <span> </span><span class="NLM_article-title">Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>394</i></span>,  <span class="NLM_fpage">737</span>– <span class="NLM_lpage">745</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(19)31606-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=10.1016%2FS0140-6736%2819%2931606-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=31311674" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlOjtrvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=394&publication_year=2019&pages=737-745&author=R.+Croopauthor=P.+J.+Goadsbyauthor=D.+A.+Stockauthor=C.+M.+Conwayauthor=M.+Forshawauthor=E.+G.+Stockauthor=V.+Coricauthor=R.+B.+Lipton&title=Efficacy%2C+safety%2C+and+tolerability+of+rimegepant+orally+disintegrating+tablet+for+the+acute+treatment+of+migraine%3A+a+randomised%2C+phase+3%2C+double-blind%2C+placebo-controlled+trial&doi=10.1016%2FS0140-6736%2819%2931606-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial</span></div><div class="casAuthors">Croop, Robert; Goadsby, Peter J.; Stock, David A.; Conway, Charles M.; Forshaw, Micaela; Stock, Elyse G.; Coric, Vladimir; Lipton, Richard B.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">394</span>
        (<span class="NLM_cas:issue">10200</span>),
    <span class="NLM_cas:pages">737-745</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">In this double-blind, randomised, placebo-controlled, multicentre phase 3 trial, adults aged 18 years or older with history of migraine of at least 1 yr were recruited to 69 study centers in the USA.  This study is registered with ClinicalTrials.gov, no. NCT03461757, and is closed to accrual.  Between Feb 27 and Aug 28, 2018, 1811 participants were recruited and assessed for eligibility. 1466 participants were randomly assigned to the rimegepant (n=732) or placebo (n=734) groups, of whom 1375 received treatment with rimegepant (n=682) or placebo (n=693), and 1351 were evaluated for efficacy (rimegepant n=669, placebo n=682).  At 2 h postdose, rimegepant orally disintegrating tablet was superior to placebo for freedom from pain (21% vs 11%, p<0·0001; risk difference 10, 95% CI 6-14) and freedom from the most bothersome symptom (35% vs 27%, p=0·0009; risk difference 8, 95% CI 3-13).  The most common adverse events were nausea (rimegepant n=11 [2%]; placebo n=3 [<1%]) and UTI (rimegepant n=10 [1%]; placebo n=4 [1%]).  Each treatment group had a transaminase concn. of more than 3 × the upper limit of normal; neither was related to study medication, and no elevations in bilirubin greater than 2 × the upper limit of normal were reported.  In the acute treatment of migraine, a single 75 mg dose of rimegepant in an orally disintegrating tablet formulation was more effective than placebo.  Tolerability was similar to placebo, with no safety concerns.Biohaven Pharmaceuticals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoidQI9-1-aZLVg90H21EOLACvtfcHk0lh8VwphnqiiIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlOjtrvL&md5=37885d5210b0c9bf3da45d477bc27c8e</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2819%2931606-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252819%252931606-X%26sid%3Dliteratum%253Aachs%26aulast%3DCroop%26aufirst%3DR.%26aulast%3DGoadsby%26aufirst%3DP.%2BJ.%26aulast%3DStock%26aufirst%3DD.%2BA.%26aulast%3DConway%26aufirst%3DC.%2BM.%26aulast%3DForshaw%26aufirst%3DM.%26aulast%3DStock%26aufirst%3DE.%2BG.%26aulast%3DCoric%26aufirst%3DV.%26aulast%3DLipton%26aufirst%3DR.%2BB.%26atitle%3DEfficacy%252C%2520safety%252C%2520and%2520tolerability%2520of%2520rimegepant%2520orally%2520disintegrating%2520tablet%2520for%2520the%2520acute%2520treatment%2520of%2520migraine%253A%2520a%2520randomised%252C%2520phase%25203%252C%2520double-blind%252C%2520placebo-controlled%2520trial%26jtitle%3DLancet%26date%3D2019%26volume%3D394%26spage%3D737%26epage%3D745%26doi%3D10.1016%2FS0140-6736%2819%2931606-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scott, L. J.</span></span> <span> </span><span class="NLM_article-title">Ubrogepant: first approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>80</i></span>,  <span class="NLM_fpage">323</span>– <span class="NLM_lpage">328</span>, <span class="refDoi"> DOI: 10.1007/s40265-020-01264-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=10.1007%2Fs40265-020-01264-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=32020557" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=1%3ACAS%3A280%3ADC%252BB38%252FotlKlsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2020&pages=323-328&author=L.+J.+Scott&title=Ubrogepant%3A+first+approval&doi=10.1007%2Fs40265-020-01264-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Ubrogepant: First Approval</span></div><div class="casAuthors">Scott Lesley J</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">80</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">323-328</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Ubrogepant (Ubrelvy®) is an orally administered, small molecule, highly-selective, calcitonin gene-related peptide (CGRP) antagonist that was developed by Allergan under license to Merck & Co. as an acute treatment for migraine.  In December 2019, ubrogepant received its first global approval in the USA for the acute treatment of migraine (± aura) in adults.  This article summarizes the milestones in the development of ubrogepant leading to its first global approval for the acute treatment of migraine (± aura) in adults.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTbpElibNSrFMvLc4ARHEmzfW6udTcc2eYWtXJgY-URLbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB38%252FotlKlsA%253D%253D&md5=dee277e0c6d6835ea105dbb4024f8a92</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1007%2Fs40265-020-01264-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-020-01264-5%26sid%3Dliteratum%253Aachs%26aulast%3DScott%26aufirst%3DL.%2BJ.%26atitle%3DUbrogepant%253A%2520first%2520approval%26jtitle%3DDrugs%26date%3D2020%26volume%3D80%26spage%3D323%26epage%3D328%26doi%3D10.1007%2Fs40265-020-01264-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ornello, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casalena, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frattale, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabriele, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Affaitati, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giamberardino, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Assetta, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maddestra, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marzoli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viola, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cerone, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marini, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pistoia, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sacco, S.</span></span> <span> </span><span class="NLM_article-title">Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy</span>. <i>J. Headache Pain</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>21</i></span>, <span class="NLM_elocation-id">32</span> <span class="refDoi"> DOI: 10.1186/s10194-020-01102-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=10.1186%2Fs10194-020-01102-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=32264820" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=1%3ACAS%3A528%3ADC%252BB3cXms1Srtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2020&author=R.+Ornelloauthor=A.+Casalenaauthor=I.+Frattaleauthor=A.+Gabrieleauthor=G.+Affaitatiauthor=M.+A.+Giamberardinoauthor=M.+Assettaauthor=M.+Maddestraauthor=F.+Marzoliauthor=S.+Violaauthor=D.+Ceroneauthor=C.+Mariniauthor=F.+Pistoiaauthor=S.+Sacco&title=Real-life+data+on+the+efficacy+and+safety+of+erenumab+in+the+Abruzzo+region%2C+central+Italy&doi=10.1186%2Fs10194-020-01102-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy</span></div><div class="casAuthors">Ornello, Raffaele; Casalena, Alfonsina; Frattale, Ilaria; Gabriele, Amleto; Affaitati, Giannapia; Giamberardino, Maria Adele; Assetta, Maurizio; Maddestra, Maurizio; Marzoli, Fabio; Viola, Stefano; Cerone, Davide; Marini, Carmine; Pistoia, Francesca; Sacco, Simona</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Headache and Pain</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">32</span>CODEN:
                <span class="NLM_cas:coden">JHPOAT</span>;
        ISSN:<span class="NLM_cas:issn">1129-2369</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">We aimed to assess the efficacy and safety of erenumab, a fully human monoclonal antibody inhibiting the calcitonin gene-related peptide receptor (CGRPr), for the prevention of migraine in a real-life setting.  We included in our observational study all patients with episodic or chronic migraine treated with erenumab during the year 2019 in the Abruzzo region, central Italy, and with a 6-mo follow-up.  We included 89 patients; 76 (85.4%) received 6 doses of erenumab, 11 (12.4%) autonomously withdrew the drug due to perceived inefficacy, and 2 (2.2%) due to adverse events.  Seventy-eight patients (87.6%) were female, with a mean age of 46.8 ± 11.2 years; 84 (94.4%) had chronic migraine, and 64 (71.9%) medication overuse.  Fifty-three patients had a 50% decrease in monthly migraine days (MMDs) within the first three doses; 46 of 64 patients withdrew medication overuse.  In the 76 patients who completed a 6-dose treatment, erenumab decreased median MMDs from 19 (interquartile range [IQR] 12-27.5) to 4 (IQR 2-9.5; P < 0.001), median monthly days of analgesic use from 10, and median monthly days of triptan use from 5 (IQR 0-15.5) to 1 (IQR 0-4; P < 0.001).  We recorded 27 adverse events in 20 (22.5%) patients, the most common being constipation (13.5%).  Our real-life data confirm the efficacy and tolerability of erenumab for the prevention of migraine in a difficult-to-treat population of patients with a high prevalence of chronic migraine and medication overuse.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmOonB2vGajLVg90H21EOLACvtfcHk0lh8VwphnqiiIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXms1Srtr8%253D&md5=898468bba5d28a0cb07d3626c7ddd9c6</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1186%2Fs10194-020-01102-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs10194-020-01102-9%26sid%3Dliteratum%253Aachs%26aulast%3DOrnello%26aufirst%3DR.%26aulast%3DCasalena%26aufirst%3DA.%26aulast%3DFrattale%26aufirst%3DI.%26aulast%3DGabriele%26aufirst%3DA.%26aulast%3DAffaitati%26aufirst%3DG.%26aulast%3DGiamberardino%26aufirst%3DM.%2BA.%26aulast%3DAssetta%26aufirst%3DM.%26aulast%3DMaddestra%26aufirst%3DM.%26aulast%3DMarzoli%26aufirst%3DF.%26aulast%3DViola%26aufirst%3DS.%26aulast%3DCerone%26aufirst%3DD.%26aulast%3DMarini%26aufirst%3DC.%26aulast%3DPistoia%26aufirst%3DF.%26aulast%3DSacco%26aufirst%3DS.%26atitle%3DReal-life%2520data%2520on%2520the%2520efficacy%2520and%2520safety%2520of%2520erenumab%2520in%2520the%2520Abruzzo%2520region%252C%2520central%2520Italy%26jtitle%3DJ.%2520Headache%2520Pain%26date%3D2020%26volume%3D21%26doi%3D10.1186%2Fs10194-020-01102-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lipton, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goadsby, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaeffler, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biondi, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pederson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cady, R.</span></span> <span> </span><span class="NLM_article-title">Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2</span>. <i>Neurology</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>94</i></span>,  <span class="NLM_fpage">E1365</span>– <span class="NLM_lpage">E1377</span>, <span class="refDoi"> DOI: 10.1212/WNL.0000000000009169</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=10.1212%2FWNL.0000000000009169" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=32209650" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=1%3ACAS%3A528%3ADC%252BB3cXlvVGns7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=2020&pages=E1365-E1377&author=R.+B.+Liptonauthor=P.+J.+Goadsbyauthor=J.+Smithauthor=B.+A.+Schaefflerauthor=D.+M.+Biondiauthor=J.+Hirmanauthor=S.+Pedersonauthor=B.+Allanauthor=R.+Cady&title=Efficacy+and+safety+of+eptinezumab+in+patients+with+chronic+migraine%3A+PROMISE-2&doi=10.1212%2FWNL.0000000000009169"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2</span></div><div class="casAuthors">Lipton, Richard B.; Goadsby, Peter J.; Smith, Jeff; Schaeffler, Barbara A.; Biondi, David M.; Hirman, Joe; Pederson, Susan; Allan, Brent; Cady, Roger</div><div class="citationInfo"><span class="NLM_cas:title">Neurology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">e1365-e1377</span>CODEN:
                <span class="NLM_cas:coden">NEURAI</span>;
        ISSN:<span class="NLM_cas:issn">0028-3878</span>.
    
            (<span class="NLM_cas:orgname">Wolters Kluwer</span>)
        </div><div class="casAbstract">Objective: To evaluate the efficacy and safety of eptinezumab, a humanized anti-calcitonin gene-related peptide monoclonal antibody, in the preventive treatment of chronic migraine (CM).  Methods: The Prevention of Migraine via I.v. ALD403 Safety and Efficacy-2 (PROMISE-2) study was a phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.  Adults with CM were randomly assigned to receive IV eptinezumab 100 mg, eptinezumab 300 mg, or placebo administered on day 0 and week 12.  The primary endpoint was change from baseline in mean monthly migraine days (MMDs) over weeks 1 to 12.  Results: Among treated participants (n = 1,072), baseline mean no. of MMDs was ≈16.1 across groups.  Treatment with eptinezumab 100 and 300 mg was assocd. with significant redns. in MMDs across weeks 1 to 12 compared with placebo (placebo -5.6, 100 mg -7.7, p < 0.0001 vs placebo; 300 mg -8.2, p < 0.0001 vs placebo).  Treatment-emergent adverse events (TEAEs) were reported by 43.5% (100 mg), 52.0% (300 mg), and 46.7% (placebo) of patients.  Nasopharyngitis was the only TEAE reported for >2% of eptinezumab-treated patients at an incidence of >2% over placebo; it occurred in the 300 mg eptinezumab arm (eptinezumab 9.4%, placebo 6.0%).  Conclusion: In patients with CM, eptinezumab 100 and 300 mg was assocd. with a significant redn. in MMDs from the day after IV administration through week 12, was well tolerated, and demonstrated an acceptable safety profile.  Classification of evidence: This study provides Class I evidence that for patients with CM, a single dose of eptinezumab reduces MMDs over 12 wk of treatment.  CLINICALTRIALS.GOV Identifier: NCT02974153.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6BTPomCLBR7Vg90H21EOLACvtfcHk0lhMlkBj2HD0Uw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXlvVGns7Y%253D&md5=a9373129ed07d44034c0662b3c9abeaf</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1212%2FWNL.0000000000009169&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1212%252FWNL.0000000000009169%26sid%3Dliteratum%253Aachs%26aulast%3DLipton%26aufirst%3DR.%2BB.%26aulast%3DGoadsby%26aufirst%3DP.%2BJ.%26aulast%3DSmith%26aufirst%3DJ.%26aulast%3DSchaeffler%26aufirst%3DB.%2BA.%26aulast%3DBiondi%26aufirst%3DD.%2BM.%26aulast%3DHirman%26aufirst%3DJ.%26aulast%3DPederson%26aufirst%3DS.%26aulast%3DAllan%26aufirst%3DB.%26aulast%3DCady%26aufirst%3DR.%26atitle%3DEfficacy%2520and%2520safety%2520of%2520eptinezumab%2520in%2520patients%2520with%2520chronic%2520migraine%253A%2520PROMISE-2%26jtitle%3DNeurology%26date%3D2020%26volume%3D94%26spage%3DE1365%26epage%3DE1377%26doi%3D10.1212%2FWNL.0000000000009169" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bangs, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kudrow, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oakes, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terwindt, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magis, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yunes-Medina, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stauffer, V. L.</span></span> <span> </span><span class="NLM_article-title">Safety and tolerability of monthly galcanezumab injections in patients with migraine: integrated results from migraine clinical studies</span>. <i>BMC Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>20</i></span>, <span class="NLM_elocation-id">25</span> <span class="refDoi"> DOI: 10.1186/s12883-020-1609-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=10.1186%2Fs12883-020-1609-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=31952501" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=1%3ACAS%3A528%3ADC%252BB3cXkslCns78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2020&author=M.+E.+Bangsauthor=D.+Kudrowauthor=S.+Wangauthor=T.+M.+Oakesauthor=G.+M.+Terwindtauthor=D.+Magisauthor=L.+Yunes-Medinaauthor=V.+L.+Stauffer&title=Safety+and+tolerability+of+monthly+galcanezumab+injections+in+patients+with+migraine%3A+integrated+results+from+migraine+clinical+studies&doi=10.1186%2Fs12883-020-1609-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Safety and tolerability of monthly galcanezumab injections in patients with migraine: integrated results from migraine clinical studies</span></div><div class="casAuthors">Bangs, Mark E.; Kudrow, David; Wang, Shufang; Oakes, Tina M.; Terwindt, Gisela M.; Magis, Delphine; Yunes-Medina, Laura; Stauffer, Virginia L.</div><div class="citationInfo"><span class="NLM_cas:title">BMC Neurology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">25</span>CODEN:
                <span class="NLM_cas:coden">BNMEC8</span>;
        ISSN:<span class="NLM_cas:issn">1471-2377</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Abstr.: Background: Galcanezumab, a humanized monoclonal antibody that selectively binds to calcitonin gene-related peptide, has demonstrated a significant redn. in monthly migraine headache days in phase 2 and 3 trials.  In these analyses, we aimed to evaluate the safety and tolerability of galcanezumab compared with placebo for prevention of episodic or chronic migraine.  Methods: Data were integrated from three double-blind clin. studies for the up to 6-mo galcanezumab exposure group (N = 1435), and from five clin. studies for the up to 1-yr all-galcanezumab exposure group (N = 2276).  Patients received a monthly 120 mg s.c. injection of galcanezumab (with a 240 mg loading dose in month 1), 240 mg galcanezumab, or placebo.  Outcomes measured were treatment-emergent adverse events (TEAEs), serious AEs (SAEs), and discontinuation due to AEs (DCAEs).  Lab. results, vital signs, ECG (ECG), suicidal ideation and behavior results were evaluated.  Results: TEAEs that occurred more frequently in galcanezumab-treated patients included injection site pain, injection site reactions excluding pain, constipation, vertigo, and pruritus.  The proportion of DCAEs among galcanezumab-treated patients ranged between 1.8 and 3.0%, and differed from placebo group for galcanezumab 240 mg (P < 0.05).  Fewer than 2.0% of patients in either galcanezumab dose-group compared with 1.0% of placebo-treated patients reported a SAE.  There were no clin. meaningful differences between galcanezumab and placebo in lab. measures, vital signs including blood pressure, ECGs, cardiovascular-related AEs, or suicidal ideation and behavior.  Conclusions: Galcanezumab demonstrated a favorable safety and tolerability profile for up to 1 yr of treatment for the prevention of migraine.  Trial registration: Clin. Trials CGAB = NCT02163993, EVOLVE-1 = NCT02614183, EVOLVE-2 = NCT02614196, REGAIN = NCT02614261, and CGAJ = NCT02614287.  All were first posted on 25 Nov. 2015, except CGAB posted on 16 June 2014, and before enrolling the first patient.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpej1FhW5OZdrVg90H21EOLACvtfcHk0lhMlkBj2HD0Uw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXkslCns78%253D&md5=7228272780e5c059cba1c533a97fe011</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1186%2Fs12883-020-1609-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12883-020-1609-7%26sid%3Dliteratum%253Aachs%26aulast%3DBangs%26aufirst%3DM.%2BE.%26aulast%3DKudrow%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DOakes%26aufirst%3DT.%2BM.%26aulast%3DTerwindt%26aufirst%3DG.%2BM.%26aulast%3DMagis%26aufirst%3DD.%26aulast%3DYunes-Medina%26aufirst%3DL.%26aulast%3DStauffer%26aufirst%3DV.%2BL.%26atitle%3DSafety%2520and%2520tolerability%2520of%2520monthly%2520galcanezumab%2520injections%2520in%2520patients%2520with%2520migraine%253A%2520integrated%2520results%2520from%2520migraine%2520clinical%2520studies%26jtitle%3DBMC%2520Neurol.%26date%3D2020%26volume%3D20%26doi%3D10.1186%2Fs12883-020-1609-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Archbold, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flanagan, J. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gingell, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hay, D. L.</span></span> <span> </span><span class="NLM_article-title">Structural insights into RAMP modification of secretin family G protein-coupled receptors: implications for drug development</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">591</span>– <span class="NLM_lpage">600</span>, <span class="refDoi"> DOI: 10.1016/j.tips.2011.05.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=10.1016%2Fj.tips.2011.05.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=21722971" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1Gkur7N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2011&pages=591-600&author=J.+K.+Archboldauthor=J.+U.+Flanaganauthor=H.+A.+Watkinsauthor=J.+J.+Gingellauthor=D.+L.+Hay&title=Structural+insights+into+RAMP+modification+of+secretin+family+G+protein-coupled+receptors%3A+implications+for+drug+development&doi=10.1016%2Fj.tips.2011.05.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Structural insights into RAMP modification of secretin family G protein-coupled receptors: implications for drug development</span></div><div class="casAuthors">Archbold, Julia K.; Flanagan, Jack U.; Watkins, Harriet A.; Gingell, Joseph J.; Hay, Debbie L.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">591-600</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Secretin family G protein-coupled receptors (GPCRs) are important therapeutic targets for migraine, diabetes, bone disorders, inflammatory disorders and cardiovascular disease.  They possess a large N-terminal extracellular domain (ECD) known to be the primary ligand-binding determinant.  Structural detn. of several secretin family GPCR ECDs in complex with peptide ligands has been achieved recently, providing insight into the mol. determinants of hormone binding.  Some secretin family GPCRs assoc. with receptor activity-modifying proteins (RAMPs), resulting in changes to receptor pharmacol.  Recently, the first crystal structure of a RAMP ECD in complex with a secretin family GPCR was solved, revealing the elegant mechanism governing receptor selectivity of small mol. antagonists of the calcitonin gene-related peptide (CGRP) receptor.  Here we review the structural basis of ligand binding to secretin family GPCRs, concg. on recent progress made on the structural basis of RAMP-modified GPCR pharmacol. and its implications for rational drug design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYsel-YOVbvrVg90H21EOLACvtfcHk0lhMlkBj2HD0Uw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1Gkur7N&md5=b47c3f513ed3bb3e24558860b8341869</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2011.05.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2011.05.007%26sid%3Dliteratum%253Aachs%26aulast%3DArchbold%26aufirst%3DJ.%2BK.%26aulast%3DFlanagan%26aufirst%3DJ.%2BU.%26aulast%3DWatkins%26aufirst%3DH.%2BA.%26aulast%3DGingell%26aufirst%3DJ.%2BJ.%26aulast%3DHay%26aufirst%3DD.%2BL.%26atitle%3DStructural%2520insights%2520into%2520RAMP%2520modification%2520of%2520secretin%2520family%2520G%2520protein-coupled%2520receptors%253A%2520implications%2520for%2520drug%2520development%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2011%26volume%3D32%26spage%3D591%26epage%3D600%26doi%3D10.1016%2Fj.tips.2011.05.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brain, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grant, A. D.</span></span> <span> </span><span class="NLM_article-title">Vascular actions of calcitonin gene-related peptide and adrenomedullin</span>. <i>Physiol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>84</i></span>,  <span class="NLM_fpage">903</span>– <span class="NLM_lpage">934</span>, <span class="refDoi"> DOI: 10.1152/physrev.00037.2003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=10.1152%2Fphysrev.00037.2003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=15269340" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmtlCnu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=2004&pages=903-934&author=S.+D.+Brainauthor=A.+D.+Grant&title=Vascular+actions+of+calcitonin+gene-related+peptide+and+adrenomedullin&doi=10.1152%2Fphysrev.00037.2003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Vascular actions of calcitonin gene-related peptide and adrenomedullin</span></div><div class="casAuthors">Brain, Susan D.; Grant, Andrew D.</div><div class="citationInfo"><span class="NLM_cas:title">Physiological Reviews</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">84</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">903-934</span>CODEN:
                <span class="NLM_cas:coden">PHREA7</span>;
        ISSN:<span class="NLM_cas:issn">0031-9333</span>.
    
            (<span class="NLM_cas:orgname">American Physiological Society</span>)
        </div><div class="casAbstract">This review summarizes the receptor-mediated vascular activities of calcitonin gene-related peptide (CGRP) and the structurally related peptide adrenomedullin (AM).  CGRP is a 37-amino acid neuropeptide, primarily released from sensory nerves, while AM is produced by stimulated vascular cells, and amylin is secreted from the pancreas.  They share vasodilator activity, albeit to varying extents depending on species and tissue.  In particular, CGRP has potent activity in the cerebral circulation, which is possibly relevant to the pathol. of migraine, while vascular sources of AM contribute to dysfunction in cardiovascular disease.  Both peptides exhibit potent activity in microvascular beds.  All 3 peptides can act on a family of CGRP receptors that consist of calcitonin receptor-like receptor (CL) linked to one of 3 receptor activity-modifying proteins (RAMPs) that are essential for functional activity.  The assocn. of CL with RAMP1 produces a CGRP receptor, with RAMP2 an AM receptor and with RAMP3 a CGRP/AM receptor.  Evidence for the selective activity of the first nonpeptide CGRP antagonist BIBN4096BS for the CGRP receptor is presented.  The cardiovascular activity of these peptides in a range of species and in human clin. conditions is detailed, and potential therapeutic applications based on use of antagonists and gene targeting of agonists are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_Jum9315jsrVg90H21EOLACvtfcHk0lis06eRPllCnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmtlCnu7w%253D&md5=1912eea830cd128022bd2468cb4f31eb</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1152%2Fphysrev.00037.2003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fphysrev.00037.2003%26sid%3Dliteratum%253Aachs%26aulast%3DBrain%26aufirst%3DS.%2BD.%26aulast%3DGrant%26aufirst%3DA.%2BD.%26atitle%3DVascular%2520actions%2520of%2520calcitonin%2520gene-related%2520peptide%2520and%2520adrenomedullin%26jtitle%3DPhysiol.%2520Rev.%26date%3D2004%26volume%3D84%26spage%3D903%26epage%3D934%26doi%3D10.1152%2Fphysrev.00037.2003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shindo, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakurai, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamiyoshi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ichikawa-Shindo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimoyama, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iinuma, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arai, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyagawa, S.</span></span> <span> </span><span class="NLM_article-title">Regulation of adrenomedullin and its family peptide by RAMP system - lessons from genetically engineered mice</span>. <i>Curr. Protein Pept. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">347</span>– <span class="NLM_lpage">357</span>, <span class="refDoi"> DOI: 10.2174/13892037113149990052</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=10.2174%2F13892037113149990052" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=23745699" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1Gmu7fO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2013&pages=347-357&author=T.+Shindoauthor=T.+Sakuraiauthor=A.+Kamiyoshiauthor=Y.+Ichikawa-Shindoauthor=N.+Shimoyamaauthor=N.+Iinumaauthor=T.+Araiauthor=S.+Miyagawa&title=Regulation+of+adrenomedullin+and+its+family+peptide+by+RAMP+system+-+lessons+from+genetically+engineered+mice&doi=10.2174%2F13892037113149990052"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of Adrenomedullin and its Family Peptide by RAMP System - Lessons from Genetically Engineered Mice</span></div><div class="casAuthors">Shindo, Takayuki; Sakurai, Takayuki; Kamiyoshi, Akiko; Ichikawa-Shindo, Yuka; Shimoyama, Natsumi; Iinuma, Nobuyoshi; Arai, Takuma; Miyagawa, Shinichi</div><div class="citationInfo"><span class="NLM_cas:title">Current Protein and Peptide Science</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">347-357</span>CODEN:
                <span class="NLM_cas:coden">CPPSCM</span>;
        ISSN:<span class="NLM_cas:issn">1389-2037</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Adrenomedullin (ADM), originally identified as a vasodilating peptide, is now recognized to be a pleiotropic mol. involved in both the pathogenesis of cardiovascular diseases and circulatory homeostasis.  Homozygotes of ADM knockout mice (ADM-/-) were lethal at mid-gestation with abnormalities of vascular development and this finding clarified the angiogenic potency of ADM.  Calcitonin gene-related peptide (CGRP), which has a structure and function similar to that of ADM, has been identified as a family peptide of ADM.  Unlike ADM-/-, CGRP-/- were apparently normal.  Therefore, the study of knockout mice first clarified the distinctly different physiol. roles between ADM and CGRP.  In contrast, heterozygotes of ADM knockout mice (ADM+/-) were alive but showed blood pressure elevation, reduced neovascularization, and enhanced neointimal formation by arterial injury.  Based on these observations, there was hope ADM would have a therapeutic use.  However, ADM has a short half-life in the blood stream and its application in chronic disease has limitations.  Therefore, we focused on the ADM receptor system.  The calcitonin-receptor-like receptor (CLR), which is the ADM receptor, assocs. with one of the accessory proteins, called receptor activity-modifying proteins (RAMPs).  By interacting with RAMP1, CLR exhibits a high affinity for CGRP, whereas by interacting with either RAMP2 or -3, CLR exhibits a high affinity for ADM.  We generated RAMP knockout mice and found that vascular phenotypes similar to ADM-/- were reproduced only in RAMP2-/-.  This shows that RAMP2 is the key determinant of the vascular functions of ADM.  RAMP2 could be an attractive therapeutic target in cardiovascular diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpE847bSXcnx7Vg90H21EOLACvtfcHk0lis06eRPllCnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1Gmu7fO&md5=a4bea647953bafbea570a7f02366009e</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.2174%2F13892037113149990052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F13892037113149990052%26sid%3Dliteratum%253Aachs%26aulast%3DShindo%26aufirst%3DT.%26aulast%3DSakurai%26aufirst%3DT.%26aulast%3DKamiyoshi%26aufirst%3DA.%26aulast%3DIchikawa-Shindo%26aufirst%3DY.%26aulast%3DShimoyama%26aufirst%3DN.%26aulast%3DIinuma%26aufirst%3DN.%26aulast%3DArai%26aufirst%3DT.%26aulast%3DMiyagawa%26aufirst%3DS.%26atitle%3DRegulation%2520of%2520adrenomedullin%2520and%2520its%2520family%2520peptide%2520by%2520RAMP%2520system%2520-%2520lessons%2520from%2520genetically%2520engineered%2520mice%26jtitle%3DCurr.%2520Protein%2520Pept.%2520Sci.%26date%3D2013%26volume%3D14%26spage%3D347%26epage%3D357%26doi%3D10.2174%2F13892037113149990052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Larráyoz, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martínez-Herrero, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">García-Sanmartín, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ochoa-Callejero, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martínez, A.</span></span> <span> </span><span class="NLM_article-title">Adrenomedullin and tumour microenvironment</span>. <i>J. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>12</i></span>, <span class="NLM_elocation-id">339</span> <span class="refDoi"> DOI: 10.1186/s12967-014-0339-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=10.1186%2Fs12967-014-0339-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=25475159" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=1%3ACAS%3A528%3ADC%252BC2MXit1OitLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2014&author=I.+M.+Larr%C3%A1yozauthor=S.+Mart%C3%ADnez-Herreroauthor=J.+Garc%C3%ADa-Sanmart%C3%ADnauthor=L.+Ochoa-Callejeroauthor=A.+Mart%C3%ADnez&title=Adrenomedullin+and+tumour+microenvironment&doi=10.1186%2Fs12967-014-0339-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Adrenomedullin and tumour microenvironment</span></div><div class="casAuthors">Larrayoz, Ignacio M.; Martinez-Herrero, Sonia; Garcia-Sanmartin, Josune; Ochoa-Callejero, Laura; Martinez, Alfredo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Translational Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">339/1-339/33, 33 pp.</span>CODEN:
                <span class="NLM_cas:coden">JTMOBV</span>;
        ISSN:<span class="NLM_cas:issn">1479-5876</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">A review.  Adrenomedullin (AM) is a regulatory peptide whose involvement in tumor progression is becoming more relevant with recent studies.  AM is produced and secreted by the tumor cells but also by numerous stromal cells including macrophages, mast cells, endothelial cells, and vascular smooth muscle cells.  Most cancer patients present high levels of circulating AM and in some cases these higher levels correlate with a worst prognosis.  In some cases it has been shown that the high AM levels return to normal following surgical removal of the tumor, thus indicating the tumor as the source of this excessive prodn. of AM.  Expression of this peptide is a good investment for the tumor cell since AM acts as an autocrine/paracrine growth factor, prevents apoptosis-mediated cell death, increases tumor cell motility and metastasis, induces angiogenesis, and blocks immunosurveillance by inhibiting the immune system.  In addn., AM expression gets rapidly activated by hypoxia through a HIF-1α mediated mechanism, thus characterizing AM as a major survival factor for tumor cells.  Accordingly, a no. of studies have shown that inhibition of this peptide or its receptors results in a significant redn. in tumor progression.  In conclusion, AM is a great target for drug development and new drugs interfering with this system are being developed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr03Zy8I9oN27Vg90H21EOLACvtfcHk0lis06eRPllCnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXit1OitLY%253D&md5=4f1143a6a72d68da71b3ee062bcb9fd2</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1186%2Fs12967-014-0339-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12967-014-0339-2%26sid%3Dliteratum%253Aachs%26aulast%3DLarr%25C3%25A1yoz%26aufirst%3DI.%2BM.%26aulast%3DMart%25C3%25ADnez-Herrero%26aufirst%3DS.%26aulast%3DGarc%25C3%25ADa-Sanmart%25C3%25ADn%26aufirst%3DJ.%26aulast%3DOchoa-Callejero%26aufirst%3DL.%26aulast%3DMart%25C3%25ADnez%26aufirst%3DA.%26atitle%3DAdrenomedullin%2520and%2520tumour%2520microenvironment%26jtitle%3DJ.%2520Transl.%2520Med.%26date%3D2014%26volume%3D12%26doi%3D10.1186%2Fs12967-014-0339-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hay, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poyner, D. R.</span></span> <span> </span><span class="NLM_article-title">Adrenomedullin and calcitonin gene-related peptide receptors in endocrine-related cancers: opportunities and challenges</span>. <i>Endocr.-Relat. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">C1</span>– <span class="NLM_lpage">C14</span>, <span class="refDoi"> DOI: 10.1677/ERC-10-0244</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=10.1677%2FERC-10-0244" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=21051558" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjsFWqtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2011&pages=C1-C14&author=D.+L.+Hayauthor=C.+S.+Walkerauthor=D.+R.+Poyner&title=Adrenomedullin+and+calcitonin+gene-related+peptide+receptors+in+endocrine-related+cancers%3A+opportunities+and+challenges&doi=10.1677%2FERC-10-0244"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Adrenomedullin and calcitonin gene-related peptide receptors in endocrine-related cancers: opportunities and challenges</span></div><div class="casAuthors">Hay, Debbie L.; Walker, Christopher S.; Poyner, David R.</div><div class="citationInfo"><span class="NLM_cas:title">Endocrine-Related Cancer</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">C1-C14</span>CODEN:
                <span class="NLM_cas:coden">ERCAE9</span>;
        ISSN:<span class="NLM_cas:issn">1351-0088</span>.
    
            (<span class="NLM_cas:orgname">BioScientifica Ltd.</span>)
        </div><div class="casAbstract">A review.  Adrenomedullin (AM), adrenomedullin 2 (AM2/intermedin) and calcitonin gene-related peptide (CGRP) are members of the calcitonin family of peptides.  They can act as growth or survival factors for a no. of tumors, including those that are endocrine-related.  One mechanism through which this occurs is stimulating angiogenesis and lymphangiogenesis.  AM is expressed by numerous tumor types and for some cancers, plasma AM levels can be correlated with the severity of the disease.  In cancer models, lowering AM content or blocking AM receptors can reduce tumor mass.  AM receptors are complexes formed between a seven transmembrane protein, calcitonin receptor-like receptor and one of the two accessory proteins, receptor activity-modifying proteins (RAMPs) 2 or 3 to give the AM1 and AM2 receptors resp.  AM also has affinity at the CGRP receptor, which uses RAMP1.  Unfortunately, due to a lack of selective pharmacol. tools or antibodies to distinguish AM and CGRP receptors, the precise receptors and signal transduction pathways used by the peptides are often uncertain.  Two other membrane proteins, RDC1 and L1/G10D (the 'ADMR'), are not currently considered to be genuine CGRP or AM receptors.  In order to properly evaluate whether AM or CGRP receptor inhibition has a role in cancer therapy, it is important to identify which receptors mediate the effects of these peptides.  To effectively distinguish AM1 and AM2 receptors, selective receptor antagonists need to be developed.  The development of specific CGRP receptor antagonists suggests that this is now feasible.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVRGmWq_pGxrVg90H21EOLACvtfcHk0liPdjLkp6Fs_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjsFWqtLY%253D&md5=0b7543a7b04991ae89eb351493b65c43</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1677%2FERC-10-0244&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1677%252FERC-10-0244%26sid%3Dliteratum%253Aachs%26aulast%3DHay%26aufirst%3DD.%2BL.%26aulast%3DWalker%26aufirst%3DC.%2BS.%26aulast%3DPoyner%26aufirst%3DD.%2BR.%26atitle%3DAdrenomedullin%2520and%2520calcitonin%2520gene-related%2520peptide%2520receptors%2520in%2520endocrine-related%2520cancers%253A%2520opportunities%2520and%2520challenges%26jtitle%3DEndocr.-Relat.%2520Cancer%26date%3D2011%26volume%3D18%26spage%3DC1%26epage%3DC14%26doi%3D10.1677%2FERC-10-0244" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qiao, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ni, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akuo, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, S.</span></span> <span> </span><span class="NLM_article-title">The role of adrenomedullin in the pathogenesis of gastric cancer</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">88464</span>– <span class="NLM_lpage">88474</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.18881</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=10.18632%2Foncotarget.18881" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=29179449" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=1%3ACAS%3A280%3ADC%252BC1M3ltlOntw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=88464-88474&author=F.+Qiaoauthor=J.+Fangauthor=J.+Xuauthor=W.+Zhaoauthor=Y.+Niauthor=B.+A.+Akuoauthor=W.+Zhangauthor=Y.+Liuauthor=F.+Dingauthor=G.+Liauthor=B.+Liuauthor=H.+Wangauthor=S.+Shao&title=The+role+of+adrenomedullin+in+the+pathogenesis+of+gastric+cancer&doi=10.18632%2Foncotarget.18881"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">The role of adrenomedullin in the pathogenesis of gastric cancer</span></div><div class="casAuthors">Qiao Fuhao; Fang Jian; Xu Jinfeng; Zhao Wenqiu; Ni Ying; Akuo Bufugdi Andreas; Zhang Wei; Liu Yun; Ding Fangfang; Wang Hua; Shao Shihe; Qiao Fuhao; Li Guanlin; Liu Baoguo</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">51</span>),
    <span class="NLM_cas:pages">88464-88474</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Adrenomedullin has been shown to be overexpressed in many tumors, including gastric cancer tumors; however, its mechanism of action remains unclear.  In this study, we examined the role of adrenomedullin in the pathogenesis of gastric cancer.  Using clinical specimens and immunohistochemistry, we found that the expression levels of adrenomedullin and its receptors are inordinately elevated as compared to the adjacent non-tumor gastric tissues.  We used siRNA gene silencing, in BGC-823 gastric cancer cell lines, to target adrenomedullin genes, and found that increased adrenomedullin expression results in the proliferation of tumor cells, tumor invasion, and metastasis.  Furthermore, we found that under hypoxic conditions, gastric cancer BGC-823 cells exhibit higher expression levels of adrenomedullin and various other related proteins.  Our results indicate the involvement of adrenomedullin in microvessel proliferation and partially in the release of hypoxia in solid tumors.  Knockdown of adrenomedullin expression, at the protein level, reduced the levels of phosphoprotein kinase B and B-cell lymphoma 2 but increased the levels of cleaved-caspase3 and Bcl 2 associated x protein (Bax).  Therefore, we hypothesized siRNA targeting of adrenomedullin genes inhibits various serine/threonine kinases via a signaling pathway that induces cell apoptosis.  SiRNA targeting of adrenomedullin genes and green fluorescent control vectors were used to transfect BGC-823 cells, and western blot analyses were used to detect changes in the rates of autophagy in related proteins using confocal laser scanning microscopy.  No significant changes were detected.  Therefore, the knockdown of adrenomedullin and its receptors may represent a novel treatment strategy for gastric cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR5yvT6h5Erjs-crCu0nI_sfW6udTcc2eYNeUtoAe7U57ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M3ltlOntw%253D%253D&md5=92fd0f166620f05fdd61748b9f1a4886</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.18881&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.18881%26sid%3Dliteratum%253Aachs%26aulast%3DQiao%26aufirst%3DF.%26aulast%3DFang%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DW.%26aulast%3DNi%26aufirst%3DY.%26aulast%3DAkuo%26aufirst%3DB.%2BA.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DDing%26aufirst%3DF.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DShao%26aufirst%3DS.%26atitle%3DThe%2520role%2520of%2520adrenomedullin%2520in%2520the%2520pathogenesis%2520of%2520gastric%2520cancer%26jtitle%3DOncotarget%26date%3D2017%26volume%3D8%26spage%3D88464%26epage%3D88474%26doi%3D10.18632%2Foncotarget.18881" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dai, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamiyoshi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakurai, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ichikawa-Shindo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawate, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kakihara, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsui, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shindo, T.</span></span> <span> </span><span class="NLM_article-title">Deficiency of the adrenomedullin-RAMP3 system suppresses metastasis through the modification of cancer-associated fibroblasts</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">1914</span>– <span class="NLM_lpage">1930</span>, <span class="refDoi"> DOI: 10.1038/s41388-019-1112-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=10.1038%2Fs41388-019-1112-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=31754214" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=1%3ACAS%3A528%3ADC%252BC1MXit1Smt7nO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2020&pages=1914-1930&author=K.+Daiauthor=M.+Tanakaauthor=A.+Kamiyoshiauthor=T.+Sakuraiauthor=Y.+Ichikawa-Shindoauthor=H.+Kawateauthor=N.+Cuiauthor=Y.+Weiauthor=M.+Tanakaauthor=S.+Kakiharaauthor=S.+Matsuiauthor=T.+Shindo&title=Deficiency+of+the+adrenomedullin-RAMP3+system+suppresses+metastasis+through+the+modification+of+cancer-associated+fibroblasts&doi=10.1038%2Fs41388-019-1112-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Deficiency of the adrenomedullin-RAMP3 system suppresses metastasis through the modification of cancer-associated fibroblasts</span></div><div class="casAuthors">Dai, Kun; Tanaka, Megumu; Kamiyoshi, Akiko; Sakurai, Takayuki; Ichikawa-Shindo, Yuka; Kawate, Hisaka; Cui, Nanqi; Wei, Yangxuan; Tanaka, Masaaki; Kakihara, Shinji; Matsui, Shuhei; Shindo, Takayuki</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1914-1930</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Tumor metastasis is a primary source of morbidity and mortality in cancer.  Adrenomedullin (AM) is a multifunctional peptide regulated by receptor activity-modifying proteins (RAMPs).  We previously reported that the AM-RAMP2 system is involved in tumor angiogenesis, but the function of the AM-RAMP3 system remains largely unknown.  Here, we investigated the actions of the AM-RAMP2 and 3 systems in the tumor microenvironment and their impact on metastasis.  PAN02 pancreatic cancer cells were injected into the spleens of mice, leading to spontaneous liver metastasis.  Tumor metastasis was enhanced in vascular endothelial cell-specific RAMP2 knockout mice (DI-E-RAMP2-/-).  By contrast, metastasis was suppressed in RAMP3-/- mice, where the no. of podoplanin (PDPN)-pos. cancer-assocd. fibroblasts (CAFs) was reduced in the periphery of tumors at metastatic sites.  Because PDPN-pos. CAFs are a hallmark of tumor malignancy, we assessed the regulation of PDPN and found that Src/Cas/PDPN signaling is mediated by RAMP3.  In fact, RAMP3 deficiency CAFs suppressed migration, proliferation, and metastasis in co-cultures with tumor cells in vitro and in vivo.  Moreover, the activation of RAMP2 in RAMP3-/- mice suppressed both tumor growth and metastasis.  Based on these results, we suggest that the upregulation of PDPN in DI-E-RAMP2-/- mice increases malignancy, while the downregulation of PDPN in RAMP3-/- mice reduces it.  Selective activation of RAMP2 and inhibition of RAMP3 would therefore be expected to suppress tumor metastasis.  This study provides the first evidence that understanding and targeting to AM-RAMP systems could contribute to the development of novel therapeutics against metastasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGop648nEd65s7Vg90H21EOLACvtfcHk0liPdjLkp6Fs_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXit1Smt7nO&md5=84853e55ce395d762292b803ce571a9a</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1038%2Fs41388-019-1112-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41388-019-1112-z%26sid%3Dliteratum%253Aachs%26aulast%3DDai%26aufirst%3DK.%26aulast%3DTanaka%26aufirst%3DM.%26aulast%3DKamiyoshi%26aufirst%3DA.%26aulast%3DSakurai%26aufirst%3DT.%26aulast%3DIchikawa-Shindo%26aufirst%3DY.%26aulast%3DKawate%26aufirst%3DH.%26aulast%3DCui%26aufirst%3DN.%26aulast%3DWei%26aufirst%3DY.%26aulast%3DTanaka%26aufirst%3DM.%26aulast%3DKakihara%26aufirst%3DS.%26aulast%3DMatsui%26aufirst%3DS.%26aulast%3DShindo%26aufirst%3DT.%26atitle%3DDeficiency%2520of%2520the%2520adrenomedullin-RAMP3%2520system%2520suppresses%2520metastasis%2520through%2520the%2520modification%2520of%2520cancer-associated%2520fibroblasts%26jtitle%3DOncogene%26date%3D2020%26volume%3D39%26spage%3D1914%26epage%3D1930%26doi%3D10.1038%2Fs41388-019-1112-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Greillier, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tounsi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berenguer-Daize, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dussault, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delfino, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benyahia, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cayol, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mabrouk, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barlesi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouafik, L.</span></span> <span> </span><span class="NLM_article-title">Functional analysis of the adrenomedullin pathway in malignant pleural mesothelioma</span>. <i>J. Thorac. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">94</span>– <span class="NLM_lpage">107</span>, <span class="refDoi"> DOI: 10.1016/j.jtho.2015.09.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=10.1016%2Fj.jtho.2015.09.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=26762744" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=1%3ACAS%3A280%3ADC%252BC28ngsVaqtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=94-107&author=L.+Greillierauthor=A.+Tounsiauthor=C.+Berenguer-Daizeauthor=N.+Dussaultauthor=C.+Delfinoauthor=Z.+Benyahiaauthor=M.+Cayolauthor=K.+Mabroukauthor=S.+Garciaauthor=P.+M.+Martinauthor=F.+Barlesiauthor=L.+Ouafik&title=Functional+analysis+of+the+adrenomedullin+pathway+in+malignant+pleural+mesothelioma&doi=10.1016%2Fj.jtho.2015.09.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Functional Analysis of the Adrenomedullin Pathway in Malignant Pleural Mesothelioma</span></div><div class="casAuthors">Greillier Laurent; Tounsi Asma; Berenguer-Daize Caroline; Dussault Nadege; Delfino Christine; Benyahia Zohra; Cayol Mylene; Mabrouk Kamel; Garcia Stephane; Martin Pierre-Marie; Ouafik L'Houcine; Barlesi Fabrice</div><div class="citationInfo"><span class="NLM_cas:title">Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">94-107</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">INTRODUCTION:  Malignant pleural mesothelioma (MPM) grows aggressively within the thoracic cavity and has a very low cure rate, thus highlighting the need for identification of new therapeutic targets.  Adrenomedullin (AM) is a multifunctional peptide that is highly expressed in several tumors and plays an important role in angiogenesis and tumor growth after binding to its receptors, calcitonin receptor-like receptor/receptor activity-modifying protein 2 (CLR/RAMP2) and calcitonin receptor-like receptor/receptor activity-modifying protein 3 (CLR/RAMP3).  METHODS:  Real time quantitative reverse transcriptase polymerase chain reaction (RT-PCR) was used to assess the steady-state levels of AM, CLR, RAMP2 and RAMP3 messenger RNA (mRNA) transcripts in normal pleural tissue (n=5) and MPM (n=24).  The expression of these candidates at protein level was revealed by immunohistochemistry.  We also characterized the expression and regulation by hypoxia of AM system in MPM cell lines and MeT-5A cells.  In vitro and in vivo studies were performed to determine the functional role of AM system in MPM.  RESULTS:  In this study, real-time quantitative reverse transcriptase polymerase chain reaction showed twofold to 10-fold higher levels of AM messenger RNA in MPM tissue than in normal pleural tissue.  The MPM cell lines H2452, H2052, and human mesothelioma cell line MSTO-211H showed a significant increase in expression of AM messenger RNA under hypoxic conditions.  Our results also show that AM stimulates cell proliferation in vitro through the Raf1 proto-oncogene, serine/threonine kinase (CRAF)/ Mitogen-activated protein kinase kinase 1 (MEK)/Extracellular regulated MAPKinase (ERK) pathway.  Furthermore, the proliferation, migration, and invasion of MPM cells were decreased after treatment with anti-AM (αAM) and anti-AM receptor antibodies, thus indicating that MPM cells are regulated by AM.  The action of AM was specific and mediated by CLR/RAMP2 and CLR/RAMP3 receptors.  In vivo, αAM and AM22-52 antagonist therapies blocked angiogenesis and induced apoptosis in MSTO-211H xenografts, thereby resulting in tumor regression.  Histologic examination of tumors treated with AM22-52 and αAM antibody showed evidence of disruption of tumor vasculature with depletion of vascular endothelial cells and a significant decrease in lymphatic endothelial cells.  CONCLUSIONS:  Our findings highlight the importance of the AM pathway in growth of MPM and in neovascularization by supplying and amplifying signals that are essential for pathologic neoangiogenesis and lymphangiogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRXL591qi4wo7P3FVUi_gf8fW6udTcc2ebtiinXW-fn7bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28ngsVaqtA%253D%253D&md5=39b2547c1c0da50a93e005fcba25ee6e</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2Fj.jtho.2015.09.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jtho.2015.09.004%26sid%3Dliteratum%253Aachs%26aulast%3DGreillier%26aufirst%3DL.%26aulast%3DTounsi%26aufirst%3DA.%26aulast%3DBerenguer-Daize%26aufirst%3DC.%26aulast%3DDussault%26aufirst%3DN.%26aulast%3DDelfino%26aufirst%3DC.%26aulast%3DBenyahia%26aufirst%3DZ.%26aulast%3DCayol%26aufirst%3DM.%26aulast%3DMabrouk%26aufirst%3DK.%26aulast%3DGarcia%26aufirst%3DS.%26aulast%3DMartin%26aufirst%3DP.%2BM.%26aulast%3DBarlesi%26aufirst%3DF.%26aulast%3DOuafik%26aufirst%3DL.%26atitle%3DFunctional%2520analysis%2520of%2520the%2520adrenomedullin%2520pathway%2520in%2520malignant%2520pleural%2520mesothelioma%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2016%26volume%3D11%26spage%3D94%26epage%3D107%26doi%3D10.1016%2Fj.jtho.2015.09.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brekhman, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lugassie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaffryar-Eilot, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kessler, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golding, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neufeld, G.</span></span> <span> </span><span class="NLM_article-title">Receptor activity modifying protein-3 mediates the protumorigenic activity of lysyl oxidase-like protein-2</span>. <i>FASEB J.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">55</span>– <span class="NLM_lpage">65</span>, <span class="refDoi"> DOI: 10.1096/fj.10-162677</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=10.1096%2Ffj.10-162677" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=20802105" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=1%3ACAS%3A528%3ADC%252BC3MXls1GnsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2011&pages=55-65&author=V.+Brekhmanauthor=J.+Lugassieauthor=S.+Zaffryar-Eilotauthor=E.+Saboauthor=O.+Kesslerauthor=V.+Smithauthor=H.+Goldingauthor=G.+Neufeld&title=Receptor+activity+modifying+protein-3+mediates+the+protumorigenic+activity+of+lysyl+oxidase-like+protein-2&doi=10.1096%2Ffj.10-162677"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Receptor activity modifying protein-3 mediates the protumorigenic activity of lysyl oxidase-like protein-2</span></div><div class="casAuthors">Brekhman, Vera; Lugassie, Jennie; Zaffryar-Eilot, Shelly; Sabo, Edmond; Kessler, Ofra; Smith, Victoria; Golding, Hana; Neufeld, Gera</div><div class="citationInfo"><span class="NLM_cas:title">FASEB Journal</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">55-65, 10.1096/fj.10-162677</span>CODEN:
                <span class="NLM_cas:coden">FAJOEC</span>;
        ISSN:<span class="NLM_cas:issn">0892-6638</span>.
    
            (<span class="NLM_cas:orgname">Federation of American Societies for Experimental Biology</span>)
        </div><div class="casAbstract">Lysyl oxidase-like protein-2 (LOXL2) induces epithelial to mesenchymal transition and promotes invasiveness.  To understand the mechanisms involved, we examd. the effect of LOXL2 overexpression in MCF-7 cells on gene expression.  We found that LOXL2 up-regulated the expression of receptor activity modifying protein-3 (RAMP3).  Expression of RAMP3 in MDA-MB-231 cells in which LOXL2 expression was inhibited restored vimentin expression, invasiveness, and tumor development.  Inhibition of RAMP3 expression in MDA-MB-231 cells mimicked the effects produced by inhibition of LOXL2 expression and was accompanied by inhibition of p38 phosphorylation.  LOXL2 overexpression in these cells did not restore invasiveness, suggesting that RAMP3 functions downstream to LOXL2.  LOXL2 and RAMP3 are strongly coexpressed in human colon, breast, and gastric carcinomas but not in normal colon or gastric epithelial cells.  RAMP3 assocs. with several G-protein-coupled receptors forming receptors for peptides, such as adrenomedullin and amylin.  We hypothesized that RAMP3 could function as a transducer of autocrine signals induced by such peptides.  However, the proinvasive effects of RAMP3 could not be abrogated following inhibition of the expression or activity of these peptides.  Our expts. suggest that the protumorigenic effects of LOXL2 are partially mediated by RAMP3 and that RAMP3 inhibitors may function as antitumorigenic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXWC73S7YgtbVg90H21EOLACvtfcHk0lj9Z8V3fU6Raw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXls1GnsQ%253D%253D&md5=bd999d5fb9816056ef51844b2327509d</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1096%2Ffj.10-162677&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1096%252Ffj.10-162677%26sid%3Dliteratum%253Aachs%26aulast%3DBrekhman%26aufirst%3DV.%26aulast%3DLugassie%26aufirst%3DJ.%26aulast%3DZaffryar-Eilot%26aufirst%3DS.%26aulast%3DSabo%26aufirst%3DE.%26aulast%3DKessler%26aufirst%3DO.%26aulast%3DSmith%26aufirst%3DV.%26aulast%3DGolding%26aufirst%3DH.%26aulast%3DNeufeld%26aufirst%3DG.%26atitle%3DReceptor%2520activity%2520modifying%2520protein-3%2520mediates%2520the%2520protumorigenic%2520activity%2520of%2520lysyl%2520oxidase-like%2520protein-2%26jtitle%3DFASEB%2520J.%26date%3D2011%26volume%3D25%26spage%3D55%26epage%3D65%26doi%3D10.1096%2Ffj.10-162677" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Siclari, V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohammad, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tompkins, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKenna, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wessner, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niewolna, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guise, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suvannasankha, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chirgwin, J. M.</span></span> <span> </span><span class="NLM_article-title">Tumor-expressed adrenomedullin accelerates breast cancer bone metastasis</span>. <i>Breast Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>16</i></span>, <span class="NLM_elocation-id">458</span> <span class="refDoi"> DOI: 10.1186/s13058-014-0458-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=10.1186%2Fs13058-014-0458-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=25439669" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjtVCrtrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2014&author=V.+A.+Siclariauthor=K.+S.+Mohammadauthor=D.+R.+Tompkinsauthor=H.+Davisauthor=C.+R.+McKennaauthor=X.+Pengauthor=L.+L.+Wessnerauthor=M.+Niewolnaauthor=T.+A.+Guiseauthor=A.+Suvannasankhaauthor=J.+M.+Chirgwin&title=Tumor-expressed+adrenomedullin+accelerates+breast+cancer+bone+metastasis&doi=10.1186%2Fs13058-014-0458-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Tumor-expressed adrenomedullin accelerates breast cancer bone metastasis</span></div><div class="casAuthors">Siclari, Valerie A.; Mohammad, Khalid S.; Tompkins, Douglas R.; Davis, Holly; McKenna, C. Ryan; Peng, Xianghong; Wessner, Lisa L.; Niewolna, Maria; Guise, Theresa A.; Suvannasankha, Attaya; Chirgwin, John M.</div><div class="citationInfo"><span class="NLM_cas:title">Breast Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">458/1-458/14, 14 pp.</span>CODEN:
                <span class="NLM_cas:coden">BRCRFS</span>;
        ISSN:<span class="NLM_cas:issn">1465-542X</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Introduction: Adrenomedullin (AM) is secreted by breast cancer cells and increased by hypoxia.  It is a multifunctional peptide that stimulates angiogenesis and proliferation.  The peptide is also a potent paracrine stimulator of osteoblasts and bone formation, suggesting a role in skeletal metastases-a major site of treatment-refractory tumor growth in patients with advanced disease.  Methods: The role of adrenomedullin in bone metastases was tested by stable overexpression in MDA-MB-231 breast cancer cells, which cause osteolytic bone metastases in a std. animal model.  Cells with fivefold increased expression of AM were characterized in vitro, inoculated into immunodeficient mice and compared for their ability to form bone metastases vs. control subclones.  Bone destruction was monitored by X-ray, and tumor burden and osteoclast nos. were detd. by quant. histomorphometry.  The effects of AM overexpression on tumor growth and angiogenesis in the mammary fat pad were detd.  The effects of AM peptide on osteoclast-like multinucleated cell formation were tested in vitro.  A small-mol. AM antagonist was tested for its effects on AM-stimulated ex vivo bone cell cultures and co-cultures with tumor cells, where responses of tumor and bone were distinguished by species-specific real-time PCR.  Results: Overexpression of AM mRNA did not alter cell proliferation in vitro, expression of tumor-secreted factors or cell cycle progression.  AM-overexpressing cells caused osteolytic bone metastases to develop more rapidly, which was accompanied by decreased survival.  In the mammary fat pad, tumors grew more rapidly with unchanged blood vessel formation.  Tumor growth in the bone was also more rapid, and osteoclasts were increased.  AM peptide potently stimulated bone cultures ex vivo; responses that were blocked by small-mol. adrenomedullin antagonists in the absence of cellular toxicity.  Antagonist treatment dramatically suppressed tumor growth in bone and decreased markers of osteoclast activity.  Conclusions: The results identify AM as a target for therapeutic intervention against bone metastases.  Adrenomedullin potentiates osteolytic responses in bone to metastatic breast cancer cells.  Small-mol. antagonists can effectively block bone-mediated responses to tumor-secreted adrenomedullin, and such agents warrant development for testing in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlXnDtx05gIrVg90H21EOLACvtfcHk0lj9Z8V3fU6Raw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjtVCrtrg%253D&md5=821749d2bc9e4947351a044f21c63960</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1186%2Fs13058-014-0458-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13058-014-0458-y%26sid%3Dliteratum%253Aachs%26aulast%3DSiclari%26aufirst%3DV.%2BA.%26aulast%3DMohammad%26aufirst%3DK.%2BS.%26aulast%3DTompkins%26aufirst%3DD.%2BR.%26aulast%3DDavis%26aufirst%3DH.%26aulast%3DMcKenna%26aufirst%3DC.%2BR.%26aulast%3DPeng%26aufirst%3DX.%26aulast%3DWessner%26aufirst%3DL.%2BL.%26aulast%3DNiewolna%26aufirst%3DM.%26aulast%3DGuise%26aufirst%3DT.%2BA.%26aulast%3DSuvannasankha%26aufirst%3DA.%26aulast%3DChirgwin%26aufirst%3DJ.%2BM.%26atitle%3DTumor-expressed%2520adrenomedullin%2520accelerates%2520breast%2520cancer%2520bone%2520metastasis%26jtitle%3DBreast%2520Cancer%2520Res.%26date%3D2014%26volume%3D16%26doi%3D10.1186%2Fs13058-014-0458-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Avgoustou, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jailani, A. B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zirimwabagabo, J.-O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tozer, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibson, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glossop, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mills, J. E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porter, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blaney, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bungay, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bigos, K. J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holmes, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warrington, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skerry, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrity, J. P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richards, G. O.</span></span> <span> </span><span class="NLM_article-title">Discovery of a first-in-class potent small molecule antagonist against the adrenomedullin-2 receptor</span>. <i>ACS Pharmacol. Transl. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">706</span>– <span class="NLM_lpage">719</span>, <span class="refDoi"> DOI: 10.1021/acsptsci.0c00032</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsptsci.0c00032" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=1%3ACAS%3A528%3ADC%252BB3cXht1CltLvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2020&pages=706-719&author=P.+Avgoustouauthor=A.+B.+A.+Jailaniauthor=J.-O.+Zirimwabagaboauthor=M.+J.+Tozerauthor=K.+R.+Gibsonauthor=P.+A.+Glossopauthor=J.+E.+J.+Millsauthor=R.+A.+Porterauthor=P.+Blaneyauthor=P.+Bungayauthor=N.+Wangauthor=A.+Shawauthor=K.+J.+A.+Bigosauthor=J.+L.+Holmesauthor=J.+I.+Warringtonauthor=T.+M.+Skerryauthor=J.+P.+A.+Harrityauthor=G.+O.+Richards&title=Discovery+of+a+first-in-class+potent+small+molecule+antagonist+against+the+adrenomedullin-2+receptor&doi=10.1021%2Facsptsci.0c00032"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a First-in-Class Potent Small Molecule Antagonist against the Adrenomedullin-2 Receptor</span></div><div class="casAuthors">Avgoustou, Paris; Jailani, Ameera B. A.; Zirimwabagabo, Jean-Olivier; Tozer, Matthew J.; Gibson, Karl R.; Glossop, Paul A.; Mills, James E. J.; Porter, Roderick A.; Blaney, Paul; Bungay, Peter J.; Wang, Ning; Shaw, Alice P.; Bigos, Kamilla J. A.; Holmes, Joseph L.; Warrington, Jessica I.; Skerry, Timothy M.; Harrity, Joseph P. A.; Richards, Gareth O.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Pharmacology & Translational Science</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">706-719</span>CODEN:
                <span class="NLM_cas:coden">APTSFN</span>;
        ISSN:<span class="NLM_cas:issn">2575-9108</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The hormone adrenomedullin has both physiol. and pathol. roles in biol.  As a potent vasodilator, adrenomedullin is critically important in the regulation of blood pressure, but it also has several roles in disease, of which its actions in cancer are becoming recognized to have clin. importance.  Reduced circulating adrenomedullin causes increased blood pressure but also reduces tumor progression, so drugs blocking all effects of adrenomedullin would be unacceptable clin.  However, there are two distinct receptors for adrenomedullin, each comprising the same G protein-coupled receptor (GPCR), the calcitonin receptor-like receptor (CLR), together with a different accessory protein known as a receptor activity-modifying protein (RAMP).  The CLR with RAMP2 forms an adrenomedullin-1 receptor, and the CLR with RAMP3 forms an adrenomedullin-2 receptor.  Recent research suggests that a selective blockade of adrenomedullin-2 receptors would be therapeutically valuable.  Here we describe the design, synthesis, and characterization of potent small-mol. adrenomedullin-2 receptor antagonists with 1000-fold selectivity over the adrenomedullin-1 receptor, although retaining activity against the CGRP receptor.  These mols. have clear effects on markers of pancreatic cancer progression in vitro, drug-like pharmacokinetic properties, and inhibit xenograft tumor growth and extend life in a mouse model of pancreatic cancer.  Taken together, our data support the promise of a new class of anticancer therapeutics as well as improved understanding of the pharmacol. of the adrenomedullin receptors and other GPCR/RAMP heteromers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqag5PL8Hif27Vg90H21EOLACvtfcHk0liKtbvtkgX2mQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXht1CltLvI&md5=cd030e8fd531b0773e2c32ed89655ea2</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Facsptsci.0c00032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsptsci.0c00032%26sid%3Dliteratum%253Aachs%26aulast%3DAvgoustou%26aufirst%3DP.%26aulast%3DJailani%26aufirst%3DA.%2BB.%2BA.%26aulast%3DZirimwabagabo%26aufirst%3DJ.-O.%26aulast%3DTozer%26aufirst%3DM.%2BJ.%26aulast%3DGibson%26aufirst%3DK.%2BR.%26aulast%3DGlossop%26aufirst%3DP.%2BA.%26aulast%3DMills%26aufirst%3DJ.%2BE.%2BJ.%26aulast%3DPorter%26aufirst%3DR.%2BA.%26aulast%3DBlaney%26aufirst%3DP.%26aulast%3DBungay%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DN.%26aulast%3DShaw%26aufirst%3DA.%26aulast%3DBigos%26aufirst%3DK.%2BJ.%2BA.%26aulast%3DHolmes%26aufirst%3DJ.%2BL.%26aulast%3DWarrington%26aufirst%3DJ.%2BI.%26aulast%3DSkerry%26aufirst%3DT.%2BM.%26aulast%3DHarrity%26aufirst%3DJ.%2BP.%2BA.%26aulast%3DRichards%26aufirst%3DG.%2BO.%26atitle%3DDiscovery%2520of%2520a%2520first-in-class%2520potent%2520small%2520molecule%2520antagonist%2520against%2520the%2520adrenomedullin-2%2520receptor%26jtitle%3DACS%2520Pharmacol.%2520Transl.%2520Sci.%26date%3D2020%26volume%3D3%26spage%3D706%26epage%3D719%26doi%3D10.1021%2Facsptsci.0c00032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kusano, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kukimoto-Niino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hino, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohsawa, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okuda, K.-i.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakamoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shirouzu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shindo, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yokoyama, S.</span></span> <span> </span><span class="NLM_article-title">Structural basis for extracellular interactions between calcitonin receptor-like receptor and receptor activity-modifying protein 2 for adrenomedullin-specific binding</span>. <i>Protein Sci.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">199</span>– <span class="NLM_lpage">210</span>, <span class="refDoi"> DOI: 10.1002/pro.2003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=10.1002%2Fpro.2003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=22102369" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=1%3ACAS%3A528%3ADC%252BC38Xpslyqtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2012&pages=199-210&author=S.+Kusanoauthor=M.+Kukimoto-Niinoauthor=N.+Hinoauthor=N.+Ohsawaauthor=K.-i.+Okudaauthor=K.+Sakamotoauthor=M.+Shirouzuauthor=T.+Shindoauthor=S.+Yokoyama&title=Structural+basis+for+extracellular+interactions+between+calcitonin+receptor-like+receptor+and+receptor+activity-modifying+protein+2+for+adrenomedullin-specific+binding&doi=10.1002%2Fpro.2003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis for extracellular interactions between calcitonin receptor-like receptor and receptor activity-modifying protein 2 for adrenomedullin-specific binding</span></div><div class="casAuthors">Kusano, Seisuke; Kukimoto-Niino, Mutsuko; Hino, Nobumasa; Ohsawa, Noboru; Okuda, Ken-ichi; Sakamoto, Kensaku; Shirouzu, Mikako; Shindo, Takayuki; Yokoyama, Shigeyuki</div><div class="citationInfo"><span class="NLM_cas:title">Protein Science</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">199-210</span>CODEN:
                <span class="NLM_cas:coden">PRCIEI</span>;
        ISSN:<span class="NLM_cas:issn">1469-896X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The calcitonin receptor-like receptor (CRLR), a class B GPCR, forms a heterodimer with receptor activity-modifying protein 2 (RAMP2), and serves as the adrenomedullin (AM) receptor to control neovascularization, while CRLR and RAMP1 form the calcitonin gene-related peptide (CGRP) receptor.  Here, the authors report the crystal structures of the RAMP2 extracellular domain alone and in the complex with the CRLR extracellular domain.  The CRLR-RAMP2 complex exhibits several intermol. interactions that were not obsd. in the previously reported CRLR-RAMP1 complex, and thus the shape of the putative ligand-binding pocket of CRLR-RAMP2 is distinct from that of CRLR-RAMP1.  The CRLR-RAMP2 interactions were confirmed for the full-length proteins on the cell surface by site-specific photo-crosslinking.  Mutagenesis revealed that AM binding requires RAMP2 residues that are not conserved in RAMP1.  Therefore, the differences in both the shapes and the key residues of the binding pocket are essential for the ligand specificity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiC362DktsB7Vg90H21EOLACvtfcHk0liKtbvtkgX2mQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xpslyqtw%253D%253D&md5=91a86ba3ae2e23dfb12fc7e0f91c4eeb</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1002%2Fpro.2003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpro.2003%26sid%3Dliteratum%253Aachs%26aulast%3DKusano%26aufirst%3DS.%26aulast%3DKukimoto-Niino%26aufirst%3DM.%26aulast%3DHino%26aufirst%3DN.%26aulast%3DOhsawa%26aufirst%3DN.%26aulast%3DOkuda%26aufirst%3DK.-i.%26aulast%3DSakamoto%26aufirst%3DK.%26aulast%3DShirouzu%26aufirst%3DM.%26aulast%3DShindo%26aufirst%3DT.%26aulast%3DYokoyama%26aufirst%3DS.%26atitle%3DStructural%2520basis%2520for%2520extracellular%2520interactions%2520between%2520calcitonin%2520receptor-like%2520receptor%2520and%2520receptor%2520activity-modifying%2520protein%25202%2520for%2520adrenomedullin-specific%2520binding%26jtitle%3DProtein%2520Sci.%26date%3D2012%26volume%3D21%26spage%3D199%26epage%3D210%26doi%3D10.1002%2Fpro.2003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">ter
Haar, E.</span></span> <span> </span><span class="NLM_article-title">Crystal structure of the ectodomain complex of the CGRP receptor, a Class-B GPCR, reveals the site of drug antagonism</span>. <i>Structure</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">1083</span>– <span class="NLM_lpage">1093</span>, <span class="refDoi"> DOI: 10.1016/j.str.2010.05.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=10.1016%2Fj.str.2010.05.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=20826335" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFalsLnM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2010&pages=1083-1093&author=E.+ter%0AHaar&title=Crystal+structure+of+the+ectodomain+complex+of+the+CGRP+receptor%2C+a+Class-B+GPCR%2C+reveals+the+site+of+drug+antagonism&doi=10.1016%2Fj.str.2010.05.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal Structure of the Ectodomain Complex of the CGRP Receptor, a Class-B GPCR, Reveals the Site of Drug Antagonism</span></div><div class="casAuthors">ter Haar, Ernst; Koth, Christopher M.; Abdul-Manan, Norzehan; Swenson, Lora; Coll, Joyce T.; Lippke, Judith A.; Lepre, Christopher A.; Garcia-Guzman, Miguel; Moore, Jonathan M.</div><div class="citationInfo"><span class="NLM_cas:title">Structure (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1083-1093</span>CODEN:
                <span class="NLM_cas:coden">STRUE6</span>;
        ISSN:<span class="NLM_cas:issn">0969-2126</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Dysregulation of the calcitonin gene-related peptide (CGRP), a potent vasodilator, is directly implicated in the pathogenesis of migraine.  CGRP binds to and signals through the CGRP receptor (CGRP-R), a heterodimer contg. the calcitonin receptor-like receptor (CLR), a class B GPCR, and RAMP1, a receptor activity-modifying protein.  We have solved the crystal structure of the CLR/RAMP1 N-terminal ectodomain heterodimer, revealing how RAMPs bind to and potentially modulate the activities of the CLR GPCR subfamily.  We also report the structures of CLR/RAMP1 in complex with the clin. receptor antagonists olcegepant (BIBN4096BS) and telcagepant (MK0974).  Both drugs act by blocking access to the peptide-binding cleft at the interface of CLR and RAMP1.  These structures illustrate, for the first time, how small mols. bind to and modulate the activity of a class B GPCR, and highlight the challenges of designing potent receptor antagonists for the treatment of migraine and other class B GPCR-related diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJl19cAutQ5rVg90H21EOLACvtfcHk0liKtbvtkgX2mQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFalsLnM&md5=2b17356889336fafc9a6ec2a965e3db3</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2Fj.str.2010.05.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.str.2010.05.014%26sid%3Dliteratum%253Aachs%26aulast%3Dter%2BHaar%26aufirst%3DE.%26atitle%3DCrystal%2520structure%2520of%2520the%2520ectodomain%2520complex%2520of%2520the%2520CGRP%2520receptor%252C%2520a%2520Class-B%2520GPCR%252C%2520reveals%2520the%2520site%2520of%2520drug%2520antagonism%26jtitle%3DStructure%26date%3D2010%26volume%3D18%26spage%3D1083%26epage%3D1093%26doi%3D10.1016%2Fj.str.2010.05.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Boyle, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banck, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morley, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vandermeersch, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutchison, G. R.</span></span> <span> </span><span class="NLM_article-title">Open babel: an open chemical toolbox</span>. <i>J. Cheminf.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>3</i></span>, <span class="NLM_elocation-id">33</span> <span class="refDoi"> DOI: 10.1186/1758-2946-3-33</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=10.1186%2F1758-2946-3-33" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=21982300" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVWjurbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2011&author=N.+M.+O%E2%80%99Boyleauthor=M.+Banckauthor=C.+A.+Jamesauthor=C.+Morleyauthor=T.+Vandermeerschauthor=G.+R.+Hutchison&title=Open+babel%3A+an+open+chemical+toolbox&doi=10.1186%2F1758-2946-3-33"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Open Babel: an open chemical toolbox</span></div><div class="casAuthors">O'Boyle, Noel M.; Banck, Michael; James, Craig A.; Morley, Chris; Vandermeersch, Tim; Hutchison, Geoffrey R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cheminformatics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">33</span>CODEN:
                <span class="NLM_cas:coden">JCOHB3</span>;
        ISSN:<span class="NLM_cas:issn">1758-2946</span>.
    
            (<span class="NLM_cas:orgname">Chemistry Central Ltd.</span>)
        </div><div class="casAbstract">Background: A frequent problem in computational modeling is the interconversion of chem. structures between different formats.  While std. interchange formats exist (for example, Chem. Markup Language) and de facto stds. have arisen (for example, SMILES format), the need to interconvert formats is a continuing problem due to the multitude of different application areas for chem. data, differences in the data stored by different formats (0D vs. 3D, for example), and competition between software along with a lack of vendor-neutral formats.  Results: We discuss, for the first time, Open Babel, an open-source chem. toolbox that speaks the many languages of chem. data.  Open Babel version 2.3 interconverts over 110 formats.  The need to represent such a wide variety of chem. and mol. data requires a library that implements a wide range of cheminformatics algorithms, from partial charge assignment and aromaticity detection, to bond order perception and canonicalization.  We detail the implementation of Open Babel, describe key advances in the 2.3 release, and outline a variety of uses both in terms of software products and scientific research, including applications far beyond simple format interconversion.  Conclusions: Open Babel presents a soln. to the proliferation of multiple chem. file formats.  In addn., it provides a variety of useful utilities from conformer searching and 2D depiction, to filtering, batch conversion, and substructure and similarity searching.  For developers, it can be used as a programming library to handle chem. data in areas such as org. chem., drug design, materials science, and computational chem.  It is freely available under an open-source license.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfQ1lvaS5767Vg90H21EOLACvtfcHk0liKtbvtkgX2mQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVWjurbF&md5=74e4f19b7f87417f916d57f7abcfb761</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1186%2F1758-2946-3-33&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1758-2946-3-33%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Boyle%26aufirst%3DN.%2BM.%26aulast%3DBanck%26aufirst%3DM.%26aulast%3DJames%26aufirst%3DC.%2BA.%26aulast%3DMorley%26aufirst%3DC.%26aulast%3DVandermeersch%26aufirst%3DT.%26aulast%3DHutchison%26aufirst%3DG.%2BR.%26atitle%3DOpen%2520babel%253A%2520an%2520open%2520chemical%2520toolbox%26jtitle%3DJ.%2520Cheminf.%26date%3D2011%26volume%3D3%26doi%3D10.1186%2F1758-2946-3-33" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Crowley, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stump, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, D. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potteiger, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McWherter, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paone, D. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quigley, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruno, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Culberson, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danziger, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fandozzi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gauvreau, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kemmerer, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menzel, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mosser, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salvatore, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kane, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selnick, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fraley, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burgey, C. S.</span></span> <span> </span><span class="NLM_article-title">Novel oxazolidinone calcitonin gene-related peptide (CGRP) receptor antagonists for the acute treatment of migraine</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">4777</span>– <span class="NLM_lpage">4781</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2015.07.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=10.1016%2Fj.bmcl.2015.07.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=26231160" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFOktL7N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=4777-4781&author=B.+M.+Crowleyauthor=C.+A.+Stumpauthor=D.+N.+Nguyenauthor=C.+M.+Potteigerauthor=M.+A.+McWherterauthor=D.+V.+Paoneauthor=A.+G.+Quigleyauthor=J.+G.+Brunoauthor=D.+Cuiauthor=J.+C.+Culbersonauthor=A.+Danzigerauthor=C.+Fandozziauthor=D.+Gauvreauauthor=A.+L.+Kemmererauthor=K.+Menzelauthor=E.+L.+Mooreauthor=S.+D.+Mosserauthor=V.+Reddyauthor=R.+B.+Whiteauthor=C.+A.+Salvatoreauthor=S.+A.+Kaneauthor=I.+M.+Bellauthor=H.+G.+Selnickauthor=M.+E.+Fraleyauthor=C.+S.+Burgey&title=Novel+oxazolidinone+calcitonin+gene-related+peptide+%28CGRP%29+receptor+antagonists+for+the+acute+treatment+of+migraine&doi=10.1016%2Fj.bmcl.2015.07.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Novel oxazolidinone calcitonin gene-related peptide (CGRP) receptor antagonists for the acute treatment of migraine</span></div><div class="casAuthors">Crowley, Brendan M.; Stump, Craig A.; Nguyen, Diem N.; Potteiger, Craig M.; McWherter, Melody A.; Paone, Daniel V.; Quigley, Amy G.; Bruno, Joseph G.; Cui, Dan; Culberson, J. Christopher; Danziger, Andrew; Fandozzi, Christine; Gauvreau, Danny; Kemmerer, Amanda L.; Menzel, Karsten; Moore, Eric L.; Mosser, Scott D.; Reddy, Vijay; White, Rebecca B.; Salvatore, Christopher A.; Kane, Stefanie A.; Bell, Ian M.; Selnick, Harold G.; Fraley, Mark E.; Burgey, Christopher S.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">4777-4781</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">In the authors' efforts to develop CGRP receptor antagonists as backups to MK-3207, the authors employed a scaffold hopping approach to identify a series of novel oxazolidinone-based compds.  The development of a structurally diverse, potent ((I), cAMP + HS IC50 = 0.67 nM), and selective compd. (hERG IC50 = 19 μM) with favorable rodent pharmacokinetics (F = 100%, t1/2 = 7 h) is described.  Key to this development was identification of a 3-substituted spirotetrahydropyran ring that afforded a substantial gain in potency (10 to 35-fold).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrebgkfNpm2nrVg90H21EOLACvtfcHk0lhArrmRT3BA0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFOktL7N&md5=1f943f701866efddce9400141a3fa6c9</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.07.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.07.021%26sid%3Dliteratum%253Aachs%26aulast%3DCrowley%26aufirst%3DB.%2BM.%26aulast%3DStump%26aufirst%3DC.%2BA.%26aulast%3DNguyen%26aufirst%3DD.%2BN.%26aulast%3DPotteiger%26aufirst%3DC.%2BM.%26aulast%3DMcWherter%26aufirst%3DM.%2BA.%26aulast%3DPaone%26aufirst%3DD.%2BV.%26aulast%3DQuigley%26aufirst%3DA.%2BG.%26aulast%3DBruno%26aufirst%3DJ.%2BG.%26aulast%3DCui%26aufirst%3DD.%26aulast%3DCulberson%26aufirst%3DJ.%2BC.%26aulast%3DDanziger%26aufirst%3DA.%26aulast%3DFandozzi%26aufirst%3DC.%26aulast%3DGauvreau%26aufirst%3DD.%26aulast%3DKemmerer%26aufirst%3DA.%2BL.%26aulast%3DMenzel%26aufirst%3DK.%26aulast%3DMoore%26aufirst%3DE.%2BL.%26aulast%3DMosser%26aufirst%3DS.%2BD.%26aulast%3DReddy%26aufirst%3DV.%26aulast%3DWhite%26aufirst%3DR.%2BB.%26aulast%3DSalvatore%26aufirst%3DC.%2BA.%26aulast%3DKane%26aufirst%3DS.%2BA.%26aulast%3DBell%26aufirst%3DI.%2BM.%26aulast%3DSelnick%26aufirst%3DH.%2BG.%26aulast%3DFraley%26aufirst%3DM.%2BE.%26aulast%3DBurgey%26aufirst%3DC.%2BS.%26atitle%3DNovel%2520oxazolidinone%2520calcitonin%2520gene-related%2520peptide%2520%2528CGRP%2529%2520receptor%2520antagonists%2520for%2520the%2520acute%2520treatment%2520of%2520migraine%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D4777%26epage%3D4781%26doi%3D10.1016%2Fj.bmcl.2015.07.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Neese, F.</span></span> <span> </span><span class="NLM_article-title">The ORCA program system</span>. <i>Wiley Interdiscip. Rev.: Comput. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">73</span>– <span class="NLM_lpage">78</span>, <span class="refDoi"> DOI: 10.1002/wcms.81</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=10.1002%2Fwcms.81" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvFGls7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2012&pages=73-78&author=F.+Neese&title=The+ORCA+program+system&doi=10.1002%2Fwcms.81"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">The ORCA program system</span></div><div class="casAuthors">Neese, Frank</div><div class="citationInfo"><span class="NLM_cas:title">Wiley Interdisciplinary Reviews: Computational Molecular Science</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">73-78</span>CODEN:
                <span class="NLM_cas:coden">WIRCAH</span>;
        ISSN:<span class="NLM_cas:issn">1759-0884</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  ORCA is a general-purpose quantum chem. program package that features virtually all modern electronic structure methods (d. functional theory, many-body perturbation and coupled cluster theories, and multireference and semiempirical methods).  It is designed with the aim of generality, extendibility, efficiency, and user friendliness.  Its main field of application is larger mols., transition metal complexes, and their spectroscopic properties.  ORCA uses std. Gaussian basis functions and is fully parallelized.  The article provides an overview of its current possibilities and documents its efficiency.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq39ez8fWMbr7Vg90H21EOLACvtfcHk0lhArrmRT3BA0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvFGls7s%253D&md5=a753e33a6f9a326553295596f5c754e5</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1002%2Fwcms.81&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fwcms.81%26sid%3Dliteratum%253Aachs%26aulast%3DNeese%26aufirst%3DF.%26atitle%3DThe%2520ORCA%2520program%2520system%26jtitle%3DWiley%2520Interdiscip.%2520Rev.%253A%2520Comput.%2520Mol.%2520Sci.%26date%3D2012%26volume%3D2%26spage%3D73%26epage%3D78%26doi%3D10.1002%2Fwcms.81" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jones, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willett, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glen, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leach, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, R.</span></span> <span> </span><span class="NLM_article-title">Development and validation of a genetic algorithm for flexible docking</span>. <i>J. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>267</i></span>,  <span class="NLM_fpage">727</span>– <span class="NLM_lpage">748</span>, <span class="refDoi"> DOI: 10.1006/jmbi.1996.0897</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=10.1006%2Fjmbi.1996.0897" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=9126849" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=1%3ACAS%3A528%3ADyaK2sXis1KntLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=267&publication_year=1997&pages=727-748&author=G.+Jonesauthor=P.+Willettauthor=R.+C.+Glenauthor=A.+R.+Leachauthor=R.+Taylor&title=Development+and+validation+of+a+genetic+algorithm+for+flexible+docking&doi=10.1006%2Fjmbi.1996.0897"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Development and validation of a genetic algorithm for flexible docking</span></div><div class="casAuthors">Jones, Gareth; Willett, Peter; Glen, Robert C.; Leach, Andrew R.; Taylor, Robin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">267</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">727-748</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Academic</span>)
        </div><div class="casAbstract">Prediction of small mol. binding modes to macromols. of known three-dimensional structure is a problem of paramount importance in rational drug design (the "docking" problem).  We report the development and validation of the program GOLD (Genetic Optimization for Ligand Docking).  GOLD is an automated ligand docking program that uses a genetic algorithm to explore the full range of ligand conformational flexibility with partial flexibility of the protein and satisfies the fundamental requirement that the ligand must displace loosely bound water on binding.  Numerous enhancements and modifications have been applied to the original technique resulting in a substantial increase in the reliability and the applicability of the algorithm.  The advanced algorithm has been tested on a dataset of 100 complexes extd. from the Brookhaven Protein Data Bank.  When used to dock the ligand back into the binding site, GOLD achieved a 71% success rate in identifying the exptl. binding mode.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrP3I60Rl2uorVg90H21EOLACvtfcHk0lhArrmRT3BA0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXis1KntLo%253D&md5=476a2b1d8f80f3ba418052fe29d735ca</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1006%2Fjmbi.1996.0897&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fjmbi.1996.0897%26sid%3Dliteratum%253Aachs%26aulast%3DJones%26aufirst%3DG.%26aulast%3DWillett%26aufirst%3DP.%26aulast%3DGlen%26aufirst%3DR.%2BC.%26aulast%3DLeach%26aufirst%3DA.%2BR.%26aulast%3DTaylor%26aufirst%3DR.%26atitle%3DDevelopment%2520and%2520validation%2520of%2520a%2520genetic%2520algorithm%2520for%2520flexible%2520docking%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D1997%26volume%3D267%26spage%3D727%26epage%3D748%26doi%3D10.1006%2Fjmbi.1996.0897" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wood, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schirripa, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quigley, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stump, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bednar, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fay, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruno, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mosser, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roller, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salvatore, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kane, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vacca, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selnick, H. G.</span></span> <span> </span><span class="NLM_article-title">Novel CGRP receptor antagonists through a design strategy of target simplification with addition of molecular flexibility</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">5787</span>– <span class="NLM_lpage">5790</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2009.07.134</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=10.1016%2Fj.bmcl.2009.07.134" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=19703767" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFakurrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=5787-5790&author=M.+R.+Woodauthor=K.+M.+Schirripaauthor=J.+J.+Kimauthor=A.+G.+Quigleyauthor=C.+A.+Stumpauthor=I.+M.+Bellauthor=R.+A.+Bednarauthor=J.+F.+Fayauthor=J.+G.+Brunoauthor=E.+L.+Mooreauthor=S.+D.+Mosserauthor=S.+Rollerauthor=C.+A.+Salvatoreauthor=S.+A.+Kaneauthor=J.+P.+Vaccaauthor=H.+G.+Selnick&title=Novel+CGRP+receptor+antagonists+through+a+design+strategy+of+target+simplification+with+addition+of+molecular+flexibility&doi=10.1016%2Fj.bmcl.2009.07.134"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Novel CGRP receptor antagonists through a design strategy of target simplification with addition of molecular flexibility</span></div><div class="casAuthors">Wood, Michael R.; Schirripa, Kathy M.; Kim, June J.; Quigley, Amy G.; Stump, Craig A.; Bell, Ian M.; Bednar, Rodney A.; Fay, John F.; Bruno, Joseph G.; Moore, Eric L.; Mosser, Scott D.; Roller, Shane; Salvatore, Christopher A.; Kane, Stefanie A.; Vacca, Joseph P.; Selnick, Harold G.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">5787-5790</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A novel class of CGRP receptor antagonists was rationally designed by modifying a highly potent, but structurally complex, CGRP receptor antagonist.  Initial modifications focused on simplified structures, with increased flexibility.  Subsequent to the prepn. of a less-potent but more flexible lead, classic medicinal chem. methods were applied to restore high affinity ((I), CGRP K i = 0.035 nM) while maintaining structural diversity relative to the lead.  Good selectivity against the closely related adrenomedullin-2 receptor was also achieved.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWvr7UslFgILVg90H21EOLACvtfcHk0ljWl8fvZIRfPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFakurrF&md5=a58c696445b1d323576990a5e824642a</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.07.134&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.07.134%26sid%3Dliteratum%253Aachs%26aulast%3DWood%26aufirst%3DM.%2BR.%26aulast%3DSchirripa%26aufirst%3DK.%2BM.%26aulast%3DKim%26aufirst%3DJ.%2BJ.%26aulast%3DQuigley%26aufirst%3DA.%2BG.%26aulast%3DStump%26aufirst%3DC.%2BA.%26aulast%3DBell%26aufirst%3DI.%2BM.%26aulast%3DBednar%26aufirst%3DR.%2BA.%26aulast%3DFay%26aufirst%3DJ.%2BF.%26aulast%3DBruno%26aufirst%3DJ.%2BG.%26aulast%3DMoore%26aufirst%3DE.%2BL.%26aulast%3DMosser%26aufirst%3DS.%2BD.%26aulast%3DRoller%26aufirst%3DS.%26aulast%3DSalvatore%26aufirst%3DC.%2BA.%26aulast%3DKane%26aufirst%3DS.%2BA.%26aulast%3DVacca%26aufirst%3DJ.%2BP.%26aulast%3DSelnick%26aufirst%3DH.%2BG.%26atitle%3DNovel%2520CGRP%2520receptor%2520antagonists%2520through%2520a%2520design%2520strategy%2520of%2520target%2520simplification%2520with%2520addition%2520of%2520molecular%2520flexibility%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D5787%26epage%3D5790%26doi%3D10.1016%2Fj.bmcl.2009.07.134" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Booe, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barwell, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuteyi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simms, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jamaluddin, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warner, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bill, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brimble, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poyner, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hay, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pioszak, A. A.</span></span> <span> </span><span class="NLM_article-title">Structural basis for receptor activity-modifying protein-dependent selective peptide recognition by a G protein-coupled receptor</span>. <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">1040</span>– <span class="NLM_lpage">1052</span>, <span class="refDoi"> DOI: 10.1016/j.molcel.2015.04.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=10.1016%2Fj.molcel.2015.04.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=25982113" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=1%3ACAS%3A528%3ADC%252BC2MXosVaqtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=1040-1052&author=J.+M.+Booeauthor=C.+S.+Walkerauthor=J.+Barwellauthor=G.+Kuteyiauthor=J.+Simmsauthor=M.+A.+Jamaluddinauthor=M.+L.+Warnerauthor=R.+M.+Billauthor=P.+W.+Harrisauthor=M.+A.+Brimbleauthor=D.+R.+Poynerauthor=D.+L.+Hayauthor=A.+A.+Pioszak&title=Structural+basis+for+receptor+activity-modifying+protein-dependent+selective+peptide+recognition+by+a+G+protein-coupled+receptor&doi=10.1016%2Fj.molcel.2015.04.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Basis for Receptor Activity-Modifying Protein-Dependent Selective Peptide Recognition by a G Protein-Coupled Receptor</span></div><div class="casAuthors">Booe, Jason M.; Walker, Christopher S.; Barwell, James; Kuteyi, Gabriel; Simms, John; Jamaluddin, Muhammad A.; Warner, Margaret L.; Bill, Roslyn M.; Harris, Paul W.; Brimble, Margaret A.; Poyner, David R.; Hay, Debbie L.; Pioszak, Augen A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1040-1052</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Assocn. of receptor activity-modifying proteins (RAMP1-3) with the G protein-coupled receptor (GPCR) calcitonin receptor-like receptor (CLR) enables selective recognition of the peptides calcitonin gene-related peptide (CGRP) and adrenomedullin (AM) that have diverse functions in the cardiovascular and lymphatic systems.  How peptides selectively bind GPCR:RAMP complexes is unknown.  We report crystal structures of CGRP analog-bound CLR:RAMP1 and AM-bound CLR:RAMP2 extracellular domain heterodimers at 2.5 and 1.8 Å resolns., resp.  The peptides similarly occupy a shared binding site on CLR with conformations characterized by a β-turn structure near their C termini rather than the α-helical structure common to peptides that bind related GPCRs.  The RAMPs augment the binding site with distinct contacts to the variable C-terminal peptide residues and elicit subtly different CLR conformations.  The structures and accompanying pharmacol. data reveal how a class of accessory membrane proteins modulate ligand binding of a GPCR and may inform drug development targeting CLR:RAMP complexes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqO56KMgeClFLVg90H21EOLACvtfcHk0ljWl8fvZIRfPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXosVaqtr4%253D&md5=5e38aa2169f83e1b5c46868c1cd5650b</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2015.04.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2015.04.018%26sid%3Dliteratum%253Aachs%26aulast%3DBooe%26aufirst%3DJ.%2BM.%26aulast%3DWalker%26aufirst%3DC.%2BS.%26aulast%3DBarwell%26aufirst%3DJ.%26aulast%3DKuteyi%26aufirst%3DG.%26aulast%3DSimms%26aufirst%3DJ.%26aulast%3DJamaluddin%26aufirst%3DM.%2BA.%26aulast%3DWarner%26aufirst%3DM.%2BL.%26aulast%3DBill%26aufirst%3DR.%2BM.%26aulast%3DHarris%26aufirst%3DP.%2BW.%26aulast%3DBrimble%26aufirst%3DM.%2BA.%26aulast%3DPoyner%26aufirst%3DD.%2BR.%26aulast%3DHay%26aufirst%3DD.%2BL.%26aulast%3DPioszak%26aufirst%3DA.%2BA.%26atitle%3DStructural%2520basis%2520for%2520receptor%2520activity-modifying%2520protein-dependent%2520selective%2520peptide%2520recognition%2520by%2520a%2520G%2520protein-coupled%2520receptor%26jtitle%3DMol.%2520Cell%26date%3D2015%26volume%3D58%26spage%3D1040%26epage%3D1052%26doi%3D10.1016%2Fj.molcel.2015.04.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bell, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallicchio, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quigley, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stump, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zartman, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fay, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lynch, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mosser, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prueksaritanont, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Regan, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roller, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salvatore, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kane, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vacca, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selnick, H. G.</span></span> <span> </span><span class="NLM_article-title">Discovery of MK-3207: a highly potent, orally bioavailable CGRP receptor antagonist</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">24</span>– <span class="NLM_lpage">29</span>, <span class="refDoi"> DOI: 10.1021/ml900016y</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml900016y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=1%3ACAS%3A528%3ADC%252BC3cXksFegsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2010&pages=24-29&author=I.+M.+Bellauthor=S.+N.+Gallicchioauthor=M.+R.+Woodauthor=A.+G.+Quigleyauthor=C.+A.+Stumpauthor=C.+B.+Zartmanauthor=J.+F.+Fayauthor=C.+C.+Liauthor=J.+J.+Lynchauthor=E.+L.+Mooreauthor=S.+D.+Mosserauthor=T.+Prueksaritanontauthor=C.+P.+Reganauthor=S.+Rollerauthor=C.+A.+Salvatoreauthor=S.+A.+Kaneauthor=J.+P.+Vaccaauthor=H.+G.+Selnick&title=Discovery+of+MK-3207%3A+a+highly+potent%2C+orally+bioavailable+CGRP+receptor+antagonist&doi=10.1021%2Fml900016y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of MK-3207: A Highly Potent, Orally Bioavailable CGRP Receptor Antagonist</span></div><div class="casAuthors">Bell, Ian M.; Gallicchio, Steven N.; Wood, Michael R.; Quigley, Amy G.; Stump, Craig A.; Zartman, C. Blair; Fay, John F.; Li, Chi-Chung; Lynch, Joseph J.; Moore, Eric L.; Mosser, Scott D.; Prueksaritanont, Thomayant; Regan, Christopher P.; Roller, Shane; Salvatore, Christopher A.; Kane, Stefanie A.; Vacca, Joseph P.; Selnick, Harold G.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">24-29</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Incorporation of polar functionality into a series of highly potent calcitonin gene-related peptide (CGRP) receptor antagonists was explored in an effort to improve pharmacokinetics.  This strategy identified piperazinone analogs that possessed improved soly. at acidic pH and increased oral bioavailability in monkeys.  Further optimization led to the discovery of the clin. candidate 2-[(8R)-8-(3,5-difluorophenyl)-10-oxo-6,9-diazaspiro[4.5]dec-9-yl]-N-[(2R)-2'-oxo-1,1',2',3-tetrahydrospiro[indene-2,3'-pyrrolo[2,3-b]pyridin]-5-yl]acetamide (MK-3207) (4), the most potent orally active CGRP receptor antagonist described to date.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIThxRCo8aD7Vg90H21EOLACvtfcHk0ljvOLL8wl22Xw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXksFegsQ%253D%253D&md5=2060a1762781cce87db2263731e9d85a</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1021%2Fml900016y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml900016y%26sid%3Dliteratum%253Aachs%26aulast%3DBell%26aufirst%3DI.%2BM.%26aulast%3DGallicchio%26aufirst%3DS.%2BN.%26aulast%3DWood%26aufirst%3DM.%2BR.%26aulast%3DQuigley%26aufirst%3DA.%2BG.%26aulast%3DStump%26aufirst%3DC.%2BA.%26aulast%3DZartman%26aufirst%3DC.%2BB.%26aulast%3DFay%26aufirst%3DJ.%2BF.%26aulast%3DLi%26aufirst%3DC.%2BC.%26aulast%3DLynch%26aufirst%3DJ.%2BJ.%26aulast%3DMoore%26aufirst%3DE.%2BL.%26aulast%3DMosser%26aufirst%3DS.%2BD.%26aulast%3DPrueksaritanont%26aufirst%3DT.%26aulast%3DRegan%26aufirst%3DC.%2BP.%26aulast%3DRoller%26aufirst%3DS.%26aulast%3DSalvatore%26aufirst%3DC.%2BA.%26aulast%3DKane%26aufirst%3DS.%2BA.%26aulast%3DVacca%26aufirst%3DJ.%2BP.%26aulast%3DSelnick%26aufirst%3DH.%2BG.%26atitle%3DDiscovery%2520of%2520MK-3207%253A%2520a%2520highly%2520potent%252C%2520orally%2520bioavailable%2520CGRP%2520receptor%2520antagonist%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D1%26spage%3D24%26epage%3D29%26doi%3D10.1021%2Fml900016y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rudolf, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eberlein, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engel, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pieper, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Entzeroth, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hallermayer, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doods, H.</span></span> <span> </span><span class="NLM_article-title">Development of human calcitonin gene-related peptide (CGRP) receptor antagonists. 1. Potent and selective small molecule CGRP antagonists. 1-[<i>N</i><sup>2</sup>-[3,5-Dibromo-<i>N</i>-[[4-(3,4-dihydro-2(1<i>H</i>)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)piperazine: the first CGRP antagonist for clinical trials in acute migraine</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">5921</span>– <span class="NLM_lpage">5931</span>, <span class="refDoi"> DOI: 10.1021/jm0490641</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0490641" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=1%3ACAS%3A528%3ADC%252BD2MXpt1WhsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=5921-5931&author=K.+Rudolfauthor=W.+Eberleinauthor=W.+Engelauthor=H.+Pieperauthor=M.+Entzerothauthor=G.+Hallermayerauthor=H.+Doods&title=Development+of+human+calcitonin+gene-related+peptide+%28CGRP%29+receptor+antagonists.+1.+Potent+and+selective+small+molecule+CGRP+antagonists.+1-%5BN2-%5B3%2C5-Dibromo-N-%5B%5B4-%283%2C4-dihydro-2%281H%29-oxoquinazolin-3-yl%29-1-piperidinyl%5Dcarbonyl%5D-D-tyrosyl%5D-L-lysyl%5D-4-%284-pyridinyl%29piperazine%3A+the+first+CGRP+antagonist+for+clinical+trials+in+acute+migraine&doi=10.1021%2Fjm0490641"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Development of Human Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonists. Potent and Selective Small Molecule CGRP Antagonists. 1-[N2-[3,5-Dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1- piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)piperazine: The First CGRP Antagonist for Clinical Trials in Acute Migraine</span></div><div class="casAuthors">Rudolf, Klaus; Eberlein, Wolfgang; Engel, Wolfhard; Pieper, Helmut; Entzeroth, Michael; Hallermayer, Gerhard; Doods, Henri</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">5921-5931</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Although the triptans have greatly improved the acute treatment of migraine headache, there are yet many shortcomings.  Therefore, new strategies for the treatment of migraine are needed which offer advantages over current therapy, e.g. triptans.  Our novel approach was based on the hypothesis that the release of calcitonin gene-related peptide (CGRP) could play a causative role in migraine headache.  Thus the authors initiated a program aimed at the design and synthesis of small mol. CGRP receptor antagonists.  High throughput screening led to the identification of (R)-Tyr-(S)-Lys dipeptide-like compds. that showed weak but unequivocal binding to the human CGRP receptor.  Lead optimization afforded highly potent CGRP antagonists, the prototype being compd. (I) (BIBN4096).  This compd. exhibiting a favorable biol. profile was selected for initial clin. trials.  A proof of concept study indicated that i.v. application of I was effective in the treatment of acute migraine headache.  This finding strongly supports our initial working hypothesis that CGRP plays an important role in the pathophysiol. of migraine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTkWy0CNrVprVg90H21EOLACvtfcHk0ljvOLL8wl22Xw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXpt1WhsL8%253D&md5=802a2111a5507db63f9c91cb07469449</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1021%2Fjm0490641&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0490641%26sid%3Dliteratum%253Aachs%26aulast%3DRudolf%26aufirst%3DK.%26aulast%3DEberlein%26aufirst%3DW.%26aulast%3DEngel%26aufirst%3DW.%26aulast%3DPieper%26aufirst%3DH.%26aulast%3DEntzeroth%26aufirst%3DM.%26aulast%3DHallermayer%26aufirst%3DG.%26aulast%3DDoods%26aufirst%3DH.%26atitle%3DDevelopment%2520of%2520human%2520calcitonin%2520gene-related%2520peptide%2520%2528CGRP%2529%2520receptor%2520antagonists.%25201.%2520Potent%2520and%2520selective%2520small%2520molecule%2520CGRP%2520antagonists.%25201-%255BN2-%255B3%252C5-Dibromo-N-%255B%255B4-%25283%252C4-dihydro-2%25281H%2529-oxoquinazolin-3-yl%2529-1-piperidinyl%255Dcarbonyl%255D-D-tyrosyl%255D-L-lysyl%255D-4-%25284-pyridinyl%2529piperazine%253A%2520the%2520first%2520CGRP%2520antagonist%2520for%2520clinical%2520trials%2520in%2520acute%2520migraine%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D5921%26epage%3D5931%26doi%3D10.1021%2Fjm0490641" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Belyk, K. M.</span>; <span class="NLM_string-name">Cleator, E.</span>; <span class="NLM_string-name">Kuo, S.-C.</span>; <span class="NLM_string-name">Maligres, P. E.</span>; <span class="NLM_string-name">Xiang, B.</span>; <span class="NLM_string-name">Yasuda, N.</span>; <span class="NLM_string-name">Yin, J.</span></span> <span> </span><span class="NLM_article-title">Process for Making CGRP Receptor Antagonists</span>. U.S. Patent <span class="NLM_patent">US9,487,523</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=K.+M.+Belyk&author=E.+Cleator&author=S.-C.+Kuo&author=P.+E.+Maligres&author=B.+Xiang&author=N.+Yasuda&author=J.+Yin&title=Process+for+Making+CGRP+Receptor+Antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBelyk%26aufirst%3DK.%2BM.%26atitle%3DProcess%2520for%2520Making%2520CGRP%2520Receptor%2520Antagonists%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belyk, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reamer, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yasuda, N.</span></span> <span> </span><span class="NLM_article-title">Discovery and application of doubly quaternized cinchona-alkaloid-based phase-transfer catalysts</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">8375</span>– <span class="NLM_lpage">8378</span>, <span class="refDoi"> DOI: 10.1002/anie.201404084</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=10.1002%2Fanie.201404084" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVamtrbE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2014&pages=8375-8378&author=B.+Xiangauthor=K.+M.+Belykauthor=R.+A.+Reamerauthor=N.+Yasuda&title=Discovery+and+application+of+doubly+quaternized+cinchona-alkaloid-based+phase-transfer+catalysts&doi=10.1002%2Fanie.201404084"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and application of doubly quaternized cinchona-alkaloid-based phase-transfer catalysts</span></div><div class="casAuthors">Xiang, Bangping; Belyk, Kevin M.; Reamer, Robert A.; Yasuda, Nobuyoshi</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">32</span>),
    <span class="NLM_cas:pages">8375-8378</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Novel N,N'-disubstituted cinchona alkaloids were reported as efficient phase-transfer catalysts for the assembly of stereogenic quaternary centers.  In comparison to traditional cinchona-alkaloid-based phase-transfer catalysts, these new catalysts afford substantial improvements in enantioselectivity and reaction rate for intramol. spirocyclization reactions of 3-[2-(chloromethyl)aryl]-γ-lactams with catalyst loadings as low as 0.3 mol% under mild conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqN80hfS6mXArVg90H21EOLACvtfcHk0ljvOLL8wl22Xw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVamtrbE&md5=dcd37cc490895354bf52ce22784d230b</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1002%2Fanie.201404084&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201404084%26sid%3Dliteratum%253Aachs%26aulast%3DXiang%26aufirst%3DB.%26aulast%3DBelyk%26aufirst%3DK.%2BM.%26aulast%3DReamer%26aufirst%3DR.%2BA.%26aulast%3DYasuda%26aufirst%3DN.%26atitle%3DDiscovery%2520and%2520application%2520of%2520doubly%2520quaternized%2520cinchona-alkaloid-based%2520phase-transfer%2520catalysts%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2014%26volume%3D53%26spage%3D8375%26epage%3D8378%26doi%3D10.1002%2Fanie.201404084" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dräger, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solodenko, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Messinger, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schon, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirschning, A.</span></span> <span> </span><span class="NLM_article-title">A new reagent and its polymer-supported variant for the amidination of amines</span>. <i>Tetrahedron Lett.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">1401</span>– <span class="NLM_lpage">1403</span>, <span class="refDoi"> DOI: 10.1016/S0040-4039(01)02403-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=10.1016%2FS0040-4039%2801%2902403-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;key=1%3ACAS%3A528%3ADC%252BD38Xpsl2lsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2002&pages=1401-1403&author=G.+Dr%C3%A4gerauthor=W.+Solodenkoauthor=J.+Messingerauthor=U.+Schonauthor=A.+Kirschning&title=A+new+reagent+and+its+polymer-supported+variant+for+the+amidination+of+amines&doi=10.1016%2FS0040-4039%2801%2902403-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">A new reagent and its polymer-supported variant for the amidination of amines</span></div><div class="casAuthors">Drager, Gerald; Solodenko, Wladimir; Messinger, Josef; Schon, Uwe; Kirschning, Andreas</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron Letters</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1401-1403</span>CODEN:
                <span class="NLM_cas:coden">TELEAY</span>;
        ISSN:<span class="NLM_cas:issn">0040-4039</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">New reagents for the high yielding amidination of primary and secondary amines are described.  By attaching a benzyl substituent to the 3,5-dimethyl-1H-pyrazole-1-carboxamidine ring, a reagent I is obtained which allows easy work-up after amidination because of soly. of byproducts in org. solvents.  In addn., the polystyrene-bound analog was prepd. which allows amidination of various amines with high purity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEAeQ0BBcJD7Vg90H21EOLACvtfcHk0li5X1rcw5cG2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xpsl2lsg%253D%253D&md5=7bca90187eb9317b641c915d42ea0eda</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1016%2FS0040-4039%2801%2902403-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0040-4039%252801%252902403-0%26sid%3Dliteratum%253Aachs%26aulast%3DDr%25C3%25A4ger%26aufirst%3DG.%26aulast%3DSolodenko%26aufirst%3DW.%26aulast%3DMessinger%26aufirst%3DJ.%26aulast%3DSchon%26aufirst%3DU.%26aulast%3DKirschning%26aufirst%3DA.%26atitle%3DA%2520new%2520reagent%2520and%2520its%2520polymer-supported%2520variant%2520for%2520the%2520amidination%2520of%2520amines%26jtitle%3DTetrahedron%2520Lett.%26date%3D2002%26volume%3D43%26spage%3D1401%26epage%3D1403%26doi%3D10.1016%2FS0040-4039%2801%2902403-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3AQF" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3AQF','PDB','3AQF'); return false;">PDB: 3AQF</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3N7R" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3N7R','PDB','3N7R'); return false;">PDB: 3N7R</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4RWF" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4RWF','PDB','4RWF'); return false;">PDB: 4RWF</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i112"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02191">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_04023"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c02191?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c02191</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">AM<sub>2</sub> hybrid model (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02191/suppl_file/jm0c02191_si_001.pdb">PDB</a>)</p></li><li><p class="inline">Telcagepant docking (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02191/suppl_file/jm0c02191_si_002.pdb">PDB</a>)</p></li><li><p class="inline">Compound <b>1</b> docking (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02191/suppl_file/jm0c02191_si_003.pdb">PDB</a>)</p></li><li><p class="inline">Compound (<i>R</i>)-<b>25</b> docking (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02191/suppl_file/jm0c02191_si_004.pdb">PDB</a>)</p></li><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02191/suppl_file/jm0c02191_si_005.csv">CSV</a>)</p></li><li><p class="inline">X-ray crystal structure analysis of (<i>R</i>)-CLR-binding unit <b>30</b> and key compounds <b>12</b>, <b>14</b>, (±)-<b>25</b>, and (<i>R</i>)-<b>25</b> chemical data (<sup>1</sup>H NMR, HPLC, LC-MS) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02191/suppl_file/jm0c02191_si_006.pdf">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c02191/suppl_file/jm0c02191_liveslides.mp4">jm0c02191_liveslides.mp4 (8.14 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c02191/suppl_file/jm0c02191_si_001.pdb">jm0c02191_si_001.pdb (105.62 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c02191/suppl_file/jm0c02191_si_002.pdb">jm0c02191_si_002.pdb (3.45 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c02191/suppl_file/jm0c02191_si_003.pdb">jm0c02191_si_003.pdb (3.09 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c02191/suppl_file/jm0c02191_si_004.pdb">jm0c02191_si_004.pdb (2.7 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c02191/suppl_file/jm0c02191_si_005.csv">jm0c02191_si_005.csv (2.74 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c02191/suppl_file/jm0c02191_si_006.pdf">jm0c02191_si_006.pdf (1.33 MB)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c02191&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2021.64.issue-6%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c02191%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c02191" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                4MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6799467e7b6824c7","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
